{"e426b264e79121f8e686a3baf974e9b774d02353": [["LCA overview for thermal conversion techniquesMassive population growth and subsequent society evolution raise problems such as higher levels of waste production, which also become more complex and difficult to treat and dispose correctly (Sinha-Khetriwal et al., 2005; Scharnhorst et al., 2005) .", [["thermal conversion techniques", "TREATMENT", 17, 46], ["Massive population growth", "PROBLEM", 46, 71], ["higher levels of waste production", "PROBLEM", 128, 161], ["Massive", "OBSERVATION_MODIFIER", 46, 53], ["population", "OBSERVATION_MODIFIER", 54, 64], ["growth", "OBSERVATION_MODIFIER", 65, 71], ["waste production", "OBSERVATION", 145, 161]]], ["Currently, waste management is considered a hot topic and concepts such as WtE are becoming increasingly explored, endorsing residues as one of the possible novel energy sources (Reimann, 2005; Zheng et al., 2014; Ramos et al., 2018a) .", [["WtE", "GENE_OR_GENE_PRODUCT", 75, 78], ["waste management", "TREATMENT", 11, 27], ["a hot topic", "TREATMENT", 42, 53]]], ["Technology related to waste treatment is now at the forefront of development, aiming to manage large amounts of waste in the most sustainable way (Rizwan et al., 2018; Fruergaard et al., 2010; Tavares et al., 2018) .", [["waste treatment", "TREATMENT", 22, 37]]], ["Thermal treatments are one of the most commonly employed procedures to deal with numerous waste streams including MSW (Pavlas et al., 2010; Tavares et al., 2019) , achieving mass reductions of 70-80% and volume reductions of 80-90% (Bosmans et al., 2013; M\u00fcnster and Meibom, 2011) .", [["Thermal treatments", "TREATMENT", 0, 18], ["mass reductions", "PROBLEM", 174, 189], ["volume reductions", "TEST", 204, 221], ["mass", "OBSERVATION", 174, 178]]], ["Incineration is by far the most widely used thermally-based treatment technique, whereas gasification-based conversion schemes are in lesser use (Astrup et al., 2015) .", [["thermally-based treatment technique", "TREATMENT", 44, 79]]], ["Gaseous emissions related to the thermal treatments depict environmental damages such as dioxin and furans formation, heavy metals, and other contaminants which need further treatment (Lopes et al., 2015; Tabasova et al., 2012; Peng et al., 2016) .", [["dioxin", "CHEMICAL", 89, 95], ["furans", "CHEMICAL", 100, 106], ["dioxin", "CHEMICAL", 89, 95], ["furans", "CHEMICAL", 100, 106], ["dioxin", "SIMPLE_CHEMICAL", 89, 95], ["furans", "SIMPLE_CHEMICAL", 100, 106], ["heavy metals", "SIMPLE_CHEMICAL", 118, 130], ["Gaseous emissions", "PROBLEM", 0, 17], ["the thermal treatments", "TREATMENT", 29, 51], ["environmental damages", "PROBLEM", 59, 80], ["dioxin and furans formation", "TREATMENT", 89, 116], ["heavy metals", "PROBLEM", 118, 130], ["further treatment", "TREATMENT", 166, 183]]], ["Otherwise, advanced technologies like regular and plasma gasification apply much higher temperatures and avoid most of the hazardous emissions, enhancing conversion efficiency (Ray et al., 2012; Tang et al., 2013; Ramos et al., 2019a) .LCA overview for thermal conversion techniquesLCA enables the quantification of the impacts related to a specific process or combination of processes, e.g. waste management (McDougall et al., 2008) .", [["plasma", "ANATOMY", 50, 56], ["plasma", "ORGANISM_SUBSTANCE", 50, 56], ["advanced technologies", "PROBLEM", 11, 32], ["regular and plasma gasification", "TREATMENT", 38, 69], ["enhancing conversion efficiency", "PROBLEM", 144, 175], ["thermal conversion techniquesLCA", "TREATMENT", 253, 285], ["the impacts", "PROBLEM", 316, 327], ["a specific process", "PROBLEM", 339, 357], ["waste management", "TREATMENT", 392, 408]]], ["It evaluates the drawbacks and benefits of each step of the overall process from raw material to production, use and disposal of the product, calculating dedicated impact categories, providing easy interpretation and comparison of alternative strategies (Rajaeifar et al., 2015) .", [["alternative strategies", "TREATMENT", 231, 253]]], ["The International Standard Organization has settled the principles and framework for LCA and four main phases have been established.", [["LCA", "TEST", 85, 88]]], ["These are goal and scope definition, life cycle inventory (LCI) collection, life cycle impact assessment (LCIA) and life cycle interpretation phase (ISO, 2006) .", [["scope definition", "TEST", 19, 35], ["life cycle inventory (LCI) collection", "PROBLEM", 37, 74], ["life cycle impact assessment", "TEST", 76, 104]]], ["Distinct methodologies are available to characterize the impact categories (Chevalier et al., 2011) , CML being one of the most commonly used for environmental assessments (Zaman, 2013; Frischknecht et al., 2007) .", [["CML", "ANATOMY", 102, 105], ["CML", "DISEASE", 102, 105], ["CML", "CANCER", 102, 105], ["CML", "PROBLEM", 102, 105], ["environmental assessments", "TEST", 146, 171]]], ["This methodology was developed by the Institute of Environmental Sciences of Leiden University (CML) and embodies eleven impact categories, namely: global warming potential (GWP), eutrophication potential (EP), acidification potential (AP), abiotic depletion (ADP), ozone destruction potential (ODP), photochemical ozone creation potential (POCP), marine aquatic ecotoxicity potential (MAETP), fresh water aquatic ecotoxicity potential (FAETP), terrestrial ecotoxicity potential (TETP) and human toxicity potential (HTP), detailed in (Stranddorf et al., 2005) .LCA overview for thermal conversion techniquesIn the last decades, numerous studies reporting LCA approaches for several waste streams have been published and distinct WtE were evaluated.", [["ADP", "CHEMICAL", 260, 263], ["ozone", "CHEMICAL", 266, 271], ["ozone", "CHEMICAL", 315, 320], ["toxicity", "DISEASE", 496, 504], ["ADP", "CHEMICAL", 260, 263], ["ozone", "CHEMICAL", 266, 271], ["ozone", "CHEMICAL", 315, 320], ["CML", "CANCER", 96, 99], ["ADP", "SIMPLE_CHEMICAL", 260, 263], ["ozone", "SIMPLE_CHEMICAL", 266, 271], ["human", "ORGANISM", 490, 495], ["WtE", "SIMPLE_CHEMICAL", 729, 732], ["WtE", "DNA", 729, 732], ["human", "SPECIES", 490, 495], ["human", "SPECIES", 490, 495], ["acidification potential (AP), abiotic depletion (ADP)", "PROBLEM", 211, 264], ["ozone destruction potential (ODP)", "PROBLEM", 266, 299], ["terrestrial ecotoxicity potential (TETP)", "PROBLEM", 445, 485], ["human toxicity", "PROBLEM", 490, 504], ["thermal conversion techniques", "TREATMENT", 578, 607], ["numerous studies", "TEST", 628, 644], ["several waste streams", "PROBLEM", 674, 695], ["abiotic depletion", "OBSERVATION", 241, 258], ["LCA", "OBSERVATION_MODIFIER", 655, 658], ["distinct", "OBSERVATION_MODIFIER", 720, 728]]], ["WtE classifies all the techniques that decompose waste by thermal means, with the double advantage of recovering its energy, enabling the production of power (Zhang et al., 2015a; Ryu and Shin, 2012) .", [["Shin", "ANATOMY", 188, 192]]], ["This can be applied to the (pre-)construction stage of municipal engineering projects, predicting their impacts and preventing possible adverse situations (Gangolells et al., 2014) .", [["adverse situations", "PROBLEM", 136, 154], ["preventing possible", "UNCERTAINTY", 116, 135]]], ["In this study, the assessed WtE procedures are incineration, regular gasification and two-stage plasma gasification.", [["plasma", "ANATOMY", 96, 102], ["plasma", "ORGANISM_SUBSTANCE", 96, 102], ["this study", "TEST", 3, 13], ["regular gasification", "TREATMENT", 61, 81], ["two-stage plasma gasification", "PROBLEM", 86, 115], ["plasma gasification", "OBSERVATION", 96, 115]]], ["Briefly, incineration is the combustion of solid residues in the presence of oxygen producing heat and steam, which are utilized in a turbine to generate electricity (Bosmans et al., 2013) .", [["oxygen", "CHEMICAL", 77, 83], ["oxygen", "CHEMICAL", 77, 83], ["oxygen", "SIMPLE_CHEMICAL", 77, 83], ["solid residues", "PROBLEM", 43, 57], ["a turbine", "TREATMENT", 132, 141], ["combustion", "OBSERVATION_MODIFIER", 29, 39], ["solid residues", "OBSERVATION", 43, 57]]], ["Although temperatures are sufficiently high to burn the debris, pollutants such as ash, slag and contaminated flue gases are produced requiring additional treatment before being sent to the environment (Van Caneghem et al., 2012) .", [["temperatures", "TEST", 9, 21], ["the debris", "PROBLEM", 52, 62], ["pollutants", "PROBLEM", 64, 74], ["slag", "TREATMENT", 88, 92], ["contaminated flue gases", "PROBLEM", 97, 120], ["additional treatment", "TREATMENT", 144, 164], ["high", "OBSERVATION_MODIFIER", 39, 43], ["debris", "OBSERVATION", 56, 62]]], ["Gasification concerns the conversion of solid waste into a synthetic gas (syngas), in sub-stoichiometric conditions at higher temperatures.", [["syngas", "SIMPLE_CHEMICAL", 74, 80], ["Gasification", "TREATMENT", 0, 12], ["solid waste", "TREATMENT", 40, 51], ["a synthetic gas (syngas", "TEST", 57, 80], ["stoichiometric conditions", "OBSERVATION", 90, 115], ["higher temperatures", "OBSERVATION_MODIFIER", 119, 138]]], ["Syngas is mainly composed of H 2 , CO, CO 2 and short-branched hydrocarbons and may be utilized for the production of power, chemicals, hydrogen and liquid fuels (Siedlecki et al., 2011) .", [["hydrogen", "CHEMICAL", 136, 144], ["H 2", "CHEMICAL", 29, 32], ["CO", "CHEMICAL", 35, 37], ["CO 2", "CHEMICAL", 39, 43], ["short-branched hydrocarbons", "CHEMICAL", 48, 75], ["hydrogen", "CHEMICAL", 136, 144], ["Syngas", "SIMPLE_CHEMICAL", 0, 6], ["H 2", "SIMPLE_CHEMICAL", 29, 32], ["CO", "SIMPLE_CHEMICAL", 35, 37], ["CO 2", "SIMPLE_CHEMICAL", 39, 43], ["short-branched hydrocarbons", "SIMPLE_CHEMICAL", 48, 75], ["hydrogen", "SIMPLE_CHEMICAL", 136, 144], ["Syngas", "TEST", 0, 6], ["CO", "TEST", 35, 37], ["CO", "TEST", 39, 41], ["short-branched hydrocarbons", "PROBLEM", 48, 75]]], ["This technique is divided into four stages: drying, pyrolysis, oxidation and reduction where specific chemical reactions occur (Ramos et al., 2018a) .", [["This technique", "TREATMENT", 0, 14], ["oxidation", "TREATMENT", 63, 72], ["reduction", "TREATMENT", 77, 86], ["specific chemical reactions", "PROBLEM", 93, 120]]], ["Two-stage plasma gasification constitutes an upgrade from regular gasification, adding an extra cleaning step to syngas due to the action of plasma (Ray et al., 2012) .", [["plasma", "ANATOMY", 10, 16], ["plasma", "ANATOMY", 141, 147], ["syngas", "DISEASE", 113, 119], ["plasma", "ORGANISM_SUBSTANCE", 10, 16], ["plasma", "ORGANISM_SUBSTANCE", 141, 147], ["Two-stage plasma gasification", "PROBLEM", 0, 29], ["regular gasification", "TREATMENT", 58, 78], ["an extra cleaning step to syngas", "TREATMENT", 87, 119], ["stage plasma", "OBSERVATION_MODIFIER", 4, 16], ["gasification", "OBSERVATION", 17, 29], ["gasification", "OBSERVATION", 66, 78]]], ["Plasma is considered the fourth state of matter, part of the gaseous elements being in an ionized form, permitting charged particles to interact with neighbouring ones as well as be influenced by an electromagnetic field created by the other charges as a consequence of the very high temperatures (Pourali, 2010) .", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["the gaseous elements", "PROBLEM", 57, 77], ["gaseous elements", "OBSERVATION", 61, 77]]], ["The combination of these highly reactive species with these elevated temperatures is favourable for waste degradation in which inorganic materials are more efficiently melted and a cleaner syngas is achieved (Lombardi et al., 2012) .", [["these highly reactive species", "PROBLEM", 19, 48], ["these elevated temperatures", "PROBLEM", 54, 81], ["waste degradation", "PROBLEM", 100, 117], ["inorganic materials", "TREATMENT", 127, 146], ["a cleaner syngas", "TREATMENT", 179, 195], ["highly", "OBSERVATION_MODIFIER", 25, 31], ["reactive species", "OBSERVATION", 32, 48]]], ["Rajaeifar et al. (Rajaeifar et al., 2015) made a compilation of several LCA studies for MSW management systems highlighting the need to report complete and specific information and address malpractices such as deficiencies in goal and scope definition or using unrepresentative waste compositions.", [["MSW management systems", "TREATMENT", 88, 110], ["unrepresentative waste compositions", "TREATMENT", 261, 296]]], ["Mendes et al. (Mendes et al., 2004), Liamsanguan and Gheewala (Liamsanguan and Gheewala, 2008) and Parkes et al. (Parkes et al., 2015) compared incineration and landfill-based operations in different locations, namely: Brazil, Thailand and England.", [["landfill-based operations", "TREATMENT", 161, 186]]], ["Pikon and Gaska (Pikon and Gaska, 2010) compared incineration impacts to non-thermal processes also reporting lower greenhouse gas emissions for incineration.", [["Pikon", "TEST", 0, 5], ["lower greenhouse gas emissions", "PROBLEM", 110, 140], ["gas emissions", "OBSERVATION", 127, 140]]], ["Ouda et al. (Ouda et al., 2016) compared incineration to other options such as bio-methanation for the treatment of MSW in the Kingdom of Saudi Arabia, incineration proving to be efficient and adequate in terms of power generation and cost.", [["bio-methanation", "TREATMENT", 79, 94]]], ["Zaman (Zaman, 2013 ) performed a comparative LCA study for MSW incineration and gasification, this last technique showing lower results for GWP and ecotoxicity categories.", [["GWP", "CHEMICAL", 140, 143], ["GWP", "SIMPLE_CHEMICAL", 140, 143], ["a comparative LCA study", "TEST", 31, 54], ["MSW incineration", "TREATMENT", 59, 75], ["gasification", "PROBLEM", 80, 92], ["this last technique", "TEST", 94, 113], ["GWP", "PROBLEM", 140, 143], ["ecotoxicity categories", "PROBLEM", 148, 170], ["ecotoxicity categories", "OBSERVATION", 148, 170]]], ["Al-Salem et al. (Al-Salem et al., 2014) , who appraised alternative scenarios for the waste management in the Greater London area, report lower greenhouse gas emissions from a technology based on gasification.", [["the waste management", "TREATMENT", 82, 102], ["lower greenhouse gas emissions", "PROBLEM", 138, 168]]], ["Gunamantha and Sarto (Gunamantha and Sarto, 2012) made a LCA assessment between landfilling, incineration and gasification for solid waste in Indonesia and concluded that gasification portrayed the best environmental profile.", [["Gunamantha", "CHEMICAL", 0, 10], ["a LCA assessment", "TEST", 55, 71], ["landfilling", "TREATMENT", 80, 91], ["incineration", "TREATMENT", 93, 105], ["gasification", "TREATMENT", 110, 122], ["solid waste", "PROBLEM", 127, 138], ["gasification", "PROBLEM", 171, 183], ["gasification", "OBSERVATION", 171, 183]]], ["Regarding advanced WtE options, Tagliaferri et al. (Tagliaferri et al., 2016) analyzed different scenarios in the UK including plasma gasification for the treatment of MSW.", [["plasma", "ANATOMY", 127, 133], ["plasma", "ORGANISM_SUBSTANCE", 127, 133], ["advanced WtE options", "TREATMENT", 10, 30], ["Tagliaferri et al", "TREATMENT", 32, 49], ["plasma gasification", "TREATMENT", 127, 146], ["the treatment of MSW", "TREATMENT", 151, 171]]], ["This new approach depicted higher efficiency in the production of renewable methane, which might replace natural gas in the future.", [["methane", "CHEMICAL", 76, 83], ["methane", "CHEMICAL", 76, 83], ["methane", "SIMPLE_CHEMICAL", 76, 83], ["renewable methane", "TREATMENT", 66, 83], ["natural gas", "TREATMENT", 105, 116], ["higher", "OBSERVATION_MODIFIER", 27, 33], ["efficiency", "OBSERVATION_MODIFIER", 34, 44], ["renewable methane", "OBSERVATION", 66, 83]]], ["The advanced plasma technique depicted improved overall profile compared to pyrolysis, combustion and classic gasification, mostly due to its higher electrical efficiency.", [["plasma", "ANATOMY", 13, 19], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["The advanced plasma technique", "TEST", 0, 29], ["classic gasification", "PROBLEM", 102, 122], ["its higher electrical efficiency", "PROBLEM", 138, 170], ["improved", "OBSERVATION_MODIFIER", 39, 47], ["overall profile", "OBSERVATION_MODIFIER", 48, 63], ["classic gasification", "OBSERVATION", 102, 122], ["higher", "OBSERVATION_MODIFIER", 142, 148], ["electrical efficiency", "OBSERVATION", 149, 170]]], ["Other studies reported high conversion efficiencies attained with this plasma-based technology (Ray et al., 2012; Taylor et al., 2013) as well as volume reductions of up to 99%, substantially higher than conventional incineration (Byun et al., 2010) .LCA overview for thermal conversion techniquesMost of the times, one specific feature of a new technology is emphasized and, rather than conducting an integrated study, other aspects of the low carbon technologies are assessed separately (Braulio-Gonzalo et al., 2015) .", [["plasma", "ANATOMY", 71, 77], ["carbon", "CHEMICAL", 445, 451], ["plasma", "ORGANISM_SUBSTANCE", 71, 77], ["Other studies", "TEST", 0, 13], ["high conversion efficiencies", "PROBLEM", 23, 51], ["volume reductions", "TEST", 146, 163], ["thermal conversion techniques", "TREATMENT", 268, 297], ["an integrated study", "TEST", 399, 418], ["the low carbon technologies", "PROBLEM", 437, 464], ["higher", "OBSERVATION_MODIFIER", 192, 198]]], ["This results in a reduced social acceptance of a novel project's implementation, especially when waste management is the topic, since people tend to relate it to social discomfort.", [["people", "ORGANISM", 134, 140], ["people", "SPECIES", 134, 140], ["social discomfort", "PROBLEM", 162, 179]]], ["Hence, Bartolacci et al. (Bartolacci et al., 2019) developed an efficiency indicator combining economic and environmental aspects for companies operating in the collection, transport and treatment of municipal solid waste.", [["an efficiency", "PROBLEM", 61, 74], ["municipal solid waste", "TREATMENT", 200, 221]]], ["Mavrotas et al. (Mavrotas et al., 2015) propose a multi-objective optimization to assess several WtE techniques for MSW management.", [["a multi-objective optimization", "TREATMENT", 48, 78], ["several WtE techniques", "TREATMENT", 89, 111], ["MSW management", "TREATMENT", 116, 130]]], ["Lombardi et al. (Lombardi et al., 2017) have recently summarized what has been done regarding urban carbon footprint assessments, stating that combined approaches are the most complete for providing supplementary information related to energy and climate.", [["carbon", "CHEMICAL", 100, 106], ["carbon footprint assessments", "TEST", 100, 128]]], ["This will have a direct effect on people's living conditions, potentially challenging them to change their habits.LCA overview for thermal conversion techniquesThis new study reviews the municipal solid waste composition in several world cities and, as a specific application of the gathered knowledge, presents a case study for the enhancement of a pre-existing facility.", [["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["thermal conversion techniques", "TREATMENT", 131, 160], ["This new study", "TEST", 160, 174], ["a case study", "TEST", 312, 324]]], ["The environmental and energetic performances of the thermal treatment of one tonne of MSW by incineration, regular gasification and two-stage plasma gasification are assessed.", [["plasma", "ANATOMY", 142, 148], ["plasma", "ORGANISM_SUBSTANCE", 142, 148], ["the thermal treatment", "TREATMENT", 48, 69], ["two-stage plasma gasification", "PROBLEM", 132, 161], ["plasma gasification", "OBSERVATION", 142, 161]]], ["This evaluation enables the calculation of the ratio between waste produced and energy consumed per capita in several areas, potentially serving as an average indicator for social wealth and development, also showing innovation.Waste composition across different regionsDepending on the composition of the waste, different management solutions may be suggested in order to comply with the strategy imposed by the EU (Engineering, I.I.o.S.a.P, 2011).", [["This evaluation", "TEST", 0, 15], ["the waste", "TREATMENT", 302, 311], ["different management solutions", "TREATMENT", 313, 343], ["regions", "ANATOMY_MODIFIER", 263, 270]]], ["Ciuta et al. (Ciuta et al., 2015) investigated several MSW streams from different areas and concluded that in urban areas, the plastic fraction is almost six-fold higher than in rural areas, which enhances the calorific content of MSW, enlarging its energy recovery possibilities.", [["calorific", "SIMPLE_CHEMICAL", 210, 219], ["several MSW streams", "PROBLEM", 47, 66], ["the plastic fraction", "TEST", 123, 143], ["plastic fraction", "OBSERVATION", 127, 143], ["almost", "OBSERVATION_MODIFIER", 147, 153], ["six-fold", "OBSERVATION_MODIFIER", 154, 162], ["higher", "OBSERVATION_MODIFIER", 163, 169], ["calorific content", "OBSERVATION", 210, 227], ["enlarging", "OBSERVATION_MODIFIER", 236, 245], ["energy recovery", "OBSERVATION", 250, 265]]], ["This is also seen for different types of waste streams and disposal options (Sinha-Khetriwal et al., 2005) , waste availability being also an aspect that contributes to different composition (Bergeron, 2017) .", [["waste streams", "OBSERVATION", 41, 54]]], ["The composition and rate of production of MSW contribute to the improvement of the waste management systems, aiding the development of national or regional strategies in order to meet EU regulations.Waste composition across different regionsPark and Lah (Park and Lah, 2018) compared the average composition of MSW in the EU, South Korea and the USA, showing that different standards and definitions applied in diverse world regions/ countries/socio-economic organizations leads to ambiguous comparisons: the same MSW component may be understood as waste in one country and as recyclable material elsewhere and this hampers tentative comparisons between MSW compositions.", [["the waste management systems", "TREATMENT", 79, 107], ["the USA", "TEST", 342, 349], ["regions", "ANATOMY_MODIFIER", 234, 241], ["Lah", "ANATOMY", 250, 253]]], ["In the EU, the most recent legislation on waste management is based in the Waste Framework Directive (2008/98/EC) and the Directive 2011/753/EU, which establish the calculation methodology for meeting the targets set by the European Environment Agency (Fischer et al., 2013) .", [["waste management", "TREATMENT", 42, 58]]], ["Within these standards, more than 272 \u00d7 10 6 tons of MSW were generated and almost 27% were recycled in the EU in 2015.", [["MSW", "TEST", 53, 56]]], ["In the same year, South Korea, with its waste management system based in more conservative rules and standards, recycled 59% of the MSW generated, whereas the USA recycled approximately 27% of the MSW generated (Development, O.F.E.C.-O.A, 2016) .", [["its waste management system", "TREATMENT", 36, 63], ["the USA", "TEST", 155, 162]]], ["Different changes are seen when applying each country's standards to the other participants but the major finding is that distinct definitions of the MSW or recyclable fraction lead to diverse interpretation of the results (Park and Lah, 2018; Kawai and Tasaki, 2016) .", [["participants", "SPECIES", 79, 91]]], ["The discrepancy in definitions is a result of different policies and responsibilities prevailing with respect to the waste cycle, depending on the country or legislative body as well as the political, social and economic framework (Kawai and Tasaki, 2016) .", [["body", "ANATOMY", 170, 174], ["body", "ORGANISM_SUBDIVISION", 170, 174]]], ["Table 1 cites published works that relate specific MSW composition to different world locations.Waste composition across different regionsAs noted previously, the composition of MSW for a given location may vary considerably depending on sampling method, collection season or characterization methodology as the data from Beijing in Table 1 (Ramachandra et al., 2018; Xiao et al., 2009) .", [["regions", "ANATOMY_MODIFIER", 131, 138]]], ["Other discrepancies are seen for various regions within the same country as observed for India and China, the latter country showing variances from nearly 16% to 69% in the organic fraction, and 3% to roughly 17% in the paper fraction (Xiao et al., 2009) .", [["Other discrepancies", "PROBLEM", 0, 19], ["the organic fraction", "TEST", 169, 189], ["organic fraction", "ANATOMY", 173, 189]]], ["In India, the organic fraction varies from 35% to 84% and the plastic share from 2% to 35% (Bolukbas and Akinci, 2018; Naveen, 2018; Ramachandra et al., 2018) .", [["the organic fraction", "TEST", 10, 30]]], ["Taiwan also presented divergent values among distinct cities, the organic fraction ranging from 24% in Taipei to 40% in Keelung, whereas the plastic varied from 22.5% to 15% in the same locations (Chen, 2018) .", [["the organic fraction", "TEST", 62, 82], ["divergent", "OBSERVATION_MODIFIER", 22, 31], ["distinct", "OBSERVATION_MODIFIER", 45, 53], ["cities", "OBSERVATION_MODIFIER", 54, 60], ["organic fraction", "OBSERVATION", 66, 82], ["plastic", "OBSERVATION_MODIFIER", 141, 148], ["varied", "OBSERVATION_MODIFIER", 149, 155]]], ["Metal and glass shares also varied significantly among the Taiwanese cities.", [["Metal", "CHEMICAL", 0, 5], ["Metal and glass shares", "TREATMENT", 0, 22], ["glass shares", "OBSERVATION", 10, 22], ["varied", "OBSERVATION_MODIFIER", 28, 34], ["significantly", "OBSERVATION_MODIFIER", 35, 48]]], ["By contrast, in smaller countries such as Portugal, different cities present similar MSW compositions as the consumption patterns and economic level of the population are similar (Ramos et al., 2018b; Mar\u00e7al et al., 2015) .", [["smaller", "OBSERVATION_MODIFIER", 16, 23]]], ["This has further promoted the research of a case study for a dedicated purpose, as described and discussed in chapters 2 and 3 of the present work.", [["a case study", "TEST", 42, 54]]], ["Tourism is also a great contributor for the composition of residues in a given location (Diaz-Farina et al., 2020) , geophysical features (as dry and wet seasons) also promoting diverse waste compositions in specific countries (Ibikunle et al., 2020) .Waste composition across different regionsIn the case of Nigeria, the organic fraction shows the highest discrepancy (more than 10% raise in the wet season), plastic and textile contents dropping nearly 4% and 3.4% respectively.Waste composition across different regionsMost of the selected countries/regions depict the organic fraction as the major MSW component, although there are some exceptions as in the USA, Norway and Israel.", [["geophysical features", "PROBLEM", 117, 137], ["the organic fraction", "TEST", 318, 338], ["plastic and textile contents", "TEST", 410, 438], ["diverse", "OBSERVATION_MODIFIER", 178, 185], ["waste compositions", "OBSERVATION", 186, 204], ["regions", "ANATOMY_MODIFIER", 287, 294], ["highest", "OBSERVATION_MODIFIER", 349, 356], ["discrepancy", "OBSERVATION", 357, 368], ["textile contents", "OBSERVATION", 422, 438], ["regions", "ANATOMY_MODIFIER", 515, 522], ["organic fraction", "OBSERVATION", 572, 588], ["major", "OBSERVATION_MODIFIER", 596, 601], ["MSW", "OBSERVATION_MODIFIER", 602, 605], ["component", "OBSERVATION_MODIFIER", 606, 615]]], ["Again, distinct legislation and concept definitions appear to be the reasons for these incongruences as well as the markedly different economic, social and cultural backgrounds of the listed countries (Park and Lah, 2018; Bolukbas and Akinci, 2018) .", [["these incongruences", "PROBLEM", 81, 100], ["distinct", "OBSERVATION_MODIFIER", 7, 15], ["legislation", "OBSERVATION", 16, 27]]], ["Although for the USA, data collected in Table 1 does not mention specific locations, good agreement between the three datasets is achieved for the waste fractions.", [["the USA, data", "TEST", 13, 26]]], ["These generate highly specific waste streams with their own characteristic MSW compositions (Bolukbas and Akinci, 2018) .", [["highly", "OBSERVATION_MODIFIER", 15, 21], ["specific", "OBSERVATION_MODIFIER", 22, 30], ["waste streams", "OBSERVATION", 31, 44]]], ["This is observed in Table 1 for instance in Turkey, where cities such as Ankara, Gaziantep, Sanliurfa and Tekirdag depict MSW compositions dissimilar to Izmir, for instance (Bolukbas and Akinci, 2018) .", [["Gaziantep", "TREATMENT", 81, 90], ["Sanliurfa", "TREATMENT", 92, 101]]], ["Major discrepancies are seen for the paper, metal and others fractions which range from 0.57% to almost 15%, 0.51% to 3.1% and 14% to nearly 40% respectively.", [["metal", "SIMPLE_CHEMICAL", 44, 49], ["Major discrepancies", "PROBLEM", 0, 19], ["range", "OBSERVATION_MODIFIER", 77, 82]]], ["Comparing to the other cited works, this fraction depicts higher values for locations such as Ankara, Bursa, Izmir, Hangzhou and Guiyang (apart from an unidentified city in India).", [["this fraction", "TEST", 36, 49], ["Bursa", "ANATOMY", 102, 107]]], ["Also, the climatic conditions can interfere with MSW characteristics such as moisture content, type and yield of biodegradables (Hoornweg and Bhada-Tata, 2012) .", [["the climatic conditions", "PROBLEM", 6, 29]]], ["In the case of India, the two cities Mavallipura and Bangalore, despite being close to each other, present contrasting MSW compositions.", [["MSW compositions", "OBSERVATION", 119, 135]]], ["Additionally, the type of recycling or sorting facilities available in situ influences the MSW fraction as if the population is not provided with the appropriate containers to separate different waste elements, they will mostly end up in the MSW segment (or even in open-air dumping sites).Waste composition across different regionsChand Malav et al. (Chand Malav et al., 2020) assessed the differences in MSW composition depending on the population range, interesting trends being seen: the higher the number of inhabitants, the higher the paper fraction (roughly 3% in population lower than 0.5 million people to approximately 6.5% for a population of 5 million inhabitants or higher), as well as the metal share (0.33% to 0.80% for the same population ranges).", [["people", "SPECIES", 605, 611], ["open-air dumping sites", "TREATMENT", 266, 288], ["Waste composition", "TREATMENT", 290, 307], ["waste elements", "OBSERVATION", 195, 209], ["MSW", "ANATOMY", 242, 245], ["segment", "ANATOMY_MODIFIER", 246, 253], ["air dumping", "OBSERVATION", 271, 282]]], ["Oppositely rubber, leather and synthetic fractions decrease from 0.8% to less than 0.3% in the same population range, while glass follows the same trend although the decrease pace is lower.", [["rubber", "OBSERVATION_MODIFIER", 11, 17], ["leather", "OBSERVATION_MODIFIER", 19, 26], ["synthetic", "OBSERVATION_MODIFIER", 31, 40], ["fractions", "OBSERVATION_MODIFIER", 41, 50], ["decrease", "OBSERVATION_MODIFIER", 51, 59], ["decrease", "OBSERVATION_MODIFIER", 166, 174], ["pace", "OBSERVATION", 175, 179], ["lower", "OBSERVATION_MODIFIER", 183, 188]]], ["The compostable matter also depicts a noticeable drop, except when the 2.0-5.0 million inhabitants range is considered (more than 56.5% of the share being seen).Waste composition across different regionsRelative to the waste characterization along the years, a very interesting study is presented by Diaz-Farina et al. (Diaz-Farina et al., 2020) , who evaluated the streams of recyclable waste from 2004 to 2015 in Tenerife, Spain.", [["a noticeable drop", "PROBLEM", 36, 53], ["a very interesting study", "PROBLEM", 259, 283], ["noticeable", "OBSERVATION_MODIFIER", 38, 48], ["drop", "OBSERVATION_MODIFIER", 49, 53], ["regions", "ANATOMY_MODIFIER", 196, 203]]], ["The authors show that while mixed waste has decreased from 95% to roughly 90%, glass has evolved to greater fractions (1% to roughly 3.5%) as well as paper and cardboard (0 to 2%).", [["decreased", "OBSERVATION_MODIFIER", 44, 53], ["greater fractions", "OBSERVATION_MODIFIER", 100, 117]]], ["Light packaging has also shown increasing tendency (0 to 1.5%), whereas the \"others\" fraction has varied between 4% and 5.5%.", [["Light packaging", "TREATMENT", 0, 15], ["increasing tendency", "PROBLEM", 31, 50], ["increasing", "OBSERVATION_MODIFIER", 31, 41], ["tendency", "OBSERVATION_MODIFIER", 42, 50], ["varied", "OBSERVATION_MODIFIER", 98, 104]]], ["Tenerife is a very touristic island and therefore, seasonality effects may contribute to a diverse composition.", [["a very touristic island", "PROBLEM", 12, 35], ["very", "OBSERVATION_MODIFIER", 14, 18], ["touristic", "OBSERVATION_MODIFIER", 19, 28], ["island", "OBSERVATION", 29, 35], ["diverse", "OBSERVATION_MODIFIER", 91, 98]]], ["This can sometimes lead to mismanagement practices, if an over-capacity in the treatment facilities exists.", [["mismanagement practices", "TREATMENT", 27, 50]]], ["In fact, the utilization of waste management options such as the WtE could profit from this surplus, generating more energy which becomes available for the highly demanding nowadays' society.Waste composition across different regionsMore recently, the actual pandemic situation that the world is facing due to SARS-COV 2 has led to changes in municipal waste characterization, namely due to the higher amounts of residues such as disposable face masks, rubber gloves and paper tissues (both from medical waste surge and household waste) (Kulkarni and Anantharama, 2020).Waste composition across different regionsWaste management practices and collection routes have also been adapted in developed and developing countries, in order to avoid or reduce potential contamination and spread.", [["tissues", "ANATOMY", 477, 484], ["WtE", "CHEMICAL", 65, 68], ["SARS", "DISEASE", 310, 314], ["tissues", "TISSUE", 477, 484], ["waste management options", "TREATMENT", 28, 52], ["this surplus", "TREATMENT", 87, 99], ["SARS", "PROBLEM", 310, 314], ["the higher amounts of residues", "PROBLEM", 391, 421], ["disposable face masks", "TREATMENT", 430, 451], ["rubber gloves", "TREATMENT", 453, 466], ["paper tissues", "PROBLEM", 471, 484], ["Waste composition across different regionsWaste management practices", "TREATMENT", 570, 638], ["collection routes", "TREATMENT", 643, 660], ["potential contamination", "PROBLEM", 751, 774], ["regions", "ANATOMY_MODIFIER", 226, 233], ["rubber gloves", "OBSERVATION", 453, 466], ["contamination", "OBSERVATION", 761, 774]]], ["The Asian development bank has underlined the need for new waste management infrastructures, as landfilling is still one of the most common management options in some countries (Kulkarni, 2020) .", [["new waste management infrastructures", "TREATMENT", 55, 91]]], ["In these cases, thermal treatments could also provide benefits whereas in developing countries these are rarely applied (Mayer et al., 2019) .Energy production and urban patterns of utilization\"Urban metabolism\" is a concept that first appeared in 1965 (Wolman, 1965) , and has received increasing attention up to the present (Zhang, 2013; Zhang et al., 2015b; Pincetl et al., 2012) .", [["thermal treatments", "TREATMENT", 16, 34]]], ["The environmental aspects of urban metabolism are assessed by means of different tools as LCA (Braulio-Gonzalo et al., 2015; Zhang, 2013; Baynes and Wiedmann, 2012; Ascione et al., 2008) , directly contributing to the \"urban quality\" (Garau and Pavan, 2018) .Energy production and urban patterns of utilizationAccording to the International Energy Agency (Agency, I.E, 2015) , roughly 80% of world's total primary energy supply originates from fossil fuels, with high CO 2 emissions (Agency, I.E, 2015) .", [["CO 2", "CHEMICAL", 468, 472], ["fossil fuels", "OBSERVATION", 444, 456]]], ["Together with the fact that renewable sources still make only a small contribution in energy production, there is an urgent need to develop alternative WtE techniques.", [["alternative WtE techniques", "TREATMENT", 140, 166], ["small", "OBSERVATION_MODIFIER", 64, 69], ["energy production", "OBSERVATION", 86, 103]]], ["Fig. 1 presents world energy data (Agency, I.E, 2015) and energy generating capacity from MSW over the last decades (OECD/ IEA, 2018).Energy production and urban patterns of utilizationConsidering MSW to be included in the 'other' share, it is clear that its use in the energy production sector is still low (< 6% share).", [["IEA", "ANATOMY", 123, 126]]], ["This is probably due to the increased number of thermal valorisation plants implemented over time and to the higher synthetic fraction gradually seen on waste, namely plastics, artificial fabrics and complex polymer mixtures typically characterizing urban MSW.", [["thermal valorisation plants", "TREATMENT", 48, 75], ["artificial fabrics and complex polymer mixtures", "TREATMENT", 177, 224], ["probably due to", "UNCERTAINTY", 8, 23], ["increased", "OBSERVATION_MODIFIER", 28, 37], ["number", "OBSERVATION_MODIFIER", 38, 44], ["thermal", "OBSERVATION_MODIFIER", 48, 55], ["valorisation plants", "OBSERVATION", 56, 75]]], ["Also, the fact that population is more aware of alternative options to dispose the organic fractions of daily waste or even to reduce them (new ways of cooking, separation, composting, etc.\u2026) contributes to a lower moisture content in MSW, promoting power generating capacity (Ciuta et al., 2015) .Energy production and urban patterns of utilizationCountries such as China (Zheng et al., 2014) and the USA (Park and Lah, 2018; Hoornweg and Bhada-Tata, 2012 ) that were responsible for a large share of MSW generation, energy consumption and CO 2 emissions, accounted for half the increase in renewable-based electricity production, while the EU, Japan and India represent a combined growth of 20% (OECD/IEA, 2018).", [["CO 2", "CHEMICAL", 541, 545], ["a lower moisture content", "PROBLEM", 207, 231], ["increase", "OBSERVATION_MODIFIER", 580, 588]]], ["Data in Fig. 2 presents the global contribution of each sector to the energy consumption.Energy production and urban patterns of utilizationThe chief sectors for energy consumption are transport, manufacturing, residential uses and services (Dor and Kissinger, 2017) .", [["Energy production", "PROBLEM", 89, 106], ["energy consumption", "OBSERVATION", 70, 88]]], ["The USA leads the transport sector due to its massive dependence on private motor vehicles and domestic air travel, as compared to more efficient modes of travelling such as buses and trains used in most of the European countries.", [["its massive dependence", "PROBLEM", 42, 64], ["domestic air travel", "PROBLEM", 95, 114], ["massive", "OBSERVATION_MODIFIER", 46, 53], ["dependence", "OBSERVATION_MODIFIER", 54, 64], ["air travel", "OBSERVATION", 104, 114]]], ["The manufacturing sector is mostly dependent on the major types of industries but overall, the energy consumption intensity decreased around 40% since 2000.", [["the energy consumption intensity", "PROBLEM", 91, 123], ["mostly", "OBSERVATION_MODIFIER", 28, 34], ["dependent", "OBSERVATION_MODIFIER", 35, 44], ["industries", "OBSERVATION", 67, 77], ["intensity", "OBSERVATION_MODIFIER", 114, 123], ["decreased", "OBSERVATION_MODIFIER", 124, 133]]], ["This is due to the increased operational efficiency of major industrial facilities and to the use of low carbon energy options.Energy production and urban patterns of utilizationIn the residential utilization, heating ranks first, followed by lighting and electrical appliances.", [["carbon", "CHEMICAL", 105, 111], ["low carbon energy options", "TREATMENT", 101, 126], ["Energy production", "PROBLEM", 127, 144], ["electrical appliances", "TREATMENT", 256, 277], ["increased", "OBSERVATION_MODIFIER", 19, 28]]], ["Countries such as the Netherlands, Portugal, Germany and Ireland show consumption drops of over 35% since 2000, once they have adopted the heating requirements and incorporated building features consistent with desired comfort levels and efficiency (OECD/IEA, 2018).", [["the heating requirements", "TREATMENT", 135, 159]]], ["A recent publication on the environmental performance of the urban territory for a Portuguese city identified similar sectors as hotspots in terms of climate change and fossil fuels depletion (Dias et al., 2018) .", [["fossil fuels depletion", "PROBLEM", 169, 191], ["publication", "OBSERVATION", 9, 20], ["fossil", "OBSERVATION", 169, 175], ["fuels depletion", "OBSERVATION", 176, 191]]], ["Results show more than 8.400 ton/capita/year of CO 2 -equivalent for climate change and almost 2.400 toe/capita/year for fossil fuels depletion (Dias et al., 2018) , in agreement with other European countries/cities (Ciuta et al., 2015; Vehlow, 2007; Ascione et al., 2009 ).Material and methodsIn order to assess the environmental impacts displayed by MSW treatment under the three WtE techniques considered in the present study, a life cycle inventory (LCI) for each of them was developed.", [["CO", "CHEMICAL", 48, 50], ["fossil fuels depletion", "PROBLEM", 121, 143], ["MSW treatment", "TREATMENT", 352, 365], ["fuels depletion", "OBSERVATION", 128, 143]]], ["Data modelling was achieved with product sustainability software GaBi (database version 4.131 distributed by PE International) (Stuttgart, 1992 (Stuttgart, -2016 , the environmental performance being evaluated through the calculation of eleven different impact categories using CML 2001 methodology and according to ISO 14040:2006 (ISO, 2006 .", [["Data modelling", "TEST", 0, 14], ["PE", "OBSERVATION", 109, 111]]], ["The characterization factors for CML 2001 are the most utilized for the considered impact categories, as reported elsewhere (Chevalier et al., 2011; Rosado et al., 2019) .", [["CML", "DISEASE", 33, 36], ["CML", "PROBLEM", 33, 36]]], ["The MSW sample for this case study was provided by an industrial partner, within the framework of a joint work towards the development of new strategies for the company.Scope, system boundaries and functional unitThe scope of the present study was the analysis of the environmental impacts caused by incineration, regular gasification and plasma gasification of MSW.", [["plasma", "ANATOMY", 339, 345], ["plasma", "ORGANISM_SUBSTANCE", 339, 345], ["this case study", "TEST", 19, 34], ["the present study", "TEST", 226, 243], ["the analysis", "TEST", 248, 260], ["regular gasification", "TREATMENT", 314, 334], ["plasma gasification of MSW", "TREATMENT", 339, 365], ["joint", "ANATOMY", 100, 105]]], ["Fig. 3 describes the limits of each system, dashed blue lines indicating the boundaries.", [["blue lines", "CELL", 51, 61], ["dashed blue lines", "CELL_LINE", 44, 61], ["dashed blue lines", "TREATMENT", 44, 61], ["blue lines", "OBSERVATION", 51, 61]]], ["Coloured boxes represent the processes, connected by flows (arrows).", [["flows", "OBSERVATION_MODIFIER", 53, 58]]], ["World's energy data: left) total primary energy supply and electricity generation; right) average annual growth on energy generating capacity from MSW.", [["total primary energy supply", "TREATMENT", 27, 54], ["left", "ANATOMY_MODIFIER", 21, 25], ["right", "ANATOMY_MODIFIER", 83, 88], ["growth", "OBSERVATION_MODIFIER", 105, 111]]], ["Ramos and A. Rouboa Environmental Impact Assessment Review 85 (2020) 106469 at the plant, its origin, collection and transport to the thermal treatment facilities being excluded from the boundaries of the system.", [["the thermal treatment facilities", "TREATMENT", 130, 162], ["origin", "OBSERVATION_MODIFIER", 94, 100], ["collection", "OBSERVATION", 102, 112]]], ["Also excluded were metallic scrap regeneration (in the case of incineration and gasification) and the vitrified sub-product (in the case of plasma gasification).", [["plasma", "ANATOMY", 140, 146], ["plasma", "ORGANISM_SUBSTANCE", 140, 146], ["metallic scrap regeneration", "PROBLEM", 19, 46], ["incineration and gasification", "TREATMENT", 63, 92], ["the vitrified sub-product", "TREATMENT", 98, 123], ["plasma gasification", "TREATMENT", 140, 159], ["metallic", "OBSERVATION_MODIFIER", 19, 27], ["scrap regeneration", "OBSERVATION", 28, 46]]], ["The power generated from each WtE replaced the electricity from the grid, in an auto-consumption mode, this indicated by the green route (electricity flow).", [["WtE", "DNA", 30, 33], ["an auto-consumption mode", "TREATMENT", 77, 101]]], ["The slashed green arrows stand for the seldom occasions where electricity from the grid is used to start the system, after maintenance or shut down periods.", [["green arrows", "OBSERVATION", 12, 24]]], ["For the gasification schemes, decomposition was performed using a bubbling fluidised bed in the presence of oxidizing agents (oxygen and steam).", [["oxygen", "CHEMICAL", 126, 132], ["oxygen", "CHEMICAL", 126, 132], ["oxygen", "SIMPLE_CHEMICAL", 126, 132], ["the gasification schemes", "TREATMENT", 4, 28], ["a bubbling fluidised bed", "TREATMENT", 64, 88], ["oxidizing agents (oxygen", "TREATMENT", 108, 132], ["oxidizing agents", "OBSERVATION", 108, 124]]], ["The functional unit (fu) was defined as the thermal treatment of 1 t of MSW, its characterization being shown in Table 2 .", [["the thermal treatment", "TREATMENT", 40, 61]]], ["System limits considered in this study for: top) incineration and regular gasification; bottom) two-stage plasma gasification.A. Ramos and A. RouboaEnvironmental Impact Assessment Review 85 (2020) 106469Life cycle inventoryData such as material flows, energy requirements and emissions for each process within the system boundaries are compiled and then adapted and dimensioned to the functional unit.", [["plasma", "ANATOMY", 106, 112], ["plasma", "ORGANISM_SUBSTANCE", 106, 112], ["this study", "TEST", 28, 38], ["regular gasification", "PROBLEM", 66, 86], ["bottom) two-stage plasma gasification", "PROBLEM", 88, 125], ["gasification", "OBSERVATION", 74, 86], ["plasma gasification", "OBSERVATION", 106, 125]]], ["LCI enables the calculation of balances between specific inputs and outputs, based on the main operational data for each technique (ISO, 2006) .Life cycle inventoryAs seen from Fig. 3 , major processes may be considered for each of the WtE methodologies, namely the purple, golden and orange boxes for incineration, gasification and plasma gasification, respectively, and also the landfill process (common to all).", [["plasma", "ANATOMY", 333, 339], ["plasma", "ORGANISM_SUBSTANCE", 333, 339], ["LCI", "TEST", 0, 3], ["gasification", "PROBLEM", 316, 328], ["plasma gasification", "TEST", 333, 352], ["may be considered", "UNCERTAINTY", 202, 219], ["plasma gasification", "OBSERVATION", 333, 352], ["landfill process", "OBSERVATION", 381, 397]]], ["These are focal stages where inputs and outputs need to be carefully accounted to assure robust environmental results.", [["focal stages", "PROBLEM", 10, 22], ["focal", "OBSERVATION_MODIFIER", 10, 15], ["stages", "OBSERVATION_MODIFIER", 16, 22]]], ["All the methodologies utilize auxiliary materials, the complete LCI being available in the Supplementary Material.", [["auxiliary materials", "TREATMENT", 30, 49], ["the complete LCI", "TEST", 51, 67]]], ["Positive values mean harmful impacts (grieving natural resources or emission of contaminants), while negative values represent environmental credits or avoided burdens (emissions to the environmental compartments are prevented or resources are saved).Environmental impactsSome of the main constrains associated with a new WtE facility are related to air pollution, soil and water contamination, noise and smell, social disamenity, unaesthetically landscapes and land use changes (Mavrotas et al., 2015) .", [["Positive values", "PROBLEM", 0, 15], ["air pollution", "PROBLEM", 350, 363], ["main", "OBSERVATION_MODIFIER", 284, 288], ["air pollution", "OBSERVATION", 350, 363], ["water contamination", "OBSERVATION_MODIFIER", 374, 393]]], ["Indeed, the neighbouring populations often show concern about possible impacts in public health due to waste treatments in nearby locations, which may have adverse effects on quality of life (Rajaeifar et al., 2015; Fern\u00e1ndez-Nava et al., 2014) .Environmental impactsFrom Table 3 , incineration and plasma gasification present negative values for all the categories, regular gasification generating environmental hazards for GWP, ODP, ADP fossil , FAETP and TETP, similar trends for GWP and ecotoxicity being reported in other studies (Zaman, 2013) .", [["plasma", "ANATOMY", 299, 305], ["GWP", "CHEMICAL", 425, 428], ["ADP", "CHEMICAL", 435, 438], ["FAETP", "CHEMICAL", 448, 453], ["GWP", "CHEMICAL", 483, 486], ["ADP", "CHEMICAL", 435, 438], ["plasma", "ORGANISM_SUBSTANCE", 299, 305], ["GWP", "SIMPLE_CHEMICAL", 425, 428], ["ADP", "SIMPLE_CHEMICAL", 435, 438], ["FAETP", "SIMPLE_CHEMICAL", 448, 453], ["TETP", "SIMPLE_CHEMICAL", 458, 462], ["GWP", "SIMPLE_CHEMICAL", 483, 486], ["waste treatments", "TREATMENT", 103, 119], ["plasma gasification", "TEST", 299, 318], ["GWP", "PROBLEM", 425, 428], ["ADP fossil", "TEST", 435, 445], ["FAETP", "PROBLEM", 448, 453], ["TETP", "TREATMENT", 458, 462], ["GWP", "PROBLEM", 483, 486], ["ecotoxicity", "PROBLEM", 491, 502]]], ["Despite this, regular gasification provides major environmental credits for EP, AP, MAETP and HTP.", [["EP", "SIMPLE_CHEMICAL", 76, 78], ["AP", "SIMPLE_CHEMICAL", 80, 82], ["MAETP", "SIMPLE_CHEMICAL", 84, 89], ["HTP", "PROBLEM", 94, 97]]], ["GWP result is primarily attributed to CO 2 during the production of the gasifying agent.", [["CO 2", "CHEMICAL", 38, 42], ["CO 2", "GENE_OR_GENE_PRODUCT", 38, 42], ["CO 2", "PROBLEM", 38, 42], ["the gasifying agent", "TREATMENT", 68, 87]]], ["Although positive, this GWP value is lower than other published studies (Arena et al., 2015) , mainly due to the fossil fuels saved by electricity being fed back into the grid (Zaman, 2013) .", [["this GWP value", "TEST", 19, 33], ["the fossil fuels", "PROBLEM", 109, 125], ["positive", "OBSERVATION", 9, 17]]], ["The ODP outcome is related to the emission of halogenated compounds during gasification step, which may be justified by the high level of plastics (for instance PVC) in the feedstock (Al-Salem et al., 2014) .", [["halogenated compounds", "PROBLEM", 46, 67]]], ["The major cause for the achieved ADP fossil result is the use of non-renewable resources such as hard coal, lignite, natural gas and uranium reserves during the gasification step.", [["ADP", "CHEMICAL", 33, 36], ["uranium", "CHEMICAL", 133, 140], ["ADP", "CHEMICAL", 33, 36], ["coal", "CHEMICAL", 102, 106], ["uranium", "CHEMICAL", 133, 140], ["ADP", "SIMPLE_CHEMICAL", 33, 36], ["uranium", "SIMPLE_CHEMICAL", 133, 140], ["the achieved ADP fossil", "PROBLEM", 20, 43], ["non-renewable resources", "TREATMENT", 65, 88], ["the gasification step", "TREATMENT", 157, 178], ["uranium reserves", "OBSERVATION", 133, 149]]], ["Nitrogen and oxygen production are the key contributions to FAETP, since they promote freshwater contamination with chromium and zinc (+II), while TETP is explained by the release of mercury (+II) and NO x during the syngas cleaning step (Martinez-Sanchez et al., 2017) .", [["Nitrogen", "CHEMICAL", 0, 8], ["oxygen", "CHEMICAL", 13, 19], ["FAETP", "CHEMICAL", 60, 65], ["chromium", "CHEMICAL", 116, 124], ["zinc", "CHEMICAL", 129, 133], ["TETP", "CHEMICAL", 147, 151], ["mercury", "CHEMICAL", 183, 190], ["NO", "CHEMICAL", 201, 203], ["Nitrogen", "CHEMICAL", 0, 8], ["oxygen", "CHEMICAL", 13, 19], ["FAETP", "CHEMICAL", 60, 65], ["chromium", "CHEMICAL", 116, 124], ["zinc (+II)", "CHEMICAL", 129, 139], ["TETP", "CHEMICAL", 147, 151], ["mercury (+II)", "CHEMICAL", 183, 196], ["NO", "CHEMICAL", 201, 203], ["Nitrogen", "SIMPLE_CHEMICAL", 0, 8], ["oxygen", "SIMPLE_CHEMICAL", 13, 19], ["FAETP", "SIMPLE_CHEMICAL", 60, 65], ["chromium", "SIMPLE_CHEMICAL", 116, 124], ["zinc", "SIMPLE_CHEMICAL", 129, 133], ["+II", "SIMPLE_CHEMICAL", 135, 138], ["TETP", "SIMPLE_CHEMICAL", 147, 151], ["mercury", "SIMPLE_CHEMICAL", 183, 190], ["+II", "SIMPLE_CHEMICAL", 192, 195], ["NO x", "SIMPLE_CHEMICAL", 201, 205], ["Nitrogen", "TREATMENT", 0, 8], ["oxygen production", "TREATMENT", 13, 30], ["oxygen production", "OBSERVATION", 13, 30]]], ["Regarding regular gasification, syngas cleaning is the more obvious contribution, once this step lowers SO 2 and nitrogen (enhancing AP and EP, respectively) and redeems HF (contributing to MAETP and HTP) (Ramos et al., 2018c) .", [["SO 2 and nitrogen", "CHEMICAL", 104, 121], ["HF", "DISEASE", 170, 172], ["SO 2", "CHEMICAL", 104, 108], ["nitrogen", "CHEMICAL", 113, 121], ["SO 2", "SIMPLE_CHEMICAL", 104, 108], ["nitrogen", "SIMPLE_CHEMICAL", 113, 121], ["syngas cleaning", "TREATMENT", 32, 47], ["nitrogen (enhancing AP and EP", "TREATMENT", 113, 142], ["HF", "PROBLEM", 170, 172], ["gasification", "OBSERVATION", 18, 30]]], ["Regarding ADP elements and POCP, the impacts are nearly in the same order of magnitude as those for the other techniques.Environmental impactsIncineration and two-stage plasma gasification alleviate the environmental burdens associated with the resources required by thermal conversions.", [["plasma", "ANATOMY", 169, 175], ["ADP", "CHEMICAL", 10, 13], ["ADP", "CHEMICAL", 10, 13], ["ADP", "SIMPLE_CHEMICAL", 10, 13], ["POCP", "SIMPLE_CHEMICAL", 27, 31], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["ADP elements", "DNA", 10, 22], ["Incineration", "TREATMENT", 142, 154], ["two-stage plasma gasification", "PROBLEM", 159, 188], ["the environmental burdens", "PROBLEM", 199, 224], ["stage plasma", "OBSERVATION_MODIFIER", 163, 175], ["gasification", "OBSERVATION", 176, 188]]], ["Nevertheless, while two-stage plasma gasification depicts high performance for ODP and TETP, incineration shows a more sustainable profile for categories such as GWP, ADP, FAETP, TETP and POCP.", [["plasma", "ANATOMY", 30, 36], ["ADP", "CHEMICAL", 167, 170], ["FAETP", "CHEMICAL", 172, 177], ["TETP", "CHEMICAL", 179, 183], ["POCP", "CHEMICAL", 188, 192], ["GWP", "CHEMICAL", 162, 165], ["ADP", "CHEMICAL", 167, 170], ["FAETP", "CHEMICAL", 172, 177], ["TETP", "CHEMICAL", 179, 183], ["POCP", "CHEMICAL", 188, 192], ["plasma", "ORGANISM_SUBSTANCE", 30, 36], ["TETP", "SIMPLE_CHEMICAL", 87, 91], ["GWP", "SIMPLE_CHEMICAL", 162, 165], ["ADP", "SIMPLE_CHEMICAL", 167, 170], ["FAETP", "SIMPLE_CHEMICAL", 172, 177], ["TETP", "SIMPLE_CHEMICAL", 179, 183], ["POCP", "SIMPLE_CHEMICAL", 188, 192], ["two-stage plasma gasification", "PROBLEM", 20, 49], ["ODP", "TEST", 79, 82], ["GWP", "TEST", 162, 165], ["ADP", "TEST", 167, 170], ["FAETP", "TEST", 172, 177], ["POCP", "TREATMENT", 188, 192]]], ["Detailed information about the hazard emissions may be found in Supplementary Material.Environmental impactsThe relative impacts associated with each WtE technique are shown in Fig. 4 .Environmental impactsRegarding GWP, incineration provides higher avoided emissions of CO 2 and CH 4 due to landfill, when compared to the total avoidances from gasification and plasma steps in two-stage plasma gasification.", [["plasma", "ANATOMY", 362, 368], ["plasma", "ANATOMY", 388, 394], ["GWP", "CHEMICAL", 216, 219], ["CO 2", "CHEMICAL", 271, 275], ["CH 4", "CHEMICAL", 280, 284], ["GWP", "SIMPLE_CHEMICAL", 216, 219], ["plasma", "ORGANISM_SUBSTANCE", 362, 368], ["plasma", "ORGANISM_SUBSTANCE", 388, 394], ["the hazard emissions", "PROBLEM", 27, 47], ["each WtE technique", "TREATMENT", 145, 163], ["plasma steps", "TEST", 362, 374], ["two-stage plasma gasification", "PROBLEM", 378, 407], ["impacts", "OBSERVATION_MODIFIER", 121, 128], ["plasma gasification", "OBSERVATION", 388, 407]]], ["In both cases, the reintroduction of the generated electricity in the system also aids in lowering the consumption of fossil fuels, reducing CO 2 emissions.", [["CO 2", "CHEMICAL", 141, 145], ["fossil fuels", "OBSERVATION", 118, 130]]], ["Published studies report higher GWP impacts for similar assessments (Evangelisti et al., 2015b) , the differences being attributed to biogenic CO 2 (Evangelisti et al., 2015a) .", [["CO 2", "CHEMICAL", 143, 147], ["Published studies", "TEST", 0, 17], ["similar assessments", "TEST", 48, 67]]], ["Concerning ADP fossil , the ratios are similar to GWP mainly because major savings in non-renewable sources are achieved.", [["ADP", "CHEMICAL", 11, 14], ["ADP", "CHEMICAL", 11, 14], ["ADP", "SIMPLE_CHEMICAL", 11, 14], ["ADP fossil", "TEST", 11, 21], ["the ratios", "TEST", 24, 34]]], ["Both the landfill process and the electricity production account for the recovery of 2000 MJ per functional unit in incineration.", [["landfill process", "OBSERVATION", 9, 25]]], ["This trend has also been reported by other authors although with lower efficiencies (Liamsanguan and Gheewala, 2008) .", [["lower efficiencies", "PROBLEM", 65, 83]]], ["In two-stage plasma gasification, electricity production is the major contributor to the overall results as seen in (Evangelisti et al., 2015b) , 382 MJ being produced per functional unit.", [["plasma", "ANATOMY", 13, 19], ["plasma", "ORGANISM_SUBSTANCE", 13, 19], ["two-stage plasma gasification", "PROBLEM", 3, 32], ["-stage", "OBSERVATION_MODIFIER", 6, 12], ["plasma gasification", "OBSERVATION", 13, 32]]], ["ADP elements generates a 65% contribution from incineration and only 20% from plasma gasification.", [["plasma", "ANATOMY", 78, 84], ["ADP", "CHEMICAL", 0, 3], ["ADP", "CHEMICAL", 0, 3], ["ADP", "SIMPLE_CHEMICAL", 0, 3], ["plasma", "ORGANISM_SUBSTANCE", 78, 84], ["ADP elements", "DNA", 0, 12], ["ADP elements", "TEST", 0, 12], ["plasma gasification", "TEST", 78, 97]]], ["Incineration produces savings in resources such as copper, gold, lead and molibdenum due to the electricity production (Passarini et al., 2014) , while plasma gasification results in the saving of mineral salts such as sodium chloride.", [["plasma", "ANATOMY", 152, 158], ["copper", "CHEMICAL", 51, 57], ["gold", "CHEMICAL", 59, 63], ["molibdenum", "CHEMICAL", 74, 84], ["mineral salts", "CHEMICAL", 197, 210], ["sodium chloride", "CHEMICAL", 219, 234], ["copper", "CHEMICAL", 51, 57], ["sodium chloride", "CHEMICAL", 219, 234], ["copper", "SIMPLE_CHEMICAL", 51, 57], ["gold", "SIMPLE_CHEMICAL", 59, 63], ["molibdenum", "SIMPLE_CHEMICAL", 74, 84], ["plasma", "ORGANISM_SUBSTANCE", 152, 158], ["mineral salts", "SIMPLE_CHEMICAL", 197, 210], ["sodium chloride", "SIMPLE_CHEMICAL", 219, 234], ["gold, lead and molibdenum", "PROBLEM", 59, 84], ["plasma gasification", "TEST", 152, 171], ["mineral salts", "TREATMENT", 197, 210], ["sodium chloride", "TREATMENT", 219, 234]]], ["FAETP shows 80% contribution from incineration and roughly 20% share from plasma.", [["plasma", "ANATOMY", 74, 80], ["FAETP", "CHEMICAL", 0, 5], ["FAETP", "SIMPLE_CHEMICAL", 0, 5], ["plasma", "ORGANISM_SUBSTANCE", 74, 80], ["FAETP", "PROTEIN", 0, 5], ["FAETP", "TEST", 0, 5], ["80%", "OBSERVATION_MODIFIER", 12, 15]]], ["This is attributed to the avoided emission of heavy metals into freshwater and air as a result of landfill process in incineration and plasma stage in plasma gasification.", [["plasma", "ANATOMY", 135, 141], ["plasma", "ANATOMY", 151, 157], ["plasma", "ORGANISM_SUBSTANCE", 135, 141], ["plasma", "ORGANISM_SUBSTANCE", 151, 157], ["landfill process", "PROBLEM", 98, 114], ["plasma stage in plasma gasification", "PROBLEM", 135, 170], ["air", "OBSERVATION", 79, 82], ["landfill process", "OBSERVATION", 98, 114], ["plasma gasification", "OBSERVATION", 151, 170]]], ["Both incineration and two-stage plasma gasification depict enhanced results when compared to literature ( (Evangelisti et al., 2015a; Toniolo et al., 2014) , respectively).", [["plasma", "ANATOMY", 32, 38], ["plasma", "ORGANISM_SUBSTANCE", 32, 38], ["incineration", "OBSERVATION", 5, 17]]], ["Referring to TETP, a contribution of approximately 60% from incineration and nearly 30% from plasma gasification is seen.", [["plasma", "ANATOMY", 93, 99], ["plasma", "ORGANISM_SUBSTANCE", 93, 99], ["TETP", "PROTEIN", 13, 17], ["plasma gasification", "TEST", 93, 112], ["plasma gasification", "OBSERVATION", 93, 112]]], ["Regarding incineration, the avoided heavy metals in agricultural soil is the most featured impact, altough literature reports inferior results (Toniolo et al., 2014) .", [["metals", "CHEMICAL", 42, 48], ["most featured", "OBSERVATION_MODIFIER", 77, 90]]], ["Besides agricultural soil, major environmental savings concerning the emission of heavy metals are also achieved by the two-stage plasma process.", [["plasma", "ANATOMY", 130, 136], ["plasma", "ORGANISM_SUBSTANCE", 130, 136], ["heavy metals", "PROBLEM", 82, 94], ["agricultural soil", "OBSERVATION", 8, 25], ["heavy metals", "OBSERVATION", 82, 94]]], ["In the case of MAETP, the most prevented hazard is the emission of inorganic substances such as HF, both in incineration and plasma gasification, due to electricity production and flue gas treatment, corroborated by (Passarini et al., 2014) .", [["plasma", "ANATOMY", 125, 131], ["MAETP", "CHEMICAL", 15, 20], ["MAETP", "SIMPLE_CHEMICAL", 15, 20], ["inorganic substances", "SIMPLE_CHEMICAL", 67, 87], ["HF", "SIMPLE_CHEMICAL", 96, 98], ["plasma", "ORGANISM_SUBSTANCE", 125, 131], ["inorganic substances", "PROBLEM", 67, 87], ["HF", "PROBLEM", 96, 98], ["plasma gasification", "TREATMENT", 125, 144], ["electricity production", "PROBLEM", 153, 175], ["flue gas treatment", "TREATMENT", 180, 198], ["inorganic substances", "OBSERVATION", 67, 87]]], ["Incineration results for MAETP are superior to those reported elsewhere (Toniolo et al., 2014) .", [["MAETP", "SIMPLE_CHEMICAL", 25, 30], ["MAETP", "PROTEIN", 25, 30], ["MAETP", "PROBLEM", 25, 30]]], ["A. Ramos and A. Rouboa Environmental Impact Assessment Review 85 (2020) 106469 ODP category credits are due to two-stage plasma gasification, regular gasification being responsible for environmental burdens, while incineration does not play a significant role.", [["plasma", "ANATOMY", 121, 127], ["plasma", "ORGANISM_SUBSTANCE", 121, 127], ["two-stage plasma gasification", "PROBLEM", 111, 140], ["regular gasification", "PROBLEM", 142, 162], ["environmental burdens", "PROBLEM", 185, 206], ["gasification", "OBSERVATION", 150, 162]]], ["Dichlorotetrafluoromethane is the chief emission accounting for almost 100% of the total share of environmental credits, the plasma converter proficiency and the electricity production justifying the performance of this technique.Environmental impactsRegarding plasma gasification, EP and AP denote high efficiency in the plasma converter, severely decreasing the emission of substances with surfactant and acid behaviour, respectively.", [["plasma", "ANATOMY", 125, 131], ["plasma", "ANATOMY", 261, 267], ["plasma", "ANATOMY", 322, 328], ["Dichlorotetrafluoromethane", "CHEMICAL", 0, 26], ["Dichlorotetrafluoromethane", "CHEMICAL", 0, 26], ["Dichlorotetrafluoromethane", "SIMPLE_CHEMICAL", 0, 26], ["plasma", "ORGANISM_SUBSTANCE", 125, 131], ["plasma", "ORGANISM_SUBSTANCE", 261, 267], ["AP", "SIMPLE_CHEMICAL", 289, 291], ["plasma", "ORGANISM_SUBSTANCE", 322, 328], ["surfactant", "SIMPLE_CHEMICAL", 392, 402], ["Dichlorotetrafluoromethane", "TREATMENT", 0, 26], ["the plasma converter proficiency", "PROBLEM", 121, 153], ["this technique", "TREATMENT", 215, 229], ["plasma gasification", "TEST", 261, 280], ["EP", "TEST", 282, 284], ["high efficiency", "PROBLEM", 299, 314], ["surfactant", "TREATMENT", 392, 402], ["acid behaviour", "PROBLEM", 407, 421], ["high efficiency", "OBSERVATION", 299, 314], ["severely", "OBSERVATION_MODIFIER", 340, 348], ["decreasing", "OBSERVATION_MODIFIER", 349, 359]]], ["These are improved when compared to the literature, variances in MSW composition explaining the differences (Evangelisti et al., 2015a; Evangelisti et al., 2015b) .", [["improved", "OBSERVATION_MODIFIER", 10, 18]]], ["Incineration reduces the emission of NO x , P 4 and NH 3 into the soil contributing to AP and EP (similar to (Al-Salem et al., 2014; Gunamantha and Sarto, 2012) ), attributed to the electricity generated, also seen in (Lou et al., 2015) .", [["NO", "CHEMICAL", 37, 39], ["P 4 and NH 3", "CHEMICAL", 44, 56], ["NO x", "CHEMICAL", 37, 41], ["P", "CHEMICAL", 44, 45], ["NH 3", "CHEMICAL", 52, 56], ["Al", "CHEMICAL", 110, 112], ["NO x", "SIMPLE_CHEMICAL", 37, 41], ["NH 3", "GENE_OR_GENE_PRODUCT", 52, 56], ["AP and EP", "TEST", 87, 96]]], ["HTP results for incineration rely on the abatement of emissions such as organic and inorganic compounds and heavy metals into the atmosphere as well as organic substances into freshwater (Ramos et al., 2018b) .", [["inorganic compounds", "SIMPLE_CHEMICAL", 84, 103], ["incineration", "TREATMENT", 16, 28], ["organic and inorganic compounds", "PROBLEM", 72, 103]]], ["This is due to flue gas treatment and landfill processes (Chen and Christensen, 2010) , whilst for plasma gasification the plasma converter is the major step alleviating the air emission of noxious compounds (Evangelisti et al., 2015b) .Environmental impactsInorganic (CO, NO X , SO 2 ) and organic (CH 4 ) emissions to the atmosphere are the main contributors to POCP during incineration, while two-stage plasma gasification prevents NO x and SO 2 due to the syngas cleaning step.", [["plasma", "ANATOMY", 99, 105], ["plasma", "ANATOMY", 123, 129], ["plasma", "ANATOMY", 406, 412], ["Inorganic", "CHEMICAL", 258, 267], ["NO", "CHEMICAL", 273, 275], ["CH 4", "CHEMICAL", 300, 304], ["POCP", "CHEMICAL", 364, 368], ["NO", "CHEMICAL", 435, 437], ["CO", "CHEMICAL", 269, 271], ["NO X", "CHEMICAL", 273, 277], ["SO 2", "CHEMICAL", 280, 284], ["CH 4", "CHEMICAL", 300, 304], ["NO", "CHEMICAL", 435, 437], ["SO 2", "CHEMICAL", 444, 448], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["plasma", "ORGANISM_SUBSTANCE", 123, 129], ["Inorganic", "SIMPLE_CHEMICAL", 258, 267], ["CO", "SIMPLE_CHEMICAL", 269, 271], ["NO X", "SIMPLE_CHEMICAL", 273, 277], ["POCP", "SIMPLE_CHEMICAL", 364, 368], ["plasma", "ORGANISM_SUBSTANCE", 406, 412], ["NO x", "SIMPLE_CHEMICAL", 435, 439], ["flue gas treatment", "TREATMENT", 15, 33], ["plasma gasification the plasma converter", "TREATMENT", 99, 139], ["organic (CH 4 ) emissions", "TREATMENT", 291, 316], ["two-stage plasma gasification", "TREATMENT", 396, 425], ["due to", "UNCERTAINTY", 8, 14], ["flue gas", "OBSERVATION", 15, 23], ["air emission", "OBSERVATION", 174, 186], ["NO", "UNCERTAINTY", 435, 437]]], ["Slightly improved results for this technique have been published (Evangelisti et al., 2015a; Evangelisti et al., 2015b) , given the inclusion of a by-product within the boundaries, constituting an extra avoided burden.", [["this technique", "TREATMENT", 30, 44], ["improved", "OBSERVATION_MODIFIER", 9, 17]]], ["Further discussion about the environmental results, a thorough analysis of the impact categories as well as sensitivity analysis for each may be found in (Ramos et al., 2018b; Ramos et al., 2018c; Ramos et al., 2019b) .Environmental performanceFig.", [["a thorough analysis", "TEST", 52, 71], ["sensitivity analysis", "TEST", 108, 128]]], ["As an overall observation, it may be said that material resources, energy resources and emissions to fresh water are the major outcomes from the assessed WtE techniques, especially from incineration and two-stage plasma gasification.Environmental performanceAs mentioned previously, regular gasification globally depicts a hazardous environmental profile (saving more than 240 t of emissions per tonne of treated waste), only minor credits being shown related to the emissions to industrial soil (saving nearly 1 kg of emissions per functional unit).", [["plasma", "ANATOMY", 213, 219], ["plasma", "ORGANISM_SUBSTANCE", 213, 219], ["an overall observation", "TEST", 3, 25], ["two-stage plasma gasification", "PROBLEM", 203, 232], ["plasma gasification", "OBSERVATION", 213, 232]]], ["Both incineration and plasma gasification constitute more sustainable options, saving up more than 500 t of resources and emissions per functional unit.", [["plasma", "ANATOMY", 22, 28], ["plasma", "ORGANISM_SUBSTANCE", 22, 28], ["Both incineration", "TREATMENT", 0, 17], ["plasma gasification", "TREATMENT", 22, 41]]], ["Incineration saves 295 t of material resources and 291 t of emissions to fresh water, while two-stage plasma gasification saves up to 264 t of energy resources, 130 t of material resources and similar amount of emissions to fresh water as main flows.Environmental performanceEvangelisti et al. (Evangelisti et al., 2015b) also report on the overall excellent performance of a two-stage plasma gasification treatment for MSW, considered an improved environmental solution when compared to other available technologies.", [["plasma", "ORGANISM_SUBSTANCE", 102, 108], ["plasma", "ORGANISM_SUBSTANCE", 386, 392], ["stage plasma gasification saves", "PROBLEM", 96, 127], ["material resources", "TREATMENT", 170, 188], ["a two-stage plasma gasification treatment", "TREATMENT", 374, 415]]], ["The authors argued that the electricity produced in a two-stage plasma gasification facility is generated from the combustion of a high-quality syngas which affords a high temperature gas which then supplies a gas engine, whereas the flue gas resulting from the combustion process in incineration generates steam, which is afterwards employed in a steam turbine to produce electricity, with lower levels of efficiency (Rutberg et al., 2011) .", [["plasma", "ORGANISM_SUBSTANCE", 64, 70], ["a high-quality syngas", "PROBLEM", 129, 150], ["a high temperature gas", "PROBLEM", 165, 187], ["a gas engine", "PROBLEM", 208, 220], ["the flue gas", "PROBLEM", 230, 242], ["a steam turbine", "TREATMENT", 346, 361], ["gas engine", "OBSERVATION", 210, 220], ["combustion process", "OBSERVATION", 262, 280]]], ["Another possible reason accounting for the upgraded environmental performance of two-stage plasma gasification may be the lower air pollution residues removed from the system, when compared to other WtE techniques (Byun et al., 2010) .", [["plasma", "ANATOMY", 91, 97], ["plasma", "ORGANISM_SUBSTANCE", 91, 97], ["two-stage plasma gasification", "TREATMENT", 81, 110], ["the lower air pollution residues", "PROBLEM", 118, 150], ["lower", "OBSERVATION_MODIFIER", 122, 127], ["air", "OBSERVATION", 128, 131], ["pollution residues", "OBSERVATION", 132, 150]]], ["Moreover, plasma gasification occurs in a sub-stoichiometric oxygen atmosphere resulting in lower CO 2 emissions than for incineration (Zaman, 2013) .", [["plasma", "ANATOMY", 10, 16], ["oxygen", "CHEMICAL", 61, 67], ["oxygen", "CHEMICAL", 61, 67], ["CO 2", "CHEMICAL", 98, 102], ["plasma", "ORGANISM_SUBSTANCE", 10, 16], ["oxygen", "SIMPLE_CHEMICAL", 61, 67], ["plasma gasification", "PROBLEM", 10, 29], ["a sub-stoichiometric oxygen atmosphere", "TREATMENT", 40, 78], ["lower CO 2 emissions", "PROBLEM", 92, 112], ["oxygen atmosphere", "OBSERVATION", 61, 78]]], ["This oxygen-starved situation promotes lower gas yields than incineration, which maximizes the cleaning process (Helsen and Bosmans, 2010) .", [["oxygen", "CHEMICAL", 5, 11], ["oxygen", "CHEMICAL", 5, 11], ["oxygen", "SIMPLE_CHEMICAL", 5, 11], ["This oxygen", "TREATMENT", 0, 11]]], ["Furthermore, less off-gas emissions and even less landfill requirements result from lower levels of gas produced.Waste generated vs electrical demandOur current understanding of the possible waste management scenarios available at urban, regional or even national scales has increased social awareness of the importance of renewable energy technologies (W\u00fcstenhagen et al., 2007) .", [["gas emissions", "TEST", 22, 35], ["waste management", "TREATMENT", 191, 207], ["less", "OBSERVATION_MODIFIER", 13, 17], ["gas", "OBSERVATION", 100, 103]]], ["A compilation of surveys relating to the social acceptance of low carbon energy and associated infrastructures was reported by Batel et al. (Batel et al., 2013) , noting the importance of public responses towards the development of the relationship between the communities and the new treatment facilities, their operation and the decision-making process, as discussed in (Harris and Spickett, 2011; Webler et al., 1995) .", [["carbon", "CHEMICAL", 66, 72], ["low carbon energy", "PROBLEM", 62, 79], ["their operation", "TREATMENT", 307, 322]]], ["In order to attract the interest and acceptance of large audiences, apart from the environmental arguments, even more convincing facts must be used, a worthwhile approach relating the amount of energy used and the yield of waste produced per capita.", [["a worthwhile approach", "TREATMENT", 149, 170], ["large", "OBSERVATION_MODIFIER", 51, 56], ["audiences", "OBSERVATION", 57, 66]]], ["A. Ramos and A. Rouboa Environmental Impact Assessment Review 85 (2020) 106469 Considering the average yield of waste and electric consumption per capita, it is possible to estimate the share of energy potentially produced from the waste generated per person.", [["person", "SPECIES", 252, 258]]], ["As there are few LCIs available for MSW samples and for the assessed techniques, an extrapolation of the electricity produced from the MSW amount generated in several parts of the world was conducted using the characterization in Table 2 .", [["MSW samples", "TEST", 36, 47], ["the assessed techniques", "TEST", 56, 79], ["few", "OBSERVATION_MODIFIER", 13, 16], ["LCIs", "OBSERVATION", 17, 21]]], ["This is a feasible approach as the MSW sample resembles the average global composition (Hoornweg and Bhada-Tata, 2012) .", [["the MSW sample", "TEST", 31, 45]]], ["Table 4 depicts the results achieved applying the WtE electrical efficiencies (further details may be found in Supplementary Material) with respect to different geographical regions.", [["the WtE electrical efficiencies", "TREATMENT", 46, 77]]], ["Table 4 suggests that, assuming no losses in conversion efficiency and no significant changes in MSW composition, if the MSW generated by each person was thermally converted into energy and afterwards used as electricity, a high proportion of the daily electrical consumption per capita would be achieved.", [["person", "SPECIES", 143, 149], ["losses in conversion efficiency", "PROBLEM", 35, 66], ["significant changes in MSW composition", "PROBLEM", 74, 112], ["no", "UNCERTAINTY", 71, 73], ["significant", "OBSERVATION_MODIFIER", 74, 85], ["changes", "OBSERVATION", 86, 93]]], ["Depending on the world region and its \"urban metabolism\", the thermal treatment of the daily waste produced by a citizen could afford 4% to 41% of the electricity consumed daily by that same citizen.", [["the thermal treatment", "TREATMENT", 58, 79], ["the daily waste", "TREATMENT", 83, 98]]], ["In fact, two-stage plasma gasification enables higher electricity production, followed by the regular gasification and incineration.", [["plasma", "ANATOMY", 19, 25], ["plasma", "ORGANISM_SUBSTANCE", 19, 25], ["two-stage plasma gasification", "PROBLEM", 9, 38], ["two", "OBSERVATION_MODIFIER", 9, 12], ["-stage", "OBSERVATION_MODIFIER", 12, 18], ["plasma gasification", "OBSERVATION", 19, 38], ["higher", "OBSERVATION_MODIFIER", 47, 53], ["electricity production", "OBSERVATION", 54, 76], ["gasification", "OBSERVATION", 102, 114]]], ["This is in line with the expected based on the efficiency comparison depicted in Supplementary Material.Waste generated vs electrical demandThe highest contribution to the electricity replacement is seen for Sub-Saharan Africa, where despite the fact that both the electricity consumption and the waste production are reduced compared to all evaluated geographic regions, the ratio between these two parameters is the lowest.", [["the electricity replacement", "TREATMENT", 168, 195], ["the electricity consumption", "TREATMENT", 261, 288], ["the ratio", "TEST", 372, 381], ["line", "OBSERVATION_MODIFIER", 11, 15], ["highest", "OBSERVATION_MODIFIER", 144, 151], ["electricity replacement", "OBSERVATION", 172, 195], ["waste production", "OBSERVATION", 297, 313], ["reduced", "OBSERVATION_MODIFIER", 318, 325]]], ["The Middle East and North Africa regions are closest to the world average in terms of waste generation and electrical demand, a contribution of 6% to 12% being achieved for the electricity production.", [["Middle", "ANATOMY_MODIFIER", 4, 10], ["East", "ANATOMY_MODIFIER", 11, 15], ["North", "ANATOMY_MODIFIER", 20, 25], ["Africa", "ANATOMY_MODIFIER", 26, 32], ["waste generation", "OBSERVATION", 86, 102]]], ["Fig. 6 presents the relation between the electricity use and the waste production for the same regions.Waste generated vs electrical demandSocio-economic correlations may be potentially infered for the diverse world areas, regarding population habits and regional trends.", [["the waste production", "TREATMENT", 61, 81], ["electrical demandSocio", "TREATMENT", 122, 144]]], ["Therefore, the relation between the electricity consumed and the waste produced may be suggested as a possible approach for evaluating the level of development of a country/community/society.", [["the electricity", "TREATMENT", 32, 47]]], ["Higher income countries are seen to produce more waste and to require more energy on a daily basis, which is consistent with a society with superior economies and standards of living, while for lower income countries the electrical requirements are more easily achieved and the level of waste production is significantly lower (Hoornweg and Bhada-Tata, 2012) .", [["consistent with", "UNCERTAINTY", 109, 124]]], ["As most of the nowadays' commodities depend on electric power, the social welfare is herein implied and an indicator such as the ratio of electricity consumed per waste generated might serve as a basis for strategic development of waste management options or electrical grid planning. -Sanchez et al., 2017) , once the buoyancy of some related factors such as currency valorisation, bioenergy market share and inflation rate, dramatically affect the electricity production and the final revenue (Leme et al., 2014; Li et al., 2016) .", [["waste management options", "TREATMENT", 231, 255], ["electrical grid planning", "TREATMENT", 259, 283], ["some related factors", "PROBLEM", 331, 351], ["bioenergy market", "TREATMENT", 383, 399], ["inflation rate", "TEST", 410, 424]]], ["As may be seen from Table 5 , both incineration and plasma gasification present positive net results, meaning that the treatment of the urban residues leads to profits.", [["plasma", "ANATOMY", 52, 58], ["plasma", "ORGANISM_SUBSTANCE", 52, 58], ["plasma gasification", "TEST", 52, 71], ["the urban residues", "TREATMENT", 132, 150]]], ["In fact, although the waste management costs are significantly higher in the case of incineration (representing more than 58% of the total costs) when compared to regular gasification, the later shows maintenance costs 7.5 times higher (accounting for 90% of the total costs) than the previous.", [["the waste management costs", "TREATMENT", 18, 44], ["significantly", "OBSERVATION_MODIFIER", 49, 62], ["higher", "OBSERVATION_MODIFIER", 63, 69], ["gasification", "OBSERVATION", 171, 183]]], ["Literature on waste management LCC has previously shown that operation and management costs are usually accounted as one of the chief costs in the process (Leme et al., 2014) .", [["waste management", "TREATMENT", 14, 30], ["operation", "TREATMENT", 61, 70], ["management costs", "TREATMENT", 75, 91]]], ["The economy of scale is also a factor to take into account when performing the LCC of a defined WtE technique, improved economic performance being seen for incinerators serving wider populations (Leme et al., 2014) .", [["a defined WtE technique", "TREATMENT", 86, 109]]], ["Also, both regular and plasma gasification present high revenues when compared to incineration.", [["plasma", "ANATOMY", 23, 29], ["plasma", "ORGANISM_SUBSTANCE", 23, 29], ["high revenues", "OBSERVATION", 51, 64]]], ["Nevertheless, the cost differences among these two options reveal major profits for two-stage plasma gasification.MartinezDue to the scarcity of LCC assessments for waste management techniques, as well as to the distinct scopes, functional units and system boundaries reported, only approximate comparisons of the results achieved in this study to literature data are accomplished.", [["plasma", "ANATOMY", 94, 100], ["plasma", "ORGANISM_SUBSTANCE", 94, 100], ["two-stage plasma gasification", "PROBLEM", 84, 113], ["MartinezDue", "TREATMENT", 114, 125], ["LCC assessments", "TEST", 145, 160], ["waste management techniques", "TREATMENT", 165, 192], ["this study", "TEST", 334, 344], ["plasma gasification", "OBSERVATION", 94, 113], ["LCC", "OBSERVATION", 145, 148]]], ["Nevertheless, taking into account the respective currency exchange, the costs herein presented for plasma gasification are lower than reported for a similar plant scale, and the revenues achieved are higher than expected Ducharme, 2010) .", [["plasma", "ANATOMY", 99, 105], ["plasma", "ORGANISM_SUBSTANCE", 99, 105], ["plasma gasification", "PROBLEM", 99, 118], ["a similar plant scale", "TREATMENT", 147, 168]]], ["Plasma gasification has been previously reported as a promising WtE with the possibility to maximise its economic benefits if by-products such as the vitrified slag are also commercialized (Danthurebandara et al., 2015) .", [["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["WtE", "SIMPLE_CHEMICAL", 64, 67], ["Plasma gasification", "TEST", 0, 19], ["the vitrified slag", "TREATMENT", 146, 164]]], ["As far as regular gasification is concerned, although the net result in the present study is negative (meaning no profit) the revenues afforded are 3.5 times higher than reported elsewhere (Cardoso et al., 2019) .", [["the present study", "TEST", 72, 89], ["gasification", "OBSERVATION", 18, 30], ["negative", "OBSERVATION", 93, 101]]], ["This means that if costs are optimized (especially the operation and management expenses) and the whole system is suitably managed, regular gasfication may potentially become an economically feasible treatment technique.", [["the operation", "TREATMENT", 51, 64], ["management expenses", "TREATMENT", 69, 88], ["an economically feasible treatment technique", "TREATMENT", 175, 219]]], ["Regarding incineration, the net results are positive which means it is profitable, although in a lesser extension than plasma gasification.", [["plasma", "ANATOMY", 119, 125], ["plasma", "ORGANISM_SUBSTANCE", 119, 125], ["the net results", "TEST", 24, 39], ["a lesser extension than plasma gasification", "PROBLEM", 95, 138], ["positive", "OBSERVATION", 44, 52], ["profitable", "OBSERVATION_MODIFIER", 71, 81], ["lesser", "OBSERVATION_MODIFIER", 97, 103]]], ["Nevertheless, when compared to other waste management techniques more widely used in developing economies, incineration within a properly designed integrated system is suggested as an advanced option assuring enhanced results (Menikpura et al., 2016) .MartinezIn a broader sense, considering also other social aspects that are difficult to include in LCC such as the cost of human health damage or community discomfort, the herein presented approach should be mainly viewed as a comparative tool.", [["LCC", "CANCER", 351, 354], ["human", "ORGANISM", 375, 380], ["human", "SPECIES", 375, 380], ["human", "SPECIES", 375, 380], ["other waste management techniques", "TREATMENT", 31, 64], ["MartinezIn", "TREATMENT", 252, 262], ["community discomfort", "PROBLEM", 398, 418]]], ["In other words, the LCC conducted in this study should serve only as an indicator of damage costs and not as a definitive estimate.ConclusionsThe LCA of one tonne of MSW was conducted for incineration, regular gasification and two-stage plasma gasification.", [["plasma", "ANATOMY", 237, 243], ["plasma", "ORGANISM_SUBSTANCE", 237, 243], ["this study", "TEST", 37, 47], ["damage costs", "PROBLEM", 85, 97], ["incineration", "PROBLEM", 188, 200], ["regular gasification", "PROBLEM", 202, 222], ["two-stage plasma gasification", "PROBLEM", 227, 256], ["LCA", "OBSERVATION_MODIFIER", 146, 149], ["gasification", "OBSERVATION", 210, 222], ["plasma gasification", "OBSERVATION", 237, 256]]], ["Regular A. Ramos and A. Rouboa Environmental Impact Assessment Review 85 (2020) 106469 gasification presented environmental burdens for some impact categories, however yielding excellent results for EP, AP, MAETP and HTP.", [["AP", "SIMPLE_CHEMICAL", 203, 205], ["MAETP", "SIMPLE_CHEMICAL", 207, 212], ["some impact categories", "PROBLEM", 136, 158], ["EP", "TEST", 199, 201], ["AP", "TEST", 203, 205], ["HTP", "PROBLEM", 217, 220]]], ["Incineration and two-stage plasma gasification presented negative values for all the impact categories, signifying environmental benefits.", [["plasma", "ANATOMY", 27, 33], ["plasma", "ORGANISM_SUBSTANCE", 27, 33], ["Incineration", "TREATMENT", 0, 12], ["two-stage plasma gasification", "TEST", 17, 46]]], ["This represents an increase in the wellbeing of the exposed populations and a higher degree of sustainability.", [["the exposed populations", "PROBLEM", 48, 71], ["increase", "OBSERVATION_MODIFIER", 19, 27], ["exposed", "OBSERVATION_MODIFIER", 52, 59], ["populations", "OBSERVATION_MODIFIER", 60, 71], ["higher degree", "OBSERVATION_MODIFIER", 78, 91], ["sustainability", "OBSERVATION_MODIFIER", 95, 109]]], ["High contributions were seen for Sub-Saharan Africa and South Asia due to the lower electrical demand, whereas OECD countries were seen to surpass the world average waste production and the electrical requirement per capita.", [["the lower electrical demand", "PROBLEM", 74, 101]]], ["Thus, the renewable energy potentially achieved from the thermal conversion of MSW through the WtE herein studied would enable the reduction of greenhouse gases as well as the fossil fuelsbased energy consumption, enhancing society's life quality.", [["WtE", "CHEMICAL", 95, 98], ["WtE", "SIMPLE_CHEMICAL", 95, 98], ["the thermal conversion of MSW", "TREATMENT", 53, 82], ["greenhouse gases", "TEST", 144, 160]]], ["Plasma gasification depicts an outstanding performance both in the enviornmental assessment as well as in the electricity generation capacity, combining two of the most important aspects for the enforcement of sustainability.ConclusionsAs far as the LCC assessment is concerned, two-stage plasma gasification depicts the best results in terms of revenues, 1 t of MSW delivering a net profit of 69.27 \u20ac.", [["plasma", "ANATOMY", 289, 295], ["Plasma", "ORGANISM_SUBSTANCE", 0, 6], ["plasma", "ORGANISM_SUBSTANCE", 289, 295], ["Plasma gasification", "TEST", 0, 19], ["the enviornmental assessment", "TEST", 63, 91], ["the LCC assessment", "TEST", 246, 264], ["two-stage plasma gasification", "PROBLEM", 279, 308]]], ["Incineration shows significantly lower income, while regular gasification has higher costs than revenues showing a negative net result.", [["significantly", "OBSERVATION_MODIFIER", 19, 32], ["lower", "OBSERVATION_MODIFIER", 33, 38]]], ["This supports plasma gasification as an economically feasible technique for the treatment of urban residues, within the system boundaries utilized in the present study.", [["plasma", "ANATOMY", 14, 20], ["plasma", "ORGANISM_SUBSTANCE", 14, 20], ["plasma gasification", "TREATMENT", 14, 33], ["an economically feasible technique", "TREATMENT", 37, 71], ["urban residues", "TREATMENT", 93, 107], ["the present study", "TEST", 150, 167]]], ["However, these results should not be taken as strict or immutable, as many factors can contribute to reach different values or conclusions, for instance the time value of money.ConclusionsThe current case study provides a critical analisys of the advantages and disadvantages of three different WtE technologies and thus is able to contribute to the decision process at a regional or national level.", [["three different WtE technologies", "TREATMENT", 279, 311]]], ["Sustainability is made a priority and key perspectives (technical, social and environmental) are seen as critical elements that form a base of integrated knowledge in favor of renewable and sustainable energy solutions with direct benefits to the environment and human health.", [["human", "ORGANISM", 263, 268], ["human", "SPECIES", 263, 268], ["human", "SPECIES", 263, 268], ["sustainable energy solutions", "TREATMENT", 190, 218]]], ["In the herein reported case study, two-stage plasma gasification affords significantly important results in these three pillars as well as in the economic perspective, therefore representing an interesting option to possibly replace or complement the utilization of fossil fuels.ConclusionsNonetheless, some limitations may hinder the results of this study.", [["plasma", "ANATOMY", 45, 51], ["plasma", "ORGANISM_SUBSTANCE", 45, 51], ["case study", "TEST", 23, 33], ["two-stage plasma gasification", "PROBLEM", 35, 64], ["fossil fuels", "TREATMENT", 266, 278], ["this study", "TEST", 346, 356], ["fossil fuels", "OBSERVATION", 266, 278]]], ["One is the fact that it is difficult to achieve LCI for different MSW treatment options, especially if they are used in industrial-scale.", [["LCI", "TEST", 48, 51], ["different MSW treatment options", "TREATMENT", 56, 87]]], ["Therefore, some assumptions had to be used such as extrapolating the electricity produced from the MSW generated per capita in several parts of the world using the MSW sample presented in this study, instead of being able to apply the respective MSW characterization for the defined location.", [["this study", "TEST", 188, 198], ["the respective MSW characterization", "TEST", 231, 266]]], ["At a later stage, accounting for a complete inventory of the capital costs (own investment, borrowed capital, depreciation rate, etc.) as well as considering other externality costs will also aid at performing a more accurate life cycle cost for each of the techniques, complementing the sound LCA conclusions.ConclusionsSupplementary data to this article can be found online at https:// doi.org/10.1016/j.eiar.2020.106469.Author statementAna Ramos conceived, designed and performed the experimental work, analyzed the data and wrote the paper.", [["the techniques", "TEST", 254, 268], ["capital", "ANATOMY", 61, 68], ["LCA", "OBSERVATION_MODIFIER", 294, 297]]], ["Abel Rouboa supervised the whole work.Author statementConceptualization: Ana Ramos; Methodology: Ana Ramos; Supervision: Abel Rouboa; Writing-original draft: Ana Ramos.Declaration of Competing InterestThe authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.", [["Ana Ramos", "OBSERVATION", 158, 167]]]], "f55b73cef2236c8d1c54775d5bdfc5d2e6a36d24": [["INTRODUCTIONCardiovascular disease is the highest cause of death worldwide.", [["INTRODUCTIONCardiovascular disease", "DISEASE", 0, 34], ["death", "DISEASE", 59, 64], ["INTRODUCTIONCardiovascular disease", "PROBLEM", 0, 34], ["death", "PROBLEM", 59, 64]]], ["According to the report from world health organization, 17.9 million people died from cardiovascular diseases which accounts approximately 30 % of the whole death on 2016[1].", [["cardiovascular", "ANATOMY", 86, 100], ["cardiovascular diseases", "DISEASE", 86, 109], ["death", "DISEASE", 157, 162], ["people", "ORGANISM", 69, 75], ["cardiovascular", "ANATOMICAL_SYSTEM", 86, 100], ["people", "SPECIES", 69, 75], ["cardiovascular diseases", "PROBLEM", 86, 109], ["cardiovascular", "ANATOMY", 86, 100], ["diseases", "OBSERVATION", 101, 109]]], ["Coronary artery disease (CAD) and peripheral artery disease (PAD) are major components in cardiovascular disease with increased mortality and morbidity so far [2] .INTRODUCTIONRevascularization surgery including bypass grafting is an established treatment modality for CAD and PAD.", [["Coronary artery", "ANATOMY", 0, 15], ["peripheral artery", "ANATOMY", 34, 51], ["cardiovascular", "ANATOMY", 90, 104], ["Coronary artery disease", "DISEASE", 0, 23], ["CAD", "DISEASE", 25, 28], ["peripheral artery disease", "DISEASE", 34, 59], ["PAD", "DISEASE", 61, 64], ["cardiovascular disease", "DISEASE", 90, 112], ["CAD", "DISEASE", 269, 272], ["PAD", "DISEASE", 277, 280], ["Coronary artery", "MULTI-TISSUE_STRUCTURE", 0, 15], ["peripheral artery", "MULTI-TISSUE_STRUCTURE", 34, 51], ["cardiovascular", "ANATOMICAL_SYSTEM", 90, 104], ["Coronary artery disease", "PROBLEM", 0, 23], ["CAD", "PROBLEM", 25, 28], ["peripheral artery disease (PAD)", "PROBLEM", 34, 65], ["cardiovascular disease", "PROBLEM", 90, 112], ["increased mortality", "PROBLEM", 118, 137], ["morbidity", "PROBLEM", 142, 151], [".INTRODUCTIONRevascularization surgery", "TREATMENT", 163, 201], ["bypass grafting", "TREATMENT", 212, 227], ["an established treatment modality", "TREATMENT", 231, 264], ["CAD", "PROBLEM", 269, 272], ["PAD", "PROBLEM", 277, 280], ["artery", "ANATOMY", 9, 15], ["disease", "OBSERVATION", 16, 23], ["CAD", "OBSERVATION", 25, 28], ["peripheral artery", "ANATOMY", 34, 51], ["disease", "OBSERVATION", 52, 59], ["cardiovascular disease", "OBSERVATION", 90, 112], ["increased", "OBSERVATION_MODIFIER", 118, 127], ["bypass grafting", "OBSERVATION", 212, 227]]], ["Considering relatively small size of target arteries, synthetic vascular prostheses made from expanded polytetrafluoroethylene, Dacron and others are not suitable for the revascularization of arteries with small caliber (< 4 mm) because of their poor patency rate even though their feasibility in large-(> 8 mm) or medium-(6 -8 mm) caliber arteries [3] [4] [5] .", [["arteries", "ANATOMY", 44, 52], ["vascular", "ANATOMY", 64, 72], ["arteries", "ANATOMY", 192, 200], ["polytetrafluoroethylene", "CHEMICAL", 103, 126], ["arteries", "MULTI-TISSUE_STRUCTURE", 44, 52], ["vascular", "MULTI-TISSUE_STRUCTURE", 64, 72], ["polytetrafluoroethylene", "MULTI-TISSUE_STRUCTURE", 103, 126], ["arteries", "MULTI-TISSUE_STRUCTURE", 192, 200], ["caliber arteries [3] [4", "SIMPLE_CHEMICAL", 332, 355], ["synthetic vascular prostheses", "TREATMENT", 54, 83], ["expanded polytetrafluoroethylene, Dacron", "TREATMENT", 94, 134], ["the revascularization of arteries", "TREATMENT", 167, 200], ["their poor patency rate", "PROBLEM", 240, 263], ["medium", "TEST", 315, 321], ["small", "OBSERVATION_MODIFIER", 23, 28], ["size", "OBSERVATION_MODIFIER", 29, 33], ["target arteries", "ANATOMY", 37, 52], ["vascular prostheses", "OBSERVATION", 64, 83], ["expanded", "OBSERVATION_MODIFIER", 94, 102], ["polytetrafluoroethylene", "OBSERVATION_MODIFIER", 103, 126], ["Dacron", "OBSERVATION", 128, 134], ["revascularization", "OBSERVATION", 171, 188], ["arteries", "ANATOMY", 192, 200], ["small", "OBSERVATION_MODIFIER", 206, 211], ["caliber", "OBSERVATION_MODIFIER", 212, 219], ["poor", "OBSERVATION_MODIFIER", 246, 250], ["patency", "OBSERVATION", 251, 258], ["large", "OBSERVATION_MODIFIER", 297, 302]]], ["Autologous grafts such as internal mammary arteries, radial arteries or saphenous veins are commonly used for bypass grafting in small caliber arteries instead.", [["grafts", "ANATOMY", 11, 17], ["internal mammary arteries", "ANATOMY", 26, 51], ["radial arteries", "ANATOMY", 53, 68], ["saphenous veins", "ANATOMY", 72, 87], ["small caliber arteries", "ANATOMY", 129, 151], ["grafts", "TISSUE", 11, 17], ["mammary arteries", "MULTI-TISSUE_STRUCTURE", 35, 51], ["radial arteries", "MULTI-TISSUE_STRUCTURE", 53, 68], ["saphenous veins", "MULTI-TISSUE_STRUCTURE", 72, 87], ["caliber arteries", "MULTI-TISSUE_STRUCTURE", 135, 151], ["Autologous grafts", "TREATMENT", 0, 17], ["bypass grafting in small caliber arteries", "TREATMENT", 110, 151], ["grafts", "OBSERVATION", 11, 17], ["internal mammary arteries", "ANATOMY", 26, 51], ["radial arteries", "ANATOMY", 53, 68], ["saphenous veins", "ANATOMY", 72, 87], ["bypass grafting", "OBSERVATION", 110, 125], ["small", "OBSERVATION_MODIFIER", 129, 134], ["caliber", "OBSERVATION_MODIFIER", 135, 142], ["arteries", "ANATOMY", 143, 151]]], ["However, the availability of autologous arterial conduits is rather limited in general.", [["arterial conduits", "ANATOMY", 40, 57], ["arterial conduits", "MULTI-TISSUE_STRUCTURE", 40, 57], ["autologous arterial conduits", "TREATMENT", 29, 57], ["autologous arterial conduits", "OBSERVATION", 29, 57]]], ["Although autologous saphenous vein conduits possess higher availability and flexibility in regard of length and manipulation, it is reported that 20 -45 % of patientsDNA quantificationThe samples were freeze-dried and weighted (N = 5).", [["saphenous vein conduits", "ANATOMY", 20, 43], ["samples", "ANATOMY", 188, 195], ["saphenous vein", "MULTI-TISSUE_STRUCTURE", 20, 34], ["conduits", "MULTI-TISSUE_STRUCTURE", 35, 43], ["patientsDNA", "GENE_OR_GENE_PRODUCT", 158, 169], ["autologous saphenous vein conduits", "TREATMENT", 9, 43], ["patientsDNA quantification", "TEST", 158, 184], ["The samples", "TEST", 184, 195], ["freeze", "TEST", 201, 207], ["autologous", "OBSERVATION", 9, 19], ["saphenous vein", "ANATOMY", 20, 34], ["higher", "OBSERVATION_MODIFIER", 52, 58]]], ["The 20 mg of samples were minced and digested with 20 \u03bcg/mL proteinase K in 50mM of Tris-HCl, 1 % sodium dodecyl sulfate, 100 mM of NaCl, and 25 mM of ethylenediaminetetraacetic acid -2Na solution at 55 \u00b0C for overnight.", [["samples", "ANATOMY", 13, 20], ["K", "CHEMICAL", 71, 72], ["Tris-HCl", "CHEMICAL", 84, 92], ["sodium dodecyl sulfate", "CHEMICAL", 98, 120], ["NaCl", "CHEMICAL", 132, 136], ["ethylenediaminetetraacetic acid -2Na", "CHEMICAL", 151, 187], ["Tris-HCl", "CHEMICAL", 84, 92], ["sodium dodecyl sulfate", "CHEMICAL", 98, 120], ["NaCl", "CHEMICAL", 132, 136], ["ethylenediaminetetraacetic acid -2Na", "CHEMICAL", 151, 187], ["proteinase K", "SIMPLE_CHEMICAL", 60, 72], ["Tris-HCl", "SIMPLE_CHEMICAL", 84, 92], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 98, 120], ["ethylenediaminetetraacetic acid -2Na", "SIMPLE_CHEMICAL", 151, 187], ["Tris", "TREATMENT", 84, 88], ["HCl", "TREATMENT", 89, 92], ["1 % sodium dodecyl sulfate", "TREATMENT", 94, 120], ["NaCl", "TREATMENT", 132, 136], ["ethylenediaminetetraacetic acid -2Na solution", "TREATMENT", 151, 196]]], ["DNA was isolated with a phenol/chloroform/isoamyl alcohol (25:24:1) extraction followed by ethanol precipitation.", [["phenol/chloroform/isoamyl alcohol", "CHEMICAL", 24, 57], ["25:24:1", "CHEMICAL", 59, 66], ["ethanol", "CHEMICAL", 91, 98], ["phenol", "CHEMICAL", 24, 30], ["chloroform", "CHEMICAL", 31, 41], ["isoamyl alcohol", "CHEMICAL", 42, 57], ["ethanol", "CHEMICAL", 91, 98], ["DNA", "CELLULAR_COMPONENT", 0, 3], ["phenol", "SIMPLE_CHEMICAL", 24, 30], ["chloroform", "SIMPLE_CHEMICAL", 31, 41], ["isoamyl alcohol", "SIMPLE_CHEMICAL", 42, 57], ["25:24:1", "SIMPLE_CHEMICAL", 59, 66], ["ethanol", "SIMPLE_CHEMICAL", 91, 98], ["DNA", "PROBLEM", 0, 3], ["a phenol/chloroform", "TREATMENT", 22, 41], ["isoamyl alcohol", "TREATMENT", 42, 57], ["extraction", "TREATMENT", 68, 78]]], ["The amount of residual DNA was quantified by PicoGreen assay.Tensile testThe tensile test was conducted as previously described [10] [11] [12] using a universal testing machine (Autograph AG-X, Shimadzu) at crosshead speed of 0.1 mm/min.", [["DNA", "CELLULAR_COMPONENT", 23, 26], ["residual DNA", "PROBLEM", 14, 26], ["Tensile test", "TEST", 61, 73], ["The tensile test", "TEST", 73, 89], ["a universal testing machine", "TEST", 149, 176], ["Autograph", "TEST", 178, 187], ["AG", "TEST", 188, 190], ["Shimadzu", "TEST", 194, 202], ["crosshead speed", "TEST", 207, 222], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["residual DNA", "OBSERVATION", 14, 26]]], ["The samples were cut into dumbbell shape with a length of 35 mm and a width of 2 mm.", [["samples", "ANATOMY", 4, 11], ["The samples", "TEST", 0, 11], ["dumbbell", "OBSERVATION_MODIFIER", 26, 34], ["shape", "OBSERVATION_MODIFIER", 35, 40], ["length", "OBSERVATION_MODIFIER", 48, 54], ["35 mm", "OBSERVATION_MODIFIER", 58, 63], ["width", "OBSERVATION_MODIFIER", 70, 75], ["2 mm", "OBSERVATION_MODIFIER", 79, 83]]], ["The sample thickness was measured using micrometer with 2 \u03bcm accuracy before tensile test.", [["sample", "ANATOMY", 4, 10], ["The sample thickness", "TEST", 0, 20], ["tensile test", "TEST", 77, 89], ["thickness", "OBSERVATION_MODIFIER", 11, 20]]], ["Each specimen was preloaded to 0.01 N before loading.", [["specimen", "ANATOMY", 5, 13]]], ["Four specimens from each group were separately tested.", [["specimens", "ANATOMY", 5, 14], ["Four specimens", "TEST", 0, 14]]], ["The elastic modulus was estimated from the slope of liner fit to the stress-strain curve.", [["elastic modulus", "OBSERVATION", 4, 19], ["liner fit", "OBSERVATION", 52, 61]]], ["The tests were performed with longitudinal direction of the vessels.Animal model and surgical procedure of implantationNine to ten-month-old female CLAWN miniature swine (25 -27 kg; N = 9) were anesthetized with ketamine (16 mg/kg body weight) and xylazine (1.6 mg/kg body weight) cocktail by intramuscular administration.", [["vessels", "ANATOMY", 60, 67], ["body", "ANATOMY", 231, 235], ["body", "ANATOMY", 268, 272], ["intramuscular", "ANATOMY", 293, 306], ["ketamine", "CHEMICAL", 212, 220], ["xylazine", "CHEMICAL", 248, 256], ["ketamine", "CHEMICAL", 212, 220], ["xylazine", "CHEMICAL", 248, 256], ["vessels", "MULTI-TISSUE_STRUCTURE", 60, 67], ["CLAWN", "ORGANISM", 148, 153], ["swine", "ORGANISM", 164, 169], ["ketamine", "SIMPLE_CHEMICAL", 212, 220], ["body", "ORGANISM_SUBDIVISION", 231, 235], ["xylazine", "SIMPLE_CHEMICAL", 248, 256], ["body", "ORGANISM_SUBDIVISION", 268, 272], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 293, 306], ["swine", "SPECIES", 164, 169], ["CLAWN miniature swine", "SPECIES", 148, 169], ["The tests", "TEST", 0, 9], ["Animal model", "TREATMENT", 68, 80], ["surgical procedure of implantation", "TREATMENT", 85, 119], ["ketamine", "TREATMENT", 212, 220], ["xylazine", "TREATMENT", 248, 256], ["cocktail", "TREATMENT", 281, 289], ["vessels", "ANATOMY", 60, 67], ["surgical", "OBSERVATION", 85, 93]]], ["Animals were intubated (Shily Hi-Lo oral tracheal tube 7.5mm I.D. COVIDIEN JAPAN, Tokyo, Japan) and maintained on 1 -2 % isoflurane and 5 L oxygen using closed-circuit inhalation.", [["isoflurane", "CHEMICAL", 121, 131], ["oxygen", "CHEMICAL", 140, 146], ["isoflurane", "CHEMICAL", 121, 131], ["oxygen", "CHEMICAL", 140, 146], ["Animals", "ORGANISM", 0, 7], ["isoflurane", "SIMPLE_CHEMICAL", 121, 131], ["oxygen", "SIMPLE_CHEMICAL", 140, 146], ["intubated", "TREATMENT", 13, 22], ["Shily Hi-Lo oral tracheal tube", "TREATMENT", 24, 54], ["1 -2 % isoflurane", "TREATMENT", 114, 131], ["5 L oxygen", "TREATMENT", 136, 146], ["closed-circuit inhalation", "TREATMENT", 153, 178], ["tracheal", "ANATOMY", 41, 49]]], ["During surgery, anesthesia depth and hemodynamic state were monitored by invasive blood pressure and electrocardiogram.Animal model and surgical procedure of implantationDecellularized grafts with HHP were implanted into right carotid artery.", [["blood", "ANATOMY", 82, 87], ["grafts", "ANATOMY", 185, 191], ["right carotid artery", "ANATOMY", 221, 241], ["blood", "ORGANISM_SUBSTANCE", 82, 87], ["grafts", "TISSUE", 185, 191], ["right carotid artery", "MULTI-TISSUE_STRUCTURE", 221, 241], ["surgery", "TREATMENT", 7, 14], ["anesthesia depth", "TEST", 16, 32], ["invasive blood pressure", "TEST", 73, 96], ["electrocardiogram", "TEST", 101, 118], ["Animal model", "TREATMENT", 119, 131], ["surgical procedure", "TREATMENT", 136, 154], ["implantationDecellularized grafts", "TREATMENT", 158, 191], ["HHP", "TREATMENT", 197, 200], ["surgical", "OBSERVATION", 136, 144], ["implantation", "OBSERVATION_MODIFIER", 158, 170], ["Decellularized", "OBSERVATION_MODIFIER", 170, 184], ["grafts", "OBSERVATION", 185, 191], ["right carotid artery", "ANATOMY", 221, 241]]], ["After midline neck incision, right common carotid artery was exposed for approximately 8 cm from carotid bifurcation.", [["midline neck", "ANATOMY", 6, 18], ["right common carotid artery", "ANATOMY", 29, 56], ["carotid", "ANATOMY", 97, 104], ["midline neck", "MULTI-TISSUE_STRUCTURE", 6, 18], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 42, 56], ["carotid bifurcation", "MULTI-TISSUE_STRUCTURE", 97, 116], ["midline neck incision", "TREATMENT", 6, 27], ["midline", "ANATOMY_MODIFIER", 6, 13], ["neck", "ANATOMY", 14, 18], ["incision", "OBSERVATION", 19, 27], ["right", "ANATOMY_MODIFIER", 29, 34], ["common carotid artery", "ANATOMY", 35, 56], ["8 cm", "OBSERVATION_MODIFIER", 87, 91], ["carotid", "ANATOMY", 97, 104], ["bifurcation", "ANATOMY_MODIFIER", 105, 116]]], ["Heparin sodium (100 IU / kg) was administered before clamp of the artery.", [["artery", "ANATOMY", 66, 72], ["Heparin sodium", "CHEMICAL", 0, 14], ["sodium", "CHEMICAL", 8, 14], ["Heparin sodium", "SIMPLE_CHEMICAL", 0, 14], ["artery", "MULTI-TISSUE_STRUCTURE", 66, 72], ["Heparin sodium", "TREATMENT", 0, 14], ["clamp of the artery", "TREATMENT", 53, 72], ["artery", "ANATOMY", 66, 72]]], ["Right common carotid artery was interposed with HHP decellularized graft for approximately 4 cm in end-to-end fashion using 8-0 polypropylene continuous suture.Animal model and surgical procedure of implantationIn phase 1 group (N = 4), anastomoses were accomplished with similar surgical conditions with those in human bypass grafting surgery (conventional condition).", [["Right common carotid artery", "ANATOMY", 0, 27], ["polypropylene", "CHEMICAL", 128, 141], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 13, 27], ["graft", "TISSUE", 67, 72], ["human", "ORGANISM", 314, 319], ["human", "SPECIES", 314, 319], ["human", "SPECIES", 314, 319], ["HHP decellularized graft", "TREATMENT", 48, 72], ["8-0 polypropylene continuous suture", "TREATMENT", 124, 159], ["Animal model", "TREATMENT", 160, 172], ["surgical procedure of implantationIn phase", "TREATMENT", 177, 219], ["anastomoses", "TREATMENT", 237, 248], ["similar surgical conditions", "PROBLEM", 272, 299], ["human bypass grafting surgery", "TREATMENT", 314, 343], ["common carotid artery", "ANATOMY", 6, 27], ["decellularized", "OBSERVATION_MODIFIER", 52, 66], ["graft", "OBSERVATION", 67, 72], ["approximately", "OBSERVATION_MODIFIER", 77, 90], ["4 cm", "OBSERVATION_MODIFIER", 91, 95], ["anastomoses", "OBSERVATION", 237, 248], ["bypass grafting", "OBSERVATION", 320, 335]]], ["In phase 2 group (N = 5), anastomosis was carefully performed keeping the decellularized graft, especially its luminal surface always wet with water (moist condition) and not touching its luminal surface.", [["luminal surface", "ANATOMY", 111, 126], ["luminal surface", "ANATOMY", 188, 203], ["luminal", "CHEMICAL", 111, 118], ["luminal", "CHEMICAL", 188, 195], ["graft", "TISSUE", 89, 94], ["luminal surface", "CELLULAR_COMPONENT", 188, 203], ["anastomosis", "TREATMENT", 26, 37], ["the decellularized graft", "TREATMENT", 70, 94], ["anastomosis", "OBSERVATION", 26, 37], ["decellularized", "OBSERVATION_MODIFIER", 74, 88], ["graft", "OBSERVATION", 89, 94], ["luminal", "ANATOMY_MODIFIER", 111, 118], ["surface", "OBSERVATION_MODIFIER", 119, 126], ["luminal", "ANATOMY_MODIFIER", 188, 195], ["surface", "OBSERVATION_MODIFIER", 196, 203]]], ["After anastomosis, blood flow was resumed.", [["blood", "ANATOMY", 19, 24], ["blood", "ORGANISM_SUBSTANCE", 19, 24], ["anastomosis", "TREATMENT", 6, 17], ["blood flow", "TEST", 19, 29], ["anastomosis", "OBSERVATION", 6, 17], ["blood flow", "OBSERVATION", 19, 29]]], ["Blood flow velocity (time averaged maximum flow velocity) was measured by color Doppler ultrasound at the center of the implanted graft.Animal model and surgical procedure of implantationWound was closed layer by layer.", [["Blood", "ANATOMY", 0, 5], ["graft", "ANATOMY", 130, 135], ["implantationWound", "ANATOMY", 175, 192], ["Blood", "ORGANISM_SUBSTANCE", 0, 5], ["graft", "TISSUE", 130, 135], ["Blood flow velocity", "TEST", 0, 19], ["maximum flow velocity", "TEST", 35, 56], ["color Doppler ultrasound", "TEST", 74, 98], ["the implanted graft", "TREATMENT", 116, 135], ["Animal model", "TREATMENT", 136, 148], ["surgical procedure of implantationWound", "TREATMENT", 153, 192], ["flow", "OBSERVATION_MODIFIER", 6, 10], ["velocity", "OBSERVATION_MODIFIER", 11, 19], ["implanted graft", "OBSERVATION", 120, 135], ["surgical", "OBSERVATION", 153, 161], ["closed", "OBSERVATION", 197, 203], ["layer", "OBSERVATION_MODIFIER", 204, 209], ["layer", "OBSERVATION_MODIFIER", 213, 218]]], ["All animals were administered prophylactic cefazolin sodium intravenously.", [["cefazolin sodium", "CHEMICAL", 43, 59], ["cefazolin sodium", "CHEMICAL", 43, 59], ["cefazolin", "SIMPLE_CHEMICAL", 43, 52], ["All animals", "TREATMENT", 0, 11], ["prophylactic cefazolin sodium intravenously", "TREATMENT", 30, 73]]], ["After implantation, no anticoagulants nor anti-platelet agents were administrated.", [["anti-platelet", "ANATOMY", 42, 55], ["anti-platelet agents", "SIMPLE_CHEMICAL", 42, 62], ["implantation", "TREATMENT", 6, 18], ["anticoagulants", "TREATMENT", 23, 37], ["anti-platelet agents", "TREATMENT", 42, 62], ["no", "UNCERTAINTY", 20, 22]]], ["Four weeks after transplantation, decellularized graft were explanted under general anesthesia and euthanized by intravenous bolus injection of potassium chloride (1 -2 mEq/kg).Selective angiogramAngiogram for bilateral carotid arteries are performed by inserting 6 Fr guiding catheter (INTRODUCER II, TERUMO, Tokyo, Japan) at femoral artery and selective angiogram with 4 Fr straight catheter (GLIDECATH, TERUMO) from the proximal end of common carotid arteries.", [["graft", "ANATOMY", 49, 54], ["intravenous", "ANATOMY", 113, 124], ["bilateral carotid arteries", "ANATOMY", 210, 236], ["femoral artery", "ANATOMY", 327, 341], ["common carotid arteries", "ANATOMY", 439, 462], ["potassium chloride", "CHEMICAL", 144, 162], ["potassium chloride", "CHEMICAL", 144, 162], ["graft", "TISSUE", 49, 54], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 113, 124], ["potassium chloride", "SIMPLE_CHEMICAL", 144, 162], ["carotid arteries", "MULTI-TISSUE_STRUCTURE", 220, 236], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 327, 341], ["carotid arteries", "MULTI-TISSUE_STRUCTURE", 446, 462], ["transplantation", "TREATMENT", 17, 32], ["decellularized graft", "TREATMENT", 34, 54], ["general anesthesia", "TREATMENT", 76, 94], ["intravenous bolus injection of potassium chloride", "TREATMENT", 113, 162], ["Selective angiogramAngiogram", "TEST", 177, 205], ["bilateral carotid arteries", "TREATMENT", 210, 236], ["6 Fr guiding catheter (INTRODUCER II, TERUMO", "TREATMENT", 264, 308], ["selective angiogram", "TEST", 346, 365], ["4 Fr straight catheter (GLIDECATH, TERUMO)", "TREATMENT", 371, 413], ["decellularized graft", "OBSERVATION", 34, 54], ["bilateral", "ANATOMY_MODIFIER", 210, 219], ["carotid arteries", "ANATOMY", 220, 236], ["catheter", "OBSERVATION", 277, 285], ["femoral artery", "ANATOMY", 327, 341], ["catheter", "OBSERVATION", 385, 393], ["proximal", "ANATOMY_MODIFIER", 423, 431], ["common carotid arteries", "ANATOMY", 439, 462]]], ["Iopamidol (OYPLOMIN\u00ae300, FujiPharma, Toyama, Japan; 100ml) were used as contrast agent.", [["Iopamidol", "CHEMICAL", 0, 9], ["OYPLOMIN\u00ae300", "CHEMICAL", 11, 23], ["Iopamidol", "CHEMICAL", 0, 9], ["OYPLOMIN", "CHEMICAL", 11, 19], ["Iopamidol", "SIMPLE_CHEMICAL", 0, 9], ["Iopamidol (OYPLOMIN\u00ae", "TREATMENT", 0, 20], ["Toyama", "TREATMENT", 37, 43], ["Japan", "TREATMENT", 45, 50], ["contrast agent", "TREATMENT", 72, 86]]], ["The Angiogram were performed at just after implantation surgery, 2 weeks, 4 weeks after the surgery, respectively.Intravascular ultrasound (IVUS)IVUS was performed at the same timing with that of angiogram, respectively.", [["Intravascular", "ANATOMY", 114, 127], ["Intravascular", "IMMATERIAL_ANATOMICAL_ENTITY", 114, 127], ["The Angiogram", "TEST", 0, 13], ["implantation surgery", "TREATMENT", 43, 63], ["the surgery", "TREATMENT", 88, 99], ["Intravascular ultrasound", "TEST", 114, 138], ["IVUS", "TEST", 145, 149], ["angiogram", "TEST", 196, 205]]], ["VISIONS PV .018 (Philips Japan, Tokyo, Japan) were used for IVUS transducer and VOLCANO (Philips Japan) were used for the data acquisition.", [["IVUS transducer", "TREATMENT", 60, 75], ["VOLCANO (Philips Japan", "TREATMENT", 80, 102], ["the data acquisition", "TEST", 118, 138]]], ["IVUS was performed for bilateral carotid arteries (contralateral side of implanted side for control).", [["bilateral carotid arteries", "ANATOMY", 23, 49], ["carotid arteries", "MULTI-TISSUE_STRUCTURE", 33, 49], ["IVUS", "TEST", 0, 4], ["bilateral carotid arteries (contralateral side of implanted side", "TREATMENT", 23, 87], ["bilateral", "ANATOMY_MODIFIER", 23, 32], ["carotid arteries", "ANATOMY", 33, 49]]], ["The data were recorded from distal to proximal anastomosis site of the implanted graft to evaluate intraluminal stenosis and morphology.", [["intraluminal", "ANATOMY", 99, 111], ["intraluminal stenosis", "DISEASE", 99, 120], ["graft", "TISSUE", 81, 86], ["intraluminal", "IMMATERIAL_ANATOMICAL_ENTITY", 99, 111], ["The data", "TEST", 0, 8], ["the implanted graft", "TREATMENT", 67, 86], ["intraluminal stenosis", "PROBLEM", 99, 120], ["proximal", "ANATOMY_MODIFIER", 38, 46], ["anastomosis", "OBSERVATION", 47, 58], ["implanted graft", "OBSERVATION", 71, 86], ["intraluminal", "ANATOMY_MODIFIER", 99, 111], ["stenosis", "OBSERVATION", 112, 120], ["morphology", "OBSERVATION_MODIFIER", 125, 135]]], ["The data were analyzed by Image J software (version 1.50i, National Institutes of Health, Bethesda, MD) [13] .Histological analysisExplanted grafts were incised to longitudinal direction and fixed in 4 % paraformaldehyde for 48 hours.", [["grafts", "ANATOMY", 141, 147], ["paraformaldehyde", "CHEMICAL", 204, 220], ["grafts", "TISSUE", 141, 147], ["paraformaldehyde", "SIMPLE_CHEMICAL", 204, 220], ["Histological analysis", "TEST", 110, 131], ["Explanted grafts", "TREATMENT", 131, 147], ["4 % paraformaldehyde", "TREATMENT", 200, 220], ["grafts", "OBSERVATION", 141, 147]]], ["After fixation, explanted grafts were divided into proximal part and distal part, subsequentially embedded in paraffin.", [["grafts", "ANATOMY", 26, 32], ["proximal part", "ANATOMY", 51, 64], ["distal part", "ANATOMY", 69, 80], ["paraffin", "CHEMICAL", 110, 118], ["grafts", "TISSUE", 26, 32], ["fixation", "TREATMENT", 6, 14], ["explanted grafts", "TREATMENT", 16, 32], ["fixation", "OBSERVATION", 6, 14], ["grafts", "OBSERVATION", 26, 32], ["proximal", "ANATOMY_MODIFIER", 51, 59], ["distal", "ANATOMY_MODIFIER", 69, 75], ["paraffin", "OBSERVATION", 110, 118]]], ["In each part, sections with 6 \u03bcm thickness were prepared consecutively and subjected to hematoxylin and eosin staining, Elastica van Gieson staining, Sirius red staining and von Kossa staining, respectively.Histological analysisImmunostaining of von Willebrand factor for endothelium (anti-von Willebrand Factor antibody, Abcam, Cambridge, UK, 1:3000) and \u03b1-smooth muscle actin for smooth muscle cells (anti-alpha smooth muscle actin antibody, Abcam, Cambridge, UK, 1:500) were performed, respectively.", [["sections", "ANATOMY", 14, 22], ["endothelium", "ANATOMY", 272, 283], ["\u03b1-smooth muscle", "ANATOMY", 356, 371], ["smooth muscle cells", "ANATOMY", 382, 401], ["hematoxylin", "CHEMICAL", 88, 99], ["eosin", "CHEMICAL", 104, 109], ["hematoxylin", "SIMPLE_CHEMICAL", 88, 99], ["von Willebrand factor", "GENE_OR_GENE_PRODUCT", 246, 267], ["endothelium", "TISSUE", 272, 283], ["anti-von Willebrand Factor antibody", "GENE_OR_GENE_PRODUCT", 285, 320], ["Abcam", "GENE_OR_GENE_PRODUCT", 322, 327], ["UK", "GENE_OR_GENE_PRODUCT", 340, 342], ["\u03b1-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 356, 377], ["smooth muscle cells", "CELL", 382, 401], ["anti-alpha smooth muscle actin antibody", "GENE_OR_GENE_PRODUCT", 403, 442], ["Abcam", "GENE_OR_GENE_PRODUCT", 444, 449], ["UK", "GENE_OR_GENE_PRODUCT", 462, 464], ["von Willebrand factor", "PROTEIN", 246, 267], ["anti-von Willebrand Factor antibody", "PROTEIN", 285, 320], ["Abcam", "PROTEIN", 322, 327], ["Cambridge", "PROTEIN", 329, 338], ["UK", "PROTEIN", 340, 342], ["1:3000", "PROTEIN", 344, 350], ["\u03b1-smooth muscle actin", "PROTEIN", 356, 377], ["smooth muscle cells", "CELL_TYPE", 382, 401], ["anti-alpha smooth muscle actin antibody", "PROTEIN", 403, 442], ["Abcam", "PROTEIN", 444, 449], ["Cambridge", "PROTEIN", 451, 460], ["hematoxylin", "TEST", 88, 99], ["Sirius red staining", "TEST", 150, 169], ["von Kossa staining", "TEST", 174, 192], ["endothelium", "PROBLEM", 272, 283], ["anti-von Willebrand Factor antibody", "TEST", 285, 320], ["smooth muscle cells", "PROBLEM", 382, 401], ["anti-alpha smooth muscle actin antibody", "TEST", 403, 442], ["von Kossa", "OBSERVATION", 174, 183], ["von Willebrand", "OBSERVATION", 246, 260], ["\u03b1-smooth muscle", "ANATOMY", 356, 371]]], ["Sirius red staining sections were observed using polarized light microscope (BX51; Olympus, Tokyo, Japan).Scanning electron microscopy (SEM)Native bovine dorsalis pedis arteries, decellularized grafts before implantation, native porcine carotid arteries and explanted grafts were fixed into a 2.5 % Glutaraldehyde-2 % Paraformaldehyde-0.1 M Phosphate Buffer solution (pH 7.4) for 24 hours at 4 \u00b0C, respectively.", [["sections", "ANATOMY", 20, 28], ["dorsalis pedis arteries", "ANATOMY", 154, 177], ["grafts", "ANATOMY", 194, 200], ["carotid arteries", "ANATOMY", 237, 253], ["grafts", "ANATOMY", 268, 274], ["Glutaraldehyde", "CHEMICAL", 299, 313], ["Paraformaldehyde", "CHEMICAL", 318, 334], ["Phosphate", "CHEMICAL", 341, 350], ["Sirius red", "CHEMICAL", 0, 10], ["Glutaraldehyde", "CHEMICAL", 299, 313], ["Paraformaldehyde", "CHEMICAL", 318, 334], ["Phosphate", "CHEMICAL", 341, 350], ["Sirius", "GENE_OR_GENE_PRODUCT", 0, 6], ["bovine", "ORGANISM", 147, 153], ["dorsalis pedis arteries", "MULTI-TISSUE_STRUCTURE", 154, 177], ["grafts", "TISSUE", 194, 200], ["porcine", "ORGANISM", 229, 236], ["carotid arteries", "MULTI-TISSUE_STRUCTURE", 237, 253], ["grafts", "TISSUE", 268, 274], ["Glutaraldehyde", "SIMPLE_CHEMICAL", 299, 313], ["Paraformaldehyde", "SIMPLE_CHEMICAL", 318, 334], ["Phosphate Buffer solution", "SIMPLE_CHEMICAL", 341, 366], ["bovine", "SPECIES", 147, 153], ["porcine", "SPECIES", 229, 236], ["porcine", "SPECIES", 229, 236], ["Sirius red staining sections", "TEST", 0, 28], ["polarized light microscope", "TEST", 49, 75], ["Scanning electron microscopy", "TEST", 106, 134], ["Native bovine dorsalis pedis arteries", "TREATMENT", 140, 177], ["decellularized grafts", "TREATMENT", 179, 200], ["implantation", "TREATMENT", 208, 220], ["native porcine carotid arteries", "TREATMENT", 222, 253], ["explanted grafts", "TREATMENT", 258, 274], ["a 2.5 % Glutaraldehyde", "TREATMENT", 291, 313], ["Paraformaldehyde", "TREATMENT", 318, 334], ["Phosphate Buffer solution", "TREATMENT", 341, 366], ["pH", "TEST", 368, 370], ["dorsalis", "ANATOMY", 154, 162], ["pedis arteries", "ANATOMY", 163, 177], ["decellularized", "OBSERVATION_MODIFIER", 179, 193], ["grafts", "OBSERVATION", 194, 200], ["implantation", "OBSERVATION", 208, 220], ["native", "ANATOMY_MODIFIER", 222, 228], ["porcine", "ANATOMY_MODIFIER", 229, 236], ["carotid arteries", "ANATOMY", 237, 253], ["grafts", "OBSERVATION", 268, 274]]], ["After fixation, samples were immersed into 1 % osmium tetroxide for 2 hours at 4 \u00b0C , and were dehydrated by graded ethanol (50 %, 60 %, 70 %, 80 %, 90 %, 95 % and 100 %) for 30 min.", [["samples", "ANATOMY", 16, 23], ["osmium tetroxide", "CHEMICAL", 47, 63], ["ethanol", "CHEMICAL", 116, 123], ["osmium tetroxide", "CHEMICAL", 47, 63], ["ethanol", "CHEMICAL", 116, 123], ["osmium tetroxide", "SIMPLE_CHEMICAL", 47, 63], ["ethanol", "SIMPLE_CHEMICAL", 116, 123], ["fixation", "TREATMENT", 6, 14], ["samples", "TEST", 16, 23], ["1 % osmium tetroxide", "TREATMENT", 43, 63], ["fixation", "OBSERVATION", 6, 14]]], ["Subsequently, the samples were dried and coated with a thin layer of platinum palladium using an ion sputtering device (Eiko Corp.,Tokyo, Japan).Scanning electron microscopy (SEM)The sample were examined with a Hitachi S-4700 scanning electron microscope (Hitachi, Tokyo, Japan).Statistical analysisAll data analyses were performed using JMP version 11.2.0 (SAS Institute, Cary, NC, USA).", [["samples", "ANATOMY", 18, 25], ["sample", "ANATOMY", 183, 189], ["platinum palladium", "CHEMICAL", 69, 87], ["platinum palladium", "CHEMICAL", 69, 87], ["platinum palladium", "SIMPLE_CHEMICAL", 69, 87], ["the samples", "TEST", 14, 25], ["a thin layer of platinum palladium", "TREATMENT", 53, 87], ["an ion sputtering device", "TREATMENT", 94, 118], ["Scanning electron microscopy", "TEST", 145, 173], ["a Hitachi S", "TEST", 209, 220], ["Statistical analysis", "TEST", 279, 299], ["All data analyses", "TEST", 299, 316], ["JMP version", "TEST", 338, 349]]], ["Statistical analysis of the data was performed with unpaired t-tests or Fisher's exact test for 2 groups.", [["Statistical analysis of the data", "TEST", 0, 32], ["unpaired t-tests", "TEST", 52, 68], ["Fisher's exact test", "TEST", 72, 91]]], ["Values are reported as means \u00b1 SD.Physical and biochemical characteristics of decellularized vascular grafts with HHP methodMacroscopic view of decellularized bovine dorsalis pedis artery with HHP method is shown in Figure 1A .", [["vascular grafts", "ANATOMY", 93, 108], ["dorsalis pedis artery", "ANATOMY", 166, 187], ["vascular grafts", "TISSUE", 93, 108], ["bovine", "ORGANISM", 159, 165], ["dorsalis pedis artery", "MULTI-TISSUE_STRUCTURE", 166, 187], ["bovine", "SPECIES", 159, 165], ["decellularized vascular grafts", "TREATMENT", 78, 108], ["HHP method", "TREATMENT", 114, 124], ["decellularized bovine dorsalis pedis artery", "TREATMENT", 144, 187], ["HHP method", "TREATMENT", 193, 203], ["vascular", "ANATOMY", 93, 101], ["grafts", "OBSERVATION", 102, 108], ["decellularized", "OBSERVATION", 144, 158], ["bovine dorsalis", "ANATOMY", 159, 174], ["pedis artery", "ANATOMY", 175, 187]]], ["The amount of residual DNA was measured to quantify the efficiency of cell removal.", [["cell", "ANATOMY", 70, 74], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["cell", "CELL", 70, 74], ["residual DNA", "PROBLEM", 14, 26], ["cell removal", "TREATMENT", 70, 82], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["residual DNA", "OBSERVATION", 14, 26], ["efficiency", "OBSERVATION_MODIFIER", 56, 66], ["cell removal", "OBSERVATION", 70, 82]]], ["The amount of residual DNA of decellularized graft was 15.85 \u00b1 2.15 ng/mg which was significantly lower compared with those of bovine arteries, 4451.0 \u00b1 351.7 ng/mg (P < 0.0001) (Fig. 1B) .Physical and biochemical characteristics of decellularized vascular grafts with HHP methodTensile test was performed to measure physical strength of decellularized grafts.Implantation surgery of HHP-decellularized vascular graftsWe started our experiments under surgically equivalent condition with that of usual human revascularization surgeries in preparation and anastomoses of autologous vascular grafts such as saphenous vein grafts (Phase 1; N = 4).", [["graft", "ANATOMY", 45, 50], ["arteries", "ANATOMY", 134, 142], ["vascular grafts", "ANATOMY", 248, 263], ["grafts", "ANATOMY", 353, 359], ["vascular grafts", "ANATOMY", 403, 418], ["vascular grafts", "ANATOMY", 581, 596], ["saphenous vein grafts", "ANATOMY", 605, 626], ["DNA", "CELLULAR_COMPONENT", 23, 26], ["graft", "TISSUE", 45, 50], ["bovine", "ORGANISM", 127, 133], ["arteries", "MULTI-TISSUE_STRUCTURE", 134, 142], ["vascular grafts", "TISSUE", 248, 263], ["grafts", "TISSUE", 353, 359], ["vascular grafts", "TISSUE", 403, 418], ["human", "ORGANISM", 502, 507], ["vascular grafts", "TISSUE", 581, 596], ["saphenous vein grafts", "MULTI-TISSUE_STRUCTURE", 605, 626], ["bovine", "SPECIES", 127, 133], ["human", "SPECIES", 502, 507], ["bovine", "SPECIES", 127, 133], ["human", "SPECIES", 502, 507], ["residual DNA of decellularized graft", "TREATMENT", 14, 50], ["ng", "TEST", 159, 161], ["P", "TEST", 166, 167], ["Fig", "TEST", 179, 182], ["decellularized vascular grafts", "TREATMENT", 233, 263], ["HHP methodTensile test", "TEST", 269, 291], ["decellularized grafts", "TREATMENT", 338, 359], ["Implantation surgery", "TREATMENT", 360, 380], ["HHP", "TREATMENT", 384, 387], ["decellularized vascular grafts", "TREATMENT", 388, 418], ["usual human revascularization surgeries", "TREATMENT", 496, 535], ["anastomoses of autologous vascular grafts", "TREATMENT", 555, 596], ["saphenous vein grafts", "TREATMENT", 605, 626], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["residual DNA", "OBSERVATION", 14, 26], ["decellularized graft", "OBSERVATION", 30, 50], ["bovine arteries", "ANATOMY", 127, 142], ["vascular", "ANATOMY", 248, 256], ["grafts", "OBSERVATION", 257, 263], ["decellularized grafts", "OBSERVATION", 338, 359], ["decellularized", "OBSERVATION", 388, 402], ["vascular", "ANATOMY", 403, 411], ["grafts", "OBSERVATION", 412, 418], ["autologous vascular grafts", "OBSERVATION", 570, 596], ["saphenous vein", "ANATOMY", 605, 619], ["grafts", "OBSERVATION", 620, 626]]], ["We experienced that all 4 implanted grafts were occluded at 4 weeks after implantation (0/4; 0 % patency in Phase 1).", [["grafts", "ANATOMY", 36, 42], ["grafts", "TISSUE", 36, 42], ["all 4 implanted grafts", "TREATMENT", 20, 42], ["implantation", "TREATMENT", 74, 86], ["implanted grafts", "OBSERVATION", 26, 42], ["occluded", "OBSERVATION", 48, 56]]], ["We considered that the major reason of the occlusion might be the damage of the intima and exposure of basement membrane attributed by the drying of a lumen side which may affect antithrombogenicity and patency [14] , then modified condition of anastomoses to moist condition not to allow lumen of grafts to be dried as much as possible (Phase 2; N = 5) ( Fig. 2A,B ; Supplemental video 1).", [["intima", "ANATOMY", 80, 86], ["basement membrane", "ANATOMY", 103, 120], ["lumen", "ANATOMY", 151, 156], ["lumen", "ANATOMY", 289, 294], ["grafts", "ANATOMY", 298, 304], ["intima", "TISSUE", 80, 86], ["basement membrane", "CELLULAR_COMPONENT", 103, 120], ["lumen", "IMMATERIAL_ANATOMICAL_ENTITY", 289, 294], ["grafts", "TISSUE", 298, 304], ["the occlusion", "PROBLEM", 39, 52], ["basement membrane", "TREATMENT", 103, 120], ["a lumen side", "TREATMENT", 149, 161], ["patency", "TEST", 203, 210], ["anastomoses", "TREATMENT", 245, 256], ["lumen of grafts", "TREATMENT", 289, 304], ["Phase", "TEST", 338, 343], ["occlusion", "OBSERVATION", 43, 52], ["intima", "ANATOMY", 80, 86], ["anastomoses", "OBSERVATION", 245, 256], ["grafts", "OBSERVATION", 298, 304]]], ["In phase 2, we confirmed that all 5 grafts were patent at 4 weeks after implantation (5/5; 100 % patency in Phase 2) (Phase 1 vs Phase 2; P = 0.0079).", [["grafts", "ANATOMY", 36, 42], ["grafts", "TISSUE", 36, 42], ["all 5 grafts", "TREATMENT", 30, 42], ["implantation", "TREATMENT", 72, 84], ["Phase", "TEST", 118, 123], ["Phase", "TEST", 129, 134], ["P", "TEST", 138, 139], ["grafts", "OBSERVATION", 36, 42], ["patent", "OBSERVATION", 48, 54]]], ["There was no significant difference in time averaged maximum flow velocity just after anastomosis between Phase 1 and Phase 2 (Fig. 2C,D) .Evaluations for implanted graft patency and morphologyIn all cases of Phase 2, moderate stenoses of grafts were observed in the proximity of both anastomosis sites by selective angiogram (Fig. 3A) .", [["graft", "ANATOMY", 165, 170], ["grafts", "ANATOMY", 239, 245], ["anastomosis sites", "ANATOMY", 285, 302], ["stenoses", "DISEASE", 227, 235], ["graft", "TISSUE", 165, 170], ["grafts", "TISSUE", 239, 245], ["significant difference", "PROBLEM", 13, 35], ["maximum flow velocity", "TEST", 53, 74], ["anastomosis between Phase", "TREATMENT", 86, 111], ["Evaluations", "TEST", 139, 150], ["implanted graft patency", "TREATMENT", 155, 178], ["moderate stenoses of grafts", "PROBLEM", 218, 245], ["selective angiogram", "TEST", 306, 325], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["maximum", "OBSERVATION_MODIFIER", 53, 60], ["flow velocity", "OBSERVATION", 61, 74], ["anastomosis", "OBSERVATION", 86, 97], ["graft patency", "OBSERVATION", 165, 178], ["morphology", "OBSERVATION_MODIFIER", 183, 193], ["moderate", "OBSERVATION_MODIFIER", 218, 226], ["stenoses", "OBSERVATION", 227, 235], ["grafts", "OBSERVATION", 239, 245], ["both", "ANATOMY_MODIFIER", 280, 284], ["anastomosis", "OBSERVATION", 285, 296]]], ["Intimal thickening of the corresponding regions was also confirmed by IVUS (Fig. 3B) .", [["Intimal", "ANATOMY", 0, 7], ["Intimal", "TISSUE", 0, 7], ["Intimal thickening of the corresponding regions", "PROBLEM", 0, 47], ["IVUS", "TEST", 70, 74], ["thickening", "OBSERVATION", 8, 18]]], ["Stenosis ratios of proximal and distal anastomotic region were 49.4 \u00b1 0.12 % and 51.4 \u00b1 0.04 %, respectively.", [["distal anastomotic region", "ANATOMY", 32, 57], ["Stenosis", "DISEASE", 0, 8], ["Stenosis ratios of proximal and distal anastomotic region", "PROBLEM", 0, 57], ["proximal", "ANATOMY_MODIFIER", 19, 27], ["distal", "ANATOMY_MODIFIER", 32, 38], ["anastomotic", "OBSERVATION_MODIFIER", 39, 50]]], ["We optimally evaluated all explanted grafts at 4 weeks after implantation.", [["grafts", "ANATOMY", 37, 43], ["grafts", "TISSUE", 37, 43], ["all explanted grafts", "TREATMENT", 23, 43], ["implantation", "TREATMENT", 61, 73], ["grafts", "OBSERVATION", 37, 43]]], ["Luminal side of all explanted grafts were macroscopically smooth, but some explanted grafts were accompanied by small amount of thrombi (Fig. 3C) .", [["Luminal", "ANATOMY", 0, 7], ["grafts", "ANATOMY", 30, 36], ["grafts", "ANATOMY", 85, 91], ["thrombi", "ANATOMY", 128, 135], ["thrombi", "DISEASE", 128, 135], ["grafts", "TISSUE", 30, 36], ["grafts", "TISSUE", 85, 91], ["all explanted grafts", "TREATMENT", 16, 36], ["some explanted grafts", "TREATMENT", 70, 91], ["small amount of thrombi", "PROBLEM", 112, 135], ["all", "OBSERVATION_MODIFIER", 16, 19], ["explanted", "OBSERVATION_MODIFIER", 20, 29], ["grafts", "OBSERVATION", 30, 36], ["macroscopically", "OBSERVATION_MODIFIER", 42, 57], ["smooth", "OBSERVATION_MODIFIER", 58, 64], ["grafts", "OBSERVATION", 85, 91], ["small", "OBSERVATION_MODIFIER", 112, 117], ["amount", "OBSERVATION_MODIFIER", 118, 124], ["thrombi", "OBSERVATION", 128, 135]]], ["No aneurysmal change was observed in phase 2 cases.Histological evaluations for implanted grafts after implantationHematoxylin and eosin staining revealed that HHP-decellularized graft did not contain cell nuclei indicating sufficient decellularization by HHP.", [["aneurysmal", "ANATOMY", 3, 13], ["grafts", "ANATOMY", 90, 96], ["graft", "ANATOMY", 179, 184], ["cell nuclei", "ANATOMY", 201, 212], ["Hematoxylin", "CHEMICAL", 115, 126], ["eosin", "CHEMICAL", 131, 136], ["grafts", "TISSUE", 90, 96], ["Hematoxylin", "SIMPLE_CHEMICAL", 115, 126], ["cell nuclei", "CELL", 201, 212], ["aneurysmal change", "PROBLEM", 3, 20], ["Histological evaluations", "TEST", 51, 75], ["implanted grafts", "TREATMENT", 80, 96], ["implantationHematoxylin", "TREATMENT", 103, 126], ["eosin staining", "TEST", 131, 145], ["HHP-decellularized graft", "TREATMENT", 160, 184], ["cell nuclei", "PROBLEM", 201, 212], ["aneurysmal", "OBSERVATION", 3, 13], ["decellularized graft", "OBSERVATION", 164, 184], ["cell nuclei", "OBSERVATION", 201, 212], ["sufficient decellularization", "OBSERVATION", 224, 252]]], ["On the other hand, recellularization in whole layers of the grafts was confirmed at 4 weeks after implantation (Fig. 4A) .", [["whole layers", "ANATOMY", 40, 52], ["grafts", "ANATOMY", 60, 66], ["grafts", "TISSUE", 60, 66], ["recellularization", "TREATMENT", 19, 36], ["the grafts", "TREATMENT", 56, 66], ["grafts", "OBSERVATION", 60, 66]]], ["Elastica van Gieson staining and Sirius red staining exhibited a fair preservation of elastin layer (internal elastic lamina), tunica media consisted of collagen fibers and stratified elastin layers in HHP-decellularized grafts, and recellularization at 4 weeks after implantation, respectively (Fig. 4B) .", [["elastin layer", "ANATOMY", 86, 99], ["elastic lamina", "ANATOMY", 110, 124], ["collagen fibers", "ANATOMY", 153, 168], ["elastin layers", "ANATOMY", 184, 198], ["grafts", "ANATOMY", 221, 227], ["elastic lamina", "TISSUE", 110, 124], ["tunica", "TISSUE", 127, 133], ["collagen", "GENE_OR_GENE_PRODUCT", 153, 161], ["elastin layers", "TISSUE", 184, 198], ["grafts", "TISSUE", 221, 227], ["Sirius red staining", "TEST", 33, 52], ["elastin layer (internal elastic lamina)", "PROBLEM", 86, 125], ["tunica media", "TREATMENT", 127, 139], ["collagen fibers", "PROBLEM", 153, 168], ["stratified elastin layers", "TREATMENT", 173, 198], ["HHP-decellularized grafts", "TREATMENT", 202, 227], ["recellularization", "TREATMENT", 233, 250], ["implantation", "TREATMENT", 268, 280], ["fair", "OBSERVATION_MODIFIER", 65, 69], ["preservation", "OBSERVATION_MODIFIER", 70, 82], ["elastin layer", "OBSERVATION", 86, 99], ["internal", "ANATOMY_MODIFIER", 101, 109], ["elastic lamina", "OBSERVATION", 110, 124], ["tunica media", "ANATOMY", 127, 139], ["collagen fibers", "OBSERVATION", 153, 168], ["elastin layers", "OBSERVATION", 184, 198], ["decellularized grafts", "OBSERVATION", 206, 227]]], ["Polarized microscopical observations for striated elastin layer revealed that collagen I deposition was preserved among the elastin layers before implantation, and newly produced collagen III were deposited at the same region after implantation (Supplemental Fig. 1) .Histological evaluations for implanted grafts after implantationImmunostaining for von Willebrand Factor-positive endothelium revealed that the intima of implanted grafts was fairly covered by an endothelial cell layer throughout the graft (Fig. 4C) . \u03b1-smooth muscle actin (\u03b1SMA)-positive vascular smooth muscle cells are observed among tunica media (Fig. 4D) .", [["elastin layers", "ANATOMY", 124, 138], ["grafts", "ANATOMY", 307, 313], ["endothelium", "ANATOMY", 382, 393], ["intima", "ANATOMY", 412, 418], ["grafts", "ANATOMY", 432, 438], ["endothelial cell layer", "ANATOMY", 464, 486], ["graft", "ANATOMY", 502, 507], ["vascular smooth muscle cells", "ANATOMY", 558, 586], ["elastin", "GENE_OR_GENE_PRODUCT", 50, 57], ["collagen I", "GENE_OR_GENE_PRODUCT", 78, 88], ["elastin layers", "TISSUE", 124, 138], ["collagen III", "GENE_OR_GENE_PRODUCT", 179, 191], ["grafts", "TISSUE", 307, 313], ["von Willebrand Factor", "GENE_OR_GENE_PRODUCT", 351, 372], ["intima", "TISSUE", 412, 418], ["grafts", "TISSUE", 432, 438], ["endothelial cell layer", "TISSUE", 464, 486], ["graft", "TISSUE", 502, 507], ["\u03b1-smooth muscle actin", "GENE_OR_GENE_PRODUCT", 520, 541], ["\u03b1SMA", "GENE_OR_GENE_PRODUCT", 543, 547], ["collagen I", "PROTEIN", 78, 88], ["collagen III", "PROTEIN", 179, 191], ["von Willebrand Factor", "PROTEIN", 351, 372], ["\u03b1-smooth muscle actin (\u03b1SMA)-positive vascular smooth muscle cells", "CELL_LINE", 520, 586], ["Polarized microscopical observations", "TEST", 0, 36], ["striated elastin layer", "PROBLEM", 41, 63], ["collagen I deposition", "PROBLEM", 78, 99], ["the elastin layers", "TREATMENT", 120, 138], ["implantation", "TREATMENT", 146, 158], ["newly produced collagen III", "PROBLEM", 164, 191], ["implantation (Supplemental Fig", "TREATMENT", 232, 262], ["Histological evaluations", "TEST", 268, 292], ["implanted grafts", "TREATMENT", 297, 313], ["implantation", "TREATMENT", 320, 332], ["von Willebrand Factor", "TEST", 351, 372], ["positive endothelium", "PROBLEM", 373, 393], ["the intima of implanted grafts", "TREATMENT", 408, 438], ["an endothelial cell layer throughout the graft", "TREATMENT", 461, 507], ["positive vascular smooth muscle cells", "PROBLEM", 549, 586], ["collagen", "OBSERVATION", 78, 86], ["elastin", "OBSERVATION_MODIFIER", 124, 131], ["layers", "OBSERVATION_MODIFIER", 132, 138], ["collagen III", "OBSERVATION_MODIFIER", 179, 191], ["implantation", "OBSERVATION", 232, 244], ["intima", "ANATOMY", 412, 418], ["implanted grafts", "OBSERVATION", 422, 438], ["endothelial cell", "OBSERVATION", 464, 480], ["layer", "OBSERVATION_MODIFIER", 481, 486], ["graft", "OBSERVATION", 502, 507], ["muscle", "ANATOMY", 529, 535], ["actin", "OBSERVATION", 536, 541], ["SMA", "ANATOMY", 544, 547], ["vascular smooth", "ANATOMY", 558, 573], ["muscle cells", "OBSERVATION", 574, 586]]], ["These results indicate that the HHPdecellularized vascular grafts are recellularized by host-derived vascular cells in accordance with the anatomical allocations of native arteries.Histological evaluations for implanted grafts after implantationWe evaluated the stenotic regions in proximities of proximal and distal anastomoses.", [["vascular grafts", "ANATOMY", 50, 65], ["vascular cells", "ANATOMY", 101, 115], ["arteries", "ANATOMY", 172, 180], ["grafts", "ANATOMY", 220, 226], ["vascular grafts", "TISSUE", 50, 65], ["host-derived vascular cells", "CELL", 88, 115], ["arteries", "MULTI-TISSUE_STRUCTURE", 172, 180], ["grafts", "TISSUE", 220, 226], ["host-derived vascular cells", "CELL_TYPE", 88, 115], ["the HHPdecellularized vascular grafts", "TREATMENT", 28, 65], ["Histological evaluations", "TEST", 181, 205], ["implanted grafts", "TREATMENT", 210, 226], ["implantationWe", "TREATMENT", 233, 247], ["vascular", "ANATOMY", 50, 58], ["grafts", "OBSERVATION", 59, 65], ["vascular cells", "OBSERVATION", 101, 115], ["native arteries", "ANATOMY", 165, 180], ["grafts", "OBSERVATION", 220, 226], ["stenotic", "OBSERVATION", 262, 270], ["proximal", "ANATOMY_MODIFIER", 297, 305], ["distal", "OBSERVATION_MODIFIER", 310, 316], ["anastomoses", "OBSERVATION", 317, 328]]], ["Hematoxylin and eosin staining exhibited that the hypertrophic regions are filled with proliferated cellular components.", [["cellular", "ANATOMY", 100, 108], ["Hematoxylin", "CHEMICAL", 0, 11], ["eosin", "CHEMICAL", 16, 21], ["Hematoxylin", "SIMPLE_CHEMICAL", 0, 11], ["cellular", "CELL", 100, 108], ["Hematoxylin", "TEST", 0, 11], ["eosin staining", "TEST", 16, 30], ["the hypertrophic regions", "PROBLEM", 46, 70], ["proliferated cellular components", "PROBLEM", 87, 119], ["hypertrophic", "OBSERVATION_MODIFIER", 50, 62], ["filled", "OBSERVATION_MODIFIER", 75, 81], ["proliferated", "OBSERVATION_MODIFIER", 87, 99], ["cellular components", "OBSERVATION", 100, 119]]], ["Immunostaining for von Willebrand Factor revealed thin endothelial cell layer covering the luminal surface.", [["endothelial cell layer", "ANATOMY", 55, 77], ["luminal surface", "ANATOMY", 91, 106], ["luminal", "CHEMICAL", 91, 98], ["von Willebrand Factor", "GENE_OR_GENE_PRODUCT", 19, 40], ["endothelial cell layer", "TISSUE", 55, 77], ["luminal surface", "CELLULAR_COMPONENT", 91, 106], ["von Willebrand Factor", "PROTEIN", 19, 40], ["Immunostaining", "TEST", 0, 14], ["von Willebrand Factor", "TEST", 19, 40], ["thin endothelial cell layer", "PROBLEM", 50, 77], ["thin endothelial cell", "OBSERVATION", 50, 71], ["layer", "OBSERVATION_MODIFIER", 72, 77], ["luminal", "ANATOMY_MODIFIER", 91, 98], ["surface", "ANATOMY_MODIFIER", 99, 106]]], ["Immunostaining for \u03b1SMA showed that the stenotic region was mainly consisted of proliferated smooth muscle cells located between surface endothelial cell layer and internal elastic lamina ( Fig 4E) .Histological evaluations for implanted grafts after implantationVon Kossa staining showed small deposition of calcified nodules close to the suture line which are not observed in another region of the graft (Supplemental Fig. 2) .We evaluated the infiltration of inflammatory cells toward the implanted grafts.", [["stenotic region", "ANATOMY", 40, 55], ["smooth muscle cells", "ANATOMY", 93, 112], ["surface endothelial cell layer", "ANATOMY", 129, 159], ["internal elastic lamina", "ANATOMY", 164, 187], ["grafts", "ANATOMY", 238, 244], ["nodules", "ANATOMY", 319, 326], ["suture line", "ANATOMY", 340, 351], ["graft", "ANATOMY", 400, 405], ["inflammatory cells", "ANATOMY", 462, 480], ["grafts", "ANATOMY", 502, 508], ["\u03b1SMA", "GENE_OR_GENE_PRODUCT", 19, 23], ["smooth muscle cells", "CELL", 93, 112], ["surface", "CELLULAR_COMPONENT", 129, 136], ["endothelial cell layer", "TISSUE", 137, 159], ["elastic lamina", "CELLULAR_COMPONENT", 173, 187], ["grafts", "TISSUE", 238, 244], ["graft", "TISSUE", 400, 405], ["inflammatory cells", "CELL", 462, 480], ["grafts", "TISSUE", 502, 508], ["\u03b1SMA", "PROTEIN", 19, 23], ["proliferated smooth muscle cells", "CELL_TYPE", 80, 112], ["inflammatory cells", "CELL_TYPE", 462, 480], ["Immunostaining for \u03b1SMA", "TEST", 0, 23], ["the stenotic region", "PROBLEM", 36, 55], ["proliferated smooth muscle cells", "PROBLEM", 80, 112], ["internal elastic lamina ( Fig 4E", "TREATMENT", 164, 196], ["Histological evaluations", "TEST", 199, 223], ["implanted grafts", "TREATMENT", 228, 244], ["implantationVon Kossa staining", "TEST", 251, 281], ["small deposition of calcified nodules", "PROBLEM", 289, 326], ["the suture line", "TREATMENT", 336, 351], ["the graft", "TREATMENT", 396, 405], ["Supplemental Fig", "TREATMENT", 407, 423], ["inflammatory cells", "PROBLEM", 462, 480], ["the implanted grafts", "TREATMENT", 488, 508], ["SMA", "ANATOMY", 20, 23], ["stenotic", "OBSERVATION", 40, 48], ["proliferated", "OBSERVATION_MODIFIER", 80, 92], ["smooth muscle cells", "OBSERVATION", 93, 112], ["surface", "OBSERVATION_MODIFIER", 129, 136], ["endothelial cell", "OBSERVATION", 137, 153], ["layer", "OBSERVATION_MODIFIER", 154, 159], ["internal", "ANATOMY_MODIFIER", 164, 172], ["elastic lamina", "OBSERVATION", 173, 187], ["small", "OBSERVATION_MODIFIER", 289, 294], ["deposition", "OBSERVATION_MODIFIER", 295, 305], ["calcified", "OBSERVATION_MODIFIER", 309, 318], ["nodules", "OBSERVATION", 319, 326], ["suture line", "OBSERVATION", 340, 351], ["not observed", "UNCERTAINTY", 362, 374], ["graft", "OBSERVATION", 400, 405], ["Supplemental Fig", "OBSERVATION", 407, 423], ["infiltration", "OBSERVATION", 446, 458], ["inflammatory cells", "OBSERVATION", 462, 480], ["implanted grafts", "OBSERVATION", 492, 508]]], ["CD45immunostaining revealed that the implanted grafts were not infiltrated with inflammatory cells except some regions close to luminal surface (Supplemental Fig. 3 ).SEMThe ultrastructure of luminal surface of vessels are evaluated by SEM.", [["grafts", "ANATOMY", 47, 53], ["inflammatory cells", "ANATOMY", 80, 98], ["luminal surface", "ANATOMY", 128, 143], ["luminal surface", "ANATOMY", 192, 207], ["vessels", "ANATOMY", 211, 218], ["luminal", "CHEMICAL", 128, 135], ["luminal", "CHEMICAL", 192, 199], ["grafts", "TISSUE", 47, 53], ["cells", "CELL", 93, 98], ["luminal surface", "CELLULAR_COMPONENT", 128, 143], ["luminal surface", "MULTI-TISSUE_STRUCTURE", 192, 207], ["vessels", "MULTI-TISSUE_STRUCTURE", 211, 218], ["inflammatory cells", "CELL_TYPE", 80, 98], ["CD45immunostaining", "TEST", 0, 18], ["the implanted grafts", "TREATMENT", 33, 53], ["inflammatory cells", "PROBLEM", 80, 98], ["implanted grafts", "OBSERVATION", 37, 53], ["not", "UNCERTAINTY", 59, 62], ["infiltrated", "OBSERVATION_MODIFIER", 63, 74], ["inflammatory cells", "OBSERVATION", 80, 98], ["luminal", "ANATOMY_MODIFIER", 128, 135], ["surface", "OBSERVATION_MODIFIER", 136, 143], ["luminal", "ANATOMY_MODIFIER", 192, 199], ["surface", "ANATOMY_MODIFIER", 200, 207], ["vessels", "ANATOMY", 211, 218]]], ["The luminal surface of native bovine artery (graft animal) was covered with endothelium exhibiting cobblestone-like appearance (Fig. 5A) .", [["luminal surface", "ANATOMY", 4, 19], ["bovine artery", "ANATOMY", 30, 43], ["graft", "ANATOMY", 45, 50], ["endothelium", "ANATOMY", 76, 87], ["luminal", "CHEMICAL", 4, 11], ["luminal surface", "CELLULAR_COMPONENT", 4, 19], ["bovine", "ORGANISM", 30, 36], ["artery", "MULTI-TISSUE_STRUCTURE", 37, 43], ["graft", "TISSUE", 45, 50], ["endothelium", "TISSUE", 76, 87], ["bovine", "SPECIES", 30, 36], ["native bovine artery (graft", "TREATMENT", 23, 50], ["luminal", "ANATOMY_MODIFIER", 4, 11], ["surface", "ANATOMY_MODIFIER", 12, 19], ["native bovine artery", "ANATOMY", 23, 43], ["graft", "OBSERVATION", 45, 50], ["endothelium", "ANATOMY", 76, 87], ["cobblestone", "OBSERVATION", 99, 110]]], ["After decellularization by HHP processes, the luminal surface of decellularized grafts exhibited acellular smooth surface without endothelium (Fig. 5B) .", [["luminal surface", "ANATOMY", 46, 61], ["grafts", "ANATOMY", 80, 86], ["smooth surface", "ANATOMY", 107, 121], ["endothelium", "ANATOMY", 130, 141], ["luminal", "CHEMICAL", 46, 53], ["luminal surface", "CELLULAR_COMPONENT", 46, 61], ["grafts", "TISSUE", 80, 86], ["smooth surface", "TISSUE", 107, 121], ["endothelium", "TISSUE", 130, 141], ["decellularization", "TREATMENT", 6, 23], ["the luminal surface of decellularized grafts", "TREATMENT", 42, 86], ["luminal", "ANATOMY_MODIFIER", 46, 53], ["surface", "OBSERVATION_MODIFIER", 54, 61], ["decellularized grafts", "OBSERVATION", 65, 86], ["acellular", "ANATOMY_MODIFIER", 97, 106], ["smooth", "OBSERVATION_MODIFIER", 107, 113], ["surface", "OBSERVATION_MODIFIER", 114, 121], ["without", "UNCERTAINTY", 122, 129], ["endothelium", "OBSERVATION", 130, 141]]], ["The luminal surface of decellularized bovine graft implanted at porcine carotid artery for 4 weeks showed endothelium with cobblestone-like appearance by fair recellularization similar with those in bovine and porcine native arteries (recipient animal) (Fig. 5A , C, D).", [["luminal surface", "ANATOMY", 4, 19], ["graft", "ANATOMY", 45, 50], ["carotid artery", "ANATOMY", 72, 86], ["endothelium", "ANATOMY", 106, 117], ["arteries", "ANATOMY", 225, 233], ["luminal", "CHEMICAL", 4, 11], ["luminal surface", "CELLULAR_COMPONENT", 4, 19], ["bovine", "ORGANISM", 38, 44], ["graft", "TISSUE", 45, 50], ["carotid artery", "MULTI-TISSUE_STRUCTURE", 72, 86], ["endothelium", "TISSUE", 106, 117], ["bovine", "ORGANISM", 199, 205], ["porcine", "ORGANISM", 210, 217], ["arteries", "MULTI-TISSUE_STRUCTURE", 225, 233], ["bovine", "SPECIES", 38, 44], ["bovine", "SPECIES", 199, 205], ["porcine", "SPECIES", 210, 217], ["bovine", "SPECIES", 199, 205], ["porcine", "SPECIES", 210, 217], ["decellularized bovine graft", "TREATMENT", 23, 50], ["endothelium", "PROBLEM", 106, 117], ["cobblestone-like appearance", "PROBLEM", 123, 150], ["those in bovine and porcine native arteries", "TREATMENT", 190, 233], ["luminal", "ANATOMY_MODIFIER", 4, 11], ["surface", "OBSERVATION_MODIFIER", 12, 19], ["decellularized", "OBSERVATION_MODIFIER", 23, 37], ["bovine graft", "OBSERVATION", 38, 50], ["implanted", "OBSERVATION", 51, 60], ["porcine", "ANATOMY_MODIFIER", 64, 71], ["carotid artery", "ANATOMY", 72, 86], ["endothelium", "OBSERVATION", 106, 117], ["cobblestone", "OBSERVATION", 123, 134], ["porcine", "ANATOMY_MODIFIER", 210, 217], ["native arteries", "ANATOMY", 218, 233]]], ["For patients requiring revascularization surgery, unavailability of autologous bypass grafts may lead to loss of an opportunity for appropriate therapy and consequent poor prognosis.", [["grafts", "ANATOMY", 86, 92], ["patients", "ORGANISM", 4, 12], ["grafts", "TISSUE", 86, 92], ["patients", "SPECIES", 4, 12], ["revascularization surgery", "TREATMENT", 23, 48], ["autologous bypass grafts", "TREATMENT", 68, 92], ["appropriate therapy", "TREATMENT", 132, 151]]], ["Although cryopreserved arterial allografts can be a surrogate for autologous small-caliber grafts with acceptable long-term patency, the availability is rather limited because of the shortage of donors and insufficient operation of organ / tissue banks to preserve and provide allografts [15] [16] [17] .", [["arterial allografts", "ANATOMY", 23, 42], ["small-caliber grafts", "ANATOMY", 77, 97], ["organ", "ANATOMY", 232, 237], ["tissue", "ANATOMY", 240, 246], ["arterial allografts", "MULTI-TISSUE_STRUCTURE", 23, 42], ["grafts", "TISSUE", 91, 97], ["donors", "ORGANISM", 195, 201], ["organ", "ORGAN", 232, 237], ["tissue", "TISSUE", 240, 246], ["cryopreserved arterial allografts", "TREATMENT", 9, 42], ["autologous small-caliber grafts", "TREATMENT", 66, 97], ["donors", "TREATMENT", 195, 201], ["insufficient operation", "TREATMENT", 206, 228], ["organ / tissue banks", "TREATMENT", 232, 252], ["arterial", "ANATOMY", 23, 31], ["allografts", "OBSERVATION", 32, 42], ["caliber", "OBSERVATION_MODIFIER", 83, 90], ["grafts", "OBSERVATION", 91, 97], ["long-term patency", "OBSERVATION_MODIFIER", 114, 131]]], ["The present study was designed to address this healthcare problem through validating the feasibility of xenogeneic implantation of HHP-decellularized vascular grafts using bovine arterial grafts and a porcine carotid arterial interpose model.SEMNumerous methods for decellularization of living tissues have been reported so far [18] [19] [20] .", [["vascular grafts", "ANATOMY", 150, 165], ["arterial grafts", "ANATOMY", 179, 194], ["carotid arterial", "ANATOMY", 209, 225], ["tissues", "ANATOMY", 294, 301], ["vascular grafts", "TISSUE", 150, 165], ["bovine", "ORGANISM", 172, 178], ["arterial grafts", "MULTI-TISSUE_STRUCTURE", 179, 194], ["carotid arterial", "MULTI-TISSUE_STRUCTURE", 209, 225], ["tissues", "TISSUE", 294, 301], ["[18] [19] [20]", "SIMPLE_CHEMICAL", 328, 342], ["bovine", "SPECIES", 172, 178], ["bovine", "SPECIES", 172, 178], ["The present study", "TEST", 0, 17], ["xenogeneic implantation of HHP", "TREATMENT", 104, 134], ["decellularized vascular grafts", "TREATMENT", 135, 165], ["bovine arterial grafts", "TREATMENT", 172, 194], ["a porcine carotid arterial interpose model", "TREATMENT", 199, 241], ["decellularization of living tissues", "TREATMENT", 266, 301], ["vascular", "ANATOMY", 150, 158], ["grafts", "OBSERVATION", 159, 165], ["bovine arterial grafts", "OBSERVATION", 172, 194], ["carotid arterial", "ANATOMY", 209, 225]]], ["In previous reports of the implantation of decellularized small-caliber vascular grafts by chemical or biological decellularization methods, insufficient outcomes such as graft occlusion, thrombus formation, and intimal proliferation throughout the graft were observed [21, 22] .", [["vascular grafts", "ANATOMY", 72, 87], ["graft", "ANATOMY", 171, 176], ["thrombus", "ANATOMY", 188, 196], ["intimal", "ANATOMY", 212, 219], ["graft", "ANATOMY", 249, 254], ["thrombus", "DISEASE", 188, 196], ["vascular grafts", "MULTI-TISSUE_STRUCTURE", 72, 87], ["graft", "TISSUE", 171, 176], ["thrombus", "PATHOLOGICAL_FORMATION", 188, 196], ["intimal", "TISSUE", 212, 219], ["graft", "TISSUE", 249, 254], ["the implantation", "TREATMENT", 23, 39], ["decellularized small-caliber vascular grafts", "TREATMENT", 43, 87], ["biological decellularization methods", "TREATMENT", 103, 139], ["insufficient outcomes", "PROBLEM", 141, 162], ["graft occlusion", "TREATMENT", 171, 186], ["thrombus formation", "PROBLEM", 188, 206], ["intimal proliferation throughout the graft", "PROBLEM", 212, 254], ["implantation", "OBSERVATION", 27, 39], ["decellularized", "OBSERVATION_MODIFIER", 43, 57], ["small", "OBSERVATION_MODIFIER", 58, 63], ["caliber", "OBSERVATION_MODIFIER", 64, 71], ["vascular", "ANATOMY", 72, 80], ["grafts", "OBSERVATION", 81, 87], ["biological decellularization", "OBSERVATION", 103, 131], ["graft occlusion", "OBSERVATION", 171, 186], ["thrombus", "OBSERVATION", 188, 196], ["intimal", "OBSERVATION_MODIFIER", 212, 219], ["proliferation", "OBSERVATION_MODIFIER", 220, 233], ["graft", "OBSERVATION", 249, 254]]], ["We previously reported that the HHP decellularization, a novel method utilizing a physical basis can almost completely wash out the cellular components of porcine aorta and radial arteries with preserved mechanical properties such as elastic modulus [9] .", [["cellular", "ANATOMY", 132, 140], ["aorta", "ANATOMY", 163, 168], ["radial arteries", "ANATOMY", 173, 188], ["cellular", "CELL", 132, 140], ["porcine", "ORGANISM", 155, 162], ["aorta", "MULTI-TISSUE_STRUCTURE", 163, 168], ["radial arteries", "MULTI-TISSUE_STRUCTURE", 173, 188], ["the HHP decellularization", "TREATMENT", 28, 53], ["porcine", "ANATOMY_MODIFIER", 155, 162], ["aorta", "ANATOMY", 163, 168], ["radial arteries", "ANATOMY", 173, 188], ["preserved", "OBSERVATION", 194, 203], ["mechanical properties", "OBSERVATION", 204, 225], ["elastic modulus", "OBSERVATION", 234, 249]]], ["In the present study, we decellularized bovine dorsalis pedis arteries by HHP and confirmed that the efficiency of cellular wash-out was >99% calculated by residual DNA amounts compared to those of untreated bovine dorsalis pedis artery.", [["dorsalis pedis arteries", "ANATOMY", 47, 70], ["cellular", "ANATOMY", 115, 123], ["dorsalis pedis artery", "ANATOMY", 215, 236], ["bovine", "ORGANISM", 40, 46], ["dorsalis pedis arteries", "MULTI-TISSUE_STRUCTURE", 47, 70], ["cellular", "CELL", 115, 123], ["DNA", "CELLULAR_COMPONENT", 165, 168], ["bovine", "ORGANISM", 208, 214], ["dorsalis pedis artery", "MULTI-TISSUE_STRUCTURE", 215, 236], ["bovine", "SPECIES", 40, 46], ["bovine", "SPECIES", 208, 214], ["cellular wash", "TEST", 115, 128], ["residual DNA amounts", "PROBLEM", 156, 176], ["untreated bovine dorsalis pedis artery", "TREATMENT", 198, 236], ["dorsalis pedis arteries", "ANATOMY", 47, 70], ["untreated", "OBSERVATION", 198, 207], ["bovine", "ANATOMY_MODIFIER", 208, 214], ["dorsalis pedis artery", "ANATOMY", 215, 236]]], ["Residual DNA amounts in the present study (15.85 \u00b1 2.15 ng/mg) satisfied the recommended criteria of successful decellularization as <50 ng/mg [23] .", [["DNA", "CELLULAR_COMPONENT", 9, 12], ["Residual DNA amounts", "PROBLEM", 0, 20], ["the present study", "TEST", 24, 41], ["successful decellularization", "TREATMENT", 101, 129], ["DNA", "OBSERVATION_MODIFIER", 9, 12], ["amounts", "OBSERVATION_MODIFIER", 13, 20]]], ["In mechanical tensile tests, there was no significant difference between HHP-decellularized and native arteries in the early and late elastic modulus representing the elastin phase and the collagen phase, respectively [24] .", [["arteries", "ANATOMY", 103, 111], ["decellularized", "TISSUE", 77, 91], ["arteries", "MULTI-TISSUE_STRUCTURE", 103, 111], ["collagen", "GENE_OR_GENE_PRODUCT", 189, 197], ["mechanical tensile tests", "TEST", 3, 27], ["the elastin phase", "TEST", 163, 180], ["mechanical tensile", "OBSERVATION", 3, 21], ["no", "UNCERTAINTY", 39, 41], ["significant", "OBSERVATION_MODIFIER", 42, 53], ["difference", "OBSERVATION", 54, 64], ["decellularized", "OBSERVATION", 77, 91], ["native arteries", "ANATOMY", 96, 111], ["early", "OBSERVATION_MODIFIER", 119, 124], ["late", "OBSERVATION_MODIFIER", 129, 133], ["elastic modulus", "OBSERVATION", 134, 149], ["elastin phase", "OBSERVATION_MODIFIER", 167, 180], ["collagen phase", "OBSERVATION_MODIFIER", 189, 203]]], ["In the present study, implantation surgeries were performed in 2 phases which were different in surgical conditions especially in moist conditions of the graft (Phase 1; conventional condition, Phase 2; no touch of luminal surface of the graft keeping moist condition).", [["luminal surface", "ANATOMY", 215, 230], ["graft", "ANATOMY", 238, 243], ["luminal", "CHEMICAL", 215, 222], ["graft", "TISSUE", 154, 159], ["graft", "TISSUE", 238, 243], ["the present study", "TEST", 3, 20], ["implantation surgeries", "TREATMENT", 22, 44], ["the graft", "TREATMENT", 150, 159], ["the graft", "TREATMENT", 234, 243], ["surgical conditions", "OBSERVATION", 96, 115], ["graft", "OBSERVATION", 154, 159], ["luminal", "ANATOMY_MODIFIER", 215, 222], ["graft", "OBSERVATION", 238, 243]]], ["Flow patterns in 2 phases immediately after implantation did not differ each other, indicating that the qualities of anastomoses were not different in the 2 phases.SEMHowever, the patency was significantly lower in Phase 1 compared to that in Phase 2 at 4 weeks after implantation.", [["Flow patterns", "TEST", 0, 13], ["implantation", "TREATMENT", 44, 56], ["anastomoses", "TREATMENT", 117, 128], ["implantation", "TREATMENT", 268, 280], ["anastomoses", "OBSERVATION", 117, 128], ["patency", "OBSERVATION_MODIFIER", 180, 187], ["significantly", "OBSERVATION_MODIFIER", 192, 205], ["lower", "OBSERVATION_MODIFIER", 206, 211]]], ["In Phase 1, all implanted grafts were resulted in thromboembolism, whereas all grafts in Phase 2 were patent with small amount of thrombi without any postoperative antiplatelet drugs or anticoagulants.", [["grafts", "ANATOMY", 26, 32], ["grafts", "ANATOMY", 79, 85], ["thrombi", "ANATOMY", 130, 137], ["antiplatelet", "ANATOMY", 164, 176], ["thromboembolism", "DISEASE", 50, 65], ["thrombi", "DISEASE", 130, 137], ["grafts", "TISSUE", 26, 32], ["grafts", "TISSUE", 79, 85], ["all implanted grafts", "TREATMENT", 12, 32], ["thromboembolism", "PROBLEM", 50, 65], ["thrombi", "PROBLEM", 130, 137], ["postoperative antiplatelet drugs", "TREATMENT", 150, 182], ["anticoagulants", "TREATMENT", 186, 200], ["implanted", "OBSERVATION_MODIFIER", 16, 25], ["grafts", "OBSERVATION", 26, 32], ["thromboembolism", "OBSERVATION", 50, 65], ["grafts", "OBSERVATION", 79, 85], ["patent", "OBSERVATION", 102, 108], ["small", "OBSERVATION_MODIFIER", 114, 119], ["amount", "OBSERVATION_MODIFIER", 120, 126], ["thrombi", "OBSERVATION", 130, 137]]], ["These results suggest that the luminal surface of HHP-decellularized vascular grafts possesses fair antithrombogenicity when the intimal surface was not damaged by intraoperative grasping or drying.", [["luminal surface", "ANATOMY", 31, 46], ["vascular grafts", "ANATOMY", 69, 84], ["intimal surface", "ANATOMY", 129, 144], ["luminal", "CHEMICAL", 31, 38], ["luminal surface", "CELLULAR_COMPONENT", 31, 46], ["vascular grafts", "TISSUE", 69, 84], ["intimal surface", "TISSUE", 129, 144], ["decellularized vascular grafts", "TREATMENT", 54, 84], ["luminal", "ANATOMY_MODIFIER", 31, 38], ["surface", "OBSERVATION_MODIFIER", 39, 46], ["decellularized", "OBSERVATION", 54, 68], ["vascular", "ANATOMY", 69, 77], ["grafts", "OBSERVATION", 78, 84], ["intimal", "OBSERVATION_MODIFIER", 129, 136], ["surface", "OBSERVATION_MODIFIER", 137, 144], ["not", "UNCERTAINTY", 149, 152], ["damaged", "OBSERVATION_MODIFIER", 153, 160]]], ["Although a careful manipulation would be required in bypass grafting surgeries, HHP-decellularized vascular grafts might hold promise as a novel vascular graft without antiplatelet agents or anticoagulants in the future.CONCLUSIONXenogeneic HHP decellularized graft showed feasible capacity for recellularization and vascular remodeling without thrombogenicity.", [["vascular grafts", "ANATOMY", 99, 114], ["vascular", "ANATOMY", 145, 153], ["antiplatelet", "ANATOMY", 168, 180], ["vascular", "ANATOMY", 317, 325], ["vascular grafts", "TISSUE", 99, 114], ["vascular graft", "MULTI-TISSUE_STRUCTURE", 145, 159], ["antiplatelet agents", "SIMPLE_CHEMICAL", 168, 187], ["graft", "TISSUE", 260, 265], ["vascular", "MULTI-TISSUE_STRUCTURE", 317, 325], ["a careful manipulation", "TREATMENT", 9, 31], ["bypass grafting surgeries", "TREATMENT", 53, 78], ["HHP", "TREATMENT", 80, 83], ["decellularized vascular grafts", "TREATMENT", 84, 114], ["a novel vascular graft", "TREATMENT", 137, 159], ["antiplatelet agents", "TREATMENT", 168, 187], ["anticoagulants", "TREATMENT", 191, 205], ["CONCLUSIONXenogeneic HHP decellularized graft", "TREATMENT", 220, 265], ["feasible capacity", "PROBLEM", 273, 290], ["recellularization", "PROBLEM", 295, 312], ["vascular remodeling", "PROBLEM", 317, 336], ["thrombogenicity", "PROBLEM", 345, 360], ["bypass grafting", "OBSERVATION", 53, 68], ["vascular", "ANATOMY", 99, 107], ["grafts", "OBSERVATION", 108, 114], ["vascular", "ANATOMY", 145, 153], ["graft", "OBSERVATION", 154, 159], ["graft", "OBSERVATION", 260, 265], ["vascular", "ANATOMY", 317, 325], ["remodeling", "OBSERVATION", 326, 336], ["without", "UNCERTAINTY", 337, 344], ["thrombogenicity", "OBSERVATION", 345, 360]]], ["HHP decellularized vascular grafts may be utilized as new medical products for revascularization surgeries.", [["vascular grafts", "ANATOMY", 19, 34], ["vascular grafts", "TISSUE", 19, 34], ["HHP decellularized vascular grafts", "TREATMENT", 0, 34], ["new medical products", "TREATMENT", 54, 74], ["revascularization surgeries", "TREATMENT", 79, 106], ["vascular", "ANATOMY", 19, 27], ["grafts", "OBSERVATION", 28, 34]]]], "e26a92250c015babf746da24ccb5d75ceb37582b": [["However, previous studies showed that EHRs have issues, especially regarding the effective sharing of complete patient data between heterogeneous information technology (IT) systems [2] [3] [4] .", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["previous studies", "TEST", 9, 25]]], ["These interoperability issues, that lead to incompatible data exchange, hindering health care and research, need still heavy improvement and research [5] .IntroductionIn order to solve these problems, several standards have been proposed to represent and exchange electronic health data [6] [7] [8] [9] .", [["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 287, 302], ["These interoperability issues", "PROBLEM", 0, 29], ["these problems", "PROBLEM", 185, 199]]], ["Currently, the top standard is HL7, which provides a complete framework for the exchange, integration, sharing, and retrieval of electronic health information [9 ] .", [["the exchange", "TREATMENT", 76, 88]]], ["FHIR consists of two main parts -a content model (for clinical or administrative contents of the health records) in the form of 'resources', and a specification for the exchange of these resources [9] .", [["these resources", "TREATMENT", 181, 196]]], ["Although widely spread, FHIR presents some drawbacks, which are addressed by other standards.IntroductionopenEHR is another standard that comprises a set of open specifications for EHR architecture, aiming at enabling semantic health information interoperability between EHR systems. openEHR consists of a two-level framework: the reference model and the archetype model [12] .", [["EHR architecture", "TEST", 181, 197], ["widely", "OBSERVATION_MODIFIER", 9, 15], ["spread", "OBSERVATION_MODIFIER", 16, 22]]], ["The main approach difference between openEHR and FHIR is that archetypes are maximal datasets, expected to represent all the clinical content, while FHIR resources only contain the most commonly used clinical information, but can be extended with additional items for a specific use case.", [["main", "OBSERVATION_MODIFIER", 4, 8], ["approach", "OBSERVATION_MODIFIER", 9, 17], ["difference", "OBSERVATION", 18, 28], ["openEHR", "OBSERVATION_MODIFIER", 37, 44], ["maximal datasets", "OBSERVATION", 77, 93]]], ["Thus, openEHR archetype development is more prone to be performed by or with the direct involvement of healthcare professionals, who present the knowledge that is necessary to develop these maximal clinical content datasets [10, 14] .IntroductionPromoting the interchangeability of patient health information among different medical care providers and services, is crucial, namely in oncology.", [["patient", "ORGANISM", 282, 289], ["patient", "SPECIES", 282, 289]]], ["In fact, cancer has been considered, in many cases, a chronic disease [15] .", [["cancer", "ANATOMY", 9, 15], ["cancer", "DISEASE", 9, 15], ["cancer", "CANCER", 9, 15], ["cancer", "PROBLEM", 9, 15], ["a chronic disease", "PROBLEM", 52, 69], ["cancer", "OBSERVATION", 9, 15], ["chronic", "OBSERVATION_MODIFIER", 54, 61], ["disease", "OBSERVATION", 62, 69]]], ["The number of patients who live longer with the disease has increased [16] , stressing the care support on the healthcare systems.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["the disease", "PROBLEM", 44, 55]]], ["Furthermore, EHR has the potential to enhance oncological disease diagnosis and management, by allowing quicker pathology identification and, therefore, helping to prevent diagnostic delay, through alerts, reminders, personalized suggestions from clinical guidelines, among others [17] [18] [19] .", [["[17] [18] [19]", "SIMPLE_CHEMICAL", 281, 295]]], ["Nevertheless, many critical data in oncology, some crucial to treatment decisions, such as biomarkers, disease staging, including metastasis location, and disease progression [20] , do not have EHR support, while over half of the cancer variables are collected in an incomplete and unstructured form [21] .", [["cancer", "ANATOMY", 230, 236], ["cancer", "DISEASE", 230, 236], ["cancer", "CANCER", 230, 236], ["disease staging", "TEST", 103, 118], ["metastasis location", "PROBLEM", 130, 149], ["disease progression", "PROBLEM", 155, 174], ["EHR support", "TREATMENT", 194, 205], ["the cancer variables", "PROBLEM", 226, 246], ["metastasis", "OBSERVATION", 130, 140], ["cancer", "OBSERVATION", 230, 236]]], ["The potential importance of structured EHR data collection and interoperability is supported by the relevance given to the development of a guide with minimal common oncology Data Elements (mCODE\u2122), implemented in HL7 FHIR. mCODE\u2122 is an initiative intended to assemble a core set of structured data elements for oncology EHRs and is a step towards capturing research-quality data from the treatment of all cancer patients.", [["cancer", "ANATOMY", 406, 412], ["cancer", "DISEASE", 406, 412], ["cancer", "CANCER", 406, 412], ["patients", "ORGANISM", 413, 421], ["HL7 FHIR", "DNA", 214, 222], ["patients", "SPECIES", 413, 421], ["structured EHR data collection", "TEST", 28, 58], ["all cancer patients", "PROBLEM", 402, 421], ["cancer", "OBSERVATION", 406, 412]]], ["CodeX will expand around mCODE\u2122 to encompass additional use cases, accelerating opportunities to create a learning health system based on interoperable data and improved patient care [22] .", [["patient", "ORGANISM", 170, 177], ["patient", "SPECIES", 170, 177], ["interoperable data", "TEST", 138, 156]]], ["Also, in openEHR a few initiatives have been underway, namely targeting the development of oncology-specific archetypes. , for example, modeled chemotherapy guidelines, and, by reusing several existing archetypes and authoring new archetypes and templates, were able to represent a lymphoma treatment guideline into an openEHRtemplate [23] .", [["lymphoma", "ANATOMY", 282, 290], ["lymphoma", "DISEASE", 282, 290], ["lymphoma", "CANCER", 282, 290], ["modeled chemotherapy guidelines", "TREATMENT", 136, 167], ["a lymphoma treatment guideline", "TREATMENT", 280, 310], ["chemotherapy", "OBSERVATION", 144, 156], ["lymphoma", "OBSERVATION", 282, 290]]], ["The modelled archetypes, however, were not submitted nor peer-reviewed by the Clinical Knowledge Manager (CKM), an international archetype repository.", [["modelled", "OBSERVATION_MODIFIER", 4, 12], ["archetypes", "OBSERVATION", 13, 23]]], ["The openEHR-CKM has an ongoing project on cancer reporting; however, it is still very limited [24] .IntroductionNutrition management is particularly relevant regarding the care of cancer patients [25, 26] .", [["cancer", "ANATOMY", 42, 48], ["cancer", "ANATOMY", 180, 186], ["cancer", "DISEASE", 42, 48], ["cancer", "DISEASE", 180, 186], ["cancer", "CANCER", 42, 48], ["cancer", "CANCER", 180, 186], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["Nutrition management", "TREATMENT", 112, 132], ["cancer", "OBSERVATION", 42, 48]]], ["It is known that patients with cancer often present nutritional deficiencies, malnutrition and consequently weight loss up to 40%, depending on the type of cancer [27, 28] .", [["cancer", "ANATOMY", 31, 37], ["cancer", "ANATOMY", 156, 162], ["cancer", "DISEASE", 31, 37], ["nutritional deficiencies", "DISEASE", 52, 76], ["malnutrition", "DISEASE", 78, 90], ["weight loss", "DISEASE", 108, 119], ["cancer", "DISEASE", 156, 162], ["patients", "ORGANISM", 17, 25], ["cancer", "CANCER", 31, 37], ["cancer", "CANCER", 156, 162], ["patients", "SPECIES", 17, 25], ["cancer", "PROBLEM", 31, 37], ["nutritional deficiencies", "PROBLEM", 52, 76], ["malnutrition", "PROBLEM", 78, 90], ["weight loss", "PROBLEM", 108, 119], ["cancer", "PROBLEM", 156, 162], ["cancer", "OBSERVATION", 31, 37], ["nutritional deficiencies", "OBSERVATION", 52, 76], ["cancer", "OBSERVATION", 156, 162]]], ["These numbers led to the development of specific guidelines to support better nutrition care for cancer patients.", [["cancer", "ANATOMY", 97, 103], ["cancer", "DISEASE", 97, 103], ["cancer", "CANCER", 97, 103], ["patients", "ORGANISM", 104, 112], ["patients", "SPECIES", 104, 112], ["cancer patients", "PROBLEM", 97, 112]]], ["Nonetheless, current EHRs are not adapted to the specificities of nutrition care, namely with a lack of specific documentation on nutrition safety and effectiveness [29] .", [["nutrition care", "TREATMENT", 66, 80], ["nutrition safety", "TREATMENT", 130, 146]]], ["Despite the need to enhance EHR in oncology and nutrition contexts, studies approaching strategies to improve these issues are very scarce.", [["studies", "TEST", 68, 75]]], ["Developing specific templates to record clinical data suggested in guidelines for nutrition in cancer care can support a better access to clinical data and ultimately lead to better patient care, especially if using a standard that allows structured data representation and interoperability.IntroductionThe present study aimed to develop openEHR-archetypes capable of representing clinical concepts in nutrition for cancer care, as well as to develop an openEHR-template using the developed archetypes.Material and methodsThis study was performed using the approach suggested by Bacelar-Silva et al. [30] Braun et al. [31] and Moner et al. [32] , comprising the following sequential steps (Fig. 1 ).Clinical concepts identificationThe first task was to identify the clinical statements in the European Society for Clinical Nutrition and Metabolism (ESPEN) guideline on nutrition for cancer patients [26] .", [["cancer", "ANATOMY", 95, 101], ["cancer", "ANATOMY", 416, 422], ["cancer", "ANATOMY", 883, 889], ["cancer", "DISEASE", 95, 101], ["cancer", "DISEASE", 416, 422], ["cancer", "DISEASE", 883, 889], ["cancer", "CANCER", 95, 101], ["patient", "ORGANISM", 182, 189], ["cancer", "CANCER", 416, 422], ["cancer", "CANCER", 883, 889], ["patients", "ORGANISM", 890, 898], ["patient", "SPECIES", 182, 189], ["patients", "SPECIES", 890, 898], ["clinical data", "TEST", 40, 53], ["nutrition in cancer care", "TREATMENT", 82, 106], ["clinical data", "TEST", 138, 151], ["The present study", "TEST", 303, 320], ["cancer care", "TREATMENT", 416, 427], ["an openEHR-template", "TREATMENT", 451, 470], ["This study", "TEST", 522, 532], ["the approach", "TREATMENT", 553, 565], ["Clinical Nutrition and Metabolism (ESPEN)", "TREATMENT", 814, 855]]], ["This guideline was chosen because it is the most up to date in supporting nutrition management in cancer patients.", [["cancer", "ANATOMY", 98, 104], ["cancer", "DISEASE", 98, 104], ["cancer", "CANCER", 98, 104], ["patients", "ORGANISM", 105, 113], ["patients", "SPECIES", 105, 113], ["nutrition management", "TREATMENT", 74, 94], ["cancer", "OBSERVATION", 98, 104]]], ["The task was performed by three authors, one nutritionist, and two physicians, that independently identified and listed the clinical statements (e.g. body composition, body mass index) within the ESPEN guidelines.", [["body", "ANATOMY", 150, 154], ["body", "ANATOMY", 168, 172], ["body", "ORGANISM_SUBDIVISION", 150, 154], ["body", "ORGANISM_SUBDIVISION", 168, 172]]], ["Thereafter, the identified clinical statements were organized and structured as archetype-friendly concepts, as described by Bacelar-Silva et al. [30] and Maranh\u00e3o et al. [33] .Clinical concepts identificationAfter reviewing the ESPEN guidelines on nutrition for cancer patients, the authors identified 71 clinical statements and organized them into 23 archetype-friendly concepts (Table 1) .Clinical Knowledge Manager (CKM) analysisSubsequently, a CKM analysis was performed.", [["cancer", "ANATOMY", 263, 269], ["cancer", "DISEASE", 263, 269], ["cancer", "CANCER", 263, 269], ["patients", "ORGANISM", 270, 278], ["patients", "SPECIES", 270, 278], ["cancer", "PROBLEM", 263, 269], ["a CKM analysis", "TEST", 447, 461]]], ["CKM repositories, namely international (International CKM -http://www.openehr.org/ ckm/), Australia (NEHTA -http://dcm.nehta.org.au/ckm/) and United Kingdom (NHS -http://ckm.apperta.org/ckm/) were used to search for the concepts listed by the authors in order to avoid the development of duplicate archetypes.", [["International CKM", "TEST", 40, 57], ["NEHTA", "TEST", 101, 106], ["duplicate archetypes", "OBSERVATION", 288, 308]]], ["The study questionnaire was developed by a multidisciplinary team including a nutritionist and a physician.", [["The study questionnaire", "TEST", 0, 23]]], ["A pilot test was performed with healthcare professional volunteers (n = 5) aiming to detect errors and collect opinions about the survey questions.", [["A pilot test", "TEST", 0, 12]]], ["The questionnaire was considered easy to understand and no change was suggested.Clinical concept validationThe experts are co-authors of the main guidelines on nutrition, namely from the ESPEN, American Cancer Society (ACS), and American Society for Parenteral and Enteral Nutrition (ASPEN), and were contacted individually by email to fill a questionnaire comprising one question on the relevance of the archetype-concepts chosen by the paper authors (\"Which are the five most relevant clinical statements to be registered in cancer patient records regarding nutritional information?\").", [["cancer", "ANATOMY", 527, 533], ["Cancer", "DISEASE", 203, 209], ["ACS", "DISEASE", 219, 222], ["cancer", "DISEASE", 527, 533], ["cancer", "CANCER", 527, 533], ["patient", "ORGANISM", 534, 541], ["patient", "SPECIES", 534, 541], ["Clinical concept validation", "TEST", 80, 107], ["Parenteral and Enteral Nutrition", "TREATMENT", 250, 282], ["Cancer", "OBSERVATION", 203, 209]]], ["Archetype modelling has been widely applied in previous studies [30, 32, 34] .", [["previous studies", "TEST", 47, 63], ["widely", "OBSERVATION_MODIFIER", 29, 35]]], ["Afterwards, the archetype data was structured considering that each data is internally coded by a term code (at-code), which provides identity to the data nodes of the archetypes (i.e. to \"name\" the data) and value sets for leaf attributes [35] .Archetype modelling in openEHRThe Ocean Archetype Editor software was used to model the archetype concepts [36] .", [["leaf", "ANATOMY", 224, 228], ["nodes", "OBSERVATION", 155, 160]]], ["All archetypes were modelled in English.CKM submission for reviewAfter development, the archetypes were submitted to the CKM review-board through the openEHR.org platform.", [["openEHR", "DNA", 150, 157]]], ["If the archetype is approved by CKM reviewers, it will have passed through the rigorous review of an international clinical community.openEHR-template and user interfaceThe final step was the creation of an example openEHRtemplate, including both archetypes conceived in this study and some previously developed ones.", [["an example openEHRtemplate", "TREATMENT", 204, 230], ["this study", "TEST", 271, 281], ["openEHRtemplate", "OBSERVATION", 215, 230]]], ["VCIntegrator allowed the automatic conversion of openEHR-template into a readily usable EHR, as mentioned by Sousa, E. et al. [38] and Trindade-Vila\u00e7a et al. [39] .Statistical analysisDescriptive statistics were used to summarize the voting process by the nutrition experts.", [["VCIntegrator", "PROTEIN", 0, 12], ["openEHR", "PROTEIN", 49, 56], ["Trindade-Vila\u00e7a et al", "TREATMENT", 135, 156]]], ["The score was calculated considering the relevance (1st-5th) stipulated by the experts, using the following correspondence: 1st = 5 points, 2nd =4 points, 3rd = 3 points; 4th = 2 points and 5th = 1 point.", [["The score", "TEST", 0, 9]]], ["Individual scores were summed to give the final score to each archetype-concept.", [["Individual scores", "TEST", 0, 17]]], ["Ties were settled by the number of votes; however, if the ties remained after these two classification systems, the last tied archetypes were considered to be modeled.ResultsA total of 34 nutrition experts were contacted, and 7 answered the questionnaire (3 nutritionists and 4 physicians).", [["these two classification systems", "PROBLEM", 78, 110]]], ["The first 5 concepts were: body composition, Patient-Generated Subjective Global Assessment (PG-SGA), diet plan, quality of life scale (QoLs) and dietary nutrients (Table 2) .", [["body", "ANATOMY", 27, 31], ["body", "ORGANISM_SUBDIVISION", 27, 31], ["Patient", "SPECIES", 45, 52], ["Global Assessment", "TEST", 74, 91]]], ["However, PG-SGA and QoL scale are copyrighted instruments and cannot be directly modelled as openEHR-archetypes without formal authorization from the authors; these concepts were replaced by the following most voted archetypes, dietary supplements (phytochemicals) (6th), and dietary intake assessment and malnutrition screening tool (MST), tied in the 7th place.ResultsAfter successful development, these 6 archetypes were submitted to the International CKM repository, and 4 (body composition, dietary nutrients, dietary supplements (phytochemicals) and MST) were approved by the CKM editors.", [["body", "ANATOMY", 478, 482], ["PG", "CHEMICAL", 9, 11], ["malnutrition", "DISEASE", 306, 318], ["PG", "SIMPLE_CHEMICAL", 9, 11], ["body", "ORGANISM_SUBDIVISION", 478, 482], ["PG", "TEST", 9, 11], ["copyrighted instruments", "TREATMENT", 34, 57], ["dietary supplements", "TREATMENT", 228, 247], ["dietary intake assessment", "TEST", 276, 301], ["malnutrition screening tool", "TEST", 306, 333], ["dietary nutrients", "TREATMENT", 496, 513], ["dietary supplements (phytochemicals", "TREATMENT", 515, 550]]], ["The archetype \"dietary intake assessment\" was not approved, since, according to the CKM editor, it comprises many concepts (e.g. food frequency questionnaire, 24-h diet recall, among others) that should be represented independently.ResultsAll created archetypes are available at https://github.com/ priscilamaranhao/oncology-archetypes_ODISSEIA.gitResultsThe example openEHR-template was successfully created (Fig. 2) and was further represented in the user interface built with VCIntegrator (Fig. 3).", [["The example openEHR-template", "TREATMENT", 355, 383]]], ["Figures with an enhanced andThe score was calculated considering the relevance (1st-5th) stipulated by the experts, using the following correspondence: 1th = 5 points, 2th = 4 points, 3th = 3 points; 4th = 2 points and 5th = 1 point.", [["The score", "TEST", 28, 37]]], ["To tiebreak, the number of votes was considered. a One expert suggested, additionally, \"Nutrition impact on symptom profile (e.g.: nausea, etc.) wider detail of the example template and user interface are available as supplementary material.DiscussionThis study focused on describing the development process of openEHR archetype-based structures, used to represent cancer clinical statements proposing nutritional care.", [["cancer", "ANATOMY", 365, 371], ["nausea", "DISEASE", 131, 137], ["cancer", "DISEASE", 365, 371], ["cancer", "CANCER", 365, 371], ["symptom profile", "TEST", 108, 123], ["nausea", "PROBLEM", 131, 137], ["This study", "TEST", 251, 261], ["nutritional care", "TREATMENT", 402, 418], ["cancer", "OBSERVATION", 365, 371]]], ["Some authors have suggested that EHRs have a strong potential to improve cancer outcome research [41] and patient care [42, 43] .", [["cancer", "ANATOMY", 73, 79], ["cancer", "DISEASE", 73, 79], ["cancer", "CANCER", 73, 79], ["patient", "ORGANISM", 106, 113], ["patient", "SPECIES", 106, 113]]], ["However, EHRs usage in oncology presents, currently, many challenges related to structural (e.g.: interoperability, incorporation of different data forms...), clinical (e.g.: codification, linking of departments and care continuity) and research-related issues (e.g.: missing data, generalizability, privacy) [41, 44] .", [["missing data", "PROBLEM", 268, 280]]], ["The core set of cancer data elements established by mCODE and leveraged by CodeX are a recent attempt to solve the challenges related to the EHR storage of oncology data [44] .", [["cancer", "ANATOMY", 16, 22], ["cancer", "DISEASE", 16, 22], ["cancer", "CANCER", 16, 22], ["cancer", "OBSERVATION", 16, 22]]], ["Nevertheless, in nutrition management for cancer patients, which is unanimously a relevant issue, no information is available about which variables should be stored.DiscussionDespite obtaining nutrition expert opinions, we cannot assert that we created the most important clinical concepts in the nutrition and cancer context, since some of the identified concepts were already represented in CKM (i.e. body mass index, weight, body surface area) and did not have their relevance assessed by the experts; moreover, only the ESPEN guidelines were considered in the identification of the clinical statements, and additional relevant concepts could be present in other guidelines.", [["cancer", "ANATOMY", 42, 48], ["cancer", "ANATOMY", 311, 317], ["body", "ANATOMY", 403, 407], ["body surface area", "ANATOMY", 428, 445], ["cancer", "DISEASE", 42, 48], ["cancer", "DISEASE", 311, 317], ["cancer", "CANCER", 42, 48], ["patients", "ORGANISM", 49, 57], ["cancer", "CANCER", 311, 317], ["body", "ORGANISM_SUBDIVISION", 403, 407], ["body", "ORGANISM_SUBDIVISION", 428, 432], ["patients", "SPECIES", 49, 57], ["nutrition management", "TREATMENT", 17, 37], ["cancer", "PROBLEM", 42, 48], ["body mass index", "TEST", 403, 418]]], ["Nevertheless, the \"dietary intake assessment\" archetype was not approved by CKM.", [["the \"dietary intake assessment", "TEST", 14, 44]]], ["Kanas et al. described the importance of having medical professionals guiding the development of EHR systems as a way to improve the quality of Fig. 2 Oncology template modelled from Template Design Fig. 3 View of the template after automatic conversion into an EHR, by VCIntegrator cancer care through oncology outcome research [42] .", [["cancer", "ANATOMY", 283, 289], ["cancer", "DISEASE", 283, 289], ["VCIntegrator cancer", "CANCER", 270, 289], ["medical professionals", "TREATMENT", 48, 69], ["EHR systems", "TREATMENT", 97, 108]]], ["As a result, openEHR-archetype modelling has been used in many studies to enhance EHR in specific clinical areas, such as nutrigenomics and multiple sclerosis functional assessments [31, 46] .", [["multiple sclerosis functional assessments", "PROBLEM", 140, 181], ["multiple", "OBSERVATION_MODIFIER", 140, 148], ["sclerosis", "OBSERVATION", 149, 158]]], ["Nonetheless, despite these efforts, the CKM repository presents few archetypes to answer clinical management demands in some areas.", [["the CKM repository", "TEST", 36, 54], ["clinical management demands", "TREATMENT", 89, 116]]], ["Therefore, to make this approach more effective, there is a paramount need for more archetypes to be modelled, always respecting guidelines, published clinical research and expert opinions, to develop trustworthily and validated tools.DiscussionNevertheless, copyrighted tools cannot be represented into the openEHR standard without a formal acceptance from the authors, agreeing, during the process, on a more open license.DiscussionopenEHR is an open industry specification, not compatible with copyright-related restrictions.", [["not compatible", "UNCERTAINTY", 477, 491]]], ["In the present study, despite being considered an important tool by the experts, the most adequate oncology-specific QoL scales and PG-SGA presented copyrights and could not be directly designed as an openEHR-archetypes.", [["PG", "CHEMICAL", 132, 134], ["the present study", "TEST", 3, 20], ["PG", "TEST", 132, 134]]], ["This issue limits the modelling of some important tools (e.g. questionnaires, scales, etc) that, if modeled in openEHR, could provide better support to the improvement of cancer management.DiscussionTo the best of our knowledge, this study is the first to develop openEHR-archetypes, approved by the CKM, and a template representation for the management of nutrition in cancer patients. openEHR archetypes modelling is a relevant tool not only for nutrition but also for many other issues in cancer management and treatment.", [["cancer", "ANATOMY", 171, 177], ["cancer", "ANATOMY", 370, 376], ["cancer", "ANATOMY", 492, 498], ["cancer", "DISEASE", 171, 177], ["cancer", "DISEASE", 370, 376], ["cancer", "DISEASE", 492, 498], ["cancer", "CANCER", 171, 177], ["cancer", "CANCER", 370, 376], ["patients", "ORGANISM", 377, 385], ["cancer", "CANCER", 492, 498], ["patients", "SPECIES", 377, 385], ["cancer management", "TREATMENT", 171, 188], ["this study", "TEST", 229, 239], ["nutrition in cancer patients", "TREATMENT", 357, 385], ["cancer management", "TREATMENT", 492, 509], ["treatment", "TREATMENT", 514, 523], ["cancer", "OBSERVATION", 171, 177], ["cancer", "OBSERVATION", 492, 498]]], ["In fact, despite the scarcity of oncology openEHR-archetypes available in CKM repository, some researchers have used them to model an EHR capable of identifying and improving breast cancer treatment processes and chemotherapy guideline uses [47] .", [["breast cancer", "ANATOMY", 175, 188], ["breast cancer", "DISEASE", 175, 188], ["breast cancer", "CANCER", 175, 188], ["improving breast cancer treatment processes", "PROBLEM", 165, 208], ["chemotherapy guideline", "TREATMENT", 213, 235], ["breast", "ANATOMY", 175, 181], ["cancer", "OBSERVATION", 182, 188]]], ["Those studies applied openEHR-archetypes because they allowed the EHR to become more structured, which may improve the interoperability, contributing to better clinical care and research.DiscussionopenEHR is optimised to provide a data platform with a focus on the persistence of data, and the better way to store medical information [48] , allowing the creation of standards, to build information and interoperability solutions.", [["Those studies", "TEST", 0, 13], ["interoperability solutions", "TREATMENT", 402, 428]]], ["There are more than 500 archetypes in different medical areas that were already developed, such as related to nutrition, COVID-19, genomics, obstetrics/gynaecology, and so on.", [["COVID", "TEST", 121, 126], ["different", "OBSERVATION_MODIFIER", 38, 47]]], ["Conversely, HL7 FHIR, despite being focused on interoperability and data as well, is optimized for exchange of data, through the provision of simple and easy to use REST API's.", [["REST API's", "TREATMENT", 165, 175]]], ["The basic building block of FHIR is a resource, which is used, for instance, to exchange clinical content, create care plans and diagnostic orders [48, 49] .DiscussionFinally, we demonstrated an example of the conversion of a specific-template, built with openEHR-archetypes, into an EHR form, which also supports the practical and borderless applicability of the developed openEHR-archetypes.", [["openEHR", "PROTEIN", 374, 381]]], ["Health professionals that download openEHR-archetypes from the CKM website can create a specific template for oncology treatment and automatically convert it in an EHR form, without the need for information technology (IT) professionals.DiscussionThis study has some limitations.", [["CKM", "DNA", 63, 66], ["oncology treatment", "TREATMENT", 110, 128], ["This study", "TEST", 247, 257]]], ["First, there are many available guidelines for nutrition management in cancer patients, but they were not reviewed in this study.", [["cancer", "ANATOMY", 71, 77], ["cancer", "DISEASE", 71, 77], ["cancer", "CANCER", 71, 77], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["nutrition management", "TREATMENT", 47, 67], ["this study", "TEST", 118, 128]]], ["Nevertheless, the clinical concepts were selected for further development by nutrition experts (nutrition guidelines authors) in this area, supporting the relevance of the openEHR-archetypes that were modelled herein.DiscussionThe choice of the concepts to develop was based on oneround questionnaire.", [["nutrition guidelines", "TREATMENT", 96, 116]]], ["Digital surveys usually present a lower response rate than the paper counterpart [50] , thus a low number of responses was expected.", [["Digital surveys", "TEST", 0, 15]]], ["Moreover, the focus on guideline authors limited the number of potentially contactable individuals, further reducing the total number of participants, but ensuring that those who answered were experts on the subject.DiscussionSubsequently, our future perspective is to model a complete set of clinical statements for nutrition care in oncology and test it in a real-life study.ConclusionsThe present study described the process to identify and to model openEHR-archetypes for nutrition management in oncology patients and produced an example openEHR-template and EHR user interface.", [["patients", "ORGANISM", 509, 517], ["participants", "SPECIES", 137, 149], ["patients", "SPECIES", 509, 517], ["nutrition care", "TREATMENT", 317, 331], ["a real-life study", "TEST", 359, 376], ["The present study", "TEST", 388, 405], ["nutrition management", "TREATMENT", 476, 496]]], ["These tools can be applied by health and IT professionals to enhance structured data collection and promote interoperability between EHR systems.ConclusionsAuthors 'contributions PAM and AMP -contributed to study design, conceptualization, modelled the openEHR archetypes and wrote the original draft; CC, PR -contributed to conceptualization, elaborated the paper methodology and questionnaire and wrote the original draft; FB, AL, LI, EB, MH -analyzed the ESPEN guideline and wrote the original draft and reviewed the paper; PVM, RJCC -conceptualized and reviewed the paper.ConclusionsAvailability of data and materials The archetypes generated during the current study are available at oncology-archetypes_ODISSEIA repository, [https://github.com/priscilamaranhao/oncology-archetypes_ ODISSEIA.git].ConclusionsFunding North Portugal Regional Operational Programme (NORTE 2020), under the PORTUGAL 2020 Partnership Agreement, and through the European Regional Development Fund (ERDF) and European Social Fund (ESF) respectively.", [["AMP", "CHEMICAL", 187, 190], ["CC", "CHEMICAL", 302, 304], ["AMP", "CHEMICAL", 187, 190], ["AMP", "SIMPLE_CHEMICAL", 187, 190], ["PR", "PROTEIN", 306, 308], ["structured data collection", "TEST", 69, 95], ["AMP", "TEST", 187, 190], ["PVM", "PROBLEM", 527, 530], ["the current study", "TEST", 654, 671]]]], "d1596ea36bd6c2c0dd1b46ab282106c68765df9c": [["INTRODUCTIONCoronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is highly contagious.", [["COVID-19", "CHEMICAL", 38, 46], ["acute respiratory syndrome coronavirus", "DISEASE", 66, 104], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 59, 106], ["SARS-CoV-2", "ORGANISM", 108, 118], ["INTRODUCTIONCoronavirus Disease 2019 (COVID-19", "SPECIES", 0, 46], ["severe acute respiratory syndrome coronavirus", "SPECIES", 59, 104], ["SARS-CoV-2", "SPECIES", 108, 118], ["INTRODUCTIONCoronavirus Disease", "PROBLEM", 0, 31], ["COVID", "TEST", 38, 43], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 59, 104], ["severe", "OBSERVATION_MODIFIER", 59, 65], ["acute", "OBSERVATION_MODIFIER", 66, 71], ["respiratory syndrome", "OBSERVATION", 72, 92], ["highly", "OBSERVATION_MODIFIER", 124, 130], ["contagious", "OBSERVATION", 131, 141]]], ["In recognition of the global threat it poses, on March 11, 2020, the World Health Organization (WHO) declared COVID-19 to be a pandemic.", [["COVID", "TEST", 110, 115], ["a pandemic", "PROBLEM", 125, 135], ["global", "OBSERVATION_MODIFIER", 22, 28], ["threat", "OBSERVATION", 29, 35], ["pandemic", "OBSERVATION", 127, 135]]], ["COVID-19 has high mortality throughout the world, being especially high in Italy (n = 236,076, mortality with 32,867/236,076), Spain (n = 264,836, mortality with 28,422/264,836), Russia (n = 783,328, mortality with 12,580/783,328), Brazil (n = 2,098,389, mortality with 79,488/2,098,389), the United States (n = 3,748,248, mortality with 139,964/3,748,248), and South Africa (n = 373,628, mortality with 5,173/373,628) (https://covid19.who.int/, https://www.epicentro.iss.it/en/coronavirus/bollettino/ Infografica_10giugno%20ENG.pdf).", [["COVID-19", "CHEMICAL", 0, 8], ["COVID", "TEST", 0, 5], ["high mortality", "PROBLEM", 13, 27], ["high mortality", "OBSERVATION_MODIFIER", 13, 27]]], ["The high incidence and mortality of COVID-19 puts pressure on the need for urgent and special requirements for global medical resources and infrastructures.PURPOSE AND SIGNIFICANCE OF A TEMPORARY COVID-19 ICUData provided by the Chinese Center for Disease Control and Prevention revealed a total of 44,672 confirmed COVID-19 cases in China by February 11, 2020 .", [["COVID", "TEST", 36, 41], ["pressure", "TREATMENT", 50, 58], ["urgent and special requirements", "TREATMENT", 75, 106], ["global medical resources", "TREATMENT", 111, 135], ["Disease Control", "TREATMENT", 248, 263], ["COVID", "TEST", 316, 321], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["Of these, the majority (87%) were aged between 30 and 79, while 3% were aged 80 or more.", [["majority", "OBSERVATION_MODIFIER", 14, 22]]], ["A total of 14% of these patients were, or had been, severely ill, and 5% required critical care (1) .", [["patients", "ORGANISM", 24, 32], ["patients", "SPECIES", 24, 32], ["severely ill", "PROBLEM", 52, 64], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["Data from a single-center, retrospective study of 52 critically ill COVID-19 patients showed that 61.5% died at 28 days, 71% required mechanical ventilation, and 67% had acute respiratory distress syndrome (ARDS).", [["respiratory", "ANATOMY", 176, 187], ["critically ill", "DISEASE", 53, 67], ["acute respiratory distress syndrome", "DISEASE", 170, 205], ["ARDS", "DISEASE", 207, 211], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["retrospective study", "TEST", 27, 46], ["mechanical ventilation", "TREATMENT", 134, 156], ["acute respiratory distress syndrome", "PROBLEM", 170, 205], ["ARDS", "PROBLEM", 207, 211], ["mechanical ventilation", "OBSERVATION", 134, 156], ["acute", "OBSERVATION_MODIFIER", 170, 175], ["respiratory distress syndrome", "OBSERVATION", 176, 205], ["ARDS", "OBSERVATION", 207, 211]]], ["Patients who died from the disease were recorded longer lingering time from onset of symptoms to ICU admission than those who survived (2) .PURPOSE AND SIGNIFICANCE OF A TEMPORARY COVID-19 ICUAs the number of newly-confirmed and critical COVID-19 cases rose sharply from December 2019 onwards in Wuhan, isolated hospitals charged with caring for such patients had to solve immense challenges in terms of finding sufficient bed space, personnel, and resources, particularly in relation to the provision of care for the critically ill patients (3) .", [["critically ill", "DISEASE", 518, 532], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 351, 359], ["patients", "ORGANISM", 533, 541], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 351, 359], ["patients", "SPECIES", 533, 541], ["the disease", "PROBLEM", 23, 34], ["symptoms", "PROBLEM", 85, 93], ["critical COVID", "TEST", 229, 243], ["disease", "OBSERVATION", 27, 34]]], ["As COVID-19 is characterized by a high rate of contagion and rapid progression coupled with a high mortality rate, especially in the case of critical patients, it was essential to identify potentially critical cases at the earliest possible stage so they could be transferred to ICU timely to achieve necessary respiratory or circulation support in order to reduce mortality rates (4) .PURPOSE AND SIGNIFICANCE OF A TEMPORARY COVID-19 ICUGiven the shortage of critical care facilities and resources in isolated hospitals (5) , the establishment of temporary ICUs in such hospitals was an essential part of the infrastructure for providing care to critically ill COVID-19 patients.", [["respiratory", "ANATOMY", 311, 322], ["critically ill", "DISEASE", 647, 661], ["patients", "ORGANISM", 150, 158], ["patients", "ORGANISM", 671, 679], ["COVID-19", "DNA", 3, 11], ["patients", "SPECIES", 150, 158], ["patients", "SPECIES", 671, 679], ["COVID", "TEST", 3, 8], ["a high rate of contagion", "PROBLEM", 32, 56], ["rapid progression", "PROBLEM", 61, 78], ["a high mortality rate", "PROBLEM", 92, 113], ["circulation support", "TREATMENT", 326, 345], ["mortality rates", "TEST", 365, 380]]], ["The government thus made the decision to allocate an estimated 2,500 beds in three general hospitals in the city of Wuhan as temporary isolated wards for the treatment of severely infected patients.", [["patients", "ORGANISM", 189, 197], ["patients", "SPECIES", 189, 197], ["temporary isolated wards", "TREATMENT", 125, 149], ["the treatment", "TREATMENT", 154, 167], ["severely infected patients", "PROBLEM", 171, 197], ["severely", "OBSERVATION_MODIFIER", 171, 179], ["infected", "OBSERVATION", 180, 188]]], ["Each member of the teams represented a different department; thus, uniform and normative team management and patient care were challenging.", [["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["normative team management", "TREATMENT", 79, 104]]], ["Existing medical resources were leveraged to meet the needs of these ICUs, and the training of non-ICU staff was also critically important.PURPOSE AND SIGNIFICANCE OF A TEMPORARY COVID-19 ICUOver the course of a month in Wuhan, after the temporary ICU was established, a total of 157 critically ill patients were admitted into our temporary ward; they had characteristics of a mean age at 62 years old, a mean hospital stay at 16.01 days, 14.0% requiring invasive or non-invasive mechanical ventilation, and 3.82% died at discharge.", [["critically ill", "DISEASE", 284, 298], ["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 299, 307], ["invasive or non-invasive mechanical ventilation", "TREATMENT", 455, 502], ["mechanical ventilation", "OBSERVATION", 480, 502]]], ["Hence, the current paper shares best practices gleaned from the establishment and management of temporary ICUs in isolated hospitals during the epidemic in Wuhan; the centralization of severe confirmed cases enabled reintegration and maximum use of existing medical resources, thus facilitating effective professional treatments for COVID-19 patients.ESTABLISHMENT OF A TEMPORARY COVID-19 ICUOn February 7, 2020, a national medical team from Xiangya Hospital, Hunan, took over the 51-bed ophthalmic ward in the Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan, in response to the insufficient number of ICU beds in isolated hospitals to cope with the rapidly increasing numbers of cases presenting with COVID-19.", [["COVID-19", "CHEMICAL", 745, 753], ["patients", "ORGANISM", 342, 350], ["patients", "SPECIES", 342, 350], ["existing medical resources", "TREATMENT", 249, 275], ["effective professional treatments", "TREATMENT", 295, 328], ["COVID", "TEST", 333, 338], ["COVID", "TEST", 745, 750]]], ["Combining the characteristics of the ward and taking into consideration severe cases, we planned to establish a temporary ICU in the Ophthalmic Ward; however, given its previous use, not all beds were supplied with sufficient oxygen pressure to run the necessary ventilators.Early Identification and Sorting of Critical CasesThe first stage in the care of COVID-19 patients is to identify those who are critically ill.", [["oxygen", "CHEMICAL", 226, 232], ["critically ill", "DISEASE", 403, 417], ["oxygen", "CHEMICAL", 226, 232], ["oxygen", "SIMPLE_CHEMICAL", 226, 232], ["patients", "ORGANISM", 365, 373], ["patients", "SPECIES", 365, 373], ["all beds", "TREATMENT", 187, 195], ["sufficient oxygen pressure", "TREATMENT", 215, 241], ["the necessary ventilators", "TREATMENT", 249, 274]]], ["For this purpose, we modified the National Early Warning Score (News) (6) and SOFA score and added two further predicted risk factors for severe COVID-19 infection: age \u2265 66 years old (2, 7, 8) and persistent lymphocytopenia (2, 8, 9) (Figure 1) .", [["infection", "DISEASE", 154, 163], ["lymphocytopenia", "DISEASE", 209, 224], ["SOFA score", "TEST", 78, 88], ["severe COVID-19 infection", "PROBLEM", 138, 163], ["persistent lymphocytopenia", "PROBLEM", 198, 224], ["persistent", "OBSERVATION_MODIFIER", 198, 208], ["lymphocytopenia", "OBSERVATION", 209, 224]]], ["Post-admission, critically ill patients were sorted into one of four risk categories on the basis of their scores on the severity grading scales: mild, moderate, critical, and severe critical.", [["critically ill", "DISEASE", 16, 30], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["mild, moderate, critical, and severe critical", "PROBLEM", 146, 191], ["mild", "OBSERVATION_MODIFIER", 146, 150], ["moderate", "OBSERVATION_MODIFIER", 152, 160], ["severe", "OBSERVATION_MODIFIER", 176, 182]]], ["It was important to recognize that critically ill patients who presented with silent hypoxemia (severe hypoxemia without signs of respiratory distress), particularly older ones, required vigilant monitoring.", [["respiratory", "ANATOMY", 130, 141], ["critically ill", "DISEASE", 35, 49], ["hypoxemia", "DISEASE", 85, 94], ["hypoxemia", "DISEASE", 103, 112], ["respiratory distress", "DISEASE", 130, 150], ["patients", "ORGANISM", 50, 58], ["patients", "SPECIES", 50, 58], ["silent hypoxemia", "PROBLEM", 78, 94], ["severe hypoxemia", "PROBLEM", 96, 112], ["respiratory distress", "PROBLEM", 130, 150], ["vigilant monitoring", "TEST", 187, 206], ["hypoxemia", "OBSERVATION", 85, 94], ["severe", "OBSERVATION_MODIFIER", 96, 102], ["hypoxemia", "OBSERVATION", 103, 112], ["without signs of", "UNCERTAINTY", 113, 129], ["respiratory distress", "OBSERVATION", 130, 150]]], ["Initially, due to the lack of severe respiratory distress symptoms at the early stage of COVID-19 in some severe confirmed patients, clinicians might delay tracheal intubation, and invasive ventilation.", [["respiratory", "ANATOMY", 37, 48], ["tracheal", "ANATOMY", 156, 164], ["respiratory distress", "DISEASE", 37, 57], ["patients", "ORGANISM", 123, 131], ["tracheal", "MULTI-TISSUE_STRUCTURE", 156, 164], ["patients", "SPECIES", 123, 131], ["severe respiratory distress symptoms", "PROBLEM", 30, 66], ["COVID", "TEST", 89, 94], ["tracheal intubation", "TREATMENT", 156, 175], ["invasive ventilation", "TREATMENT", 181, 201], ["severe", "OBSERVATION_MODIFIER", 30, 36], ["respiratory distress", "OBSERVATION", 37, 57], ["tracheal", "ANATOMY", 156, 164], ["intubation", "OBSERVATION", 165, 175], ["invasive ventilation", "OBSERVATION", 181, 201]]], ["This postponing would bring disastrous consequences for these patients.", [["patients", "ORGANISM", 62, 70], ["patients", "SPECIES", 62, 70]]], ["Hence, early identification of severe critical patients was crucial in enabling personnel to offer optimized treatment within the temporary ICU in the shortest time.Dividing the Ward Into SectorsThe ward was divided into three sectors according to the results of the severity grading scales to facilitate clinical management (Figures 2, 3) .Dividing the Ward Into SectorsThe first sector, containing 12 beds supplied with sufficient oxygen pressure to run ventilators, was designated for the management of severe critically ill patients, including those requiring invasive ventilator support or prone ventilation, exhibiting hemodynamic instability.", [["oxygen", "CHEMICAL", 433, 439], ["critically ill", "DISEASE", 513, 527], ["hemodynamic instability", "DISEASE", 625, 648], ["oxygen", "CHEMICAL", 433, 439], ["patients", "ORGANISM", 47, 55], ["oxygen", "SIMPLE_CHEMICAL", 433, 439], ["patients", "ORGANISM", 528, 536], ["patients", "SPECIES", 47, 55], ["patients", "SPECIES", 528, 536], ["optimized treatment", "TREATMENT", 99, 118], ["the severity grading scales", "TEST", 263, 290], ["clinical management", "TREATMENT", 305, 324], ["sufficient oxygen pressure", "TREATMENT", 422, 448], ["run ventilators", "TREATMENT", 452, 467], ["severe critically ill patients", "PROBLEM", 506, 536], ["invasive ventilator support", "TREATMENT", 564, 591], ["prone ventilation", "TREATMENT", 595, 612], ["hemodynamic instability", "PROBLEM", 625, 648], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["oxygen pressure", "OBSERVATION", 433, 448], ["severe", "OBSERVATION_MODIFIER", 506, 512], ["hemodynamic instability", "OBSERVATION", 625, 648]]], ["This sector was located close to the nurses' and doctors' workstations, enabling staff to monitor patients closely and provide immediate attention.", [["patients", "ORGANISM", 98, 106], ["patients", "SPECIES", 98, 106]]], ["The beds were placed at least two meters apart to prevent cross-infection.", [["The beds", "TREATMENT", 0, 8], ["cross-infection", "PROBLEM", 58, 73], ["beds", "ANATOMY", 4, 8], ["cross-infection", "OBSERVATION", 58, 73]]], ["Figure 4 displays the special medical equipment required in the temporary ICU, including non-invasive and invasive ventilators, high-flow nasal cannula (HFNC), renal replacement machines, extracorporeal membrane oxygenation machines, videobronchoscopes (with external monitor), equipment to monitor central venous pressure (CVP) or invasive arterial blood pressure, ultrasound machines, videolaryngoscopes, infusion or syringe pumps, vibrating expectoration machines, and closed tracheal suction catheters.Dividing the Ward Into SectorsThe second sector of the temporary ICU consisted of a ring of 25 beds outside the critical care sector and was designated for the care of moderate to critical patients, typically requiring lowparameter high flow oxygen therapy with a maximum flow rate of 40 L/min and inspired oxygen (FiO2) of 50%, or mask oxygen support with a maximum flow of 5 L/min.", [["nasal", "ANATOMY", 138, 143], ["renal", "ANATOMY", 160, 165], ["extracorporeal membrane", "ANATOMY", 188, 211], ["central venous", "ANATOMY", 299, 313], ["arterial", "ANATOMY", 341, 349], ["blood", "ANATOMY", 350, 355], ["tracheal", "ANATOMY", 479, 487], ["oxygen", "CHEMICAL", 748, 754], ["oxygen", "CHEMICAL", 813, 819], ["oxygen", "CHEMICAL", 843, 849], ["oxygen", "CHEMICAL", 748, 754], ["oxygen", "CHEMICAL", 813, 819], ["FiO2", "CHEMICAL", 821, 825], ["oxygen", "CHEMICAL", 843, 849], ["renal", "ORGAN", 160, 165], ["venous", "MULTI-TISSUE_STRUCTURE", 307, 313], ["arterial", "MULTI-TISSUE_STRUCTURE", 341, 349], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["patients", "ORGANISM", 695, 703], ["oxygen", "SIMPLE_CHEMICAL", 748, 754], ["oxygen", "SIMPLE_CHEMICAL", 813, 819], ["FiO2", "SIMPLE_CHEMICAL", 821, 825], ["oxygen", "SIMPLE_CHEMICAL", 843, 849], ["patients", "SPECIES", 695, 703], ["non-invasive and invasive ventilators", "TREATMENT", 89, 126], ["high-flow nasal cannula (HFNC", "TREATMENT", 128, 157], ["renal replacement machines", "TREATMENT", 160, 186], ["extracorporeal membrane oxygenation machines", "TREATMENT", 188, 232], ["videobronchoscopes", "TREATMENT", 234, 252], ["external monitor", "TEST", 259, 275], ["equipment", "TREATMENT", 278, 287], ["central venous pressure", "TEST", 299, 322], ["CVP", "TEST", 324, 327], ["invasive arterial blood pressure", "TEST", 332, 364], ["ultrasound machines", "TREATMENT", 366, 385], ["videolaryngoscopes", "TREATMENT", 387, 405], ["infusion", "TREATMENT", 407, 415], ["syringe pumps", "TREATMENT", 419, 432], ["vibrating expectoration machines", "TREATMENT", 434, 466], ["closed tracheal suction catheters", "TREATMENT", 472, 505], ["a ring of 25 beds", "TREATMENT", 588, 605], ["lowparameter high flow oxygen therapy", "TREATMENT", 725, 762], ["a maximum flow rate", "TREATMENT", 768, 787], ["inspired oxygen (FiO2", "TREATMENT", 804, 825], ["mask oxygen support", "TREATMENT", 838, 857], ["a maximum flow", "TREATMENT", 863, 877], ["renal", "ANATOMY", 160, 165], ["replacement", "OBSERVATION", 166, 177], ["central", "ANATOMY_MODIFIER", 299, 306], ["venous", "ANATOMY", 307, 313], ["tracheal", "ANATOMY", 479, 487], ["suction catheters", "OBSERVATION", 488, 505], ["moderate", "OBSERVATION_MODIFIER", 674, 682], ["high flow", "OBSERVATION", 738, 747], ["oxygen therapy", "OBSERVATION", 748, 762]]], ["The third part, which consisted of 14 beds around the perimeter of the ward, was for the use of patients identified as moderate, or who were in the recovery stage or requiring nasal catheter oxygen.COVID-19 Infection Special Intensive Care Teams EstablishWith insufficient trained ICU personnel to meet demand, we set up a multidisciplinary intensive care team led by senior intensive care specialists, and an intensive nurse team led by experienced intensive care nurses.", [["nasal", "ANATOMY", 176, 181], ["oxygen", "CHEMICAL", 191, 197], ["oxygen", "CHEMICAL", 191, 197], ["patients", "ORGANISM", 96, 104], ["oxygen", "SIMPLE_CHEMICAL", 191, 197], ["patients", "SPECIES", 96, 104], ["nasal catheter oxygen", "TREATMENT", 176, 197], ["moderate", "OBSERVATION_MODIFIER", 119, 127], ["nasal", "ANATOMY", 176, 181], ["catheter oxygen", "OBSERVATION", 182, 197]]], ["Our first task was to evaluate isolation conditions, after which we divided the ward into inner and outer zones to give workers a space in which they could rest safely.", [["inner", "TISSUE", 90, 95], ["a space", "TREATMENT", 128, 135]]], ["Since every patient under our care was suffering from the same disease, we then took steps to standardize treatments by establishing protection strategy for each healthcare operation, for example routine medical care, tracheal intubation, and percutaneous tracheotomy.Protecting Patients and Health WorkersPreventing a nosocomial outbreak of COVID-19 through transmission from patients to healthcare workers was of vital importance.", [["tracheal", "ANATOMY", 218, 226], ["percutaneous", "ANATOMY", 243, 255], ["COVID-19", "CHEMICAL", 342, 350], ["patient", "ORGANISM", 12, 19], ["tracheal", "MULTI-TISSUE_STRUCTURE", 218, 226], ["Patients", "ORGANISM", 279, 287], ["patients", "ORGANISM", 377, 385], ["patient", "SPECIES", 12, 19], ["Patients", "SPECIES", 279, 287], ["patients", "SPECIES", 377, 385], ["the same disease", "PROBLEM", 54, 70], ["standardize treatments", "TREATMENT", 94, 116], ["each healthcare operation", "TREATMENT", 157, 182], ["routine medical care", "TREATMENT", 196, 216], ["tracheal intubation", "TREATMENT", 218, 237], ["percutaneous tracheotomy", "TREATMENT", 243, 267], ["tracheal", "ANATOMY", 218, 226], ["intubation", "OBSERVATION", 227, 237], ["tracheotomy", "OBSERVATION", 256, 267]]], ["To this end, every health worker had to be equipped with the correct personal protective equipment (PPE) and given training in its use before they could start caring for patients.", [["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178]]], ["After donning a medical protective mask, every worker was required to ask another to check if it was sufficiently tight, and, after they took their PPE off, they used quick-drying hand sanitizer.", [["hand", "ANATOMY", 180, 184], ["hand", "ORGANISM_SUBDIVISION", 180, 184], ["a medical protective mask", "TREATMENT", 14, 39], ["quick-drying hand sanitizer", "TREATMENT", 167, 194]]], ["Different levels of PPE were assigned to healthcare workers according to the severity of the patients under their care, as showed in Figure 5 .", [["PPE", "GENE_OR_GENE_PRODUCT", 20, 23], ["patients", "ORGANISM", 93, 101], ["patients", "SPECIES", 93, 101], ["PPE", "TREATMENT", 20, 23]]], ["Workers administering oxygen therapy to confirmed COVID-19 patients in the third sector wore level-II protection consisting of protective clothing, gloves, shoe covers, head covers, a N95 mask, and protective (anti-fog) glasses, and they also carried out hand hygiene measures.", [["head", "ANATOMY", 169, 173], ["hand", "ANATOMY", 255, 259], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "CHEMICAL", 22, 28], ["oxygen", "SIMPLE_CHEMICAL", 22, 28], ["patients", "ORGANISM", 59, 67], ["head", "ORGANISM_SUBDIVISION", 169, 173], ["hand", "ORGANISM_SUBDIVISION", 255, 259], ["patients", "SPECIES", 59, 67], ["oxygen therapy", "TREATMENT", 22, 36], ["COVID", "TEST", 50, 55], ["II protection", "TREATMENT", 99, 112], ["protective clothing", "TREATMENT", 127, 146], ["gloves", "TREATMENT", 148, 154], ["head covers", "TREATMENT", 169, 180], ["a N95 mask", "TREATMENT", 182, 192], ["protective (anti-fog) glasses", "TREATMENT", 198, 227], ["hand hygiene measures", "TREATMENT", 255, 276], ["head", "ANATOMY", 169, 173]]], ["Personnel carrying out operations among patients that might be associated with aerosol generating procedures, like sampling or sputum suction, wore level III-1 protection consisting of all the above items plus a waterproof isolation gown, and a face shield and also carried out the hand hygiene procedures.", [["sputum", "ANATOMY", 127, 133], ["hand", "ANATOMY", 282, 286], ["patients", "ORGANISM", 40, 48], ["hand", "ORGANISM_SUBDIVISION", 282, 286], ["patients", "SPECIES", 40, 48], ["aerosol generating procedures", "TREATMENT", 79, 108], ["sputum suction", "TREATMENT", 127, 141], ["a waterproof isolation gown", "TREATMENT", 210, 237], ["a face shield", "TREATMENT", 243, 256]]], ["Personnel caring for sectortwo patients, suffering from severe respiratory distress but not requiring invasive ventilation treatment, were also obliged to use level III-1 PPE (8).", [["respiratory", "ANATOMY", 63, 74], ["respiratory distress", "DISEASE", 63, 83], ["patients", "ORGANISM", 31, 39], ["patients", "SPECIES", 31, 39], ["severe respiratory distress", "PROBLEM", 56, 83], ["invasive ventilation treatment", "TREATMENT", 102, 132], ["severe", "OBSERVATION_MODIFIER", 56, 62], ["respiratory", "ANATOMY", 63, 74], ["distress", "OBSERVATION", 75, 83]]], ["According to recent recommendations (10, 11), the highest level of PPE, level III-2, which included an air-purifying respirators (PAPRs), was reserved for high risk operations including tracheal intubation, tracheotomy, or fiberoptic bronchoscopy.Education and Training of Health WorkersIt is estimated that a considerable proportion of healthcare workers have been infected since the COVID-19 outbreak (for example, infected rates of health workers were 28603/236076 (12.1%) in Italy (https://www.epicentro.iss.it/en/coronavirus/ bollettino/Infografica_10giugno%20ENG.pdf).", [["tracheal", "ANATOMY", 186, 194], ["tracheal", "MULTI-TISSUE_STRUCTURE", 186, 194], ["workers", "ORGANISM", 348, 355], ["an air-purifying respirators", "TREATMENT", 100, 128], ["high risk operations", "TREATMENT", 155, 175], ["tracheal intubation", "TREATMENT", 186, 205], ["tracheotomy", "TREATMENT", 207, 218], ["fiberoptic bronchoscopy", "TEST", 223, 246], ["the COVID", "TEST", 381, 390], ["tracheal", "ANATOMY", 186, 194], ["intubation", "OBSERVATION", 195, 205], ["tracheotomy", "OBSERVATION", 207, 218], ["considerable", "OBSERVATION_MODIFIER", 310, 322]]], ["Minimizing the risk of nosocomial outbreak amplification and protecting healthcare workers are of critical importance (8, 12) .", [["nosocomial outbreak amplification", "PROBLEM", 23, 56], ["nosocomial", "OBSERVATION_MODIFIER", 23, 33]]], ["Widespread use of recommended barrier precautions in isolated wards must be of highly priority.", [["barrier precautions", "TREATMENT", 30, 49]]], ["The temporary ICUs set up to manage the epidemic in China established protocols for both the prevention of infection and contingency management, including PPE regulations, procedures for entering and leaving quarantined zones, emergency plans to cope with occupational exposure, checks on the hygiene standards observed by healthcare workers, and management of preventive medication.", [["infection", "DISEASE", 107, 116], ["infection", "PROBLEM", 107, 116], ["contingency management", "TREATMENT", 121, 143], ["PPE regulations", "TREATMENT", 155, 170], ["procedures", "TREATMENT", 172, 182], ["preventive medication", "TREATMENT", 361, 382], ["infection", "OBSERVATION", 107, 116]]], ["It is imperative that ensuring every healthcare worker is properly trained, continually protected against droplet infection, and versed in all the necessary checks and precautions, including the use of PPE.", [["infection", "DISEASE", 114, 123], ["droplet infection", "PROBLEM", 106, 123], ["versed", "TREATMENT", 129, 135], ["precautions", "TREATMENT", 168, 179], ["PPE", "TREATMENT", 202, 205]]], ["This is vital in the battle against a highly infectious disease such as COVID-19.MANAGEMENTData from a follow-up study of 99 COVID-19 cases, dated January 25, 2020, reveal that 11% died, 9% required invasive FIGURE 2 | Dividing a ward into sectors.", [["a highly infectious disease", "PROBLEM", 36, 63], ["COVID", "TEST", 72, 77], ["a follow-up study", "TEST", 101, 118], ["COVID", "TEST", 125, 130], ["infectious", "OBSERVATION", 45, 55]]], ["(B) A team led by specialized ICU physicians viewing critically ill COVID-19 patients in a temporary ICU. mechanical ventilation, and 3% required extracorporeal membrane oxygenation (ECMO) (13) .", [["extracorporeal membrane", "ANATOMY", 146, 169], ["critically ill", "DISEASE", 53, 67], ["patients", "ORGANISM", 77, 85], ["patients", "SPECIES", 77, 85], ["mechanical ventilation", "TREATMENT", 106, 128], ["extracorporeal membrane oxygenation", "TREATMENT", 146, 181], ["ventilation", "OBSERVATION", 117, 128]]], ["Among the significant findings was that before January 30, 2020, only about 25% of patients who died from COVID-19 received invasive mechanical ventilation or ECMO, and that HFNC and/or non-invasive ventilation (NIV) were used for an average of 6 (4-8) days before intubation or death (14) .", [["death", "DISEASE", 279, 284], ["patients", "ORGANISM", 83, 91], ["patients", "SPECIES", 83, 91], ["COVID", "TEST", 106, 111], ["invasive mechanical ventilation", "TREATMENT", 124, 155], ["ECMO", "TREATMENT", 159, 163], ["HFNC", "TREATMENT", 174, 178], ["non-invasive ventilation", "TREATMENT", 186, 210], ["NIV)", "TREATMENT", 212, 216], ["intubation", "TREATMENT", 265, 275], ["death", "PROBLEM", 279, 284], ["significant", "OBSERVATION_MODIFIER", 10, 21], ["mechanical ventilation", "OBSERVATION", 133, 155]]], ["It can be inferred that invasive mechanical ventilation was delayed, possibly due to a lack of the necessary equipment, specialist staff, or areas in which the procedure could be carried out or to a fear of infection during the operation of trachea intubation.MANAGEMENTCOVID-19 is an infectious disease characterized as an acute hypoxemic respiratory insufficiency or failure which requires Frontiers in Medicine | www.frontiersin.org the use of oxygen and ventilation therapies.", [["trachea", "ANATOMY", 241, 248], ["respiratory", "ANATOMY", 340, 351], ["infection", "DISEASE", 207, 216], ["infectious disease", "DISEASE", 285, 303], ["respiratory insufficiency", "DISEASE", 340, 365], ["oxygen", "CHEMICAL", 447, 453], ["oxygen", "CHEMICAL", 447, 453], ["trachea", "ORGAN", 241, 248], ["oxygen", "SIMPLE_CHEMICAL", 447, 453], ["invasive mechanical ventilation", "TREATMENT", 24, 55], ["the procedure", "TREATMENT", 156, 169], ["infection", "PROBLEM", 207, 216], ["the operation", "TREATMENT", 224, 237], ["trachea intubation", "TREATMENT", 241, 259], ["an infectious disease", "PROBLEM", 282, 303], ["an acute hypoxemic respiratory insufficiency", "PROBLEM", 321, 365], ["failure", "PROBLEM", 369, 376], ["oxygen", "TREATMENT", 447, 453], ["ventilation therapies", "TREATMENT", 458, 479], ["invasive", "OBSERVATION_MODIFIER", 24, 32], ["mechanical ventilation", "OBSERVATION", 33, 55], ["infection", "OBSERVATION", 207, 216], ["trachea", "ANATOMY", 241, 248], ["intubation", "OBSERVATION", 249, 259], ["infectious", "OBSERVATION", 285, 295], ["acute", "OBSERVATION_MODIFIER", 324, 329], ["hypoxemic", "OBSERVATION_MODIFIER", 330, 339], ["respiratory insufficiency", "OBSERVATION", 340, 365], ["failure", "OBSERVATION", 369, 376]]], ["Most infected patients suffer mild symptoms and are self-healing; however, in severe cases, progression is rapid and can lead to ARDS, septic shock, metabolic acidosis, and coagulopathy (15) , especially when combined with old age, comorbidities, or persistent lymphocytopenia, which is difficult to correct.", [["ARDS", "DISEASE", 129, 133], ["septic shock", "DISEASE", 135, 147], ["metabolic acidosis", "DISEASE", 149, 167], ["coagulopathy", "DISEASE", 173, 185], ["lymphocytopenia", "DISEASE", 261, 276], ["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["mild symptoms", "PROBLEM", 30, 43], ["self-healing", "PROBLEM", 52, 64], ["ARDS", "PROBLEM", 129, 133], ["septic shock", "PROBLEM", 135, 147], ["metabolic acidosis", "PROBLEM", 149, 167], ["coagulopathy", "PROBLEM", 173, 185], ["comorbidities", "PROBLEM", 232, 245], ["persistent lymphocytopenia", "PROBLEM", 250, 276], ["mild", "OBSERVATION_MODIFIER", 30, 34], ["symptoms", "OBSERVATION", 35, 43], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["ARDS", "OBSERVATION", 129, 133], ["septic shock", "OBSERVATION", 135, 147], ["metabolic acidosis", "OBSERVATION", 149, 167], ["coagulopathy", "OBSERVATION", 173, 185], ["persistent", "OBSERVATION_MODIFIER", 250, 260], ["lymphocytopenia", "OBSERVATION", 261, 276]]], ["As standardizing the management of care is a vital element in improving survival rates, the National Health Commission of the People's Republic of China (http://www.nhc.gov.cn/yzygj/s7653p/ 202002/d4b895337e19445f8d728fcaf1e3e13a.shtml) and the WHO (https://www.who.int/docs/default-source/coronaviruse/ clinical-management-of-novel-cov.pdf) have established a protocol for the treatment of COVID-19.", [["COVID-19", "CHEMICAL", 391, 399], ["People", "SPECIES", 126, 132], ["a protocol", "TREATMENT", 359, 369], ["COVID", "TEST", 391, 396]]], ["Timely and effective airway management and maximized first-pass success rate of airway operation for COVID-19 patients are recommended (8, 11) .MANAGEMENTFor patients in the third sector of the temporary ICU (who have mild symptoms), healthcare workers must give supportive care and ensure monitoring at 6-h intervals of the vital symptoms, such as breathing rate, oxygen saturation (SpO2), and heart rate.", [["airway", "ANATOMY", 21, 27], ["airway", "ANATOMY", 80, 86], ["heart", "ANATOMY", 395, 400], ["oxygen", "CHEMICAL", 365, 371], ["oxygen", "CHEMICAL", 365, 371], ["airway", "MULTI-TISSUE_STRUCTURE", 21, 27], ["airway", "MULTI-TISSUE_STRUCTURE", 80, 86], ["patients", "ORGANISM", 110, 118], ["patients", "ORGANISM", 158, 166], ["oxygen", "SIMPLE_CHEMICAL", 365, 371], ["heart", "ORGAN", 395, 400], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 158, 166], ["effective airway management", "TREATMENT", 11, 38], ["airway operation", "TREATMENT", 80, 96], ["COVID", "TEST", 101, 106], ["mild symptoms", "PROBLEM", 218, 231], ["supportive care", "TREATMENT", 263, 278], ["the vital symptoms", "PROBLEM", 321, 339], ["breathing rate", "TEST", 349, 363], ["oxygen saturation", "TEST", 365, 382], ["SpO2", "TEST", 384, 388], ["heart rate", "TEST", 395, 405], ["airway", "ANATOMY", 21, 27], ["airway", "ANATOMY", 80, 86], ["heart", "ANATOMY", 395, 400]]], ["Oxygen therapy should be initiated at 5 L/min and titrated to SpO2 \u2265 92% in COVID-19 patients.", [["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "CHEMICAL", 0, 6], ["Oxygen", "SIMPLE_CHEMICAL", 0, 6], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["Oxygen therapy", "TREATMENT", 0, 14], ["SpO2", "TEST", 62, 66]]], ["For patients with high risk factors (\u226566 years old and comorbidities), nurses must ensure close monitoring of vital symptoms at 4-h intervals.", [["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["vital symptoms", "PROBLEM", 110, 124]]], ["In the following conditions, patients must be swiftly transferred to the second (moderate) sector, in case they need HFNC oxygenation or NIV: breathing rate \u226524/min, SpO2 <92% with oxygen therapy at 5 L/min, or heart rate >130/min, or persistent lymphocytopenia.", [["heart", "ANATOMY", 211, 216], ["oxygen", "CHEMICAL", 181, 187], ["lymphocytopenia", "DISEASE", 246, 261], ["oxygen", "CHEMICAL", 181, 187], ["patients", "ORGANISM", 29, 37], ["oxygen", "SIMPLE_CHEMICAL", 181, 187], ["heart", "ORGAN", 211, 216], ["patients", "SPECIES", 29, 37], ["HFNC oxygenation", "TREATMENT", 117, 133], ["NIV", "TREATMENT", 137, 140], ["breathing rate", "TEST", 142, 156], ["SpO2", "TEST", 166, 170], ["oxygen therapy", "TREATMENT", 181, 195], ["heart rate", "TEST", 211, 221], ["persistent lymphocytopenia", "PROBLEM", 235, 261], ["heart", "ANATOMY", 211, 216], ["persistent", "OBSERVATION_MODIFIER", 235, 245], ["lymphocytopenia", "OBSERVATION", 246, 261]]], ["Throughout treatment, conservative intravenous fluid strategies must be strictly implemented unless septic shock occurs.MANAGEMENTIn the case of severe patients with persistent respiratory distress, a respiratory rate >30/min, oxygenation index <150 mmHg, or showing no improvement after HFNC or NIV, continuous monitoring is necessary from an experienced ICU team.", [["intravenous", "ANATOMY", 35, 46], ["respiratory", "ANATOMY", 177, 188], ["respiratory", "ANATOMY", 201, 212], ["septic shock", "DISEASE", 100, 112], ["respiratory distress", "DISEASE", 177, 197], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 35, 46], ["patients", "ORGANISM", 152, 160], ["patients", "SPECIES", 152, 160], ["Throughout treatment", "TREATMENT", 0, 20], ["conservative intravenous fluid strategies", "TREATMENT", 22, 63], ["septic shock", "PROBLEM", 100, 112], ["persistent respiratory distress", "PROBLEM", 166, 197], ["a respiratory rate", "TEST", 199, 217], ["oxygenation index", "TEST", 227, 244], ["HFNC", "TREATMENT", 288, 292], ["NIV", "TREATMENT", 296, 299], ["continuous monitoring", "TEST", 301, 322], ["severe", "OBSERVATION_MODIFIER", 145, 151], ["persistent", "OBSERVATION_MODIFIER", 166, 176], ["respiratory distress", "OBSERVATION", 177, 197], ["no", "UNCERTAINTY", 267, 269], ["improvement", "OBSERVATION_MODIFIER", 270, 281]]], ["The vital symptoms must be monitored after HFNC or NIV treatment at intervals of no more than 2 h (16) .", [["HFNC", "CHEMICAL", 43, 47], ["HFNC", "CHEMICAL", 43, 47], ["NIV", "CHEMICAL", 51, 54], ["The vital symptoms", "PROBLEM", 0, 18], ["HFNC", "TREATMENT", 43, 47], ["NIV treatment", "TREATMENT", 51, 64]]], ["If there is no improvement after 2 h, or the patient's condition worsens, the team should consider early invasive ventilation (8), followed by lung-protective ventilation strategies and early prone positioning during mechanical ventilation for more than 12 hours per day (Figure 6 ).CONCLUSIONSThe sudden outbreak of the highly contagious disease now known as COVID-19 in China in December 2019 has impacted healthcare system and societies more widely across the world.", [["lung", "ANATOMY", 143, 147], ["COVID-19", "CHEMICAL", 360, 368], ["patient", "ORGANISM", 45, 52], ["lung", "ORGAN", 143, 147], ["patient", "SPECIES", 45, 52], ["the patient's condition", "PROBLEM", 41, 64], ["early invasive ventilation", "TREATMENT", 99, 125], ["lung-protective ventilation strategies", "TREATMENT", 143, 181], ["early prone positioning", "TREATMENT", 186, 209], ["mechanical ventilation", "TREATMENT", 217, 239], ["the highly contagious disease", "PROBLEM", 317, 346], ["no", "UNCERTAINTY", 12, 14], ["improvement", "OBSERVATION_MODIFIER", 15, 26], ["lung", "ANATOMY", 143, 147], ["protective ventilation", "OBSERVATION", 148, 170], ["highly", "OBSERVATION_MODIFIER", 321, 327], ["contagious disease", "OBSERVATION", 328, 346]]], ["Should another virus of this type emerge, it will be vital to first control the source of infection and second prevent transmission.", [["infection", "DISEASE", 90, 99], ["infection", "PROBLEM", 90, 99], ["infection", "OBSERVATION", 90, 99]]], ["Moreover, the identification, sorting, and management of infected patients in different isolated sectors according to level of severity is crucial in ensuring full use is made of the medical resources available.", [["patients", "ORGANISM", 66, 74], ["patients", "SPECIES", 66, 74], ["the identification", "TEST", 10, 28], ["management", "TREATMENT", 43, 53], ["infected", "OBSERVATION_MODIFIER", 57, 65]]], ["Public anxiety around COVID-19 centers on the large numbers of critically ill patients and high death rates.", [["anxiety", "DISEASE", 7, 14], ["critically ill", "DISEASE", 63, 77], ["death", "DISEASE", 96, 101], ["patients", "ORGANISM", 78, 86], ["patients", "SPECIES", 78, 86], ["Public anxiety", "PROBLEM", 0, 14], ["high death rates", "PROBLEM", 91, 107], ["large", "OBSERVATION_MODIFIER", 46, 51], ["numbers", "OBSERVATION_MODIFIER", 52, 59], ["critically ill", "OBSERVATION_MODIFIER", 63, 77]]], ["In this regard, setting up a temporary ICU in isolated hospitals, run by multidisciplinary staff under the leadership of intensive care specialists and nurses, is crucial not only in caring for critically ill patients and bringing down mortality rates, but also in allaying public fear.DATA AVAILABILITY STATEMENTThe original contributions presented in the study are included in the article/supplementary material, further inquiries can be directed to the corresponding author/s.", [["critically ill", "DISEASE", 194, 208], ["patients", "ORGANISM", 209, 217], ["patients", "SPECIES", 209, 217], ["the study", "TEST", 353, 362]]]], "PMC6356844": [], "PMC4709057": [["IntroductionChronic infection with hepatitis C virus (HCV) is a serious global health problem.", [["IntroductionChronic infection", "DISEASE", 0, 29], ["hepatitis C", "DISEASE", 35, 46], ["HCV", "DISEASE", 54, 57], ["hepatitis C virus", "ORGANISM", 35, 52], ["HCV", "ORGANISM", 54, 57], ["hepatitis C virus", "SPECIES", 35, 52], ["hepatitis C virus", "SPECIES", 35, 52], ["HCV", "SPECIES", 54, 57], ["IntroductionChronic infection", "PROBLEM", 0, 29], ["hepatitis C virus (HCV", "PROBLEM", 35, 57], ["a serious global health problem", "PROBLEM", 62, 93], ["infection", "OBSERVATION", 20, 29], ["hepatitis", "OBSERVATION", 35, 44], ["serious", "OBSERVATION_MODIFIER", 64, 71], ["global", "OBSERVATION_MODIFIER", 72, 78], ["health problem", "OBSERVATION", 79, 93]]], ["It affects ~170 million people worldwide and can lead to liver cirrhosis, hepatocellular carcinoma and end-stage liver diseases [1\u20133].", [["liver", "ANATOMY", 57, 62], ["hepatocellular carcinoma", "ANATOMY", 74, 98], ["liver", "ANATOMY", 113, 118], ["liver cirrhosis", "DISEASE", 57, 72], ["hepatocellular carcinoma", "DISEASE", 74, 98], ["end-stage liver diseases", "DISEASE", 103, 127], ["people", "ORGANISM", 24, 30], ["liver", "ORGAN", 57, 62], ["hepatocellular carcinoma", "CANCER", 74, 98], ["liver", "ORGAN", 113, 118], ["people", "SPECIES", 24, 30], ["liver cirrhosis", "PROBLEM", 57, 72], ["hepatocellular carcinoma", "PROBLEM", 74, 98], ["end-stage liver diseases", "PROBLEM", 103, 127], ["liver", "ANATOMY", 57, 62], ["cirrhosis", "OBSERVATION", 63, 72], ["hepatocellular", "ANATOMY", 74, 88], ["carcinoma", "OBSERVATION", 89, 98], ["stage", "OBSERVATION_MODIFIER", 107, 112], ["liver", "ANATOMY", 113, 118], ["diseases", "OBSERVATION", 119, 127]]], ["Current treatment of chronic HCV infection is limited to combination drug therapies, which are highly expensive, have serious side effects and have variable success rates in different viral genotypes and patient populations [4].", [["HCV infection", "DISEASE", 29, 42], ["HCV", "ORGANISM", 29, 32], ["patient", "ORGANISM", 204, 211], ["patient", "SPECIES", 204, 211], ["HCV", "SPECIES", 29, 32], ["chronic HCV infection", "PROBLEM", 21, 42], ["drug therapies", "TREATMENT", 69, 83], ["serious side effects", "PROBLEM", 118, 138], ["variable success rates", "PROBLEM", 148, 170], ["different viral genotypes", "PROBLEM", 174, 199], ["chronic", "OBSERVATION_MODIFIER", 21, 28], ["HCV", "OBSERVATION_MODIFIER", 29, 32], ["infection", "OBSERVATION", 33, 42]]], ["Development of vaccines to prevent and/or cure HCV infection is of paramount importance.IntroductionNatural protection from infection is often used to model strategies to develop new vaccines.", [["HCV infection", "DISEASE", 47, 60], ["infection", "DISEASE", 124, 133], ["HCV", "ORGANISM", 47, 50], ["HCV", "SPECIES", 47, 50], ["vaccines", "TREATMENT", 15, 23], ["cure HCV infection", "PROBLEM", 42, 60], ["Natural protection", "TREATMENT", 100, 118], ["infection", "PROBLEM", 124, 133], ["new vaccines", "TREATMENT", 179, 191], ["infection", "OBSERVATION", 51, 60], ["infection", "OBSERVATION", 124, 133]]], ["The immune mechanisms and correlates of viral clearance and protection from HCV infection have been studied extensively, but they still remain unclear [5\u20137].", [["HCV infection", "DISEASE", 76, 89], ["HCV", "ORGANISM", 76, 79], ["HCV", "SPECIES", 76, 79], ["The immune mechanisms", "PROBLEM", 0, 21], ["viral clearance", "PROBLEM", 40, 55], ["protection", "TREATMENT", 60, 70], ["HCV infection", "PROBLEM", 76, 89], ["viral clearance", "OBSERVATION", 40, 55]]], ["A number of studies have correlated the natural clearance of HCV infection with the appearance of vigorous and multi-specific CD8+ and sustained CD4+ T cell responses [8\u201310].", [["CD4+ T cell", "ANATOMY", 145, 156], ["HCV infection", "DISEASE", 61, 74], ["HCV", "ORGANISM", 61, 64], ["CD8", "GENE_OR_GENE_PRODUCT", 126, 129], ["CD4", "GENE_OR_GENE_PRODUCT", 145, 148], ["CD8", "PROTEIN", 126, 129], ["CD4", "PROTEIN", 145, 148], ["HCV", "SPECIES", 61, 64], ["studies", "TEST", 12, 19], ["HCV infection", "PROBLEM", 61, 74], ["multi-specific CD8", "TEST", 111, 129], ["HCV", "OBSERVATION_MODIFIER", 61, 64], ["infection", "OBSERVATION", 65, 74], ["vigorous", "OBSERVATION_MODIFIER", 98, 106]]], ["In contrast, development of chronic infection is correlated with weak or dysfunctional cellular immune responses [7, 10, 11].", [["cellular", "ANATOMY", 87, 95], ["chronic infection", "DISEASE", 28, 45], ["cellular", "CELL", 87, 95], ["chronic infection", "PROBLEM", 28, 45], ["weak or dysfunctional cellular immune responses", "PROBLEM", 65, 112], ["chronic", "OBSERVATION_MODIFIER", 28, 35], ["infection", "OBSERVATION", 36, 45]]], ["A recent meta-analysis of studies published to date with chimpanzee model concluded that humoral immune responses also play a determining role in protection from chronic HCV infection [12\u201314].", [["HCV infection", "DISEASE", 170, 183], ["chimpanzee", "ORGANISM", 57, 67], ["HCV", "ORGANISM", 170, 173], ["HCV", "SPECIES", 170, 173], ["A recent meta-analysis of studies", "TEST", 0, 33], ["chimpanzee model", "TREATMENT", 57, 73], ["humoral immune responses", "TREATMENT", 89, 113], ["chronic HCV infection", "PROBLEM", 162, 183], ["chronic", "OBSERVATION_MODIFIER", 162, 169], ["HCV", "OBSERVATION", 170, 173]]], ["Further, recent studies support a role of antibodies beyond neutralization of viral particles; extending their function to targeting intracellular pathogens [15].", [["intracellular", "ANATOMY", 133, 146], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 133, 146], ["antibodies", "PROTEIN", 42, 52], ["recent studies", "TEST", 9, 23], ["antibodies", "PROBLEM", 42, 52], ["viral particles", "PROBLEM", 78, 93], ["intracellular pathogens", "PROBLEM", 133, 156], ["viral particles", "OBSERVATION", 78, 93]]], ["Therefore, it can be envisioned that a successful prophylactic and/or therapeutic vaccine strategy would encompass the generation of both cellular and humoral responses against multiple antigens of HCV.IntroductionCases of chronic HCV infection have been reported where patients spontaneously clear the infection due to re-activation of functional cellular immune responses [16].", [["cellular", "ANATOMY", 138, 146], ["cellular", "ANATOMY", 348, 356], ["HCV", "DISEASE", 198, 201], ["HCV infection", "DISEASE", 231, 244], ["infection", "DISEASE", 303, 312], ["cellular", "CELL", 138, 146], ["HCV", "ORGANISM", 198, 201], ["HCV", "ORGANISM", 231, 234], ["patients", "ORGANISM", 270, 278], ["cellular", "CELL", 348, 356], ["patients", "SPECIES", 270, 278], ["HCV", "SPECIES", 198, 201], ["HCV", "SPECIES", 231, 234], ["a successful prophylactic and/or therapeutic vaccine strategy", "TREATMENT", 37, 98], ["HCV", "PROBLEM", 198, 201], ["chronic HCV infection", "PROBLEM", 223, 244], ["the infection", "PROBLEM", 299, 312], ["HCV", "OBSERVATION", 198, 201], ["chronic", "OBSERVATION_MODIFIER", 223, 230], ["HCV", "OBSERVATION_MODIFIER", 231, 234], ["infection", "OBSERVATION", 235, 244], ["infection", "OBSERVATION", 303, 312]]], ["However, the exact mechanism of this spontaneous reversal of cellular immune responses, from exhausted and/or dysfunctional to functional, remains to be elucidated.", [["cellular", "ANATOMY", 61, 69], ["cellular", "CELL", 61, 69], ["cellular immune", "OBSERVATION", 61, 76]]], ["In several studies, HCV-specific T cells have been expanded from the peripheral blood T-cell populations in individuals previously not infected with HCV [17, 18].", [["T cells", "ANATOMY", 33, 40], ["peripheral blood T-cell", "ANATOMY", 69, 92], ["HCV", "DISEASE", 149, 152], ["HCV", "ORGANISM", 20, 23], ["T cells", "CELL", 33, 40], ["peripheral blood T-cell populations", "CELL", 69, 104], ["individuals", "ORGANISM", 108, 119], ["HCV", "ORGANISM", 149, 152], ["T cells", "CELL_TYPE", 33, 40], ["peripheral blood T-cell populations", "CELL_TYPE", 69, 104], ["HCV", "SPECIES", 20, 23], ["HCV", "SPECIES", 149, 152], ["several studies", "TEST", 3, 18], ["HCV", "PROBLEM", 20, 23], ["specific T cells", "PROBLEM", 24, 40], ["HCV", "PROBLEM", 149, 152], ["peripheral", "ANATOMY_MODIFIER", 69, 79], ["blood", "ANATOMY", 80, 85]]], ["Among the HCV exposed individuals, 20\u201330% clear the virus after acute infection due to induction of strong multi-specific cellular immune responses [10, 19, 20].", [["cellular", "ANATOMY", 122, 130], ["acute infection", "DISEASE", 64, 79], ["HCV", "ORGANISM", 10, 13], ["cellular", "CELL", 122, 130], ["HCV", "SPECIES", 10, 13], ["the HCV exposed individuals", "PROBLEM", 6, 33], ["acute infection", "PROBLEM", 64, 79], ["acute", "OBSERVATION_MODIFIER", 64, 69], ["infection", "OBSERVATION", 70, 79]]], ["However, it is not known if pre-existing heterologous immunity has any role in the HCV clearance after infection.", [["infection", "DISEASE", 103, 112], ["HCV", "ORGANISM", 83, 86], ["HCV", "SPECIES", 83, 86], ["pre-existing heterologous immunity", "PROBLEM", 28, 62], ["the HCV clearance", "PROBLEM", 79, 96], ["infection", "PROBLEM", 103, 112], ["infection", "OBSERVATION", 103, 112]]], ["Influenza A virus infection has been shown to induce narrow heterologous cellular immune response against a single epitope from HCV NS3 antigen [18].IntroductionAdenoviruses (Ad) are non-enveloped, icosahedral viruses containing a double-stranded DNA genome of ~26\u201348 Kbp [21].", [["cellular", "ANATOMY", 73, 81], ["Influenza A virus infection", "DISEASE", 0, 27], ["Influenza A virus", "ORGANISM", 0, 17], ["cellular", "CELL", 73, 81], ["HCV NS3", "ORGANISM", 128, 135], ["Ad", "ORGANISM", 175, 177], ["DNA", "CELLULAR_COMPONENT", 247, 250], ["HCV NS3 antigen", "PROTEIN", 128, 143], ["double-stranded DNA genome", "DNA", 231, 257], ["Influenza A virus", "SPECIES", 0, 17], ["Influenza A virus", "SPECIES", 0, 17], ["HCV", "SPECIES", 128, 131], ["Influenza A virus infection", "PROBLEM", 0, 27], ["narrow heterologous cellular immune response", "PROBLEM", 53, 97], ["a single epitope", "PROBLEM", 106, 122], ["HCV NS3 antigen", "TEST", 128, 143], ["IntroductionAdenoviruses", "PROBLEM", 149, 173], ["icosahedral viruses", "TREATMENT", 198, 217], ["a double-stranded DNA genome", "TREATMENT", 229, 257], ["Kbp", "TEST", 268, 271], ["icosahedral viruses", "OBSERVATION", 198, 217]]], ["They belong to a diverse family (>50 serotypes) of DNA viruses called adenoviridae, infect ocular, respiratory or gastro-intestinal epithelium in a diverse range of hosts [21] and induce different levels of immunity [22, 23].", [["ocular", "ANATOMY", 91, 97], ["respiratory", "ANATOMY", 99, 110], ["gastro-intestinal epithelium", "ANATOMY", 114, 142], ["DNA", "CELLULAR_COMPONENT", 51, 54], ["adenoviridae", "GENE_OR_GENE_PRODUCT", 70, 82], ["ocular", "ORGAN", 91, 97], ["gastro-intestinal epithelium", "TISSUE", 114, 142], ["DNA viruses", "PROBLEM", 51, 62], ["adenoviridae", "TREATMENT", 70, 82], ["infect ocular, respiratory or gastro-intestinal epithelium", "PROBLEM", 84, 142], ["respiratory", "ANATOMY", 99, 110], ["intestinal epithelium", "ANATOMY", 121, 142]]], ["They have gained immense recognition as a vaccine antigen delivery vehicle since their initial use in gene therapy [24], and have also proven to be safe and efficient vaccine vectors for eliciting protective immune responses against the transgene antigen in many animal and human clinical studies [25, 26].", [["human", "ORGANISM", 274, 279], ["transgene antigen", "PROTEIN", 237, 254], ["human", "SPECIES", 274, 279], ["human", "SPECIES", 274, 279], ["a vaccine antigen delivery vehicle", "TREATMENT", 40, 74], ["gene therapy", "TREATMENT", 102, 114], ["efficient vaccine vectors", "TREATMENT", 157, 182], ["the transgene antigen", "PROBLEM", 233, 254], ["human clinical studies", "TEST", 274, 296]]], ["A chimpanzee-derived adenovirus, expressing HCV antigens NS3-NS5, is currently in clinical trials [27].IntroductionWe have been studying recombinant adenoviruses expressing various individual HCV antigens for their ability to modulate and induce HCV-specific immunity in an in vitro human cell culture system and in vivo in mice [28\u201332].", [["cell culture system", "ANATOMY", 289, 308], ["chimpanzee", "ORGANISM", 2, 12], ["adenovirus", "ORGANISM", 21, 31], ["HCV antigens NS3", "ORGANISM", 44, 60], ["adenoviruses", "ORGANISM", 149, 161], ["HCV", "ORGANISM", 192, 195], ["HCV", "ORGANISM", 246, 249], ["human", "ORGANISM", 283, 288], ["cell", "CELL", 289, 293], ["mice", "ORGANISM", 324, 328], ["HCV antigens", "PROTEIN", 44, 56], ["NS3", "PROTEIN", 57, 60], ["NS5", "PROTEIN", 61, 64], ["HCV antigens", "PROTEIN", 192, 204], ["human", "SPECIES", 283, 288], ["mice", "SPECIES", 324, 328], ["HCV", "SPECIES", 44, 47], ["HCV", "SPECIES", 192, 195], ["HCV", "SPECIES", 246, 249], ["human", "SPECIES", 283, 288], ["mice", "SPECIES", 324, 328], ["A chimpanzee-derived adenovirus", "TREATMENT", 0, 31], ["HCV antigens NS3", "TREATMENT", 44, 60], ["NS5", "TREATMENT", 61, 64], ["recombinant adenoviruses", "TREATMENT", 137, 161], ["various individual HCV antigens", "PROBLEM", 173, 204], ["HCV", "PROBLEM", 246, 249]]], ["During our studies, we observed that immunization of mice with control, non-recombinant adenovirus vector (Ad vector) not expressing HCV antigens, also induced HCV antigens-specific T cell responses.", [["T cell", "ANATOMY", 182, 188], ["mice", "ORGANISM", 53, 57], ["adenovirus", "ORGANISM", 88, 98], ["Ad", "ORGANISM", 107, 109], ["HCV", "ORGANISM", 133, 136], ["HCV", "ORGANISM", 160, 163], ["T cell", "CELL", 182, 188], ["HCV antigens", "PROTEIN", 133, 145], ["HCV antigens", "PROTEIN", 160, 172], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 53, 57], ["adenovirus", "SPECIES", 88, 98], ["Ad", "SPECIES", 107, 109], ["HCV", "SPECIES", 133, 136], ["HCV", "SPECIES", 160, 163], ["our studies", "TEST", 7, 18], ["immunization of mice with control", "TREATMENT", 37, 70], ["non-recombinant adenovirus vector (Ad vector", "TREATMENT", 72, 116], ["expressing HCV antigens", "PROBLEM", 122, 145], ["induced HCV antigens", "PROBLEM", 152, 172]]], ["To address this puzzling and unexpected observation, we aligned peptide sequences from different HCV proteins with various adenoviral proteins (Ad proteins) to determine the levels of homology between the proteins of the two viruses.", [["adenoviral", "ORGANISM", 123, 133], ["Ad", "ORGANISM", 144, 146], ["HCV proteins", "PROTEIN", 97, 109], ["adenoviral proteins", "PROTEIN", 123, 142], ["Ad proteins", "PROTEIN", 144, 155], ["HCV", "SPECIES", 97, 100], ["this puzzling", "PROBLEM", 11, 24], ["aligned peptide sequences", "TEST", 56, 81], ["different HCV proteins", "PROBLEM", 87, 109], ["various adenoviral proteins", "PROBLEM", 115, 142], ["Ad proteins", "TEST", 144, 155], ["two viruses", "OBSERVATION", 221, 232]]], ["Intriguingly, we discovered varying degrees of homologies (25\u201353%) between multiple HCV peptide sequences from core, F, NS3, NS4 and NS5 proteins and a number of Ad proteins (Table 1 and S1 Table).", [["NS3", "GENE_OR_GENE_PRODUCT", 120, 123], ["NS4", "GENE_OR_GENE_PRODUCT", 125, 128], ["HCV peptide sequences", "DNA", 84, 105], ["core, F, NS3, NS4 and NS5 proteins", "PROTEIN", 111, 145], ["Ad proteins", "PROTEIN", 162, 173], ["Table 1", "PROTEIN", 175, 182], ["S1 Table", "PROTEIN", 187, 195], ["HCV", "SPECIES", 84, 87], ["homologies", "TEST", 47, 57], ["multiple HCV peptide sequences", "TEST", 75, 105], ["core, F", "TEST", 111, 118], ["NS3", "TEST", 120, 123], ["NS4", "TEST", 125, 128], ["NS5 proteins", "TEST", 133, 145], ["varying", "OBSERVATION_MODIFIER", 28, 35]]], ["In this study, we conclusively demonstrate that immunization of mice with Ad vector not expressing exogenous HCV antigen(s), induces robust cross-reactive humoral and cellular immune responses against multiple HCV antigens.", [["cellular", "ANATOMY", 167, 175], ["mice", "ORGANISM", 64, 68], ["Ad", "ORGANISM", 74, 76], ["HCV antigen", "GENE_OR_GENE_PRODUCT", 109, 120], ["cellular", "CELL", 167, 175], ["HCV", "ORGANISM", 210, 213], ["HCV antigen", "PROTEIN", 109, 120], ["HCV antigens", "PROTEIN", 210, 222], ["mice", "SPECIES", 64, 68], ["mice", "SPECIES", 64, 68], ["Ad", "SPECIES", 74, 76], ["HCV", "SPECIES", 109, 112], ["HCV", "SPECIES", 210, 213], ["this study", "TEST", 3, 13], ["immunization of mice with Ad vector", "TREATMENT", 48, 83], ["exogenous HCV antigen", "PROBLEM", 99, 120], ["multiple HCV antigens", "PROBLEM", 201, 222], ["cellular immune", "OBSERVATION", 167, 182]]], ["Further, reduction in viral titers in mice infected with vaccinia virus expressing recombinant HCV antigens as a surrogate model corroborated the relevance of cross-reactive immune responses to antiviral immunity.", [["mice", "ORGANISM", 38, 42], ["vaccinia virus", "ORGANISM", 57, 71], ["recombinant HCV antigens", "ORGANISM", 83, 107], ["recombinant HCV antigens", "PROTEIN", 83, 107], ["mice", "SPECIES", 38, 42], ["vaccinia virus", "SPECIES", 57, 71], ["mice", "SPECIES", 38, 42], ["vaccinia virus", "SPECIES", 57, 71], ["HCV", "SPECIES", 95, 98], ["viral titers", "PROBLEM", 22, 34], ["vaccinia virus", "TREATMENT", 57, 71], ["recombinant HCV antigens", "PROBLEM", 83, 107], ["cross-reactive immune responses", "PROBLEM", 159, 190], ["antiviral immunity", "TREATMENT", 194, 212], ["reduction", "OBSERVATION_MODIFIER", 9, 18], ["viral titers", "OBSERVATION", 22, 34]]], ["Intriguingly, normal healthy human donors with no known history of HCV infection but seropositive for Ad-specific IgG, demonstrated the presence of cross-reactive antibodies and T cell responses against multiple HCV antigens.", [["T cell", "ANATOMY", 178, 184], ["HCV infection", "DISEASE", 67, 80], ["human", "ORGANISM", 29, 34], ["donors", "ORGANISM", 35, 41], ["HCV", "ORGANISM", 67, 70], ["IgG", "GENE_OR_GENE_PRODUCT", 114, 117], ["T cell", "CELL", 178, 184], ["HCV", "ORGANISM", 212, 215], ["Ad-specific IgG", "PROTEIN", 102, 117], ["cross-reactive antibodies", "PROTEIN", 148, 173], ["multiple HCV antigens", "PROTEIN", 203, 224], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["HCV", "SPECIES", 67, 70], ["HCV", "SPECIES", 212, 215], ["HCV infection", "PROBLEM", 67, 80], ["Ad-specific IgG", "TEST", 102, 117], ["cross-reactive antibodies", "PROBLEM", 148, 173], ["T cell responses", "PROBLEM", 178, 194], ["multiple HCV antigens", "PROBLEM", 203, 224], ["normal", "OBSERVATION_MODIFIER", 14, 20], ["healthy human", "OBSERVATION_MODIFIER", 21, 34], ["HCV", "OBSERVATION_MODIFIER", 67, 70], ["infection", "OBSERVATION", 71, 80], ["cross-reactive antibodies", "OBSERVATION", 148, 173], ["HCV", "OBSERVATION", 212, 215]]], ["Our study is the first to demonstrate heterologous and protective immunity induced by Ad vector against HCV.", [["Ad", "ORGANISM", 86, 88], ["HCV", "ORGANISM", 104, 107], ["Ad", "SPECIES", 86, 88], ["HCV", "SPECIES", 104, 107], ["Our study", "TEST", 0, 9], ["HCV", "PROBLEM", 104, 107]]], ["These studies have significant implications in the design of prophylactic and therapeutic vaccines against HCV.", [["HCV", "DISEASE", 107, 110], ["HCV", "ORGANISM", 107, 110], ["HCV", "SPECIES", 107, 110], ["These studies", "TEST", 0, 13], ["prophylactic and therapeutic vaccines", "TREATMENT", 61, 98], ["HCV", "PROBLEM", 107, 110]]], ["In addition, since recombinant adenovirus vectors are at the forefront as candidate vaccines for several different pathogens including HCV, Ebola virus, Plasmodium, mycobacteria, influenza virus, among others, their widespread use as vaccines could significantly impact the prevalence and natural course of HCV infection.Peptide sequences derived from HCV antigens exhibit varying degrees of homology with different adenoviral (Ad) vector proteins ::: ResultsWe aligned the amino acid (aa) sequences of peptides (15\u201320 aa long with 5 aa overlaps) derived from various HCV antigens (core, F, E1, E2, P7, NS2, NS3, NS4a, NS4b, NS5a and NS5b) of genotype 1a with different Ad proteins using the bioinformatics software ClustalW to determine homology scores.", [["Ebola virus, Plasmodium, mycobacteria", "DISEASE", 140, 177], ["influenza virus", "DISEASE", 179, 194], ["HCV infection", "DISEASE", 307, 320], ["amino acid", "CHEMICAL", 474, 484], ["amino acid", "CHEMICAL", 474, 484], ["adenovirus", "ORGANISM", 31, 41], ["HCV", "ORGANISM", 135, 138], ["Ebola virus", "ORGANISM", 140, 151], ["Plasmodium, mycobacteria", "ORGANISM", 153, 177], ["influenza virus", "ORGANISM", 179, 194], ["HCV", "ORGANISM", 307, 310], ["HCV antigens", "ORGANISM", 352, 364], ["adenoviral", "ORGANISM", 416, 426], ["Ad", "ORGANISM", 428, 430], ["amino acid", "AMINO_ACID", 474, 484], ["F", "GENE_OR_GENE_PRODUCT", 588, 589], ["E1", "GENE_OR_GENE_PRODUCT", 591, 593], ["E2", "GENE_OR_GENE_PRODUCT", 595, 597], ["P7", "GENE_OR_GENE_PRODUCT", 599, 601], ["NS2", "GENE_OR_GENE_PRODUCT", 603, 606], ["NS3", "GENE_OR_GENE_PRODUCT", 608, 611], ["NS4a", "GENE_OR_GENE_PRODUCT", 613, 617], ["NS4b", "GENE_OR_GENE_PRODUCT", 619, 623], ["NS5a", "GENE_OR_GENE_PRODUCT", 625, 629], ["NS5b", "GENE_OR_GENE_PRODUCT", 634, 638], ["Ad", "ORGANISM", 670, 672], ["HCV antigens", "PROTEIN", 352, 364], ["adenoviral (Ad) vector proteins", "PROTEIN", 416, 447], ["amino acid (aa) sequences", "PROTEIN", 474, 499], ["HCV antigens", "PROTEIN", 568, 580], ["F", "PROTEIN", 588, 589], ["E1", "PROTEIN", 591, 593], ["E2", "PROTEIN", 595, 597], ["P7", "PROTEIN", 599, 601], ["NS2", "PROTEIN", 603, 606], ["NS3", "PROTEIN", 608, 611], ["NS4a", "PROTEIN", 613, 617], ["NS4b", "PROTEIN", 619, 623], ["NS5a", "PROTEIN", 625, 629], ["NS5b", "PROTEIN", 634, 638], ["genotype 1a", "PROTEIN", 643, 654], ["Ad proteins", "PROTEIN", 670, 681], ["Ebola virus", "SPECIES", 140, 151], ["influenza virus", "SPECIES", 179, 194], ["adenovirus", "SPECIES", 31, 41], ["HCV", "SPECIES", 135, 138], ["Ebola virus", "SPECIES", 140, 151], ["influenza virus", "SPECIES", 179, 194], ["HCV", "SPECIES", 307, 310], ["HCV", "SPECIES", 352, 355], ["HCV", "SPECIES", 568, 571], ["recombinant adenovirus vectors", "TREATMENT", 19, 49], ["vaccines", "TREATMENT", 84, 92], ["several different pathogens", "PROBLEM", 97, 124], ["HCV", "PROBLEM", 135, 138], ["Ebola virus", "PROBLEM", 140, 151], ["Plasmodium", "PROBLEM", 153, 163], ["mycobacteria", "PROBLEM", 165, 177], ["influenza virus", "PROBLEM", 179, 194], ["vaccines", "TREATMENT", 234, 242], ["HCV infection", "PROBLEM", 307, 320], ["Peptide sequences", "TEST", 321, 338], ["HCV antigens", "TEST", 352, 364], ["the amino acid", "TEST", 470, 484], ["peptides", "TEST", 503, 511], ["5 aa overlaps", "TREATMENT", 532, 545], ["various HCV antigens", "TEST", 560, 580], ["E1", "TEST", 591, 593], ["E2", "TEST", 595, 597], ["P7", "TEST", 599, 601], ["NS2", "TEST", 603, 606], ["NS3", "TEST", 608, 611], ["NS4a", "TEST", 613, 617], ["NS4b", "TEST", 619, 623], ["NS5a", "TEST", 625, 629], ["NS5b", "TEST", 634, 638], ["genotype 1a", "TEST", 643, 654], ["HCV", "OBSERVATION_MODIFIER", 307, 310], ["infection", "OBSERVATION", 311, 320]]], ["Table 1 summarizes the range of homologies between HCV-derived peptides and Ad proteins, and the number of HCV peptides and Ad proteins that show these homologies.", [["HCV", "ORGANISM", 51, 54], ["Ad", "ORGANISM", 76, 78], ["Ad", "GENE_OR_GENE_PRODUCT", 124, 126], ["Ad proteins", "PROTEIN", 76, 87], ["Ad proteins", "PROTEIN", 124, 135], ["HCV", "SPECIES", 51, 54], ["HCV", "SPECIES", 107, 110], ["HCV-derived peptides", "PROBLEM", 51, 71], ["Ad proteins", "PROBLEM", 76, 87], ["HCV peptides", "PROBLEM", 107, 119]]], ["Intriguingly, almost all of the compared Ad proteins (27) (S1 Table) showed homology (scores ranging between 25\u201340) with several peptides from HCV antigens core, F, NS3, NS4, NS5a and NS5b (S1\u2013S6 Datasets).", [["Ad", "ORGANISM", 41, 43], ["HCV antigens core, F", "GENE_OR_GENE_PRODUCT", 143, 163], ["NS3", "GENE_OR_GENE_PRODUCT", 165, 168], ["NS4", "GENE_OR_GENE_PRODUCT", 170, 173], ["NS5a", "GENE_OR_GENE_PRODUCT", 175, 179], ["NS5b", "GENE_OR_GENE_PRODUCT", 184, 188], ["Ad proteins", "PROTEIN", 41, 52], ["HCV antigens", "PROTEIN", 143, 155], ["F", "PROTEIN", 162, 163], ["NS3", "PROTEIN", 165, 168], ["NS4", "PROTEIN", 170, 173], ["NS5a", "PROTEIN", 175, 179], ["NS5b", "PROTEIN", 184, 188], ["S1", "PROTEIN", 190, 192], ["S6", "PROTEIN", 193, 195], ["HCV", "SPECIES", 143, 146], ["Ad proteins", "TEST", 41, 52], ["S1 Table)", "TEST", 59, 68], ["homology (scores", "TEST", 76, 92], ["HCV antigens core", "TEST", 143, 160], ["F", "TEST", 162, 163], ["NS3", "TEST", 165, 168], ["NS4", "TEST", 170, 173], ["NS5a", "TEST", 175, 179], ["NS5b", "TEST", 184, 188], ["HCV", "OBSERVATION", 143, 146], ["NS5a", "OBSERVATION", 175, 179]]], ["The maximum homology scores shown by HCV peptides was core (45\u201350), F (45\u201350), NS3 (45\u201350), NS4 (35\u201340), NS5a (40\u201345) and NS5b (40\u201345).", [["NS3", "GENE_OR_GENE_PRODUCT", 79, 82], ["NS4", "GENE_OR_GENE_PRODUCT", 92, 95], ["NS5a", "GENE_OR_GENE_PRODUCT", 105, 109], ["NS3", "PROTEIN", 79, 82], ["NS4", "PROTEIN", 92, 95], ["NS5a", "PROTEIN", 105, 109], ["40\u201345", "PROTEIN", 111, 116], ["NS5b", "PROTEIN", 122, 126], ["HCV", "SPECIES", 37, 40], ["The maximum homology scores", "TEST", 0, 27], ["HCV peptides", "TEST", 37, 49], ["NS3", "TEST", 79, 82], ["NS4", "TEST", 92, 95], ["NS5a", "TEST", 105, 109], ["NS5b", "TEST", 122, 126]]], ["Similar homologies were found with ChAd25 sequences.", [["ChAd25", "GENE_OR_GENE_PRODUCT", 35, 41], ["ChAd25 sequences", "DNA", 35, 51], ["ChAd25 sequences", "TEST", 35, 51]]], ["HCV antigens E1, E2, P7 and NS2 showed low homology (<25%) with the lowest number of Ad proteins (data not shown), therefore these were not tested for cross-reactive immune responses induced by Ad vector.DNA isolated from Ad vector does not contain HCV genes ::: ResultsTo exclude the possibility of contamination of the non-recombinant Ad vector stock with HCV transgene, we set up PCR with purified Ad DNA using HCV-specific primers (listed in S2 Table).", [["HCV", "ORGANISM", 0, 3], ["E1", "GENE_OR_GENE_PRODUCT", 13, 15], ["E2", "GENE_OR_GENE_PRODUCT", 17, 19], ["P7", "GENE_OR_GENE_PRODUCT", 21, 23], ["NS2", "GENE_OR_GENE_PRODUCT", 28, 31], ["Ad", "ORGANISM", 85, 87], ["Ad", "ORGANISM", 194, 196], ["DNA", "CELLULAR_COMPONENT", 204, 207], ["Ad", "ORGANISM", 222, 224], ["HCV", "ORGANISM", 249, 252], ["Ad", "ORGANISM", 337, 339], ["HCV", "ORGANISM", 358, 361], ["Ad", "ORGANISM", 401, 403], ["DNA", "CELLULAR_COMPONENT", 404, 407], ["HCV antigens", "PROTEIN", 0, 12], ["E1", "PROTEIN", 13, 15], ["E2", "PROTEIN", 17, 19], ["P7", "PROTEIN", 21, 23], ["NS2", "PROTEIN", 28, 31], ["Ad proteins", "PROTEIN", 85, 96], ["HCV genes", "DNA", 249, 258], ["HCV transgene", "DNA", 358, 371], ["purified Ad DNA", "DNA", 392, 407], ["HCV-specific primers", "DNA", 414, 434], ["HCV", "SPECIES", 0, 3], ["Ad", "SPECIES", 194, 196], ["Ad", "SPECIES", 222, 224], ["HCV", "SPECIES", 249, 252], ["Ad", "SPECIES", 337, 339], ["HCV", "SPECIES", 358, 361], ["Ad", "SPECIES", 401, 403], ["HCV", "SPECIES", 414, 417], ["HCV antigens E1", "TEST", 0, 15], ["E2", "TEST", 17, 19], ["P7", "TEST", 21, 23], ["NS2", "TEST", 28, 31], ["low homology", "PROBLEM", 39, 51], ["Ad proteins", "TEST", 85, 96], ["cross", "TEST", 151, 156], ["DNA", "PROBLEM", 204, 207], ["contamination", "PROBLEM", 300, 313], ["the non-recombinant Ad vector stock", "TREATMENT", 317, 352], ["HCV transgene", "TREATMENT", 358, 371], ["PCR", "TEST", 383, 386], ["HCV-specific primers", "TREATMENT", 414, 434], ["HCV", "OBSERVATION", 249, 252], ["exclude the possibility of", "UNCERTAINTY", 273, 299], ["contamination", "OBSERVATION", 300, 313]]], ["None of the primer sets specific for core, F, NS3, NS4, NS5a or NS5b genes of HCV were able to amplify HCV gene products from non-recombinant Ad vector DNA template (Fig 1).", [["F", "GENE_OR_GENE_PRODUCT", 43, 44], ["NS3", "GENE_OR_GENE_PRODUCT", 46, 49], ["NS4", "GENE_OR_GENE_PRODUCT", 51, 54], ["NS5a", "GENE_OR_GENE_PRODUCT", 56, 60], ["NS5b", "GENE_OR_GENE_PRODUCT", 64, 68], ["HCV", "ORGANISM", 78, 81], ["HCV", "ORGANISM", 103, 106], ["Ad", "ORGANISM", 142, 144], ["DNA", "CELLULAR_COMPONENT", 152, 155], ["F, NS3, NS4, NS5a or NS5b genes", "DNA", 43, 74], ["HCV gene products", "DNA", 103, 120], ["non-recombinant Ad vector DNA template", "DNA", 126, 164], ["HCV", "SPECIES", 78, 81], ["HCV", "SPECIES", 103, 106], ["Ad", "SPECIES", 142, 144], ["core", "TEST", 37, 41], ["NS3", "TEST", 46, 49], ["NS4", "TREATMENT", 51, 54], ["NS5a", "TREATMENT", 56, 60], ["NS5b genes of HCV", "PROBLEM", 64, 81], ["HCV gene products", "TREATMENT", 103, 120], ["non-recombinant Ad vector DNA template", "TREATMENT", 126, 164]]], ["Uninfected HEK cell lysate and recombinant adenoviral (rAd) vectors containing individual HCV genes were used as negative and positive controls, respectively.Immunization of mice with Ad vector induces cross-reactive cellular and humoral immune responses against multiple HCV antigens ::: ResultsThe significant homologies of HCV derived peptides with Ad proteins sequences indicated that adenoviruses might induce cross-reactive immunity against HCV antigens.", [["HEK cell lysate", "ANATOMY", 11, 26], ["cellular", "ANATOMY", 217, 225], ["HEK cell lysate", "CELL", 11, 26], ["adenoviral", "ORGANISM", 43, 53], ["rAd", "GENE_OR_GENE_PRODUCT", 55, 58], ["HCV", "ORGANISM", 90, 93], ["mice", "ORGANISM", 174, 178], ["Ad", "ORGANISM", 184, 186], ["cellular", "CELL", 217, 225], ["HCV", "ORGANISM", 272, 275], ["Ad", "ORGANISM", 352, 354], ["adenoviruses", "ORGANISM", 389, 401], ["HCV", "ORGANISM", 447, 450], ["recombinant adenoviral (rAd) vectors", "DNA", 31, 67], ["HCV genes", "DNA", 90, 99], ["HCV antigens", "PROTEIN", 272, 284], ["Ad proteins", "PROTEIN", 352, 363], ["HCV antigens", "PROTEIN", 447, 459], ["mice", "SPECIES", 174, 178], ["adenoviral", "SPECIES", 43, 53], ["HCV", "SPECIES", 90, 93], ["mice", "SPECIES", 174, 178], ["Ad", "SPECIES", 184, 186], ["HCV", "SPECIES", 272, 275], ["HCV", "SPECIES", 326, 329], ["HCV", "SPECIES", 447, 450], ["Uninfected HEK cell lysate", "TREATMENT", 0, 26], ["recombinant adenoviral (rAd) vectors", "TREATMENT", 31, 67], ["individual HCV genes", "PROBLEM", 79, 99], ["Immunization of mice with Ad vector", "TREATMENT", 158, 193], ["HCV derived peptides", "PROBLEM", 326, 346], ["Ad proteins sequences", "TEST", 352, 373], ["adenoviruses", "PROBLEM", 389, 401], ["HCV antigens", "PROBLEM", 447, 459], ["HEK cell lysate", "OBSERVATION", 11, 26], ["HCV", "OBSERVATION", 326, 329]]], ["To test this, female C57bl/6 mice (n = 5/group) were immunized intramuscularly twice (at 14 days interval) with 2x107 PFU/mouse Ad vector, Ad vector + poly I:C or PBS.", [["intramuscularly", "ANATOMY", 63, 78], ["poly I:C", "CHEMICAL", 151, 159], ["C57bl/6 mice", "ORGANISM", 21, 33], ["mouse", "ORGANISM", 122, 127], ["Ad", "ORGANISM", 128, 130], ["Ad", "ORGANISM", 139, 141], ["poly I:C", "SIMPLE_CHEMICAL", 151, 159], ["PBS", "SIMPLE_CHEMICAL", 163, 166], ["mice", "SPECIES", 29, 33], ["mouse", "SPECIES", 122, 127], ["mice", "SPECIES", 29, 33], ["mouse", "SPECIES", 122, 127], ["PFU/mouse Ad vector", "TREATMENT", 118, 137], ["PBS", "PROBLEM", 163, 166]]], ["The proliferation and IFN-\u03b3 production from spleen and lymph node T cells were determined in response to HCV core, NS3 and NS5 protein antigens and pools of their selected peptides (listed in S1\u2013S6 Datasets) (core peptides #: 5, 14, 16, 17 & 27; NS3 peptides #: 2, 5, 6, 8 &10; NS5a peptides #: 6, 24; NS5b peptides #: 5, 19, 27) (Fig 2A).", [["spleen", "ANATOMY", 44, 50], ["lymph node T cells", "ANATOMY", 55, 73], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 22, 27], ["spleen", "ORGAN", 44, 50], ["lymph node T cells", "CELL", 55, 73], ["HCV", "ORGANISM", 105, 108], ["NS3", "GENE_OR_GENE_PRODUCT", 115, 118], ["NS3", "ORGANISM", 246, 249], ["IFN", "PROTEIN", 22, 25], ["spleen and lymph node T cells", "CELL_TYPE", 44, 73], ["HCV core, NS3 and NS5 protein antigens", "PROTEIN", 105, 143], ["S1", "PROTEIN", 192, 194], ["HCV", "SPECIES", 105, 108], ["The proliferation", "TEST", 0, 17], ["IFN", "TEST", 22, 25], ["\u03b3 production", "PROBLEM", 26, 38], ["spleen", "PROBLEM", 44, 50], ["lymph node T cells", "PROBLEM", 55, 73], ["HCV core", "TEST", 105, 113], ["NS3", "TEST", 115, 118], ["NS5 protein antigens", "TEST", 123, 143], ["core peptides", "TEST", 209, 222], ["NS3 peptides", "TEST", 246, 258], ["NS5a peptides", "TEST", 278, 291], ["NS5b peptides", "TEST", 302, 315], ["proliferation", "OBSERVATION_MODIFIER", 4, 17], ["spleen", "ANATOMY", 44, 50], ["lymph node", "OBSERVATION", 55, 65]]], ["Both spleen and inguinal lymph node T cells from Ad vector immunized mice demonstrated high HCV antigens (core, NS3 and NS5)-dependent proliferation and IFN-\u03b3 production, which was further increased by co-immunization of Ad vector with poly I:C adjuvant.", [["spleen", "ANATOMY", 5, 11], ["inguinal lymph node T cells", "ANATOMY", 16, 43], ["poly I:C", "CHEMICAL", 236, 244], ["spleen", "ORGAN", 5, 11], ["inguinal lymph node T cells", "CELL", 16, 43], ["Ad", "ORGANISM", 49, 51], ["mice", "ORGANISM", 69, 73], ["NS3", "GENE_OR_GENE_PRODUCT", 112, 115], ["NS5", "GENE_OR_GENE_PRODUCT", 120, 123], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 153, 158], ["Ad", "ORGANISM", 221, 223], ["poly I:C", "SIMPLE_CHEMICAL", 236, 244], ["spleen and inguinal lymph node T cells", "CELL_TYPE", 5, 43], ["HCV antigens", "PROTEIN", 92, 104], ["NS3", "PROTEIN", 112, 115], ["NS5", "PROTEIN", 120, 123], ["IFN", "PROTEIN", 153, 156], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 69, 73], ["HCV", "SPECIES", 92, 95], ["Ad", "SPECIES", 221, 223], ["high HCV antigens (core, NS3 and NS5)", "PROBLEM", 87, 124], ["dependent proliferation", "PROBLEM", 125, 148], ["IFN-\u03b3 production", "PROBLEM", 153, 169], ["C adjuvant", "TREATMENT", 243, 253], ["spleen", "ANATOMY", 5, 11], ["inguinal", "ANATOMY", 16, 24], ["lymph node", "OBSERVATION", 25, 35], ["high", "OBSERVATION_MODIFIER", 87, 91], ["HCV", "OBSERVATION", 92, 95], ["dependent", "OBSERVATION_MODIFIER", 125, 134], ["proliferation", "OBSERVATION_MODIFIER", 135, 148], ["IFN", "OBSERVATION_MODIFIER", 153, 156], ["increased", "OBSERVATION_MODIFIER", 189, 198]]], ["Cross-reactive proliferation and IFN-\u03b3 responses against selected individual peptides of core, F, NS3, NS4 and NS5 antigens are shown in supplementary information (S1A\u2013S1F and S2 Figs).", [["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 33, 38], ["F", "GENE_OR_GENE_PRODUCT", 95, 96], ["NS3", "GENE_OR_GENE_PRODUCT", 98, 101], ["NS4", "GENE_OR_GENE_PRODUCT", 103, 106], ["NS5 antigens", "GENE_OR_GENE_PRODUCT", 111, 123], ["IFN", "PROTEIN", 33, 36], ["core, F, NS3, NS4 and NS5 antigens", "PROTEIN", 89, 123], ["S1A", "PROTEIN", 164, 167], ["S1F", "PROTEIN", 168, 171], ["Cross-reactive proliferation", "PROBLEM", 0, 28], ["IFN", "TEST", 33, 36], ["NS3", "TEST", 98, 101], ["NS4", "TEST", 103, 106], ["NS5 antigens", "TEST", 111, 123], ["S1A", "TEST", 164, 167], ["proliferation", "OBSERVATION", 15, 28]]], ["T cell proliferation and IFN-\u03b3 responses were also examined against synthetic peptides from HCV antigens NS3, NS4 and NS5 showing low (<20%) or no homology, and responses were not obtained above background (data not shown).Immunization of mice with Ad vector induces cross-reactive cellular and humoral immune responses against multiple HCV antigens ::: ResultsWe also examined the induction of cross-reactive IgG antibodies against HCV protein antigens (core, NS3, NS4 and NS5) in the serum samples obtained from immunized mice (Fig 2B).", [["T cell", "ANATOMY", 0, 6], ["cellular", "ANATOMY", 282, 290], ["serum samples", "ANATOMY", 486, 499], ["T cell", "CELL", 0, 6], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 25, 30], ["HCV", "ORGANISM", 92, 95], ["NS3", "GENE_OR_GENE_PRODUCT", 105, 108], ["NS4", "GENE_OR_GENE_PRODUCT", 110, 113], ["NS5", "GENE_OR_GENE_PRODUCT", 118, 121], ["mice", "ORGANISM", 239, 243], ["Ad", "ORGANISM", 249, 251], ["cellular", "CELL", 282, 290], ["HCV", "ORGANISM", 337, 340], ["IgG antibodies against HCV protein antigens", "GENE_OR_GENE_PRODUCT", 410, 453], ["NS3", "GENE_OR_GENE_PRODUCT", 461, 464], ["NS4", "GENE_OR_GENE_PRODUCT", 466, 469], ["NS5", "GENE_OR_GENE_PRODUCT", 474, 477], ["serum samples", "ORGANISM_SUBSTANCE", 486, 499], ["mice", "ORGANISM", 524, 528], ["IFN", "PROTEIN", 25, 28], ["HCV antigens", "PROTEIN", 92, 104], ["NS3", "PROTEIN", 105, 108], ["NS4", "PROTEIN", 110, 113], ["NS5", "PROTEIN", 118, 121], ["HCV antigens", "PROTEIN", 337, 349], ["cross-reactive IgG antibodies", "PROTEIN", 395, 424], ["HCV protein antigens", "PROTEIN", 433, 453], ["NS3", "PROTEIN", 461, 464], ["NS4", "PROTEIN", 466, 469], ["NS5", "PROTEIN", 474, 477], ["mice", "SPECIES", 239, 243], ["mice", "SPECIES", 524, 528], ["HCV", "SPECIES", 92, 95], ["mice", "SPECIES", 239, 243], ["Ad", "SPECIES", 249, 251], ["HCV", "SPECIES", 337, 340], ["HCV", "SPECIES", 433, 436], ["mice", "SPECIES", 524, 528], ["T cell proliferation", "PROBLEM", 0, 20], ["IFN", "TEST", 25, 28], ["synthetic peptides", "TEST", 68, 86], ["HCV antigens", "TEST", 92, 104], ["NS3", "TEST", 105, 108], ["NS4", "TREATMENT", 110, 113], ["NS5", "TEST", 118, 121], ["Immunization of mice with Ad vector", "TREATMENT", 223, 258], ["cross-reactive IgG antibodies", "TEST", 395, 424], ["HCV protein antigens", "TEST", 433, 453], ["NS3", "TEST", 461, 464], ["NS4", "TEST", 466, 469], ["NS5", "PROBLEM", 474, 477], ["the serum samples", "TEST", 482, 499], ["cell proliferation", "OBSERVATION", 2, 20], ["low", "OBSERVATION_MODIFIER", 130, 133]]], ["The Ad vector induced significant amounts of cross-reactive IgG against all of the HCV antigens.", [["Ad", "ORGANISM", 4, 6], ["IgG", "GENE_OR_GENE_PRODUCT", 60, 63], ["HCV", "ORGANISM", 83, 86], ["cross-reactive IgG", "PROTEIN", 45, 63], ["HCV antigens", "PROTEIN", 83, 95], ["HCV", "SPECIES", 83, 86], ["The Ad vector", "TREATMENT", 0, 13], ["cross-reactive IgG", "PROBLEM", 45, 63], ["the HCV antigens", "PROBLEM", 79, 95], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["amounts", "OBSERVATION_MODIFIER", 34, 41], ["cross-reactive IgG", "OBSERVATION", 45, 63], ["HCV", "OBSERVATION", 83, 86]]], ["Co-administration of TLR agonist poly I:C further enhanced the levels of cross-reactive antibodies.", [["poly I:C", "CHEMICAL", 33, 41], ["poly I:C", "CHEMICAL", 33, 41], ["TLR", "GENE_OR_GENE_PRODUCT", 21, 24], ["poly I:C", "SIMPLE_CHEMICAL", 33, 41], ["TLR", "PROTEIN", 21, 24], ["cross-reactive antibodies", "PROTEIN", 73, 98], ["cross-reactive antibodies", "PROBLEM", 73, 98], ["cross-reactive antibodies", "OBSERVATION", 73, 98]]], ["PBS-immunized mice did not show IgG binding to any of the HCV antigens.", [["PBS", "SIMPLE_CHEMICAL", 0, 3], ["mice", "ORGANISM", 14, 18], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["HCV", "ORGANISM", 58, 61], ["IgG", "PROTEIN", 32, 35], ["HCV antigens", "PROTEIN", 58, 70], ["mice", "SPECIES", 14, 18], ["mice", "SPECIES", 14, 18], ["HCV", "SPECIES", 58, 61], ["PBS", "TEST", 0, 3], ["IgG binding", "PROBLEM", 32, 43], ["the HCV antigens", "PROBLEM", 54, 70]]], ["Also, Ad vector immunized mice did not show antibody binding to control protein antigen rhSOD (data not shown).Immunization of mice with Ad vector induces cross-reactive cellular and humoral immune responses against multiple HCV antigens ::: ResultsTo confirm that the high proliferation responses observed in the 3H-Tdr assay are due to actual proliferation of cross-reactive HCV-specific CD4+ and CD8+ T cells, we performed a CFSE dilution assay along with staining for CD3, CD4 and CD8 markers.", [["cellular", "ANATOMY", 170, 178], ["CD4+ and CD8+ T cells", "ANATOMY", 390, 411], ["CFSE", "CHEMICAL", 428, 432], ["Ad", "ORGANISM", 6, 8], ["mice", "ORGANISM", 26, 30], ["mice", "ORGANISM", 127, 131], ["Ad", "ORGANISM", 137, 139], ["cellular", "CELL", 170, 178], ["HCV", "ORGANISM", 225, 228], ["HCV", "ORGANISM", 377, 380], ["CD4", "GENE_OR_GENE_PRODUCT", 390, 393], ["CD8", "GENE_OR_GENE_PRODUCT", 399, 402], ["CFSE", "SIMPLE_CHEMICAL", 428, 432], ["CD3", "GENE_OR_GENE_PRODUCT", 472, 475], ["CD4", "GENE_OR_GENE_PRODUCT", 477, 480], ["CD8", "GENE_OR_GENE_PRODUCT", 485, 488], ["protein antigen", "PROTEIN", 72, 87], ["rhSOD", "PROTEIN", 88, 93], ["HCV antigens", "PROTEIN", 225, 237], ["cross-reactive HCV-specific CD4+ and CD8+ T cells", "CELL_TYPE", 362, 411], ["CD3", "PROTEIN", 472, 475], ["CD4", "PROTEIN", 477, 480], ["CD8 markers", "PROTEIN", 485, 496], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 127, 131], ["Ad", "SPECIES", 6, 8], ["mice", "SPECIES", 26, 30], ["mice", "SPECIES", 127, 131], ["Ad", "SPECIES", 137, 139], ["HCV", "SPECIES", 225, 228], ["HCV", "SPECIES", 377, 380], ["antibody binding", "PROBLEM", 44, 60], ["Immunization of mice with Ad vector", "TREATMENT", 111, 146], ["the high proliferation responses", "PROBLEM", 265, 297], ["the 3H-Tdr assay", "TEST", 310, 326], ["cross-reactive HCV", "PROBLEM", 362, 380], ["specific CD4", "TEST", 381, 393], ["CD8+ T cells", "PROBLEM", 399, 411], ["a CFSE dilution assay", "TEST", 426, 447], ["staining", "TEST", 459, 467], ["CD3", "TEST", 472, 475], ["CD4", "TEST", 477, 480]]], ["Splenocytes obtained from Ad vector immunized mice were stimulated ex vivo with HCV protein antigens (core, NS3, NS4 and NS5) (Fig 3A), or selected representative peptides from these proteins (Fig 3B).", [["Splenocytes", "ANATOMY", 0, 11], ["Splenocytes", "CELL", 0, 11], ["Ad", "ORGANISM", 26, 28], ["mice", "ORGANISM", 46, 50], ["HCV", "ORGANISM", 80, 83], ["NS3", "GENE_OR_GENE_PRODUCT", 108, 111], ["NS4", "GENE_OR_GENE_PRODUCT", 113, 116], ["NS5", "GENE_OR_GENE_PRODUCT", 121, 124], ["Splenocytes", "CELL_TYPE", 0, 11], ["HCV protein antigens", "PROTEIN", 80, 100], ["NS3", "PROTEIN", 108, 111], ["NS4", "PROTEIN", 113, 116], ["NS5", "PROTEIN", 121, 124], ["Fig 3A", "PROTEIN", 127, 133], ["mice", "SPECIES", 46, 50], ["Ad", "SPECIES", 26, 28], ["mice", "SPECIES", 46, 50], ["HCV", "SPECIES", 80, 83], ["Splenocytes", "TEST", 0, 11], ["Ad vector immunized mice", "TREATMENT", 26, 50], ["HCV protein antigens", "TEST", 80, 100], ["core", "TEST", 102, 106], ["NS3", "TEST", 108, 111], ["NS4", "TEST", 113, 116], ["NS5", "TEST", 121, 124], ["these proteins", "TEST", 177, 191]]], ["Intriguingly, the stimulated splenocytes exhibited remarkable antigen-dependent proliferation of both cross-reactive CD3+CD4+ and CD3+CD8+ T cells.Immunization of mice with Ad vector induces cross-reactive cellular and humoral immune responses against multiple HCV antigens ::: ResultsTo demonstrate that the cytokines produced in culture supernatants are from CD4+ and CD8+ T cells, we performed intracellular cytokine expression analyses of splenocytes obtained from Ad vector immunized mice and stimulated ex vivo with HCV core, NS3, NS4 and NS5 protein antigens (Fig 4) and their selected peptides (Fig 5).", [["splenocytes", "ANATOMY", 29, 40], ["CD3+CD4+ and CD3+CD8+ T cells", "ANATOMY", 117, 146], ["cellular", "ANATOMY", 206, 214], ["supernatants", "ANATOMY", 339, 351], ["CD4+", "ANATOMY", 361, 365], ["CD8+", "ANATOMY", 370, 374], ["T cells", "ANATOMY", 375, 382], ["intracellular", "ANATOMY", 397, 410], ["splenocytes", "ANATOMY", 443, 454], ["splenocytes", "CELL", 29, 40], ["CD3", "GENE_OR_GENE_PRODUCT", 117, 120], ["CD4", "GENE_OR_GENE_PRODUCT", 121, 124], ["CD3", "GENE_OR_GENE_PRODUCT", 130, 133], ["CD8", "GENE_OR_GENE_PRODUCT", 134, 137], ["mice", "ORGANISM", 163, 167], ["Ad", "ORGANISM", 173, 175], ["cellular", "CELL", 206, 214], ["HCV", "ORGANISM", 261, 264], ["CD4", "GENE_OR_GENE_PRODUCT", 361, 364], ["CD8", "GENE_OR_GENE_PRODUCT", 370, 373], ["T cells", "CELL", 375, 382], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 397, 410], ["splenocytes", "CELL", 443, 454], ["Ad", "ORGANISM", 469, 471], ["mice", "ORGANISM", 489, 493], ["HCV", "ORGANISM", 522, 525], ["NS3", "GENE_OR_GENE_PRODUCT", 532, 535], ["NS4", "GENE_OR_GENE_PRODUCT", 537, 540], ["NS5 protein antigens", "GENE_OR_GENE_PRODUCT", 545, 565], ["stimulated splenocytes", "CELL_TYPE", 18, 40], ["CD3", "PROTEIN", 117, 120], ["CD4", "PROTEIN", 121, 124], ["CD3", "PROTEIN", 130, 133], ["CD8", "PROTEIN", 134, 137], ["T cells", "CELL_TYPE", 139, 146], ["HCV antigens", "PROTEIN", 261, 273], ["cytokines", "PROTEIN", 309, 318], ["CD4", "PROTEIN", 361, 364], ["CD8", "PROTEIN", 370, 373], ["T cells", "CELL_TYPE", 375, 382], ["cytokine", "PROTEIN", 411, 419], ["splenocytes", "CELL_TYPE", 443, 454], ["NS3", "PROTEIN", 532, 535], ["NS4", "PROTEIN", 537, 540], ["NS5 protein antigens", "PROTEIN", 545, 565], ["Fig 4", "PROTEIN", 567, 572], ["mice", "SPECIES", 163, 167], ["mice", "SPECIES", 489, 493], ["mice", "SPECIES", 163, 167], ["Ad", "SPECIES", 173, 175], ["HCV", "SPECIES", 261, 264], ["Ad", "SPECIES", 469, 471], ["mice", "SPECIES", 489, 493], ["HCV", "SPECIES", 522, 525], ["the stimulated splenocytes", "TEST", 14, 40], ["dependent proliferation", "PROBLEM", 70, 93], ["CD4", "TEST", 121, 124], ["CD3", "TEST", 130, 133], ["Immunization of mice with Ad vector", "TREATMENT", 147, 182], ["the cytokines", "TEST", 305, 318], ["culture supernatants", "TEST", 331, 351], ["CD4", "TEST", 361, 364], ["CD8", "TEST", 370, 373], ["intracellular cytokine expression", "TEST", 397, 430], ["splenocytes", "TEST", 443, 454], ["Ad vector immunized mice", "TREATMENT", 469, 493], ["HCV core", "TEST", 522, 530], ["NS3", "TREATMENT", 532, 535], ["NS4", "TREATMENT", 537, 540], ["NS5 protein antigens", "TREATMENT", 545, 565], ["dependent", "OBSERVATION_MODIFIER", 70, 79], ["proliferation", "OBSERVATION_MODIFIER", 80, 93], ["cross-reactive CD3+CD4", "OBSERVATION", 102, 124], ["CD8+ T cells", "OBSERVATION", 134, 146]]], ["Splenocytes from mice immunized with PBS and cultured with various HCV peptide or protein antigens, and splenocytes from mice immunized with Ad vector and incubated with medium were used as negative controls (Figs 4 & 5).", [["Splenocytes", "ANATOMY", 0, 11], ["splenocytes", "ANATOMY", 104, 115], ["Splenocytes", "CELL", 0, 11], ["mice", "ORGANISM", 17, 21], ["splenocytes", "CELL", 104, 115], ["mice", "ORGANISM", 121, 125], ["Ad", "ORGANISM", 141, 143], ["Splenocytes", "CELL_TYPE", 0, 11], ["protein antigens", "PROTEIN", 82, 98], ["splenocytes", "CELL_TYPE", 104, 115], ["Splenocytes", "SPECIES", 0, 11], ["mice", "SPECIES", 17, 21], ["mice", "SPECIES", 121, 125], ["mice", "SPECIES", 17, 21], ["HCV", "SPECIES", 67, 70], ["mice", "SPECIES", 121, 125], ["Ad", "SPECIES", 141, 143], ["Splenocytes", "TREATMENT", 0, 11], ["PBS", "TREATMENT", 37, 40], ["various HCV peptide", "PROBLEM", 59, 78], ["protein antigens", "PROBLEM", 82, 98], ["splenocytes", "PROBLEM", 104, 115], ["Ad vector", "TREATMENT", 141, 150], ["splenocytes", "ANATOMY", 104, 115]]], ["Both CD4+ and CD8+ T cells from Ad immunized mice showed increased expression of IFN-\u03b3 and IL-10 simultaneously upon stimulation with HCV proteins when compared to PBS immunized mice (Fig 4).", [["CD4+", "ANATOMY", 5, 9], ["CD8+ T cells", "ANATOMY", 14, 26], ["CD4", "GENE_OR_GENE_PRODUCT", 5, 8], ["CD8", "GENE_OR_GENE_PRODUCT", 14, 17], ["Ad", "ORGANISM", 32, 34], ["mice", "ORGANISM", 45, 49], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 81, 86], ["IL-10", "GENE_OR_GENE_PRODUCT", 91, 96], ["HCV", "ORGANISM", 134, 137], ["mice", "ORGANISM", 178, 182], ["CD4", "PROTEIN", 5, 8], ["CD8+ T cells", "CELL_TYPE", 14, 26], ["IFN", "PROTEIN", 81, 84], ["IL", "PROTEIN", 91, 93], ["HCV proteins", "PROTEIN", 134, 146], ["mice", "SPECIES", 45, 49], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 45, 49], ["HCV", "SPECIES", 134, 137], ["mice", "SPECIES", 178, 182], ["Both CD4", "TEST", 0, 8], ["CD8", "TEST", 14, 17], ["Ad immunized mice", "TEST", 32, 49], ["IFN", "TEST", 81, 84], ["IL", "TEST", 91, 93], ["HCV proteins", "PROBLEM", 134, 146], ["CD4", "OBSERVATION", 5, 8], ["increased", "OBSERVATION_MODIFIER", 57, 66]]], ["We noted that HCV core-stimulated CD4+ and CD8+ T cells showed a high frequency of IL-10 expressing cells compared to other HCV antigens.", [["CD4+", "ANATOMY", 34, 38], ["CD8+ T cells", "ANATOMY", 43, 55], ["cells", "ANATOMY", 100, 105], ["HCV", "ORGANISM", 14, 17], ["CD4", "GENE_OR_GENE_PRODUCT", 34, 37], ["CD8", "GENE_OR_GENE_PRODUCT", 43, 46], ["IL-10", "GENE_OR_GENE_PRODUCT", 83, 88], ["cells", "CELL", 100, 105], ["HCV", "ORGANISM", 124, 127], ["CD4+ and CD8+ T cells", "CELL_TYPE", 34, 55], ["IL-10 expressing cells", "CELL_LINE", 83, 105], ["HCV antigens", "PROTEIN", 124, 136], ["HCV", "SPECIES", 14, 17], ["HCV", "SPECIES", 124, 127], ["HCV core", "TEST", 14, 22], ["CD4", "TEST", 34, 37], ["CD8", "TEST", 43, 46], ["T cells", "PROBLEM", 48, 55], ["IL", "TEST", 83, 85], ["expressing cells", "PROBLEM", 89, 105], ["other HCV antigens", "PROBLEM", 118, 136], ["high", "OBSERVATION_MODIFIER", 65, 69]]], ["However, IFN-\u03b3 producing CD4+ and CD8+ T cells were high against all HCV antigens except HCV NS5 where only IFN-\u03b3 producing CD8+ T cells were increased (Fig 4).", [["CD4+ and CD8+ T cells", "ANATOMY", 25, 46], ["CD8+ T cells", "ANATOMY", 124, 136], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 9, 14], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 34, 37], ["HCV NS5", "ORGANISM", 89, 96], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 108, 113], ["CD8", "GENE_OR_GENE_PRODUCT", 124, 127], ["IFN", "PROTEIN", 9, 12], ["CD4+ and CD8+ T cells", "CELL_TYPE", 25, 46], ["HCV antigens", "PROTEIN", 69, 81], ["HCV NS5", "PROTEIN", 89, 96], ["IFN-\u03b3 producing CD8+ T cells", "CELL_TYPE", 108, 136], ["HCV", "SPECIES", 69, 72], ["HCV", "SPECIES", 89, 92], ["IFN", "TEST", 9, 12], ["CD4", "TEST", 25, 28], ["CD8", "TEST", 34, 37], ["T cells", "PROBLEM", 39, 46], ["all HCV antigens", "PROBLEM", 65, 81], ["HCV NS5", "PROBLEM", 89, 96], ["IFN", "TEST", 108, 111], ["T cells", "PROBLEM", 129, 136]]], ["Upon stimulation with HCV core, NS3, NS4 and NS5 peptides, cross-reactive CD4+ T cells showed enhanced IFN-\u03b3 and IL-10 expression in comparison to the PBS group (Fig 5).", [["cross-reactive CD4+ T cells", "ANATOMY", 59, 86], ["HCV", "ORGANISM", 22, 25], ["NS3", "GENE_OR_GENE_PRODUCT", 32, 35], ["NS4", "GENE_OR_GENE_PRODUCT", 37, 40], ["NS5", "GENE_OR_GENE_PRODUCT", 45, 48], ["CD4", "GENE_OR_GENE_PRODUCT", 74, 77], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 103, 108], ["IL-10", "GENE_OR_GENE_PRODUCT", 113, 118], ["NS3", "PROTEIN", 32, 35], ["NS4", "PROTEIN", 37, 40], ["cross-reactive CD4+ T cells", "CELL_TYPE", 59, 86], ["IFN", "PROTEIN", 103, 106], ["HCV", "SPECIES", 22, 25], ["HCV core", "TEST", 22, 30], ["NS3", "TEST", 32, 35], ["NS4", "TREATMENT", 37, 40], ["NS5 peptides", "TEST", 45, 57], ["cross-reactive CD4", "TEST", 59, 77], ["T cells", "TEST", 79, 86], ["IFN", "TEST", 103, 106], ["IL", "TEST", 113, 115]]], ["Further, IFN-\u03b3-producing CD8+ T cells were notably high with all the peptides used for in vitro stimulation (Fig 5).", [["CD8+ T cells", "ANATOMY", 25, 37], ["IFN-\u03b3-", "GENE_OR_GENE_PRODUCT", 9, 15], ["CD8", "GENE_OR_GENE_PRODUCT", 25, 28], ["IFN", "PROTEIN", 9, 12], ["CD8+ T cells", "CELL_TYPE", 25, 37], ["IFN", "TEST", 9, 12], ["T cells", "PROBLEM", 30, 37], ["the peptides", "TREATMENT", 65, 77], ["vitro stimulation", "TREATMENT", 90, 107]]], ["However, the frequency of CD8+ T cells, which express IL-10 or both IFN-\u03b3 and IL-10, were not increased with any of the selected peptides except HCV core peptide #17, which also showed increased frequency of double positive (both IFN-\u03b3 and IL-10) CD4+ T cells (Fig 5).Cross-reactive effector cells induced upon immunization with Ad vector exert cytotoxicity to target cells loaded with HCV-derived peptides ::: ResultsThe cytotoxic activity of the cross-reactive effector cells obtained from the spleens of Ad vector immunized mice and stimulated in vitro with HCV protein antigens (core, NS3, NS4, NS5 or polyprotein) was examined against EL4 target cells loaded with pools of respective HCV antigen peptides.", [["CD8+ T cells", "ANATOMY", 26, 38], ["IL-10) CD4+ T cells", "ANATOMY", 240, 259], ["effector cells", "ANATOMY", 283, 297], ["cells", "ANATOMY", 368, 373], ["effector cells", "ANATOMY", 463, 477], ["spleens", "ANATOMY", 496, 503], ["EL4", "ANATOMY", 640, 643], ["cells", "ANATOMY", 651, 656], ["CD8", "GENE_OR_GENE_PRODUCT", 26, 29], ["IL-10", "GENE_OR_GENE_PRODUCT", 54, 59], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 68, 73], ["IL-10", "GENE_OR_GENE_PRODUCT", 78, 83], ["HCV", "ORGANISM", 145, 148], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 230, 235], ["IL-10", "GENE_OR_GENE_PRODUCT", 240, 245], ["CD4", "GENE_OR_GENE_PRODUCT", 247, 250], ["effector cells", "CELL", 283, 297], ["Ad", "ORGANISM", 329, 331], ["cells", "CELL", 368, 373], ["HCV", "ORGANISM", 386, 389], ["effector cells", "CELL", 463, 477], ["spleens", "ORGAN", 496, 503], ["Ad", "ORGANISM", 507, 509], ["mice", "ORGANISM", 527, 531], ["HCV protein antigens", "GENE_OR_GENE_PRODUCT", 561, 581], ["NS3", "GENE_OR_GENE_PRODUCT", 589, 592], ["NS4", "GENE_OR_GENE_PRODUCT", 594, 597], ["NS5", "GENE_OR_GENE_PRODUCT", 599, 602], ["EL4 target cells", "CELL", 640, 656], ["HCV", "ORGANISM", 689, 692], ["CD8+ T cells", "CELL_TYPE", 26, 38], ["IL-10", "PROTEIN", 54, 59], ["IFN", "PROTEIN", 68, 71], ["IL", "PROTEIN", 78, 80], ["IFN", "PROTEIN", 230, 233], ["CD4", "PROTEIN", 247, 250], ["T cells", "CELL_TYPE", 252, 259], ["Cross-reactive effector cells", "CELL_TYPE", 268, 297], ["target cells", "CELL_TYPE", 361, 373], ["cross-reactive effector cells", "CELL_TYPE", 448, 477], ["HCV protein antigens", "PROTEIN", 561, 581], ["NS3", "PROTEIN", 589, 592], ["NS4", "PROTEIN", 594, 597], ["NS5", "PROTEIN", 599, 602], ["polyprotein", "PROTEIN", 606, 617], ["EL4 target cells", "CELL_LINE", 640, 656], ["mice", "SPECIES", 527, 531], ["HCV", "SPECIES", 145, 148], ["Ad", "SPECIES", 329, 331], ["HCV", "SPECIES", 386, 389], ["Ad", "SPECIES", 507, 509], ["mice", "SPECIES", 527, 531], ["HCV", "SPECIES", 561, 564], ["HCV", "SPECIES", 689, 692], ["CD8+ T cells", "PROBLEM", 26, 38], ["IL", "TEST", 54, 56], ["IFN", "TEST", 68, 71], ["IL", "TEST", 78, 80], ["HCV core peptide", "TEST", 145, 161], ["increased frequency of double positive", "PROBLEM", 185, 223], ["IFN", "TEST", 230, 233], ["IL", "TEST", 240, 242], ["CD4", "TEST", 247, 250], ["Fig", "TEST", 261, 264], ["Cross-reactive effector cells", "PROBLEM", 268, 297], ["immunization", "TREATMENT", 311, 323], ["Ad vector exert cytotoxicity", "TREATMENT", 329, 357], ["HCV", "PROBLEM", 386, 389], ["the cross-reactive effector cells", "PROBLEM", 444, 477], ["Ad vector immunized mice", "TREATMENT", 507, 531], ["HCV protein antigens", "TEST", 561, 581], ["NS3", "TEST", 589, 592], ["NS4", "TEST", 594, 597], ["NS5", "PROBLEM", 599, 602], ["polyprotein", "TEST", 606, 617], ["EL4 target cells", "PROBLEM", 640, 656], ["respective HCV antigen peptides", "TREATMENT", 678, 709], ["increased", "OBSERVATION_MODIFIER", 185, 194], ["effector cells", "OBSERVATION", 283, 297], ["cytotoxic", "OBSERVATION_MODIFIER", 422, 431], ["activity", "OBSERVATION_MODIFIER", 432, 440], ["cross-reactive effector cells", "OBSERVATION", 448, 477], ["spleens", "ANATOMY", 496, 503]]], ["Different sets of CFSE-stained EL4 targets were prepared by loading them with pools of HCV antigen peptides: core (peptides # 2, 14, 17, 25, 27, 28, 32), NS3 (peptides # 8, 10), NS4 (peptides # 3, 4, 8), NS5 (peptides # NS5a: 1, 2, 16, 20 and NS5b: 5, 19, 23, 39) (listed in S1\u2013S6 Datasets), all of the above peptides (ALL) or no peptide loaded (No).", [["EL4", "ANATOMY", 31, 34], ["CFSE", "CHEMICAL", 18, 22], ["ALL", "DISEASE", 319, 322], ["CFSE", "CHEMICAL", 18, 22], ["CFSE", "SIMPLE_CHEMICAL", 18, 22], ["EL4", "CELL", 31, 34], ["HCV", "ORGANISM", 87, 90], ["NS3", "GENE_OR_GENE_PRODUCT", 154, 157], ["NS4", "GENE_OR_GENE_PRODUCT", 178, 181], ["NS5", "GENE_OR_GENE_PRODUCT", 204, 207], ["20", "GENE_OR_GENE_PRODUCT", 236, 238], ["NS5b", "GENE_OR_GENE_PRODUCT", 243, 247], ["ALL", "CANCER", 319, 322], ["NS3", "PROTEIN", 154, 157], ["NS5", "PROTEIN", 204, 207], ["S1", "PROTEIN", 275, 277], ["S6", "PROTEIN", 278, 280], ["HCV", "SPECIES", 87, 90], ["CFSE", "TEST", 18, 22], ["HCV antigen peptides", "TEST", 87, 107], ["core (peptides", "TEST", 109, 123], ["NS3", "TEST", 154, 157], ["peptides", "TEST", 159, 167], ["NS4", "TEST", 178, 181], ["peptides", "TEST", 183, 191], ["NS5", "TEST", 204, 207], ["peptides", "TEST", 209, 217], ["NS5a", "TEST", 220, 224], ["NS5b", "TEST", 243, 247], ["the above peptides", "TEST", 299, 317]]], ["These different EL4 targets were cultured with corresponding splenocytes stimulated with HCV protein antigens.", [["EL4", "ANATOMY", 16, 19], ["splenocytes", "ANATOMY", 61, 72], ["EL4", "CANCER", 16, 19], ["splenocytes", "CELL", 61, 72], ["HCV", "ORGANISM", 89, 92], ["EL4 targets", "CELL_LINE", 16, 27], ["splenocytes", "CELL_TYPE", 61, 72], ["HCV protein antigens", "PROTEIN", 89, 109], ["HCV", "SPECIES", 89, 92], ["HCV protein antigens", "PROBLEM", 89, 109], ["EL4 targets", "OBSERVATION", 16, 27]]], ["The results showed that splenocytes induced after Ad vector immunization had potent cytotoxic effector function, in an antigen-specific manner.", [["splenocytes", "ANATOMY", 24, 35], ["splenocytes", "CELL", 24, 35], ["Ad", "ORGANISM", 50, 52], ["splenocytes", "CELL_TYPE", 24, 35], ["Ad", "SPECIES", 50, 52], ["splenocytes", "PROBLEM", 24, 35], ["Ad vector immunization", "TREATMENT", 50, 72], ["splenocytes", "ANATOMY", 24, 35], ["cytotoxic effector function", "OBSERVATION", 84, 111]]], ["Interestingly, ex vivo stimulation of cross-reactive effectors with core antigen showed the least antigen-specific cytotoxic activity compared to other HCV antigens (Fig 6).Role of the HCV-specific cross-reactive immune responses induced by Ad vector in reducing viral loads in Vaccinia-HCV challenged mice ::: ResultsTo demonstrate the antiviral potential of Ad vector induced cross-reactive immune responses against HCV, a surrogate Vac-HCV infection model [32] was used.", [["HCV", "DISEASE", 418, 421], ["infection", "DISEASE", 443, 452], ["HCV", "ORGANISM", 152, 155], ["HCV", "ORGANISM", 185, 188], ["Ad", "ORGANISM", 241, 243], ["Vaccinia-HCV", "ORGANISM", 278, 290], ["mice", "ORGANISM", 302, 306], ["Ad", "ORGANISM", 360, 362], ["HCV", "ORGANISM", 418, 421], ["cross-reactive effectors", "PROTEIN", 38, 62], ["core antigen", "PROTEIN", 68, 80], ["HCV antigens", "PROTEIN", 152, 164], ["mice", "SPECIES", 302, 306], ["HCV", "SPECIES", 152, 155], ["HCV", "SPECIES", 185, 188], ["Ad", "SPECIES", 241, 243], ["Vaccinia-HCV", "SPECIES", 278, 290], ["mice", "SPECIES", 302, 306], ["Ad", "SPECIES", 360, 362], ["HCV", "SPECIES", 418, 421], ["Vac-HCV", "SPECIES", 435, 442], ["cross-reactive effectors", "PROBLEM", 38, 62], ["core antigen", "TEST", 68, 80], ["the least antigen", "PROBLEM", 88, 105], ["specific cytotoxic activity", "PROBLEM", 106, 133], ["other HCV antigens", "TEST", 146, 164], ["the HCV", "PROBLEM", 181, 188], ["Ad vector", "TREATMENT", 241, 250], ["Ad vector induced cross-reactive immune responses", "TREATMENT", 360, 409], ["HCV", "PROBLEM", 418, 421], ["a surrogate Vac-HCV infection model", "TREATMENT", 423, 458], ["cytotoxic activity", "OBSERVATION", 115, 133]]], ["Although this is not a direct model of HCV infection, it is a valuable model to assess the ability of the induced immunity to kill host targets expressing HCV antigens.", [["HCV infection", "DISEASE", 39, 52], ["HCV", "ORGANISM", 39, 42], ["HCV", "ORGANISM", 155, 158], ["HCV antigens", "PROTEIN", 155, 167], ["HCV", "SPECIES", 39, 42], ["HCV", "SPECIES", 155, 158], ["HCV infection", "PROBLEM", 39, 52], ["HCV antigens", "PROBLEM", 155, 167], ["HCV", "OBSERVATION_MODIFIER", 39, 42], ["infection", "OBSERVATION", 43, 52]]], ["Reduction in Vac-HCV viral titers in this model is a critical parameter for the antiviral response against HCV.", [["HCV", "DISEASE", 107, 110], ["Vac-HCV viral", "ORGANISM", 13, 26], ["HCV", "ORGANISM", 107, 110], ["Vac-HCV", "SPECIES", 13, 20], ["HCV", "SPECIES", 107, 110], ["Reduction in Vac-HCV viral titers", "PROBLEM", 0, 33], ["HCV", "PROBLEM", 107, 110], ["viral titers", "OBSERVATION", 21, 33]]], ["C57bl/6 mice, after two immunizations with Ad vector with or without poly I:C as adjuvant, were challenged with wild-type vaccinia (WT-Vac), or Vaccinia-HCV chimeric viruses (Vac-HCV core-NS3 or Vac-HCV NS3-NS4-NS5).", [["poly I:C", "CHEMICAL", 69, 77], ["C57bl/6 mice", "ORGANISM", 0, 12], ["Ad", "ORGANISM", 43, 45], ["poly I:C", "SIMPLE_CHEMICAL", 69, 77], ["wild-type", "ORGANISM", 112, 121], ["vaccinia", "ORGANISM", 122, 130], ["WT-Vac", "ORGANISM", 132, 138], ["Vaccinia-HCV chimeric viruses", "ORGANISM", 144, 173], ["Vac-HCV", "ORGANISM", 175, 182], ["core-NS3", "ORGANISM", 183, 191], ["Vac-HCV NS3", "ORGANISM", 195, 206], ["-NS4-NS5", "ORGANISM", 206, 214], ["NS3", "PROTEIN", 188, 191], ["Vac", "PROTEIN", 195, 198], ["HCV NS3", "PROTEIN", 199, 206], ["NS4", "PROTEIN", 207, 210], ["NS5", "PROTEIN", 211, 214], ["mice", "SPECIES", 8, 12], ["mice", "SPECIES", 8, 12], ["Ad", "SPECIES", 43, 45], ["Vaccinia-HCV", "SPECIES", 144, 156], ["HCV", "SPECIES", 179, 182], ["two immunizations with Ad vector", "TREATMENT", 20, 52], ["adjuvant", "TREATMENT", 81, 89], ["type vaccinia", "TREATMENT", 117, 130], ["WT-Vac", "TREATMENT", 132, 138], ["Vaccinia", "PROBLEM", 144, 152], ["HCV chimeric viruses", "PROBLEM", 153, 173], ["Vac-HCV core", "TREATMENT", 175, 187], ["NS3", "TREATMENT", 188, 191], ["Vac", "TREATMENT", 195, 198], ["HCV NS3", "TREATMENT", 199, 206], ["NS4", "TREATMENT", 207, 210], ["NS5", "TREATMENT", 211, 214], ["Vac", "ANATOMY", 135, 138], ["Vac", "ANATOMY", 195, 198]]], ["Five days after challenge, viral loads were determined in ovaries in individual mice (Fig 7).", [["ovaries", "ANATOMY", 58, 65], ["ovaries", "ORGAN", 58, 65], ["mice", "ORGANISM", 80, 84], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 80, 84], ["viral loads", "TEST", 27, 38], ["viral loads", "OBSERVATION", 27, 38], ["ovaries", "ANATOMY", 58, 65]]], ["The mice immunized with Ad vector in the presence or absence of poly I:C had significantly (p <0.05) reduced Vac-HCV (core-NS2-NS3 or NS3-NS4-NS5) viral loads in comparison to PBS or HEK cell lysate-immunized mice (Fig 7A and 7B).", [["HEK cell lysate", "ANATOMY", 183, 198], ["mice", "ORGANISM", 4, 8], ["Ad", "ORGANISM", 24, 26], ["poly I:C", "SIMPLE_CHEMICAL", 64, 72], ["Vac-HCV", "ORGANISM", 109, 116], ["NS3-NS4-NS5", "GENE_OR_GENE_PRODUCT", 134, 145], ["HEK cell", "CELL", 183, 191], ["mice", "ORGANISM", 209, 213], ["NS2", "PROTEIN", 123, 126], ["NS3", "PROTEIN", 127, 130], ["NS3", "PROTEIN", 134, 137], ["NS4", "PROTEIN", 138, 141], ["NS5", "PROTEIN", 142, 145], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 209, 213], ["mice", "SPECIES", 4, 8], ["Ad", "SPECIES", 24, 26], ["HCV", "SPECIES", 113, 116], ["mice", "SPECIES", 209, 213], ["Ad vector", "TREATMENT", 24, 33], ["poly I:C", "PROBLEM", 64, 72], ["reduced Vac-HCV", "PROBLEM", 101, 116], ["NS2", "TEST", 123, 126], ["NS3", "TEST", 127, 130], ["NS3", "TEST", 134, 137], ["NS4", "TEST", 138, 141], ["NS5", "TREATMENT", 142, 145], ["viral loads", "TEST", 147, 158], ["PBS", "TEST", 176, 179], ["HEK cell lysate", "TEST", 183, 198]]], ["In contrast, viral titers in WT-Vaccinia challenged mice were not significantly (p = 0.8472) different in HEK lysate or Ad vector immunized mice (Fig 7A).", [["HEK lysate", "ANATOMY", 106, 116], ["WT-Vaccinia", "ORGANISM", 29, 40], ["mice", "ORGANISM", 52, 56], ["HEK lysate", "CELL", 106, 116], ["Ad", "ORGANISM", 120, 122], ["mice", "ORGANISM", 140, 144], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 140, 144], ["mice", "SPECIES", 52, 56], ["Ad", "SPECIES", 120, 122], ["mice", "SPECIES", 140, 144], ["viral titers", "TEST", 13, 25], ["WT", "TEST", 29, 31], ["viral titers", "OBSERVATION", 13, 25]]], ["These results provide strong evidence that the Ad vector induced cross-reactive immunity specifically targets HCV antigens.Humans with pre-existing Ad immunity demonstrate cross-reactive humoral and cellular immune responses against HCV antigens ::: ResultsTo understand the induction of cross-reactive immunity in HCV-naive humans, we examined Ad-specific and HCV-specific cross-reactive IgGs in healthy human blood donors (n = 19) (Fig 8A).", [["cellular", "ANATOMY", 199, 207], ["blood", "ANATOMY", 411, 416], ["Ad", "ORGANISM", 47, 49], ["HCV", "ORGANISM", 110, 113], ["Humans", "ORGANISM", 123, 129], ["Ad", "ORGANISM", 148, 150], ["cellular", "CELL", 199, 207], ["HCV", "ORGANISM", 233, 236], ["HCV", "ORGANISM", 315, 318], ["humans", "ORGANISM", 325, 331], ["Ad-", "GENE_OR_GENE_PRODUCT", 345, 348], ["HCV", "ORGANISM", 361, 364], ["IgGs", "GENE_OR_GENE_PRODUCT", 389, 393], ["human", "ORGANISM", 405, 410], ["blood", "ORGANISM_SUBSTANCE", 411, 416], ["donors", "ORGANISM", 417, 423], ["HCV antigens", "PROTEIN", 110, 122], ["HCV antigens", "PROTEIN", 233, 245], ["cross-reactive IgGs", "PROTEIN", 374, 393], ["humans", "SPECIES", 325, 331], ["human", "SPECIES", 405, 410], ["HCV", "SPECIES", 110, 113], ["HCV", "SPECIES", 233, 236], ["HCV", "SPECIES", 315, 318], ["humans", "SPECIES", 325, 331], ["HCV", "SPECIES", 361, 364], ["human", "SPECIES", 405, 410], ["the Ad vector", "TREATMENT", 43, 56], ["HCV antigens", "PROBLEM", 110, 122], ["blood donors", "TEST", 411, 423], ["cellular immune", "OBSERVATION", 199, 214]]], ["There was a significant direct correlation between the presence of Ad-specific IgG with HCV NS3 (Spearman r = 0.500, p value = 0.029) and NS4 (Spearman r = 0.486, p value = 0.035) (Fig 8AII and 8AIII).", [["Ad-", "GENE_OR_GENE_PRODUCT", 67, 70], ["IgG", "GENE_OR_GENE_PRODUCT", 79, 82], ["HCV NS3", "ORGANISM", 88, 95], ["Ad-specific IgG", "PROTEIN", 67, 82], ["HCV NS3", "PROTEIN", 88, 95], ["HCV", "SPECIES", 88, 91], ["HCV NS3", "TEST", 88, 95], ["Spearman r", "TEST", 97, 107], ["p value", "TEST", 117, 124], ["NS4", "TEST", 138, 141], ["Spearman r", "TEST", 143, 153], ["p value", "TEST", 163, 170], ["Fig", "TEST", 181, 184]]], ["We also detected cross-reactive IgG against HCV core and NS5 antigens; however the correlations between these antibodies with the Ad hexon-specific IgG (Fig 8AI and 8AIV) were not statistically significant.Humans with pre-existing Ad immunity demonstrate cross-reactive humoral and cellular immune responses against HCV antigens ::: ResultsNext, as an indication of cross-reactive cellular immune response, we determined the intracellular expression of IFN-\u03b3 and IL-10 in CD4+ and CD8+ T cell subsets upon ex vivo stimulation of PBMCs with HCV peptide pool or protein antigens for 4 days.", [["cellular", "ANATOMY", 282, 290], ["cellular", "ANATOMY", 381, 389], ["intracellular", "ANATOMY", 425, 438], ["CD4+ and CD8+", "ANATOMY", 472, 485], ["T cell", "ANATOMY", 486, 492], ["PBMCs", "ANATOMY", 529, 534], ["IgG", "GENE_OR_GENE_PRODUCT", 32, 35], ["HCV", "ORGANISM", 44, 47], ["NS5 antigens", "GENE_OR_GENE_PRODUCT", 57, 69], ["Ad", "ORGANISM", 130, 132], ["IgG", "GENE_OR_GENE_PRODUCT", 148, 151], ["Humans", "ORGANISM", 206, 212], ["Ad", "ORGANISM", 231, 233], ["cellular", "CELL", 282, 290], ["HCV", "ORGANISM", 316, 319], ["cellular", "CELL", 381, 389], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 425, 438], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 453, 458], ["IL-10", "GENE_OR_GENE_PRODUCT", 463, 468], ["CD4", "GENE_OR_GENE_PRODUCT", 472, 475], ["CD8", "GENE_OR_GENE_PRODUCT", 481, 484], ["T cell", "CELL", 486, 492], ["PBMCs", "CELL", 529, 534], ["HCV", "ORGANISM", 540, 543], ["cross-reactive IgG", "PROTEIN", 17, 35], ["HCV core and NS5 antigens", "PROTEIN", 44, 69], ["antibodies", "PROTEIN", 110, 120], ["Ad hexon-specific IgG", "PROTEIN", 130, 151], ["HCV antigens", "PROTEIN", 316, 328], ["IFN", "PROTEIN", 453, 456], ["IL", "PROTEIN", 463, 465], ["CD4", "PROTEIN", 472, 475], ["CD8", "PROTEIN", 481, 484], ["T cell subsets", "CELL_TYPE", 486, 500], ["PBMCs", "CELL_TYPE", 529, 534], ["protein antigens", "PROTEIN", 560, 576], ["HCV", "SPECIES", 44, 47], ["Ad", "SPECIES", 130, 132], ["AIV", "SPECIES", 166, 169], ["HCV", "SPECIES", 316, 319], ["HCV", "SPECIES", 540, 543], ["cross-reactive IgG", "TEST", 17, 35], ["HCV core and NS5 antigens", "PROBLEM", 44, 69], ["these antibodies", "TEST", 104, 120], ["the Ad hexon-specific IgG", "TEST", 126, 151], ["IFN", "TEST", 453, 456], ["IL", "TEST", 463, 465], ["CD4", "TEST", 472, 475], ["T cell subsets", "PROBLEM", 486, 500], ["ex vivo stimulation of PBMCs", "TREATMENT", 506, 534], ["HCV peptide pool", "TREATMENT", 540, 556], ["protein antigens", "PROBLEM", 560, 576], ["cellular immune", "OBSERVATION", 282, 297], ["cell subsets", "OBSERVATION", 488, 500]]], ["Interestingly, both CD4+ and CD8+ T cells from these healthy donors (n = 17, two donors did not provide enough blood samples to isolate PBMCs) demonstrated induction of HCV antigens-specific IFN-\u03b3 and/or IL-10 (Fig 8B).", [["CD4+", "ANATOMY", 20, 24], ["CD8+ T cells", "ANATOMY", 29, 41], ["blood samples", "ANATOMY", 111, 124], ["PBMCs", "ANATOMY", 136, 141], ["CD4", "GENE_OR_GENE_PRODUCT", 20, 23], ["CD8", "GENE_OR_GENE_PRODUCT", 29, 32], ["donors", "ORGANISM", 61, 67], ["donors", "ORGANISM", 81, 87], ["blood samples", "ORGANISM_SUBSTANCE", 111, 124], ["PBMCs", "CELL", 136, 141], ["HCV", "ORGANISM", 169, 172], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 191, 196], ["IL-10", "GENE_OR_GENE_PRODUCT", 204, 209], ["CD4", "PROTEIN", 20, 23], ["CD8+ T cells", "CELL_TYPE", 29, 41], ["PBMCs", "CELL_TYPE", 136, 141], ["HCV antigens", "PROTEIN", 169, 181], ["IFN", "PROTEIN", 191, 194], ["\u03b3", "PROTEIN", 195, 196], ["IL", "PROTEIN", 204, 206], ["HCV", "SPECIES", 169, 172], ["CD4", "TEST", 20, 23], ["CD8", "TEST", 29, 32], ["blood samples", "TEST", 111, 124], ["PBMCs", "TEST", 136, 141], ["HCV antigens", "TEST", 169, 181], ["IFN", "TEST", 191, 194], ["IL", "TEST", 204, 206]]], ["Overall, there was a propensity of IL-10 induction by CD4+ T cells upon stimulation with peptide pools from all four HCV antigens and NS3 and NS4 protein antigens.", [["CD4+ T cells", "ANATOMY", 54, 66], ["IL-10", "GENE_OR_GENE_PRODUCT", 35, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 54, 57], ["NS3", "GENE_OR_GENE_PRODUCT", 134, 137], ["NS4 protein antigens", "GENE_OR_GENE_PRODUCT", 142, 162], ["IL", "PROTEIN", 35, 37], ["CD4", "PROTEIN", 54, 57], ["T cells", "CELL_TYPE", 59, 66], ["HCV antigens", "PROTEIN", 117, 129], ["NS3 and NS4 protein antigens", "PROTEIN", 134, 162], ["HCV", "SPECIES", 117, 120], ["IL", "TREATMENT", 35, 37], ["peptide pools", "PROBLEM", 89, 102], ["all four HCV antigens", "TEST", 108, 129], ["NS3", "TEST", 134, 137], ["NS4 protein antigens", "TEST", 142, 162]]], ["However, a number of donors showed increased IFN-\u03b3 and IFN-\u03b3/IL-10 expression in both CD4+ and CD8+ T cells upon stimulation with HCV antigens (Fig 8B).DiscussionIn the present study, we demonstrate for the first time that Ad vector has the intrinsic ability to induce broad and robust cellular and humoral immune responses against a number of HCV structural and non-structural antigens.", [["CD4+ and CD8+ T cells", "ANATOMY", 86, 107], ["cellular", "ANATOMY", 286, 294], ["donors", "ORGANISM", 21, 27], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 45, 50], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 55, 60], ["IL-10", "GENE_OR_GENE_PRODUCT", 61, 66], ["CD4", "GENE_OR_GENE_PRODUCT", 86, 89], ["CD8", "GENE_OR_GENE_PRODUCT", 95, 98], ["HCV", "ORGANISM", 130, 133], ["Ad", "ORGANISM", 223, 225], ["cellular", "CELL", 286, 294], ["HCV", "ORGANISM", 344, 347], ["IFN", "PROTEIN", 45, 48], ["IFN", "PROTEIN", 55, 58], ["CD4", "PROTEIN", 86, 89], ["CD8+ T cells", "CELL_TYPE", 95, 107], ["HCV antigens", "PROTEIN", 130, 142], ["HCV structural and non-structural antigens", "PROTEIN", 344, 386], ["HCV", "SPECIES", 130, 133], ["Ad", "SPECIES", 223, 225], ["HCV", "SPECIES", 344, 347], ["donors", "TEST", 21, 27], ["increased IFN", "PROBLEM", 35, 48], ["\u03b3", "TEST", 49, 50], ["IFN", "TEST", 55, 58], ["IL", "TEST", 61, 63], ["CD4", "TEST", 86, 89], ["CD8+ T cells", "PROBLEM", 95, 107], ["stimulation", "TEST", 113, 124], ["HCV antigens", "TEST", 130, 142], ["the present study", "TEST", 165, 182], ["HCV structural and non-structural antigens", "PROBLEM", 344, 386], ["increased", "OBSERVATION_MODIFIER", 35, 44], ["both CD4", "ANATOMY", 81, 89], ["humoral immune", "OBSERVATION", 299, 313], ["HCV", "OBSERVATION", 344, 347], ["non-structural antigens", "OBSERVATION", 363, 386]]], ["The in silico sequence alignment studies (Table 1 and S1 Table, S1\u2013S6 Datasets) exhibited an interesting and unexpected pattern of homologies in the amino acid sequences between HCV and Ad protein sequences.", [["amino acid", "CHEMICAL", 149, 159], ["amino acid", "CHEMICAL", 149, 159], ["amino acid", "AMINO_ACID", 149, 159], ["Ad", "ORGANISM", 186, 188], ["amino acid sequences", "PROTEIN", 149, 169], ["HCV and Ad protein sequences", "DNA", 178, 206], ["HCV", "SPECIES", 178, 181], ["The in silico sequence alignment studies", "TEST", 0, 40], ["Table", "TEST", 42, 47], ["S1 Table", "TEST", 54, 62], ["the amino acid sequences", "TEST", 145, 169], ["HCV and Ad protein sequences", "TEST", 178, 206]]], ["Homology ranged from 25\u201353% (homologies below 25% are not reported here), with HCV core peptide epitopes showing the greatest amino acid homology to the largest number of Ad proteins.", [["amino acid", "CHEMICAL", 126, 136], ["amino acid", "CHEMICAL", 126, 136], ["amino acid", "AMINO_ACID", 126, 136], ["Ad", "ORGANISM", 171, 173], ["HCV core peptide epitopes", "PROTEIN", 79, 104], ["Ad proteins", "PROTEIN", 171, 182], ["HCV", "SPECIES", 79, 82], ["Homology", "TEST", 0, 8], ["HCV core peptide epitopes", "PROBLEM", 79, 104], ["the greatest amino acid homology", "PROBLEM", 113, 145], ["largest", "OBSERVATION_MODIFIER", 153, 160]]], ["Further, HCV frame-shift protein (F), NS3, NS4, and NS5 also showed significant levels of homology with Ad proteins.DiscussionOur results, presented in Figs 2\u20135 (and also S1 and S2 Figs), provide conclusive evidence that Ad vector induced significant levels of cross-reactive immune responses against HCV antigens.", [["HCV frame-shift protein (F)", "GENE_OR_GENE_PRODUCT", 9, 36], ["NS3", "GENE_OR_GENE_PRODUCT", 38, 41], ["NS4", "GENE_OR_GENE_PRODUCT", 43, 46], ["NS5", "GENE_OR_GENE_PRODUCT", 52, 55], ["Ad proteins", "GENE_OR_GENE_PRODUCT", 104, 115], ["Ad", "ORGANISM", 221, 223], ["HCV", "ORGANISM", 301, 304], ["HCV frame-shift protein", "PROTEIN", 9, 32], ["F", "PROTEIN", 34, 35], ["NS3", "PROTEIN", 38, 41], ["NS4", "PROTEIN", 43, 46], ["NS5", "PROTEIN", 52, 55], ["Ad proteins", "PROTEIN", 104, 115], ["S1", "PROTEIN", 171, 173], ["HCV antigens", "PROTEIN", 301, 313], ["HCV", "SPECIES", 9, 12], ["Ad", "SPECIES", 221, 223], ["HCV", "SPECIES", 301, 304], ["HCV frame", "TEST", 9, 18], ["NS3", "TEST", 38, 41], ["NS4", "TEST", 43, 46], ["NS5", "PROBLEM", 52, 55], ["significant levels of homology with Ad proteins", "PROBLEM", 68, 115], ["Ad vector", "PROBLEM", 221, 230], ["cross-reactive immune responses", "PROBLEM", 261, 292], ["HCV antigens", "PROBLEM", 301, 313]]], ["These immune responses are mediated by both CD4+ and CD8+ T cells, and cover a broad range of HCV peptide epitopes.", [["T cells", "ANATOMY", 58, 65], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["CD8", "GENE_OR_GENE_PRODUCT", 53, 56], ["T cells", "CELL", 58, 65], ["HCV", "ORGANISM", 94, 97], ["CD4", "PROTEIN", 44, 47], ["CD8", "PROTEIN", 53, 56], ["T cells", "CELL_TYPE", 58, 65], ["HCV peptide epitopes", "PROTEIN", 94, 114], ["HCV", "SPECIES", 94, 97], ["CD4", "TEST", 44, 47], ["T cells", "PROBLEM", 58, 65], ["HCV peptide epitopes", "TREATMENT", 94, 114]]], ["We also showed that heterologous effector cells, induced by Ad vector immunization, possess strong cytotoxic effector function (Fig 6).DiscussionHeterologous immunity is the term used when immune responses induced by one virus confers immunity to another unrelated virus and/or its antigens.", [["effector cells", "ANATOMY", 33, 47], ["cells", "CELL", 42, 47], ["Ad", "ORGANISM", 60, 62], ["heterologous effector cells", "CELL_TYPE", 20, 47], ["Ad", "SPECIES", 60, 62], ["heterologous effector cells", "PROBLEM", 20, 47], ["Ad vector immunization", "TREATMENT", 60, 82], ["immune responses", "PROBLEM", 189, 205], ["another unrelated virus", "PROBLEM", 247, 270], ["heterologous effector cells", "OBSERVATION", 20, 47]]], ["Indeed, there have been reports showing induction of cross-reactive T cell responses among unrelated viruses [18, 33\u201335] Adenovirus and hepatitis C virus are evolutionarily unrelated.", [["T cell", "ANATOMY", 68, 74], ["Adenovirus and hepatitis C virus", "DISEASE", 121, 153], ["T cell", "CELL", 68, 74], ["Adenovirus", "ORGANISM", 121, 131], ["hepatitis C virus", "ORGANISM", 136, 153], ["hepatitis C virus", "SPECIES", 136, 153], ["hepatitis C virus", "SPECIES", 136, 153], ["cross-reactive T cell responses", "PROBLEM", 53, 84], ["unrelated viruses", "PROBLEM", 91, 108], ["Adenovirus", "PROBLEM", 121, 131], ["hepatitis C virus", "PROBLEM", 136, 153], ["hepatitis", "OBSERVATION", 136, 145]]], ["They differ in host cell specificity and contain genomes of dsDNA and RNA, respectively.", [["cell", "ANATOMY", 20, 24], ["host cell", "CELL", 15, 24], ["dsDNA", "CELLULAR_COMPONENT", 60, 65], ["dsDNA and RNA", "RNA", 60, 73], ["genomes of dsDNA and RNA", "PROBLEM", 49, 73], ["host cell", "OBSERVATION", 15, 24], ["dsDNA", "ANATOMY", 60, 65]]], ["However, the induction of heterologous immunity does not require the entire T cell epitope to be homologous [36].", [["T cell", "ANATOMY", 76, 82], ["T cell", "CELL", 76, 82], ["T cell epitope", "PROTEIN", 76, 90], ["the entire T cell epitope", "TREATMENT", 65, 90]]], ["This immunity can result from similarities in amino acid sequences in small stretches of peptides and/or promiscuity of T cell receptors (TCR) [36\u201339].", [["T cell", "ANATOMY", 120, 126], ["amino acid", "CHEMICAL", 46, 56], ["amino acid", "CHEMICAL", 46, 56], ["amino acid", "AMINO_ACID", 46, 56], ["T cell receptors", "GENE_OR_GENE_PRODUCT", 120, 136], ["TCR", "GENE_OR_GENE_PRODUCT", 138, 141], ["T cell receptors", "PROTEIN", 120, 136], ["TCR", "PROTEIN", 138, 141], ["amino acid sequences", "TEST", 46, 66], ["small stretches of peptides", "PROBLEM", 70, 97], ["small", "OBSERVATION_MODIFIER", 70, 75]]], ["It has been shown that only 2\u20134 amino acids in the T cell epitopes actively participate in interaction with the TCR, and stronger associations in peptide-MHC and TCR is provided by co-stimulatory molecules and MHC molecules [39, 40].", [["T cell", "ANATOMY", 51, 57], ["amino acids", "CHEMICAL", 32, 43], ["TCR", "CHEMICAL", 162, 165], ["amino acids", "CHEMICAL", 32, 43], ["2\u20134", "SIMPLE_CHEMICAL", 28, 31], ["amino acids", "AMINO_ACID", 32, 43], ["T cell", "CELL", 51, 57], ["TCR", "GENE_OR_GENE_PRODUCT", 112, 115], ["peptide-MHC", "GENE_OR_GENE_PRODUCT", 146, 157], ["TCR", "GENE_OR_GENE_PRODUCT", 162, 165], ["T cell epitopes", "PROTEIN", 51, 66], ["TCR", "PROTEIN", 112, 115], ["MHC", "PROTEIN", 154, 157], ["TCR", "PROTEIN", 162, 165], ["co-stimulatory molecules", "PROTEIN", 181, 205], ["MHC molecules", "PROTEIN", 210, 223], ["2\u20134 amino acids", "TREATMENT", 28, 43], ["the T cell epitopes", "TREATMENT", 47, 66]]], ["Therefore, it is quite possible that a TCR will still recognize a peptide if its non-contact amino acid(s) are replaced with biochemically similar or even different amino acid(s) [36, 39, 40].", [["TCR", "CHEMICAL", 39, 42], ["amino acid", "CHEMICAL", 93, 103], ["amino acid", "CHEMICAL", 165, 175], ["amino acid", "CHEMICAL", 93, 103], ["amino acid", "CHEMICAL", 165, 175], ["TCR", "GENE_OR_GENE_PRODUCT", 39, 42], ["amino acid", "AMINO_ACID", 93, 103], ["amino acid", "AMINO_ACID", 165, 175], ["TCR", "PROTEIN", 39, 42], ["a TCR", "PROBLEM", 37, 42], ["its non-contact amino acid", "TEST", 77, 103]]], ["Further, MHC class I or II molecules can bind to and present a variety of peptides, which differ in amino acid composition [36, 41, 42].", [["amino acid", "CHEMICAL", 100, 110], ["amino acid", "CHEMICAL", 100, 110], ["MHC class I", "GENE_OR_GENE_PRODUCT", 9, 20], ["amino acid", "AMINO_ACID", 100, 110], ["MHC class I or II molecules", "PROTEIN", 9, 36]]], ["These properties of both MHC molecules and TCR are necessary to process and respond to a vast pool of epitopes originating from a huge number of pathogens and/or antigens [36, 39, 41, 43].", [["TCR", "CHEMICAL", 43, 46], ["TCR", "GENE_OR_GENE_PRODUCT", 43, 46], ["MHC molecules", "PROTEIN", 25, 38], ["TCR", "PROTEIN", 43, 46], ["epitopes", "PROTEIN", 102, 110], ["pathogens", "PROBLEM", 145, 154], ["huge", "OBSERVATION_MODIFIER", 130, 134], ["pathogens", "OBSERVATION", 145, 154]]], ["Various studies show that CD4+ T cells are more promiscuous than CD8+ T cells in peptide epitope recognition [40, 42, 44, 45].", [["CD4+ T cells", "ANATOMY", 26, 38], ["CD8+ T cells", "ANATOMY", 65, 77], ["CD4", "GENE_OR_GENE_PRODUCT", 26, 29], ["CD8", "GENE_OR_GENE_PRODUCT", 65, 68], ["CD4", "PROTEIN", 26, 29], ["T cells", "CELL_TYPE", 31, 38], ["CD8+ T cells", "CELL_TYPE", 65, 77], ["Various studies", "TEST", 0, 15], ["CD4", "TEST", 26, 29], ["T cells", "PROBLEM", 31, 38]]], ["Also the MHC class II peptide binding pocket is more flexible than the MHC class I peptide-binding pocket [42, 45].", [["MHC class II peptide binding pocket", "PROTEIN", 9, 44], ["MHC class I", "PROTEIN", 71, 82], ["binding pocket", "PROBLEM", 30, 44], ["pocket", "OBSERVATION_MODIFIER", 38, 44]]], ["A higher level of promiscuity occurs at the CD4+ T cell level and flexibility within peptide-MHC II binding allows for greater and less-restrictive CD4+ T cell responses.", [["CD4+ T cell", "ANATOMY", 44, 55], ["T cell", "ANATOMY", 153, 159], ["CD4", "GENE_OR_GENE_PRODUCT", 44, 47], ["peptide-MHC II", "GENE_OR_GENE_PRODUCT", 85, 99], ["CD4", "GENE_OR_GENE_PRODUCT", 148, 151], ["T cell", "CELL", 153, 159], ["CD4", "PROTEIN", 44, 47], ["MHC II", "PROTEIN", 93, 99], ["CD4", "PROTEIN", 148, 151], ["A higher level of promiscuity", "PROBLEM", 0, 29], ["restrictive", "OBSERVATION_MODIFIER", 136, 147], ["CD4", "OBSERVATION", 148, 151]]], ["This property is physiologically relevant as CD4+ T cell help is required to generate both humoral and effector T cell responses [37, 46].", [["CD4+ T cell", "ANATOMY", 45, 56], ["T cell", "ANATOMY", 112, 118], ["CD4", "GENE_OR_GENE_PRODUCT", 45, 48], ["T cell", "CELL", 112, 118], ["CD4", "PROTEIN", 45, 48]]], ["Studies have also shown that if amino acids on a peptide epitope can be substituted by amino acids with similar biochemical property, it will be still recognized by the same T cell clone [42].", [["T cell clone", "ANATOMY", 174, 186], ["amino acids", "CHEMICAL", 32, 43], ["amino acids", "CHEMICAL", 87, 98], ["amino acids", "CHEMICAL", 32, 43], ["amino acids", "CHEMICAL", 87, 98], ["amino acids", "AMINO_ACID", 32, 43], ["amino acids", "AMINO_ACID", 87, 98], ["T cell clone", "CELL", 174, 186], ["T cell clone", "CELL_LINE", 174, 186], ["Studies", "TEST", 0, 7], ["amino acids", "PROBLEM", 32, 43], ["a peptide epitope", "TREATMENT", 47, 64], ["amino acids", "TEST", 87, 98]]], ["Additionally, some T cell clones could be intrinsically more cross-reactive than others.", [["T cell clones", "ANATOMY", 19, 32], ["T cell clones", "CELL", 19, 32], ["T cell clones", "CELL_LINE", 19, 32], ["some T cell clones", "PROBLEM", 14, 32], ["cell clones", "OBSERVATION", 21, 32]]], ["In outbred human population, the repertoire of peptide presentation and T cell recognition becomes even broader due to co-dominant expression of MHC molecules.", [["T cell", "ANATOMY", 72, 78], ["human", "ORGANISM", 11, 16], ["T cell", "CELL", 72, 78], ["MHC molecules", "PROTEIN", 145, 158], ["human", "SPECIES", 11, 16], ["human", "SPECIES", 11, 16], ["T cell recognition", "PROBLEM", 72, 90], ["MHC molecules", "PROBLEM", 145, 158], ["MHC molecules", "OBSERVATION", 145, 158]]], ["Therefore, some individuals may show higher heterologous immunity against certain antigens than other individuals [47, 48].DiscussionAn interesting aspect of Ad vector induced heterologous immunity emerged in responses to core antigen of HCV.", [["individuals", "ORGANISM", 16, 27], ["Ad", "ORGANISM", 158, 160], ["HCV", "ORGANISM", 238, 241], ["Ad", "SPECIES", 158, 160], ["HCV", "SPECIES", 238, 241], ["Ad vector induced heterologous immunity", "TREATMENT", 158, 197], ["HCV", "PROBLEM", 238, 241], ["HCV", "OBSERVATION", 238, 241]]], ["We have previously reported that mice immunized with a recombinant Ad vector expressing whole HCV core protein do not generate core-specific T cell responses due to immunosuppressive effects [29, 30].", [["T cell", "ANATOMY", 141, 147], ["mice", "ORGANISM", 33, 37], ["Ad", "ORGANISM", 67, 69], ["whole HCV", "ORGANISM", 88, 97], ["T cell", "CELL", 141, 147], ["HCV core protein", "PROTEIN", 94, 110], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["Ad", "SPECIES", 67, 69], ["HCV", "SPECIES", 94, 97], ["a recombinant Ad vector", "TREATMENT", 53, 76], ["whole HCV core protein", "TREATMENT", 88, 110], ["immunosuppressive effects", "PROBLEM", 165, 190]]], ["In contrast, in the current study we unexpectedly found that an Ad vector without a transgene is able to induce robust core antigen specific humoral and cellular immune responses, due to a high degree of homology between multiple core-derived peptide sequences and various adenovirus proteins.", [["cellular", "ANATOMY", 153, 161], ["Ad", "ORGANISM", 64, 66], ["cellular", "CELL", 153, 161], ["adenovirus", "ORGANISM", 273, 283], ["adenovirus proteins", "PROTEIN", 273, 292], ["the current study", "TEST", 16, 33], ["an Ad vector", "TREATMENT", 61, 73], ["a high degree of homology between multiple core-derived peptide sequences", "PROBLEM", 187, 260], ["various adenovirus proteins", "PROBLEM", 265, 292]]], ["This could be because adenovirus does not encode for a complete sequence of HCV-core but rather exhibits homologies in short peptide sequences, and therefore core-induced immune suppression is not apparent.", [["adenovirus", "ORGANISM", 22, 32], ["HCV", "SPECIES", 76, 79], ["adenovirus", "PROBLEM", 22, 32], ["HCV", "PROBLEM", 76, 79], ["short peptide sequences", "TEST", 119, 142], ["core-induced immune suppression", "TREATMENT", 158, 189], ["immune suppression", "OBSERVATION", 171, 189], ["not apparent", "UNCERTAINTY", 193, 205]]], ["Interestingly, however, core-stimulated effector cells showed significantly less killing activity than other effectors (Fig 6).", [["cells", "ANATOMY", 49, 54], ["cells", "CELL", 49, 54], ["core-stimulated effector cells", "CELL_LINE", 24, 54], ["core-stimulated effector cells", "TEST", 24, 54], ["significantly", "OBSERVATION_MODIFIER", 62, 75], ["less killing", "OBSERVATION_MODIFIER", 76, 88]]], ["The reason is not clear yet.DiscussionTLR agonists such as poly I:C engage their receptor and trigger signaling.", [["poly I:C", "SIMPLE_CHEMICAL", 59, 67], ["poly I:C", "PROTEIN", 59, 67], ["clear", "OBSERVATION", 18, 23]]], ["This results in the upregulation of several costimulatory molecules and cytokines by antigen presenting cells and also T cells, enhancing antigen-specific responses.", [["antigen presenting cells", "ANATOMY", 85, 109], ["T cells", "ANATOMY", 119, 126], ["cells", "CELL", 104, 109], ["T cells", "CELL", 119, 126], ["antigen", "GENE_OR_GENE_PRODUCT", 138, 145], ["costimulatory molecules", "PROTEIN", 44, 67], ["cytokines", "PROTEIN", 72, 81], ["antigen presenting cells", "CELL_TYPE", 85, 109], ["T cells", "CELL_TYPE", 119, 126], ["enhancing antigen", "TEST", 128, 145], ["several", "OBSERVATION_MODIFIER", 36, 43], ["costimulatory molecules", "OBSERVATION", 44, 67]]], ["In our studies, co-administration of poly I:C along with Ad vector boosted the intrinsic heterologous immunity of Ad vector against multiple HCV antigens, further endorsing the Ad vector mediated induction of heterologous immunity against HCV (Figs 2 and 7B).DiscussionHumoral immune response is mediated by B cells, which produce antibodies against the pathogen-derived antigens.", [["B cells", "ANATOMY", 308, 315], ["poly I:C", "CHEMICAL", 37, 45], ["poly I:C", "SIMPLE_CHEMICAL", 37, 45], ["Ad", "ORGANISM", 57, 59], ["Ad", "ORGANISM", 114, 116], ["HCV", "ORGANISM", 141, 144], ["Ad", "ORGANISM", 177, 179], ["HCV", "ORGANISM", 239, 242], ["B cells", "CELL", 308, 315], ["HCV antigens", "PROTEIN", 141, 153], ["B cells", "CELL_TYPE", 308, 315], ["antibodies", "PROTEIN", 331, 341], ["pathogen-derived antigens", "PROTEIN", 354, 379], ["Ad", "SPECIES", 57, 59], ["Ad", "SPECIES", 114, 116], ["HCV", "SPECIES", 141, 144], ["Ad", "SPECIES", 177, 179], ["HCV", "SPECIES", 239, 242], ["our studies", "TEST", 3, 14], ["Ad vector", "TREATMENT", 57, 66], ["the intrinsic heterologous immunity of Ad vector", "TREATMENT", 75, 123], ["multiple HCV antigens", "PROBLEM", 132, 153], ["the Ad vector", "TREATMENT", 173, 186], ["heterologous immunity", "TREATMENT", 209, 230], ["HCV", "PROBLEM", 239, 242], ["the pathogen", "PROBLEM", 350, 362]]], ["Antibodies can recognize a linear peptide epitope or a conformational epitope [49, 50].", [["a linear peptide epitope", "PROBLEM", 25, 49]]], ["The cross-reactive antibody response is expected to be contributed by the linear peptide epitopes, which contain identical or biochemically similar amino acids at the Fab\u2019 binding site(s) [50].", [["amino acids", "CHEMICAL", 148, 159], ["amino acids", "CHEMICAL", 148, 159], ["amino acids", "AMINO_ACID", 148, 159], ["Fab", "PROTEIN", 167, 170], ["The cross-reactive antibody response", "TEST", 0, 36], ["the linear peptide epitopes", "PROBLEM", 70, 97], ["cross-reactive", "OBSERVATION_MODIFIER", 4, 18], ["antibody response", "OBSERVATION", 19, 36], ["amino acids", "OBSERVATION", 148, 159]]], ["Therefore, as HCV and Ad vector proteins show a high level of homology at different sites in their proteins, the probability of cross-reactive Ab-binding epitopes is high and our data suggest that antibodies produced in response to Ad vector immunization also show cross-reactivity with HCV antigens.", [["HCV", "ORGANISM", 14, 17], ["Ad", "ORGANISM", 22, 24], ["Ab", "GENE_OR_GENE_PRODUCT", 143, 145], ["Ad", "ORGANISM", 232, 234], ["HCV", "ORGANISM", 287, 290], ["cross-reactive Ab-binding epitopes", "PROTEIN", 128, 162], ["antibodies", "PROTEIN", 197, 207], ["HCV antigens", "PROTEIN", 287, 299], ["HCV", "SPECIES", 14, 17], ["Ad", "SPECIES", 22, 24], ["Ad", "SPECIES", 232, 234], ["HCV", "SPECIES", 287, 290], ["HCV", "PROBLEM", 14, 17], ["Ad vector proteins", "TEST", 22, 40], ["a high level of homology", "PROBLEM", 46, 70], ["cross-reactive Ab-binding epitopes", "PROBLEM", 128, 162], ["our data", "TEST", 175, 183], ["antibodies", "PROBLEM", 197, 207], ["Ad vector immunization", "TREATMENT", 232, 254], ["cross-reactivity", "PROBLEM", 265, 281], ["HCV antigens", "PROBLEM", 287, 299]]], ["This was further enhanced upon co-immunization with poly I:C (Fig 2B).DiscussionIn addition to inducing CD4+ and CD8+ T cell and antibody responses, our data clearly demonstrate the antiviral potential of heterologous immunity induced by Ad antigens.", [["CD4+ and CD8+", "ANATOMY", 104, 117], ["T cell", "ANATOMY", 118, 124], ["poly I:C", "SIMPLE_CHEMICAL", 52, 60], ["CD4", "GENE_OR_GENE_PRODUCT", 104, 107], ["CD8", "GENE_OR_GENE_PRODUCT", 113, 116], ["T cell", "CELL", 118, 124], ["Ad", "ORGANISM", 238, 240], ["poly I:C", "PROTEIN", 52, 60], ["CD4", "PROTEIN", 104, 107], ["CD8", "PROTEIN", 113, 116], ["Ad antigens", "PROTEIN", 238, 249], ["Ad", "SPECIES", 238, 240], ["CD4", "TEST", 104, 107], ["antibody responses", "TEST", 129, 147], ["our data", "TEST", 149, 157], ["heterologous immunity", "PROBLEM", 205, 226]]], ["It can significantly reduce the viral load in Vac-HCV challenged mice, but not in wild-type vaccinia challenged mice (Fig 7A and 7B), and the use of an adjuvant with Ad vector further enhances the cross-reactive antiviral immunity (Fig 7B).", [["mice", "ORGANISM", 65, 69], ["wild-type vaccinia", "ORGANISM", 82, 100], ["mice", "ORGANISM", 112, 116], ["Ad", "ORGANISM", 166, 168], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 112, 116], ["Vac-HCV", "SPECIES", 46, 53], ["mice", "SPECIES", 65, 69], ["mice", "SPECIES", 112, 116], ["Ad", "SPECIES", 166, 168], ["the viral load", "PROBLEM", 28, 42], ["type vaccinia", "TREATMENT", 87, 100], ["an adjuvant", "TREATMENT", 149, 160], ["Ad vector", "TREATMENT", 166, 175], ["the cross-reactive antiviral immunity", "TREATMENT", 193, 230], ["viral load", "OBSERVATION", 32, 42]]], ["Whether cellular and/or humoral arms of cross-reactive immunity confer viral reduction in an advanced model of HCV remains to be determined.DiscussionAdenoviruses commonly infect humans, where they have also been shown to exist persistently as normal gut flora [51].", [["cellular", "ANATOMY", 8, 16], ["gut flora", "ANATOMY", 251, 260], ["viral reduction", "DISEASE", 71, 86], ["HCV", "DISEASE", 111, 114], ["cellular", "CELL", 8, 16], ["HCV", "ORGANISM", 111, 114], ["Adenoviruses", "GENE_OR_GENE_PRODUCT", 150, 162], ["humans", "ORGANISM", 179, 185], ["gut", "ORGANISM_SUBDIVISION", 251, 254], ["humans", "SPECIES", 179, 185], ["HCV", "SPECIES", 111, 114], ["humans", "SPECIES", 179, 185], ["cross-reactive immunity", "TREATMENT", 40, 63], ["viral reduction", "TREATMENT", 71, 86], ["an advanced model of HCV", "TREATMENT", 90, 114]]], ["Therefore, we sought to detect HCV-specific cross-reactive immune responses in humans with pre-existing immunity against Ad.", [["HCV", "ORGANISM", 31, 34], ["humans", "ORGANISM", 79, 85], ["humans", "SPECIES", 79, 85], ["HCV", "SPECIES", 31, 34], ["humans", "SPECIES", 79, 85], ["Ad.", "SPECIES", 121, 124], ["HCV", "PROBLEM", 31, 34]]], ["Intriguingly, we observed that all of the healthy HCV-naive human donors (n = 19) that were seropositive for anti-Ad IgG (Fig 8A) demonstrated cross-reactive HCV-specific humoral (n = 19) and cellular (n = 17) immunity (Fig 8A and 8B).", [["cellular", "ANATOMY", 192, 200], ["HCV", "ORGANISM", 50, 53], ["human", "ORGANISM", 60, 65], ["donors", "ORGANISM", 66, 72], ["anti-Ad IgG", "GENE_OR_GENE_PRODUCT", 109, 120], ["HCV", "ORGANISM", 158, 161], ["cellular", "CELL", 192, 200], ["anti-Ad IgG", "PROTEIN", 109, 120], ["Fig 8A", "PROTEIN", 122, 128], ["human", "SPECIES", 60, 65], ["HCV", "SPECIES", 50, 53], ["human", "SPECIES", 60, 65], ["anti-Ad", "SPECIES", 109, 116], ["HCV", "SPECIES", 158, 161], ["anti-Ad IgG", "TEST", 109, 120], ["cross-reactive HCV", "PROBLEM", 143, 161], ["cellular (n", "TEST", 192, 203]]], ["Interestingly, in the majority of donors, CD4+ T cells showed higher induction of IL-10 compared to IFN-\u03b3 upon stimulation with different HCV antigens, and only a minority of donors (~17% or 3 out of 17) showed higher levels of IFN-\u03b3 expression compared to IL-10 in both CD4+ and CD8+ T cells.", [["CD4+ T cells", "ANATOMY", 42, 54], ["CD4+ and CD8+ T cells", "ANATOMY", 271, 292], ["donors", "ORGANISM", 34, 40], ["CD4", "GENE_OR_GENE_PRODUCT", 42, 45], ["IL-10", "GENE_OR_GENE_PRODUCT", 82, 87], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 100, 105], ["HCV", "ORGANISM", 138, 141], ["donors", "ORGANISM", 175, 181], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 228, 233], ["IL-10", "GENE_OR_GENE_PRODUCT", 257, 262], ["CD4", "GENE_OR_GENE_PRODUCT", 271, 274], ["CD8", "GENE_OR_GENE_PRODUCT", 280, 283], ["CD4", "PROTEIN", 42, 45], ["T cells", "CELL_TYPE", 47, 54], ["IL-10", "PROTEIN", 82, 87], ["IFN", "PROTEIN", 100, 103], ["\u03b3", "PROTEIN", 104, 105], ["HCV antigens", "PROTEIN", 138, 150], ["IFN", "PROTEIN", 228, 231], ["\u03b3", "PROTEIN", 232, 233], ["IL-10", "PROTEIN", 257, 262], ["CD4", "PROTEIN", 271, 274], ["CD8+ T cells", "CELL_TYPE", 280, 292], ["HCV", "SPECIES", 138, 141], ["CD4", "TEST", 42, 45], ["T cells", "PROBLEM", 47, 54], ["IL", "TEST", 82, 84], ["IFN", "TEST", 100, 103], ["different HCV antigens", "PROBLEM", 128, 150], ["donors", "TEST", 175, 181], ["IFN", "TEST", 228, 231], ["IL", "TEST", 257, 259], ["CD4", "TEST", 271, 274], ["T cells", "OBSERVATION", 285, 292]]], ["These results represent the existence of two discreet courses of natural cross-reactive cellular immune responses against HCV antigens in humans with pre-existing Ad-specific immunity.", [["cellular", "ANATOMY", 88, 96], ["cellular", "CELL", 88, 96], ["HCV", "ORGANISM", 122, 125], ["humans", "ORGANISM", 138, 144], ["HCV antigens", "PROTEIN", 122, 134], ["humans", "SPECIES", 138, 144], ["HCV", "SPECIES", 122, 125], ["humans", "SPECIES", 138, 144], ["natural cross-reactive cellular immune responses", "TREATMENT", 65, 113], ["HCV antigens", "PROBLEM", 122, 134], ["discreet", "OBSERVATION_MODIFIER", 45, 53], ["cross-reactive cellular immune", "OBSERVATION", 73, 103]]], ["The reasons for these two courses are not clear and could be dependent upon HLA type, T cell repertoire and/or environmental factors.", [["T cell", "ANATOMY", 86, 92], ["HLA type", "GENE_OR_GENE_PRODUCT", 76, 84], ["T cell", "CELL", 86, 92], ["T cell repertoire", "PROTEIN", 86, 103], ["environmental factors", "PROTEIN", 111, 132]]], ["However, it can be speculated that exposure of such individuals to HCV may also lead to distinct patterns of immune responses culminating in either acute/self-clearing or chronic infections, with a predisposition towards the development of chronic HCV infection in the majority of cases.", [["HCV", "DISEASE", 67, 70], ["chronic infections", "DISEASE", 171, 189], ["HCV infection", "DISEASE", 248, 261], ["HCV", "ORGANISM", 67, 70], ["HCV", "ORGANISM", 248, 251], ["HCV", "SPECIES", 67, 70], ["HCV", "SPECIES", 248, 251], ["such individuals to HCV", "PROBLEM", 47, 70], ["immune responses", "PROBLEM", 109, 125], ["chronic infections", "PROBLEM", 171, 189], ["chronic HCV infection", "PROBLEM", 240, 261], ["immune responses", "OBSERVATION", 109, 125], ["acute", "OBSERVATION_MODIFIER", 148, 153], ["clearing", "OBSERVATION_MODIFIER", 159, 167], ["chronic", "OBSERVATION_MODIFIER", 171, 178], ["infections", "OBSERVATION", 179, 189], ["chronic", "OBSERVATION_MODIFIER", 240, 247], ["HCV", "OBSERVATION_MODIFIER", 248, 251], ["infection", "OBSERVATION", 252, 261]]], ["These results are intriguing and suggest the potential impact of Ad immunity on the natural course of chronic vs. acute/clearing HCV infection, albeit with a small number of individuals.", [["HCV infection", "DISEASE", 129, 142], ["Ad", "ORGANISM", 65, 67], ["HCV", "ORGANISM", 129, 132], ["HCV", "SPECIES", 129, 132], ["chronic vs", "PROBLEM", 102, 112], ["acute/clearing HCV infection", "PROBLEM", 114, 142], ["a small number of individuals", "PROBLEM", 156, 185], ["chronic", "OBSERVATION_MODIFIER", 102, 109], ["clearing", "OBSERVATION_MODIFIER", 120, 128], ["HCV", "OBSERVATION_MODIFIER", 129, 132], ["infection", "OBSERVATION", 133, 142], ["small", "OBSERVATION_MODIFIER", 158, 163], ["number", "OBSERVATION_MODIFIER", 164, 170]]], ["Prospective immunological studies in a large cohort of individuals will be required to fully predict and correlate Ad immunity to viral clearance vs. persistence upon exposure to HCV.DiscussionIn conclusion, Ad vector has an intrinsic ability to induce broadly reactive immunity against highly conserved HCV antigens across genotypes, and may have a potential use as therapeutic/prophylactic pan-genotypic vaccine for HCV infection, even without an additional HCV transgene.", [["HCV", "DISEASE", 179, 182], ["HCV infection", "DISEASE", 418, 431], ["individuals", "ORGANISM", 55, 66], ["Ad", "ORGANISM", 115, 117], ["HCV", "ORGANISM", 179, 182], ["Ad", "ORGANISM", 208, 210], ["HCV", "ORGANISM", 304, 307], ["HCV", "ORGANISM", 418, 421], ["HCV", "ORGANISM", 460, 463], ["HCV antigens", "PROTEIN", 304, 316], ["HCV transgene", "DNA", 460, 473], ["HCV", "SPECIES", 179, 182], ["HCV", "SPECIES", 304, 307], ["HCV", "SPECIES", 418, 421], ["HCV", "SPECIES", 460, 463], ["Prospective immunological studies", "TEST", 0, 33], ["viral clearance", "TEST", 130, 145], ["HCV", "PROBLEM", 179, 182], ["therapeutic/prophylactic pan-genotypic vaccine", "TREATMENT", 367, 413], ["HCV infection", "PROBLEM", 418, 431], ["an additional HCV transgene", "TREATMENT", 446, 473], ["HCV", "OBSERVATION", 179, 182]]], ["Rare human and non-human adenoviruses are being developed for Ad vector-based vaccines, to avoid the issues of pre-existing immunity.", [["human", "ORGANISM", 5, 10], ["non-human adenoviruses", "ORGANISM", 15, 37], ["Ad", "ORGANISM", 62, 64], ["human", "SPECIES", 5, 10], ["human", "SPECIES", 5, 10], ["Ad", "SPECIES", 62, 64], ["non-human adenoviruses", "TREATMENT", 15, 37], ["Ad vector-based vaccines", "TREATMENT", 62, 86], ["non-human adenoviruses", "OBSERVATION", 15, 37]]], ["However, this strategy will not completely rule out any pre-existing inter- and intra-species cross-reactive anti-adenoviral immunity.", [["anti-adenoviral", "CANCER", 109, 124]]], ["In fact, it has been shown recently that 12% of human subjects screened are seropositive to chimp Ad virus 3 and 22% are seropositive to a rare human Ad virus 6, in contrast to 38% seropositivity to the prevalent human Ad virus 5 [52].", [["human", "ORGANISM", 48, 53], ["chimp", "ORGANISM", 92, 97], ["Ad virus 3", "ORGANISM", 98, 108], ["human", "ORGANISM", 144, 149], ["Ad virus 6", "ORGANISM", 150, 160], ["human", "ORGANISM", 213, 218], ["Ad virus 5", "ORGANISM", 219, 229], ["human", "SPECIES", 48, 53], ["human", "SPECIES", 144, 149], ["human", "SPECIES", 213, 218], ["human", "SPECIES", 48, 53], ["chimp", "SPECIES", 92, 97], ["Ad virus", "SPECIES", 98, 106], ["human Ad virus", "SPECIES", 144, 158], ["human Ad virus", "SPECIES", 213, 227], ["Ad virus", "TEST", 98, 106], ["a rare human Ad virus", "TREATMENT", 137, 158]]], ["Further, adenovirus-specific T cell immunity against conserved epitopes has been shown across various human serotypes and also across species [52].", [["T cell", "ANATOMY", 29, 35], ["adenovirus", "ORGANISM", 9, 19], ["T cell", "CELL", 29, 35], ["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107], ["adenovirus", "PROBLEM", 9, 19], ["conserved epitopes", "PROBLEM", 53, 71], ["various human serotypes", "PROBLEM", 94, 117]]], ["We observed that the homology between HCV epitopes and different adenoviruses spans across a number of adenoviral proteins, and thus it can possibly be extended to a number of uncommon human and non-human adenoviruses.DiscussionHeterologous immunity is a double-edged sword, which can modulate the breadth of the T cell repertoire, influencing the memory T cell pool and/or the immune-dominance of a specific epitope, leading to enhanced or diminished immune responses against a pathogen.", [["T cell", "ANATOMY", 313, 319], ["memory T cell", "ANATOMY", 348, 361], ["HCV", "ORGANISM", 38, 41], ["adenoviruses", "ORGANISM", 65, 77], ["adenoviral", "ORGANISM", 103, 113], ["human", "ORGANISM", 185, 190], ["non-human adenoviruses", "ORGANISM", 195, 217], ["T cell", "CELL", 313, 319], ["memory T cell", "CELL", 348, 361], ["HCV epitopes", "PROTEIN", 38, 50], ["adenoviral proteins", "PROTEIN", 103, 122], ["human", "SPECIES", 185, 190], ["HCV", "SPECIES", 38, 41], ["human", "SPECIES", 185, 190], ["the homology between HCV epitopes", "PROBLEM", 17, 50], ["different adenoviruses spans", "PROBLEM", 55, 83], ["adenoviral proteins", "PROBLEM", 103, 122], ["non-human adenoviruses", "PROBLEM", 195, 217], ["a specific epitope", "PROBLEM", 398, 416], ["diminished immune responses", "PROBLEM", 441, 468], ["a pathogen", "PROBLEM", 477, 487], ["different", "OBSERVATION_MODIFIER", 55, 64], ["adenoviruses", "OBSERVATION", 65, 77]]], ["Such cross-reactive immune responses can explain the spontaneous re-activation of HCV-specific functional immune responses and viral clearance.", [["HCV", "ORGANISM", 82, 85], ["HCV", "SPECIES", 82, 85], ["HCV", "PROBLEM", 82, 85], ["viral clearance", "PROBLEM", 127, 142]]], ["It can also explain the cases of HCV-specific memory T cells in HCV-na\u00efve individuals.", [["memory T cells", "ANATOMY", 46, 60], ["HCV", "ORGANISM", 33, 36], ["memory T cells", "CELL", 46, 60], ["HCV", "ORGANISM", 64, 67], ["individuals", "ORGANISM", 74, 85], ["memory T cells", "CELL_TYPE", 46, 60], ["HCV", "SPECIES", 33, 36], ["HCV", "SPECIES", 64, 67], ["HCV", "PROBLEM", 33, 36], ["HCV", "TEST", 64, 67]]], ["It remains to be established, however, whether and how pre-existing immunity to adenoviruses, and prevalent use of Ad vectors as vaccines for other diseases, shape the course of natural infection with HCV in the human population.Sequence Alignment ::: Materials and MethodsFifteen to twenty amino acid long sequences from various HCV antigens of genotype 1a (core, F, NS3, NS4 and NS5) were compared with human adenovirus 5 protein sequences (S1 Table) by sequence alignment using ClustalW software (Online version).", [["infection", "DISEASE", 186, 195], ["HCV", "DISEASE", 201, 204], ["amino acid", "CHEMICAL", 291, 301], ["amino acid", "CHEMICAL", 291, 301], ["adenoviruses", "ORGANISM", 80, 92], ["Ad", "ORGANISM", 115, 117], ["HCV", "ORGANISM", 201, 204], ["human", "ORGANISM", 212, 217], ["genotype 1a", "GENE_OR_GENE_PRODUCT", 346, 357], ["F", "GENE_OR_GENE_PRODUCT", 365, 366], ["NS3", "GENE_OR_GENE_PRODUCT", 368, 371], ["NS4", "GENE_OR_GENE_PRODUCT", 373, 376], ["NS5", "GENE_OR_GENE_PRODUCT", 381, 384], ["human", "ORGANISM", 405, 410], ["adenovirus 5", "ORGANISM", 411, 423], ["HCV antigens", "PROTEIN", 330, 342], ["genotype 1a", "PROTEIN", 346, 357], ["NS3", "PROTEIN", 368, 371], ["NS4", "PROTEIN", 373, 376], ["NS5", "PROTEIN", 381, 384], ["human adenovirus 5 protein sequences", "DNA", 405, 441], ["human", "SPECIES", 212, 217], ["human", "SPECIES", 405, 410], ["Ad", "SPECIES", 115, 117], ["HCV", "SPECIES", 201, 204], ["human", "SPECIES", 212, 217], ["HCV", "SPECIES", 330, 333], ["human", "SPECIES", 405, 410], ["adenoviruses", "TREATMENT", 80, 92], ["Ad vectors", "TREATMENT", 115, 125], ["vaccines", "TREATMENT", 129, 137], ["other diseases", "PROBLEM", 142, 156], ["natural infection", "PROBLEM", 178, 195], ["HCV", "PROBLEM", 201, 204], ["twenty amino acid long sequences", "TEST", 284, 316], ["various HCV antigens", "TEST", 322, 342], ["NS3", "TEST", 368, 371], ["NS5", "TEST", 381, 384], ["infection", "OBSERVATION", 186, 195]]], ["Sequence homology was documented as pairwise similarity or homology score, and a heat map was prepared by Microsoft Excel to present the distribution of each HCV antigen peptide homology across the different adenovirus proteins.", [["adenovirus", "ORGANISM", 208, 218], ["adenovirus proteins", "PROTEIN", 208, 227], ["HCV", "SPECIES", 158, 161], ["Sequence homology", "TEST", 0, 17], ["a heat map", "TEST", 79, 89], ["each HCV antigen peptide homology", "TREATMENT", 153, 186], ["different adenovirus proteins", "OBSERVATION", 198, 227]]], ["Pairwise scores in the aligned region are the number of identities between the two sequences, divided by the length of the alignment, and calculated as a percentage, so a score of 25 means 25% homology, 30 means 30% homology between aligned sequences and so on.", [["Pairwise scores", "TEST", 0, 15], ["a score", "TEST", 169, 176], ["aligned", "ANATOMY_MODIFIER", 23, 30], ["region", "ANATOMY_MODIFIER", 31, 37], ["number", "OBSERVATION_MODIFIER", 46, 52], ["length", "OBSERVATION_MODIFIER", 109, 115], ["alignment", "OBSERVATION_MODIFIER", 123, 132]]], ["The number of adenovirus proteins showing various levels of homology (25.00 to 30.00, 30.11\u201335.00, 35.11\u201340.00, 40.11\u201345.00, 45.11\u201350.00 and >50) was calculated from the heat map of scores, and summarized in Table 1 (see S1\u2013S6 Datasets for details).Adenovirus vector ::: Materials and MethodsReplication-incompetent human adenovirus 5, with no transgene insert, was amplified and titrated in human embryonic cell line 293A (HEK-293A, source ATCC# CRL 1573) transformed with adenovirus E1 gene (cat# AES 2044, QBiogene Inc., CA, USA) to provide complementarity for virus production.", [["embryonic cell line 293A", "ANATOMY", 398, 422], ["HEK-293A", "ANATOMY", 424, 432], ["ATCC# CRL 1573", "ANATOMY", 441, 455], ["HEK-293A", "CHEMICAL", 424, 432], ["adenovirus", "ORGANISM", 14, 24], ["Adenovirus", "ORGANISM", 249, 259], ["human", "ORGANISM", 316, 321], ["adenovirus 5", "ORGANISM", 322, 334], ["human", "ORGANISM", 392, 397], ["embryonic cell line 293A", "CELL", 398, 422], ["HEK-293A", "CELL", 424, 432], ["ATCC# CRL 1573", "CELL", 441, 455], ["adenovirus", "ORGANISM", 474, 484], ["E1", "ORGANISM", 485, 487], ["adenovirus proteins", "PROTEIN", 14, 33], ["S1", "PROTEIN", 221, 223], ["S6", "PROTEIN", 224, 226], ["transgene insert", "DNA", 344, 360], ["human embryonic cell line 293A", "CELL_LINE", 392, 422], ["HEK-293A", "CELL_LINE", 424, 432], ["CRL 1573", "CELL_LINE", 447, 455], ["adenovirus E1 gene", "DNA", 474, 492], ["human", "SPECIES", 316, 321], ["human", "SPECIES", 392, 397], ["Adenovirus", "SPECIES", 249, 259], ["human adenovirus", "SPECIES", 316, 332], ["human", "SPECIES", 392, 397], ["ATCC# CRL 1573", "SPECIES", 441, 455], ["adenovirus", "SPECIES", 474, 484], ["adenovirus proteins", "TEST", 14, 33], ["homology", "TEST", 60, 68], ["the heat map", "TEST", 166, 178], ["Materials", "TREATMENT", 271, 280], ["MethodsReplication", "TREATMENT", 285, 303], ["incompetent human adenovirus", "TREATMENT", 304, 332], ["transgene insert", "TREATMENT", 344, 360], ["HEK", "TEST", 424, 427], ["source ATCC# CRL", "TEST", 434, 450], ["adenovirus E1 gene", "TREATMENT", 474, 492], ["AES", "TEST", 499, 502], ["CA, USA", "TREATMENT", 524, 531], ["virus production", "PROBLEM", 564, 580]]], ["Recombinant adenoviruses (rAd) expressing HCV antigens core (rAd-core), F (rAd-F), NS3 (rAd-NS3), NS4 (rAd-NS4) or NS5 (rAd-NS5) were prepared and reported earlier by us [17, 28, 31].DNA Purification and PCR Amplification ::: Materials and MethodsDNA was purified from Ad, rAd-core, rAd-NS3, rAd-NS4, rAd-NS5a and rAd-NS5b vector stocks.", [["adenoviruses", "ORGANISM", 12, 24], ["rAd", "GENE_OR_GENE_PRODUCT", 26, 29], ["HCV antigens core (rAd-core)", "GENE_OR_GENE_PRODUCT", 42, 70], ["rAd-F", "GENE_OR_GENE_PRODUCT", 75, 80], ["NS3", "GENE_OR_GENE_PRODUCT", 83, 86], ["rAd-NS3", "GENE_OR_GENE_PRODUCT", 88, 95], ["NS4", "GENE_OR_GENE_PRODUCT", 98, 101], ["rAd-NS4", "GENE_OR_GENE_PRODUCT", 103, 110], ["NS5", "GENE_OR_GENE_PRODUCT", 115, 118], ["rAd-NS5", "GENE_OR_GENE_PRODUCT", 120, 127], ["DNA", "CELLULAR_COMPONENT", 183, 186], ["Ad", "ORGANISM", 269, 271], ["rAd", "GENE_OR_GENE_PRODUCT", 273, 276], ["rAd", "GENE_OR_GENE_PRODUCT", 283, 286], ["NS3", "GENE_OR_GENE_PRODUCT", 287, 290], ["rAd-NS4", "GENE_OR_GENE_PRODUCT", 292, 299], ["rAd-NS5a", "GENE_OR_GENE_PRODUCT", 301, 309], ["rAd-NS5b", "GENE_OR_GENE_PRODUCT", 314, 322], ["rAd", "PROTEIN", 26, 29], ["HCV antigens", "PROTEIN", 42, 54], ["rAd-core", "PROTEIN", 61, 69], ["F", "PROTEIN", 72, 73], ["rAd", "PROTEIN", 75, 78], ["F", "PROTEIN", 79, 80], ["NS3", "PROTEIN", 83, 86], ["rAd", "PROTEIN", 88, 91], ["NS3", "PROTEIN", 92, 95], ["NS4", "PROTEIN", 98, 101], ["rAd", "PROTEIN", 103, 106], ["NS4", "PROTEIN", 107, 110], ["NS5", "PROTEIN", 115, 118], ["rAd", "PROTEIN", 120, 123], ["NS5", "PROTEIN", 124, 127], ["MethodsDNA", "DNA", 240, 250], ["Ad, rAd-core, rAd-NS3, rAd-NS4, rAd-NS5a and rAd-NS5b vector stocks", "DNA", 269, 336], ["HCV", "SPECIES", 42, 45], ["Recombinant adenoviruses", "PROBLEM", 0, 24], ["NS3", "TEST", 83, 86], ["NS3", "TEST", 92, 95], ["NS4", "TEST", 98, 101], ["NS5", "PROBLEM", 115, 118], ["DNA Purification", "TEST", 183, 199], ["PCR Amplification", "TEST", 204, 221], ["MethodsDNA", "TEST", 240, 250], ["rAd", "TEST", 283, 286], ["NS3", "TEST", 287, 290], ["rAd", "TEST", 292, 295], ["NS4", "TEST", 296, 299], ["rAd", "TEST", 301, 304], ["NS5a", "TEST", 305, 309], ["adenoviruses", "OBSERVATION", 12, 24], ["rAd", "ANATOMY", 283, 286], ["NS3", "ANATOMY", 287, 290], ["rAd", "ANATOMY", 292, 295], ["rAd", "ANATOMY", 301, 304], ["NS5a", "ANATOMY", 305, 309], ["rAd", "ANATOMY", 314, 317]]], ["Briefly, 1x108 pfu of each vector was taken in individual tubes and DNA was prepared by using High-Pure Viral Nucleic Acid KitR (cat.# 11 858 874 001, Roche Applied Bio).", [["DNA", "CELLULAR_COMPONENT", 68, 71], ["each vector", "TREATMENT", 22, 33], ["tubes", "OBSERVATION", 58, 63]]], ["PCR reaction was set up with 10 \u03bcl template DNA obtained from the above preparation using 50 \u03bcl total reaction volume consisting of 1x PCR buffer, 10 \u03bcM dNTP, 25 \u03bcM of each primer (forward and reverse, listed in S2 Table) and 1.25 unit of Taq polymerase.", [["NTP", "CHEMICAL", 154, 157], ["DNA", "CELLULAR_COMPONENT", 44, 47], ["Taq polymerase", "GENE_OR_GENE_PRODUCT", 239, 253], ["\u03bcl template DNA", "DNA", 32, 47], ["Taq polymerase", "PROTEIN", 239, 253], ["PCR reaction", "TEST", 0, 12], ["the above preparation", "TREATMENT", 62, 83], ["50 \u03bcl total reaction volume", "TREATMENT", 90, 117], ["1x PCR buffer", "TREATMENT", 132, 145], ["NTP", "TREATMENT", 154, 157], ["Taq polymerase", "TREATMENT", 239, 253]]], ["PCR tubes containing reaction mixtures were incubated in a thermo-cycler with initial denaturation at 92\u00b0C and 40 amplification cycles (92\u00b0C: 30 Sec, 50\u201355\u00b0C: 30 Sec, 68\u00b0C: 60 Sec).", [["Sec", "CHEMICAL", 162, 165], ["PCR tubes containing reaction mixtures", "TREATMENT", 0, 38], ["initial denaturation", "PROBLEM", 78, 98], ["amplification cycles", "TEST", 114, 134], ["tubes", "OBSERVATION", 4, 9]]], ["PCR amplification products were run on 1% agarose gel at 80 volts to resolve amplification products along with 1 KB sized Quick Load DNA Ladder (Cat.# N0468S, NEB Biolab, Germany).Adjuvants ::: Materials and MethodsToll-like receptor-3 agonist poly I:C (Cat.# P1530, Sigma-Aldrich, St. Louis, MO, USA) was used as an adjuvant for immunization with Ad vector.Mice immunizations ::: Materials and MethodsSix to seven week-old female C57Bl/6 mice were purchased from Charles River Laboratory (Charles River, Canada) and immunized twice intramuscularly (at 14-day intervals) using an optimized dose (2x107 PFU/mouse) of Ad, in presence or absence of adjuvant (Poly I:C, 20 \u03bcg/mouse).", [["intramuscularly", "ANATOMY", 533, 548], ["poly I:C", "CHEMICAL", 244, 252], ["Poly I:C", "CHEMICAL", 656, 664], ["Poly I:C", "CHEMICAL", 656, 664], ["agarose", "SIMPLE_CHEMICAL", 42, 49], ["Toll-like receptor-3", "GENE_OR_GENE_PRODUCT", 215, 235], ["poly I:C", "SIMPLE_CHEMICAL", 244, 252], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 267, 280], ["St. Louis", "ORGANISM", 282, 291], ["Ad", "ORGANISM", 348, 350], ["Mice", "ORGANISM", 358, 362], ["C57Bl/6 mice", "ORGANISM", 431, 443], ["mouse", "ORGANISM", 606, 611], ["Ad", "ORGANISM", 616, 618], ["Poly I:C", "SIMPLE_CHEMICAL", 656, 664], ["mouse", "ORGANISM", 672, 677], ["Mice", "SPECIES", 358, 362], ["mice", "SPECIES", 439, 443], ["mouse", "SPECIES", 606, 611], ["mouse", "SPECIES", 672, 677], ["Ad", "SPECIES", 348, 350], ["mice", "SPECIES", 439, 443], ["mouse", "SPECIES", 606, 611], ["mouse", "SPECIES", 672, 677], ["PCR amplification products", "TREATMENT", 0, 26], ["1% agarose gel", "TREATMENT", 39, 53], ["amplification products", "TREATMENT", 77, 99], ["1 KB sized Quick Load DNA Ladder", "TREATMENT", 111, 143], ["N0468S", "TREATMENT", 151, 157], ["NEB Biolab", "TREATMENT", 159, 169], ["an adjuvant", "TREATMENT", 314, 325], ["immunization with Ad vector", "TREATMENT", 330, 357], ["adjuvant (Poly I:C", "TREATMENT", 646, 664]]], ["Mice were euthanized 8 days after the second immunization and various tissue samples (e.g. spleens, inguinal lymph nodes, ovaries, serum etc.) were collected.T cell proliferation assay ::: Materials and MethodsEight days after the second immunization, mice were euthanized, and spleens and/or inguinal lymph nodes were collected.", [["tissue samples", "ANATOMY", 70, 84], ["spleens", "ANATOMY", 91, 98], ["inguinal lymph nodes", "ANATOMY", 100, 120], ["ovaries", "ANATOMY", 122, 129], ["serum", "ANATOMY", 131, 136], ["T cell", "ANATOMY", 158, 164], ["spleens", "ANATOMY", 278, 285], ["inguinal lymph nodes", "ANATOMY", 293, 313], ["Mice", "ORGANISM", 0, 4], ["tissue samples", "TISSUE", 70, 84], ["spleens", "ORGAN", 91, 98], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 100, 120], ["ovaries", "ORGAN", 122, 129], ["serum", "ORGANISM_SUBSTANCE", 131, 136], ["T cell", "CELL", 158, 164], ["mice", "ORGANISM", 252, 256], ["spleens", "ORGAN", 278, 285], ["inguinal lymph nodes", "MULTI-TISSUE_STRUCTURE", 293, 313], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 252, 256], ["Mice", "SPECIES", 0, 4], ["mice", "SPECIES", 252, 256], ["the second immunization", "TREATMENT", 34, 57], ["various tissue samples", "TEST", 62, 84], ["the second immunization", "TREATMENT", 227, 250], ["spleens and/or inguinal lymph nodes", "PROBLEM", 278, 313], ["spleens", "ANATOMY", 91, 98], ["inguinal", "ANATOMY", 100, 108], ["lymph nodes", "OBSERVATION", 109, 120], ["ovaries", "ANATOMY", 122, 129], ["cell proliferation", "OBSERVATION", 160, 178], ["spleens", "ANATOMY", 278, 285], ["inguinal", "ANATOMY", 293, 301], ["lymph nodes", "OBSERVATION", 302, 313]]], ["The spleens were pooled from replicates and ground to single cell suspensions and filtered through a Falcon 100 \u03bcm nylon cell strainer.", [["spleens", "ANATOMY", 4, 11], ["cell", "ANATOMY", 61, 65], ["cell", "ANATOMY", 121, 125], ["spleens", "ORGAN", 4, 11], ["cell suspensions", "CELL", 61, 77], ["single cell suspensions", "TREATMENT", 54, 77], ["a Falcon 100 \u03bcm nylon cell strainer", "TREATMENT", 99, 134], ["spleens", "ANATOMY", 4, 11], ["single cell", "OBSERVATION_MODIFIER", 54, 65], ["suspensions", "OBSERVATION_MODIFIER", 66, 77]]], ["The cells were resuspended in 2 ml of media and passed through an equilibrated nylon wool column.", [["cells", "ANATOMY", 4, 9], ["cells", "CELL", 4, 9], ["The cells", "TREATMENT", 0, 9], ["media", "TREATMENT", 38, 43], ["an equilibrated nylon wool column", "TREATMENT", 63, 96], ["equilibrated nylon", "OBSERVATION", 66, 84], ["wool column", "OBSERVATION", 85, 96]]], ["The column was washed after 45 min of incubation at 37\u00b0C and the flow through contained the splenic T cells.", [["splenic T cells", "ANATOMY", 92, 107], ["C", "GENE_OR_GENE_PRODUCT", 55, 56], ["splenic T cells", "CELL", 92, 107], ["splenic T cells", "CELL_TYPE", 92, 107], ["the flow", "TEST", 61, 69], ["column", "ANATOMY", 4, 10], ["flow", "OBSERVATION", 65, 69], ["splenic", "ANATOMY", 92, 99], ["T cells", "OBSERVATION", 100, 107]]], ["These T cells were used in the experiments (~90% CD3+ T cells).", [["T cells", "ANATOMY", 6, 13], ["CD3+ T cells", "ANATOMY", 49, 61], ["T cells", "CELL", 6, 13], ["CD3", "GENE_OR_GENE_PRODUCT", 49, 52], ["T cells", "CELL_TYPE", 6, 13], ["CD3", "PROTEIN", 49, 52], ["T cells", "CELL_TYPE", 54, 61], ["These T cells", "TEST", 0, 13], ["the experiments", "TEST", 27, 42]]], ["Lymph nodes were also ground into single cell suspensions and used in the assays.", [["Lymph nodes", "ANATOMY", 0, 11], ["cell", "ANATOMY", 41, 45], ["Lymph nodes", "MULTI-TISSUE_STRUCTURE", 0, 11], ["cell suspensions", "CELL", 41, 57], ["Lymph nodes", "PROBLEM", 0, 11], ["single cell suspensions", "TREATMENT", 34, 57], ["the assays", "TEST", 70, 80], ["Lymph nodes", "OBSERVATION", 0, 11], ["cell suspensions", "OBSERVATION", 41, 57]]], ["Proliferative responses were measured in triplicate cultures in 96-well flat-bottomed microtiter plates.", [["Proliferative responses", "TEST", 0, 23], ["triplicate cultures", "TEST", 41, 60], ["bottomed microtiter plates", "TREATMENT", 77, 103]]], ["A total of 4\u00d7105 T cells from immunized mice and 4\u00d7105 APCs (spleen cells from unimmunized mice irradiated with 3000 rads) were mixed with different HCV-derived proteins (core = c22-3, NS3 = c33c; NS4 = c100-3; NS5 = NS5 SOD, polyprotein c25 = core+NS3+NS4; polyprotein c200 = NS3+NS4 or control protein = rhSOD, kindly provided by Chiron/Novartis) or synthetic HCV-derived peptides (see S1\u2013S6 Datasets) at different concentrations as described in the Fig legends.", [["4\u00d7105 T cells", "ANATOMY", 11, 24], ["APCs", "ANATOMY", 55, 59], ["spleen cells", "ANATOMY", 61, 73], ["T cells", "CELL", 17, 24], ["mice", "ORGANISM", 40, 44], ["4\u00d7105 APCs", "CELL", 49, 59], ["spleen cells", "CELL", 61, 73], ["mice", "ORGANISM", 91, 95], ["NS5", "ORGANISM", 211, 214], ["NS5", "ORGANISM", 217, 220], ["SOD", "GENE_OR_GENE_PRODUCT", 221, 224], ["HCV", "ORGANISM", 362, 365], ["4\u00d7105 T cells", "CELL_LINE", 11, 24], ["APCs", "CELL_TYPE", 55, 59], ["spleen cells", "CELL_TYPE", 61, 73], ["HCV-derived proteins", "PROTEIN", 149, 169], ["NS3", "PROTEIN", 185, 188], ["NS4", "PROTEIN", 197, 200], ["NS5", "PROTEIN", 211, 214], ["NS5 SOD", "PROTEIN", 217, 224], ["polyprotein c25", "PROTEIN", 226, 241], ["NS3", "PROTEIN", 249, 252], ["NS4", "PROTEIN", 253, 256], ["polyprotein c200", "PROTEIN", 258, 274], ["NS3", "PROTEIN", 277, 280], ["NS4", "PROTEIN", 281, 284], ["control protein", "PROTEIN", 288, 303], ["rhSOD", "PROTEIN", 306, 311], ["S1", "PROTEIN", 388, 390], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 40, 44], ["mice", "SPECIES", 91, 95], ["HCV", "SPECIES", 149, 152], ["HCV", "SPECIES", 362, 365], ["A total of 4\u00d7105 T cells", "TREATMENT", 0, 24], ["immunized mice", "TREATMENT", 30, 44], ["APCs", "TEST", 55, 59], ["spleen cells", "TEST", 61, 73], ["unimmunized mice irradiated", "TREATMENT", 79, 106], ["different HCV", "PROBLEM", 139, 152], ["c22", "TEST", 178, 181], ["NS3", "TEST", 185, 188], ["NS4", "TEST", 197, 200], ["c", "TEST", 203, 204], ["NS5", "TEST", 211, 214], ["NS5", "TEST", 217, 220], ["SOD", "TEST", 221, 224], ["polyprotein", "TEST", 226, 237], ["core", "TEST", 244, 248], ["NS3", "TEST", 249, 252], ["NS4", "TEST", 253, 256], ["polyprotein", "TEST", 258, 269], ["NS3", "TEST", 277, 280], ["NS4", "TREATMENT", 281, 284], ["protein", "TEST", 296, 303], ["rhSOD", "TEST", 306, 311], ["Chiron/Novartis", "TREATMENT", 332, 347], ["synthetic HCV", "PROBLEM", 352, 365], ["derived peptides", "PROBLEM", 366, 382], ["spleen", "ANATOMY", 61, 67]]], ["T cell proliferation was assessed by a radioactive 3H-thymidine incorporation assay.", [["T cell", "ANATOMY", 0, 6], ["3H-thymidine", "CHEMICAL", 51, 63], ["3H-thymidine", "CHEMICAL", 51, 63], ["T cell", "CELL", 0, 6], ["thymidine", "SIMPLE_CHEMICAL", 54, 63], ["T cell proliferation", "PROBLEM", 0, 20], ["a radioactive 3H-thymidine incorporation assay", "TREATMENT", 37, 83], ["cell proliferation", "OBSERVATION", 2, 20]]], ["Detailed methodologies for T cell proliferation assays have been reported previously by us [32].IFN-\u03b3 Cytokine ELISA ::: Materials and MethodsLevels of IFN-\u03b3 were assessed in culture supernatants collected from T cell proliferation assays using mouse IFN-\u03b3 ELISA kits supplied by eBiosciences (Cat.# 88\u20137314, eBiosciences Inc. San Diego, USA).", [["T cell", "ANATOMY", 27, 33], ["supernatants", "ANATOMY", 183, 195], ["T cell", "ANATOMY", 211, 217], ["T cell", "CELL", 27, 33], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 152, 157], ["T cell", "CELL", 211, 217], ["mouse", "ORGANISM", 245, 250], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 251, 256], ["IFN", "PROTEIN", 96, 99], ["IFN", "PROTEIN", 152, 155], ["\u03b3", "PROTEIN", 156, 157], ["IFN", "PROTEIN", 251, 254], ["mouse", "SPECIES", 245, 250], ["mouse", "SPECIES", 245, 250], ["T cell proliferation assays", "TEST", 27, 54], ["IFN", "TEST", 152, 155], ["culture supernatants", "TEST", 175, 195], ["mouse IFN", "TREATMENT", 245, 254], ["ELISA kits", "TEST", 257, 267], ["cell proliferation", "OBSERVATION", 213, 231]]], ["ELISA was performed according to the manufacturer\u2019s instructions.", [["ELISA", "TEST", 0, 5]]], ["Plates were read and data were analyzed in FluoStar ELISA reader (BMG Labtech GmbH, Ortenberg, Germany).", [["Plates", "TEST", 0, 6]]], ["Cytokine concentration per ml of culture supernatant was determined by multiplying the calculated concentration with the dilution factor.", [["supernatant", "ANATOMY", 41, 52], ["Cytokine", "GENE_OR_GENE_PRODUCT", 0, 8], ["Cytokine", "PROTEIN", 0, 8], ["Cytokine concentration", "TREATMENT", 0, 22], ["culture supernatant", "TEST", 33, 52], ["the dilution factor", "TREATMENT", 117, 136]]], ["The averages of these concentrations (pg/ml) from duplicate wells were plotted in the graphs shown here.Antibody ELISA ::: Materials and MethodsSerum was prepared from the blood of immunized mice and stored at -20\u00b0C until required.", [["blood", "ANATOMY", 172, 177], ["blood", "ORGANISM_SUBSTANCE", 172, 177], ["mice", "ORGANISM", 191, 195], ["mice", "SPECIES", 191, 195], ["mice", "SPECIES", 191, 195], ["these concentrations (pg/ml)", "TREATMENT", 16, 44], ["Antibody ELISA", "TEST", 104, 118], ["MethodsSerum", "TREATMENT", 137, 149]]], ["HCV antigen-specific cross-reactive IgG antibodies in Ad vector immunized mice, were measured in 96-well plates coated overnight at 4\u00b0C with HCV antigens (core, NS3, NS4 or NS5) at 1 \u03bcg/ml in 1xPBS.", [["HCV", "ORGANISM", 0, 3], ["IgG", "GENE_OR_GENE_PRODUCT", 36, 39], ["Ad", "ORGANISM", 54, 56], ["mice", "ORGANISM", 74, 78], ["HCV", "ORGANISM", 141, 144], ["NS3", "ORGANISM", 161, 164], ["NS4", "GENE_OR_GENE_PRODUCT", 166, 169], ["HCV antigen", "PROTEIN", 0, 11], ["cross-reactive IgG antibodies", "PROTEIN", 21, 50], ["HCV antigens", "PROTEIN", 141, 153], ["NS3", "PROTEIN", 161, 164], ["NS4", "PROTEIN", 166, 169], ["NS5", "PROTEIN", 173, 176], ["mice", "SPECIES", 74, 78], ["HCV", "SPECIES", 0, 3], ["Ad", "SPECIES", 54, 56], ["mice", "SPECIES", 74, 78], ["HCV", "SPECIES", 141, 144], ["HCV antigen", "TEST", 0, 11], ["specific cross-reactive IgG antibodies", "TEST", 12, 50], ["HCV antigens", "TEST", 141, 153], ["NS3", "TREATMENT", 161, 164], ["NS4", "TREATMENT", 166, 169], ["NS5", "TREATMENT", 173, 176]]], ["The next day, after blocking with 1% BSA at room temperature for 1 hour, serial dilutions of serum samples were added to the 96-well plate in 2\u20133 replicates and incubated again at room temperature for 2 hours.", [["serum samples", "ANATOMY", 93, 106], ["BSA", "CHEMICAL", 37, 40], ["BSA", "SIMPLE_CHEMICAL", 37, 40], ["serum samples", "ORGANISM_SUBSTANCE", 93, 106], ["serial dilutions", "TEST", 73, 89], ["serum samples", "TEST", 93, 106]]], ["After application of serum, anti-mouse IgG labeled with alkaline phosphatase (AP) (Cat.# 1031\u201304, Southern Biotech, Alabama, USA) was added and plates were incubated for 1 hour.", [["serum", "ANATOMY", 21, 26], ["serum", "ORGANISM_SUBSTANCE", 21, 26], ["anti-mouse IgG labeled with alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 28, 76], ["anti-mouse IgG", "PROTEIN", 28, 42], ["alkaline phosphatase", "PROTEIN", 56, 76], ["AP", "PROTEIN", 78, 80], ["anti-mouse", "SPECIES", 28, 38], ["anti-mouse", "SPECIES", 28, 38], ["serum, anti-mouse IgG", "TEST", 21, 42], ["alkaline phosphatase", "TEST", 56, 76]]], ["Color was developed by adding PNPP substrate (Cat.# 0201\u201301, Southern Biotech, Alabama, USA).", [["PNPP", "CHEMICAL", 30, 34], ["PNPP", "SIMPLE_CHEMICAL", 30, 34], ["PNPP substrate", "TREATMENT", 30, 44]]], ["Plates were washed with 1xPBST (1xPBS with 0.1% Tween-20) after each incubation step.", [["1xPBST", "CHEMICAL", 24, 30], ["Tween-20", "CHEMICAL", 48, 56], ["1xPBST", "CHEMICAL", 24, 30], ["Tween-20", "CHEMICAL", 48, 56], ["1xPBST", "SIMPLE_CHEMICAL", 24, 30], ["Plates", "TEST", 0, 6], ["1xPBST", "TEST", 24, 30], ["1xPBS", "TEST", 32, 37]]], ["Absorbance was read using FluoStar Optima ELISA Reader (BMG Labtech GmbH, Ortenberg, Germany), and OD values from HCV antigen-coated plates, corrected for background from OD values in SOD-coated plates, were plotted in the graphs shown here.Flow cytometry ::: Materials and MethodsMouse splenocytes were cultured with 5 \u03bcg/ml of HCV protein antigens or peptides for 5 days in RPMI-1640 media supplemented with 10% fetal bovine serum.", [["splenocytes", "ANATOMY", 287, 298], ["fetal bovine serum", "ANATOMY", 414, 432], ["RPMI-1640", "CHEMICAL", 376, 385], ["HCV", "ORGANISM", 114, 117], ["SOD", "SIMPLE_CHEMICAL", 184, 187], ["MethodsMouse splenocytes", "CELL", 274, 298], ["HCV", "ORGANISM", 329, 332], ["bovine", "ORGANISM", 420, 426], ["serum", "ORGANISM_SUBSTANCE", 427, 432], ["HCV antigen", "PROTEIN", 114, 125], ["SOD", "PROTEIN", 184, 187], ["MethodsMouse splenocytes", "CELL_LINE", 274, 298], ["HCV protein antigens", "PROTEIN", 329, 349], ["bovine", "SPECIES", 420, 426], ["HCV", "SPECIES", 114, 117], ["HCV", "SPECIES", 329, 332], ["bovine", "SPECIES", 420, 426], ["OD values", "TEST", 99, 108], ["HCV antigen", "TEST", 114, 125], ["OD values", "TEST", 171, 180], ["SOD-coated plates", "TREATMENT", 184, 201], ["MethodsMouse splenocytes", "TREATMENT", 274, 298], ["HCV protein antigens", "TREATMENT", 329, 349], ["RPMI", "TEST", 376, 380], ["10% fetal bovine serum", "TREATMENT", 410, 432]]], ["On the fifth day, cells were harvested and counted, and 1x106 cells per group were stained for T cell markers.", [["cells", "ANATOMY", 18, 23], ["cells", "ANATOMY", 62, 67], ["T cell", "ANATOMY", 95, 101], ["cells", "CELL", 18, 23], ["cells", "CELL", 62, 67], ["T cell", "CELL", 95, 101], ["1x106 cells", "CELL_LINE", 56, 67], ["T cell markers", "PROTEIN", 95, 109], ["T cell markers", "TEST", 95, 109]]], ["To perform intracellular cytokine staining, splenocytes cultured for 5 days with HCV antigens were treated with ionomycin (1 \u03bcg/ml), phorbol 12-myristate 13-acetate or PMA (50 ng/ml) and brefeldin A (1.5 \u03bcg/ml, Cat.# 00\u20134506) for 5 hours and subsequently stained by fluorochrome labeled antibodies (purchased from eBiosciences Inc. San Diego, USA) for extracellular lineage markers: CD3 (PE Cy7, Cat.# 25\u20130031), CD4 (APC, Cat.# 17\u20130441) and CD8a (APC efluor 780, Cat.# 47\u20130081); and intracellular cytokines: IFN-\u03b3 (PE, Cat.# 12\u20137311) and IL-10 (FITC, Cat.# 11\u20137101).", [["intracellular", "ANATOMY", 11, 24], ["splenocytes", "ANATOMY", 44, 55], ["extracellular lineage", "ANATOMY", 352, 373], ["intracellular", "ANATOMY", 483, 496], ["ionomycin", "CHEMICAL", 112, 121], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 133, 164], ["PMA", "CHEMICAL", 168, 171], ["brefeldin A", "CHEMICAL", 187, 198], ["# 00\u20134506", "CHEMICAL", 215, 224], ["ionomycin", "CHEMICAL", 112, 121], ["phorbol 12-myristate 13-acetate", "CHEMICAL", 133, 164], ["PMA", "CHEMICAL", 168, 171], ["brefeldin A", "CHEMICAL", 187, 198], ["FITC", "CHEMICAL", 545, 549], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 11, 24], ["splenocytes", "CELL", 44, 55], ["HCV", "ORGANISM", 81, 84], ["ionomycin", "SIMPLE_CHEMICAL", 112, 121], ["phorbol 12-myristate 13-acetate", "SIMPLE_CHEMICAL", 133, 164], ["PMA", "SIMPLE_CHEMICAL", 168, 171], ["brefeldin A", "SIMPLE_CHEMICAL", 187, 198], ["fluorochrome", "SIMPLE_CHEMICAL", 266, 278], ["extracellular lineage", "CELL", 352, 373], ["CD3", "GENE_OR_GENE_PRODUCT", 383, 386], ["Cat.# 25\u20130031", "GENE_OR_GENE_PRODUCT", 396, 409], ["CD4", "GENE_OR_GENE_PRODUCT", 412, 415], ["APC", "GENE_OR_GENE_PRODUCT", 417, 420], ["CD8a", "GENE_OR_GENE_PRODUCT", 441, 445], ["Cat.# 47\u20130081", "GENE_OR_GENE_PRODUCT", 463, 476], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 483, 496], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 508, 513], ["PE", "SIMPLE_CHEMICAL", 515, 517], ["IL-10", "GENE_OR_GENE_PRODUCT", 538, 543], ["FITC", "SIMPLE_CHEMICAL", 545, 549], ["splenocytes", "CELL_TYPE", 44, 55], ["HCV antigens", "PROTEIN", 81, 93], ["fluorochrome labeled antibodies", "PROTEIN", 266, 297], ["extracellular lineage markers", "PROTEIN", 352, 381], ["CD3", "PROTEIN", 383, 386], ["PE Cy7", "PROTEIN", 388, 394], ["Cat.# 25\u20130031", "PROTEIN", 396, 409], ["CD4", "PROTEIN", 412, 415], ["APC", "PROTEIN", 417, 420], ["17\u20130441", "PROTEIN", 428, 435], ["CD8a", "PROTEIN", 441, 445], ["APC", "PROTEIN", 447, 450], ["intracellular cytokines", "PROTEIN", 483, 506], ["IFN", "PROTEIN", 508, 511], ["\u03b3", "PROTEIN", 512, 513], ["IL", "PROTEIN", 538, 540], ["HCV", "SPECIES", 81, 84], ["intracellular cytokine staining", "TEST", 11, 42], ["splenocytes cultured", "TEST", 44, 64], ["HCV antigens", "TREATMENT", 81, 93], ["ionomycin", "TREATMENT", 112, 121], ["phorbol", "TREATMENT", 133, 140], ["myristate", "TREATMENT", 144, 153], ["PMA", "TREATMENT", 168, 171], ["brefeldin A", "TREATMENT", 187, 198], ["fluorochrome labeled antibodies", "TEST", 266, 297], ["extracellular lineage markers", "TEST", 352, 381], ["CD3", "TEST", 383, 386], ["PE", "TEST", 388, 390], ["Cy7", "TEST", 391, 394], ["Cat.", "TEST", 396, 400], ["CD4", "TEST", 412, 415], ["APC", "TEST", 417, 420], ["Cat.", "TEST", 422, 426], ["CD8a", "TEST", 441, 445], ["APC", "TEST", 447, 450], ["Cat.", "TEST", 463, 467], ["intracellular cytokines", "TEST", 483, 506], ["IFN", "TEST", 508, 511], ["PE", "TEST", 515, 517], ["Cat.", "TEST", 519, 523], ["IL", "TEST", 538, 540], ["Cat.", "TEST", 551, 555], ["cytokine staining", "OBSERVATION", 25, 42], ["PE", "OBSERVATION", 388, 390], ["PE", "OBSERVATION", 515, 517]]], ["For T cell proliferation using the CFSE dilution assay, splenocytes were enriched for T cells using nylon wool column and stained with 1 \u03bcM CFSE (Cat.# 21888, Sigma-Aldrich, St. Louis, MO, USA) in 1 ml of cell suspension for 7\u201310 minutes at room temperature.", [["T cell", "ANATOMY", 4, 10], ["splenocytes", "ANATOMY", 56, 67], ["T cells", "ANATOMY", 86, 93], ["cell", "ANATOMY", 205, 209], ["CFSE", "CHEMICAL", 35, 39], ["CFSE", "CHEMICAL", 140, 144], ["T cell", "CELL", 4, 10], ["CFSE", "SIMPLE_CHEMICAL", 35, 39], ["splenocytes", "CELL", 56, 67], ["T cells", "CELL", 86, 93], ["CFSE", "SIMPLE_CHEMICAL", 140, 144], ["St. Louis", "ORGANISM", 174, 183], ["cell", "CELL", 205, 209], ["splenocytes", "CELL_TYPE", 56, 67], ["T cells", "CELL_TYPE", 86, 93], ["T cell proliferation", "TREATMENT", 4, 24], ["the CFSE dilution assay", "TEST", 31, 54], ["splenocytes", "TEST", 56, 67], ["nylon wool column", "TREATMENT", 100, 117], ["cell suspension", "TREATMENT", 205, 220], ["cell proliferation", "OBSERVATION", 6, 24], ["splenocytes", "ANATOMY", 56, 67], ["nylon wool column", "OBSERVATION", 100, 117]]], ["These CFSE stained cells were washed in 1x PBS containing 10% fetal bovine serum, counted and plated in 24-well plate with 5 \u03bcg/ml of HCV core, NS3, NS4 or NS5 antigen or their representative peptides; and equal number of \u03b3-irradiated syngeneic splenocytes as APCs.", [["cells", "ANATOMY", 19, 24], ["fetal bovine serum", "ANATOMY", 62, 80], ["splenocytes", "ANATOMY", 245, 256], ["APCs", "ANATOMY", 260, 264], ["CFSE", "CHEMICAL", 6, 10], ["CFSE", "SIMPLE_CHEMICAL", 6, 10], ["cells", "CELL", 19, 24], ["bovine", "ORGANISM", 68, 74], ["serum", "ORGANISM_SUBSTANCE", 75, 80], ["HCV", "ORGANISM", 134, 137], ["NS3", "GENE_OR_GENE_PRODUCT", 144, 147], ["NS4", "GENE_OR_GENE_PRODUCT", 149, 152], ["NS5 antigen", "GENE_OR_GENE_PRODUCT", 156, 167], ["syngeneic splenocytes", "CELL", 235, 256], ["APCs", "CELL", 260, 264], ["CFSE stained cells", "CELL_LINE", 6, 24], ["NS3", "PROTEIN", 144, 147], ["NS4", "PROTEIN", 149, 152], ["NS5 antigen", "PROTEIN", 156, 167], ["\u03b3-irradiated syngeneic splenocytes", "CELL_TYPE", 222, 256], ["APCs", "CELL_TYPE", 260, 264], ["bovine", "SPECIES", 68, 74], ["bovine", "SPECIES", 68, 74], ["HCV", "SPECIES", 134, 137], ["These CFSE stained cells", "TEST", 0, 24], ["1x PBS", "TREATMENT", 40, 46], ["fetal bovine serum", "TEST", 62, 80], ["HCV core", "TEST", 134, 142], ["NS3", "TEST", 144, 147], ["NS4", "TEST", 149, 152], ["NS5 antigen", "TEST", 156, 167], ["stained cells", "OBSERVATION", 11, 24], ["equal", "OBSERVATION_MODIFIER", 206, 211], ["number", "OBSERVATION_MODIFIER", 212, 218], ["syngeneic splenocytes", "OBSERVATION", 235, 256]]], ["These cells were cultured for four days and stained for CD3+, CD4+ and CD8+ T cell markers.", [["cells", "ANATOMY", 6, 11], ["CD3+, CD4+ and CD8+ T cell", "ANATOMY", 56, 82], ["cells", "CELL", 6, 11], ["CD3", "GENE_OR_GENE_PRODUCT", 56, 59], ["CD4", "GENE_OR_GENE_PRODUCT", 62, 65], ["CD8", "GENE_OR_GENE_PRODUCT", 71, 74], ["CD3", "PROTEIN", 56, 59], ["CD4", "PROTEIN", 62, 65], ["CD8", "PROTEIN", 71, 74], ["T cell markers", "PROTEIN", 76, 90], ["These cells", "TEST", 0, 11], ["CD3", "TEST", 56, 59], ["CD4", "TEST", 62, 65], ["CD8", "TEST", 71, 74], ["cell markers", "OBSERVATION", 78, 90]]], ["T cells stained with isotype control antibodies with corresponding fluorochromes (PE Cy7: cat.# 25\u20134888, APC: cat.# 400511, APC eFluor 780: cat.# 47\u20134321, PE: 400507 and FITC: cat.# 400905; purchased from eBiosciences, Inc. San Diego, USA) were used to exclude non-specific binding.", [["T cells", "ANATOMY", 0, 7], ["FITC", "CHEMICAL", 170, 174], ["T cells", "CELL", 0, 7], ["APC", "GENE_OR_GENE_PRODUCT", 105, 108], ["T cells", "CELL_TYPE", 0, 7], ["isotype control antibodies", "PROTEIN", 21, 47], ["T cells", "TEST", 0, 7], ["isotype control antibodies", "PROBLEM", 21, 47], ["APC", "TEST", 105, 108], ["cat", "TEST", 110, 113], ["APC", "TEST", 124, 127], ["cat", "TEST", 140, 143], ["PE", "TEST", 155, 157], ["FITC", "TEST", 170, 174], ["cat", "TEST", 176, 179], ["non-specific binding", "PROBLEM", 261, 281], ["PE", "OBSERVATION", 82, 84], ["PE", "OBSERVATION", 155, 157]]], ["All stained cells were run in a BD FACS Canto (BD Biosciences, San Jose, CA, USA), and data were analyzed using FCS Express 4.0 software (De Novo Software, Glendale, CA, USA).T cell cytotoxicity assay ::: Materials and MethodsSplenocytes harvested from Ad vector immunized mice were stimulated in vitro with the HCV protein antigens core, NS3, NS4, NS5 or polyprotein at 5 \u03bcg/ml for 4 days.", [["cells", "ANATOMY", 12, 17], ["T cell", "ANATOMY", 175, 181], ["cells", "CELL", 12, 17], ["T cell", "CELL", 175, 181], ["Ad", "ORGANISM", 253, 255], ["mice", "ORGANISM", 273, 277], ["HCV", "ORGANISM", 312, 315], ["NS3", "GENE_OR_GENE_PRODUCT", 339, 342], ["NS4", "GENE_OR_GENE_PRODUCT", 344, 347], ["NS5", "GENE_OR_GENE_PRODUCT", 349, 352], ["stained cells", "CELL_TYPE", 4, 17], ["HCV protein antigens", "PROTEIN", 312, 332], ["NS3", "PROTEIN", 339, 342], ["NS4", "PROTEIN", 344, 347], ["NS5", "PROTEIN", 349, 352], ["mice", "SPECIES", 273, 277], ["Ad", "SPECIES", 253, 255], ["mice", "SPECIES", 273, 277], ["HCV", "SPECIES", 312, 315], ["All stained cells", "PROBLEM", 0, 17], ["Materials", "TREATMENT", 205, 214], ["MethodsSplenocytes harvested", "TREATMENT", 219, 247], ["Ad vector immunized mice", "TREATMENT", 253, 277], ["the HCV protein antigens core", "TREATMENT", 308, 337], ["NS3", "TREATMENT", 339, 342], ["NS4", "TREATMENT", 344, 347], ["NS5", "TREATMENT", 349, 352], ["polyprotein", "TREATMENT", 356, 367], ["stained cells", "OBSERVATION", 4, 17], ["cell cytotoxicity", "OBSERVATION", 177, 194], ["MethodsSplenocytes harvested", "OBSERVATION", 219, 247]]], ["The target EL4 cells were incubated with corresponding HCV peptides (core peptides #: 2, 14, 17, 25, 27, 28, 32; NS3 peptides #: 8, 10; NS4 peptides #: 3, 4, 8; NS5a peptides #: 1, 2, 16, 20, and NS5b peptides #: 5, 19, 23, 39; or All: a mixture of the above peptides from core, NS3, NS4 and NS5) overnight at 37\u00b0C. Next day, peptides loaded EL4 cells were cultured with effectors at 10:1 (effectors: target) ratio for 4\u20135 hours.", [["EL4 cells", "ANATOMY", 11, 20], ["EL4 cells", "ANATOMY", 342, 351], ["EL4 cells", "CELL", 11, 20], ["HCV", "ORGANISM", 55, 58], ["NS3", "ORGANISM", 279, 282], ["NS4", "GENE_OR_GENE_PRODUCT", 284, 287], ["EL4 cells", "CELL", 342, 351], ["EL4 cells", "CELL_LINE", 11, 20], ["NS3", "PROTEIN", 279, 282], ["NS4", "PROTEIN", 284, 287], ["NS5", "PROTEIN", 292, 295], ["EL4 cells", "CELL_LINE", 342, 351], ["HCV", "SPECIES", 55, 58], ["HCV peptides", "TEST", 55, 67], ["core peptides", "TEST", 69, 82], ["NS3 peptides", "TEST", 113, 125], ["NS4 peptides", "TEST", 136, 148], ["NS5a peptides", "TEST", 161, 174], ["NS5b peptides", "TEST", 196, 209], ["NS3", "TEST", 279, 282], ["NS4", "TREATMENT", 284, 287], ["NS5", "TEST", 292, 295], ["peptides loaded EL4 cells", "TREATMENT", 326, 351], ["EL4 cells", "OBSERVATION", 11, 20], ["EL4 cells", "OBSERVATION", 342, 351]]], ["CFSE-labeled live targets were quantified by flow cytometry and subtracted from background CFSE-labeled targets to get the numbers of killed targets.", [["CFSE", "CHEMICAL", 0, 4], ["CFSE", "CHEMICAL", 0, 4], ["CFSE", "CHEMICAL", 91, 95], ["CFSE", "SIMPLE_CHEMICAL", 0, 4], ["CFSE", "SIMPLE_CHEMICAL", 91, 95], ["CFSE", "TEST", 0, 4], ["flow cytometry", "TEST", 45, 59], ["background CFSE", "TEST", 80, 95]]], ["Empty (no peptide loaded) EL4 targets were used as a negative control.Chimeric Vac-HCV Challenge ::: Materials and MethodsEight days after the second immunization with Ad vector, Ad vector + poly I:C or PBS, mice were challenged with 1x107 PFU of Vac-HCV chimeric virus (Vac-C/NS2/NS3 including core, NS2 and NS3 antigens of HCV or Vac-NS3/NS4/NS5 including NS3, NS4 and NS5 antigens of HCV, kindly provided by Dr. Alfred Prince, NY, USA), or wild-type vaccinia (WT-Vac, not containing HCV antigens) virus intraperitoneally.", [["EL4", "ANATOMY", 26, 29], ["poly I:C", "CHEMICAL", 191, 199], ["Ad", "ORGANISM", 168, 170], ["Ad", "ORGANISM", 179, 181], ["poly I:C", "GENE_OR_GENE_PRODUCT", 191, 199], ["PBS", "SIMPLE_CHEMICAL", 203, 206], ["mice", "ORGANISM", 208, 212], ["Vac-HCV chimeric virus", "ORGANISM", 247, 269], ["Vac-C/NS2/NS3", "ORGANISM", 271, 284], ["NS2", "GENE_OR_GENE_PRODUCT", 301, 304], ["NS3", "ORGANISM", 309, 312], ["HCV", "ORGANISM", 325, 328], ["Vac-NS3", "ORGANISM", 332, 339], ["NS4", "GENE_OR_GENE_PRODUCT", 340, 343], ["NS5", "GENE_OR_GENE_PRODUCT", 344, 347], ["NS3", "GENE_OR_GENE_PRODUCT", 358, 361], ["NS4", "GENE_OR_GENE_PRODUCT", 363, 366], ["NS5 antigens", "GENE_OR_GENE_PRODUCT", 371, 383], ["HCV", "ORGANISM", 387, 390], ["wild-type", "ORGANISM", 443, 452], ["vaccinia", "ORGANISM", 453, 461], ["WT-Vac", "ORGANISM", 463, 469], ["HCV", "ORGANISM", 486, 489], ["EL4 targets", "CELL_LINE", 26, 37], ["NS2", "PROTEIN", 277, 280], ["NS3", "PROTEIN", 281, 284], ["NS2", "PROTEIN", 301, 304], ["NS3 antigens", "PROTEIN", 309, 321], ["Vac", "PROTEIN", 332, 335], ["NS3", "PROTEIN", 336, 339], ["NS4", "PROTEIN", 340, 343], ["NS5", "PROTEIN", 344, 347], ["NS3", "PROTEIN", 358, 361], ["NS4", "PROTEIN", 363, 366], ["NS5 antigens", "PROTEIN", 371, 383], ["HCV antigens", "PROTEIN", 486, 498], ["mice", "SPECIES", 208, 212], ["Ad", "SPECIES", 168, 170], ["Ad", "SPECIES", 179, 181], ["mice", "SPECIES", 208, 212], ["Vac-HCV", "SPECIES", 247, 254], ["HCV", "SPECIES", 325, 328], ["HCV", "SPECIES", 387, 390], ["HCV", "SPECIES", 486, 489], ["Empty (no peptide loaded) EL4 targets", "TREATMENT", 0, 37], ["Chimeric Vac-HCV Challenge", "TREATMENT", 70, 96], ["the second immunization", "TREATMENT", 139, 162], ["Ad vector", "TREATMENT", 168, 177], ["PBS", "TREATMENT", 203, 206], ["Vac-HCV chimeric virus", "TREATMENT", 247, 269], ["Vac", "TREATMENT", 271, 274], ["NS2", "TREATMENT", 277, 280], ["NS3", "TREATMENT", 281, 284], ["NS2", "TREATMENT", 301, 304], ["NS3 antigens", "TREATMENT", 309, 321], ["HCV", "TREATMENT", 325, 328], ["Vac", "TREATMENT", 332, 335], ["NS3", "TREATMENT", 336, 339], ["NS4", "TREATMENT", 340, 343], ["NS5", "TREATMENT", 344, 347], ["NS3", "TREATMENT", 358, 361], ["NS4", "TREATMENT", 363, 366], ["NS5 antigens", "TREATMENT", 371, 383], ["HCV", "PROBLEM", 387, 390], ["wild-type vaccinia", "TREATMENT", 443, 461], ["WT-Vac", "TREATMENT", 463, 469], ["HCV antigens", "TREATMENT", 486, 498], ["Vac", "ANATOMY", 466, 469]]], ["Five days after virus challenge, mice were euthanized and ovaries were removed, homogenized and freeze-thawed three times in 1x PBS.", [["ovaries", "ANATOMY", 58, 65], ["mice", "ORGANISM", 33, 37], ["ovaries", "ORGAN", 58, 65], ["mice", "SPECIES", 33, 37], ["mice", "SPECIES", 33, 37], ["virus challenge", "TREATMENT", 16, 31], ["ovaries", "ANATOMY", 58, 65]]], ["Homogenized samples were stored at -80\u00b0C until used for viral titer.Vac-HCV Titration by Plaque Assay ::: Materials and MethodsSerially diluted samples of ovary homogenates were added in duplicate wells in 6-well plates containing 80% confluent monolayers of mouse lymphoma cell line TK-1 (ATCC # CRL 2396) and incubated for 90 minutes.", [["samples", "ANATOMY", 12, 19], ["samples", "ANATOMY", 144, 151], ["ovary homogenates", "ANATOMY", 155, 172], ["monolayers", "ANATOMY", 245, 255], ["lymphoma cell line TK-1", "ANATOMY", 265, 288], ["ATCC # CRL 2396", "ANATOMY", 290, 305], ["lymphoma", "DISEASE", 265, 273], ["CRL 2396", "CHEMICAL", 297, 305], ["samples", "CANCER", 12, 19], ["C", "GENE_OR_GENE_PRODUCT", 39, 40], ["ovary homogenates", "ORGANISM_SUBSTANCE", 155, 172], ["monolayers", "CELL", 245, 255], ["mouse", "ORGANISM", 259, 264], ["lymphoma cell line TK-1", "CELL", 265, 288], ["ATCC # CRL 2396", "CELL", 290, 305], ["mouse lymphoma cell line", "CELL_LINE", 259, 283], ["TK-1", "CELL_LINE", 284, 288], ["ATCC # CRL 2396", "CELL_LINE", 290, 305], ["mouse", "SPECIES", 259, 264], ["HCV", "SPECIES", 72, 75], ["mouse", "SPECIES", 259, 264], ["ATCC # CRL 2396", "SPECIES", 290, 305], ["Homogenized samples", "TEST", 0, 19], ["viral titer", "PROBLEM", 56, 67], ["Materials", "TREATMENT", 106, 115], ["MethodsSerially diluted samples of ovary homogenates", "TREATMENT", 120, 172], ["mouse lymphoma", "PROBLEM", 259, 273], ["ATCC # CRL", "TEST", 290, 300], ["ovary", "ANATOMY", 155, 160], ["confluent", "OBSERVATION_MODIFIER", 235, 244], ["monolayers", "OBSERVATION_MODIFIER", 245, 255], ["mouse lymphoma cell line", "OBSERVATION", 259, 283]]], ["Subsequently, unbound virus was removed and fresh 1x DMEM medium (Cat.# 11995, Gibco by Invitrogen, NY, USA) supplemented with 3% FBS, was added, and plates were incubated for 48 hours.", [["FBS", "ANATOMY", 130, 133], ["FBS", "ORGANISM_SUBSTANCE", 130, 133], ["unbound virus", "PROBLEM", 14, 27], ["3% FBS", "TREATMENT", 127, 133], ["virus", "OBSERVATION", 22, 27]]], ["At this time, the medium was removed, and plaques were fixed by using 10% formaldehyde (Cat.# BP531-500), Fisher Scientific, NJ, USA) at room temperature for 30 minutes.", [["plaques", "ANATOMY", 42, 49], ["plaques", "DISEASE", 42, 49], ["formaldehyde", "CHEMICAL", 74, 86], ["formaldehyde", "CHEMICAL", 74, 86], ["formaldehyde", "SIMPLE_CHEMICAL", 74, 86], ["plaques", "PROBLEM", 42, 49], ["BP531", "TEST", 94, 99], ["plaques", "OBSERVATION", 42, 49]]], ["Plates were washed with PBS and the monolayers were stained for 30 minutes with 0.5% crystal violet (Cat.# C3886, Sigma-Aldrich Company, MO, USA), followed by further washing.", [["monolayers", "ANATOMY", 36, 46], ["monolayers", "CELL", 36, 46], ["PBS", "TREATMENT", 24, 27], ["the monolayers", "TEST", 32, 46]]], ["Plaques were counted, averaged and multiplied with the dilution factor to determine the viral load/mouse.", [["Plaques", "ANATOMY", 0, 7], ["mouse", "ORGANISM", 99, 104], ["mouse", "SPECIES", 99, 104], ["mouse", "SPECIES", 99, 104], ["Plaques", "PROBLEM", 0, 7], ["the dilution factor", "TEST", 51, 70], ["the viral load/mouse", "PROBLEM", 84, 104]]], ["Data are presented as % reduction of viral load, and calculated by the formula: [(Mean viral titer in control group-Titer in immunized group)/Mean viral titer in control group] X 100.", [["viral load", "PROBLEM", 37, 47], ["Mean viral titer in control group", "TREATMENT", 82, 115], ["Titer in immunized group", "TREATMENT", 116, 140], ["Mean viral titer in control group", "TREATMENT", 142, 175], ["viral load", "OBSERVATION", 37, 47]]], ["Control groups had viral titers in the range of 107\u2212108 pfu/mouse (Vac-C/NS3) and 108\u2212109 pfu/mouse (Vac-NS3/4/5).Human blood donors, Plasma and PBMCs ::: Materials and MethodsPeripheral blood samples were collected from healthy human donors of both sexes with no known history of HCV infection.", [["blood", "ANATOMY", 120, 125], ["Plasma", "ANATOMY", 134, 140], ["PBMCs", "ANATOMY", 145, 150], ["MethodsPeripheral blood samples", "ANATOMY", 169, 200], ["HCV infection", "DISEASE", 281, 294], ["mouse", "ORGANISM", 60, 65], ["Vac-C/NS3", "ORGANISM", 67, 76], ["mouse", "ORGANISM", 94, 99], ["Vac-NS3/4/5", "ORGANISM", 101, 112], ["Human", "ORGANISM", 114, 119], ["blood donors", "ORGANISM_SUBSTANCE", 120, 132], ["Plasma", "ORGANISM_SUBSTANCE", 134, 140], ["PBMCs", "CELL", 145, 150], ["MethodsPeripheral blood samples", "ORGANISM_SUBSTANCE", 169, 200], ["human", "ORGANISM", 229, 234], ["donors", "ORGANISM", 235, 241], ["HCV", "ORGANISM", 281, 284], ["NS3", "PROTEIN", 73, 76], ["NS3", "PROTEIN", 105, 108], ["PBMCs", "CELL_TYPE", 145, 150], ["mouse", "SPECIES", 60, 65], ["mouse", "SPECIES", 94, 99], ["Human", "SPECIES", 114, 119], ["human", "SPECIES", 229, 234], ["mouse", "SPECIES", 60, 65], ["mouse", "SPECIES", 94, 99], ["Human", "SPECIES", 114, 119], ["human", "SPECIES", 229, 234], ["HCV", "SPECIES", 281, 284], ["viral titers", "TEST", 19, 31], ["Vac", "TEST", 67, 70], ["NS3", "TEST", 73, 76], ["Vac", "TREATMENT", 101, 104], ["Human blood donors", "TEST", 114, 132], ["MethodsPeripheral blood samples", "TEST", 169, 200], ["HCV infection", "PROBLEM", 281, 294], ["Vac", "ANATOMY", 101, 104], ["no known", "UNCERTAINTY", 261, 269], ["HCV", "OBSERVATION_MODIFIER", 281, 284], ["infection", "OBSERVATION", 285, 294]]], ["Collected blood was processed immediately for PBMCs isolation using Ficoll gradient separation.", [["blood", "ANATOMY", 10, 15], ["PBMCs", "ANATOMY", 46, 51], ["blood", "ORGANISM_SUBSTANCE", 10, 15], ["PBMCs", "CELL", 46, 51], ["PBMCs", "CELL_TYPE", 46, 51], ["Collected blood", "TEST", 0, 15], ["PBMCs isolation", "TREATMENT", 46, 61], ["Ficoll gradient separation", "TREATMENT", 68, 94], ["Ficoll gradient", "OBSERVATION", 68, 83]]], ["The upper plasma layer was frozen in aliquots for IgG ELISA, and the middle PBMCs layer was collected, washed and frozen until use.Human IgG antibody ELISA ::: Materials and MethodsAnti-Ad IgG (hexon-specific) antibodies were detected and evaluated in the plasma of each donor using IBL Adenovirus IgG ELISA Kit (Cat# IB79202, IBL-America Inc. Minneapolis, MN, USA).", [["plasma layer", "ANATOMY", 10, 22], ["PBMCs layer", "ANATOMY", 76, 87], ["plasma", "ANATOMY", 256, 262], ["upper plasma layer", "ORGANISM_SUBSTANCE", 4, 22], ["Human", "ORGANISM", 131, 136], ["IgG", "GENE_OR_GENE_PRODUCT", 137, 140], ["Ad", "ORGANISM", 186, 188], ["IgG", "GENE_OR_GENE_PRODUCT", 189, 192], ["hexon-specific) antibodies", "GENE_OR_GENE_PRODUCT", 194, 220], ["plasma", "ORGANISM_SUBSTANCE", 256, 262], ["Adenovirus", "ORGANISM", 287, 297], ["IgG", "PROTEIN", 50, 53], ["PBMCs", "CELL_TYPE", 76, 81], ["Human IgG antibody", "PROTEIN", 131, 149], ["Ad IgG", "PROTEIN", 186, 192], ["hexon-specific) antibodies", "PROTEIN", 194, 220], ["IBL Adenovirus IgG", "PROTEIN", 283, 301], ["Human", "SPECIES", 131, 136], ["Human", "SPECIES", 131, 136], ["Adenovirus", "SPECIES", 287, 297], ["The upper plasma layer", "TREATMENT", 0, 22], ["IgG ELISA", "TEST", 50, 59], ["the middle PBMCs layer", "TREATMENT", 65, 87], ["Human IgG antibody ELISA", "TEST", 131, 155], ["Materials", "TEST", 160, 169], ["MethodsAnti", "TEST", 174, 185], ["Ad IgG", "TEST", 186, 192], ["hexon", "TEST", 194, 199], ["IBL Adenovirus", "TEST", 283, 297], ["upper", "ANATOMY_MODIFIER", 4, 9], ["middle PBMCs", "ANATOMY", 69, 81], ["layer", "OBSERVATION_MODIFIER", 82, 87]]], ["Plasma samples were assayed at 1:100 and 1:400 dilutions in duplicates according to the manufacturer\u2019s procedure.", [["Plasma samples", "ANATOMY", 0, 14], ["Plasma samples", "ORGANISM_SUBSTANCE", 0, 14], ["Plasma samples", "TEST", 0, 14], ["the manufacturer\u2019s procedure", "TREATMENT", 84, 112]]], ["HCV antigens-specific cross-reactive IgGs were determined by ELISA.", [["HCV", "ORGANISM", 0, 3], ["IgGs", "GENE_OR_GENE_PRODUCT", 37, 41], ["HCV antigens", "PROTEIN", 0, 12], ["cross-reactive IgGs", "PROTEIN", 22, 41], ["HCV", "SPECIES", 0, 3], ["HCV antigens", "TEST", 0, 12], ["specific cross-reactive IgGs", "PROBLEM", 13, 41], ["cross-reactive IgGs", "OBSERVATION", 22, 41]]], ["Briefly, ELISA plates were coated with recombinant HCV antigens: core NS3, NS4, NS5 or control protein SOD (superoxide dismutase) at 1 \u03bcg/ml overnight at 4\u00b0C followed by blocking with 1% BSA (bovine serum albumin) for 1 hour.", [["serum", "ANATOMY", 199, 204], ["superoxide", "CHEMICAL", 108, 118], ["BSA", "CHEMICAL", 187, 190], ["superoxide", "CHEMICAL", 108, 118], ["HCV", "ORGANISM", 51, 54], ["NS3", "GENE_OR_GENE_PRODUCT", 70, 73], ["NS4", "GENE_OR_GENE_PRODUCT", 75, 78], ["NS5", "GENE_OR_GENE_PRODUCT", 80, 83], ["SOD", "GENE_OR_GENE_PRODUCT", 103, 106], ["superoxide dismutase", "GENE_OR_GENE_PRODUCT", 108, 128], ["BSA", "SIMPLE_CHEMICAL", 187, 190], ["bovine", "ORGANISM", 192, 198], ["serum", "ORGANISM_SUBSTANCE", 199, 204], ["albumin", "GENE_OR_GENE_PRODUCT", 205, 212], ["recombinant HCV antigens", "PROTEIN", 39, 63], ["NS3", "PROTEIN", 70, 73], ["NS4", "PROTEIN", 75, 78], ["NS5", "PROTEIN", 80, 83], ["protein SOD", "PROTEIN", 95, 106], ["superoxide dismutase", "PROTEIN", 108, 128], ["bovine", "SPECIES", 192, 198], ["HCV", "SPECIES", 51, 54], ["ELISA plates", "TREATMENT", 9, 21], ["core NS3", "TREATMENT", 65, 73], ["NS4", "TREATMENT", 75, 78], ["NS5", "TREATMENT", 80, 83], ["control protein SOD (superoxide dismutase)", "TREATMENT", 87, 129], ["1% BSA (bovine serum albumin", "TREATMENT", 184, 212]]], ["Plasma samples (1:100 to 1:400) were added in triplicate and incubated for 2 hours at room temperature.", [["Plasma samples", "ANATOMY", 0, 14], ["Plasma samples", "ORGANISM_SUBSTANCE", 0, 14], ["Plasma samples", "TEST", 0, 14]]], ["Binding of antigen-specific Human IgG was detected by adding anti-human IgG labeled with alkaline phosphatase (AP) (Cat# 2040\u201304, Southern Biotech, Alabama, USA) for 1 hour, followed by addition of PNPP substrate (Cat#0201\u201301, Southern Biotech, Alabama, USA) for 30 minutes.", [["PNPP", "CHEMICAL", 198, 202], ["antigen", "GENE_OR_GENE_PRODUCT", 11, 18], ["Human", "ORGANISM", 28, 33], ["IgG", "GENE_OR_GENE_PRODUCT", 34, 37], ["IgG", "GENE_OR_GENE_PRODUCT", 72, 75], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 89, 109], ["AP", "SIMPLE_CHEMICAL", 111, 113], ["PNPP", "SIMPLE_CHEMICAL", 198, 202], ["Human IgG", "PROTEIN", 28, 37], ["anti-human IgG", "PROTEIN", 61, 75], ["alkaline phosphatase", "PROTEIN", 89, 109], ["AP", "PROTEIN", 111, 113], ["Human", "SPECIES", 28, 33], ["Human", "SPECIES", 28, 33], ["Binding of antigen", "TEST", 0, 18], ["specific Human IgG", "TEST", 19, 37], ["anti-human IgG", "TEST", 61, 75], ["alkaline phosphatase", "TEST", 89, 109], ["PNPP substrate", "TREATMENT", 198, 212]]], ["Plates were washed with 1x PBST (1x PBS with 0.1% Tween-20) after each incubation step.", [["Tween-20", "CHEMICAL", 50, 58], ["Tween-20", "CHEMICAL", 50, 58], ["Plates", "TEST", 0, 6], ["1x PBST", "TREATMENT", 24, 31], ["PBS", "TEST", 36, 39]]], ["Absorbance (OD) was measured at 405 nm, and corrected for background by subtracting the OD values obtained in control SOD-coated plates.", [["SOD", "SIMPLE_CHEMICAL", 118, 121], ["SOD", "PROTEIN", 118, 121], ["the OD values", "TEST", 84, 97], ["control SOD-coated plates", "TREATMENT", 110, 135]]], ["For statistical analyses, OD values from anti-Ad IgG ELISAs were arranged in increasing order and correlated with corresponding OD values from anti-HCV IgG.", [["anti-Ad IgG", "GENE_OR_GENE_PRODUCT", 41, 52], ["IgG", "GENE_OR_GENE_PRODUCT", 152, 155], ["anti-Ad IgG", "PROTEIN", 41, 52], ["anti-HCV IgG", "PROTEIN", 143, 155], ["statistical analyses", "TEST", 4, 24], ["OD values", "TEST", 26, 35], ["anti-Ad IgG ELISAs", "TEST", 41, 59], ["anti-HCV IgG", "TEST", 143, 155]]], ["Correlation coefficients were calculated by Spearman's rank correlation.Ex vivo stimulation of human PBMCs and intracellular cytokine staining ::: Materials and MethodsFrozen PBMCs were thawed and washed with warm PBS twice, counted and cultured in AIM-V serum free medium (Cat# 12055\u2013083, Gibco by Life Technologies, NY, USA) in 96-well plate at 0.5x106 cells/100 \u03bcl/well for 2 hours.", [["PBMCs", "ANATOMY", 101, 106], ["intracellular", "ANATOMY", 111, 124], ["PBMCs", "ANATOMY", 175, 180], ["serum", "ANATOMY", 255, 260], ["cells", "ANATOMY", 355, 360], ["human", "ORGANISM", 95, 100], ["PBMCs", "CELL", 101, 106], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 111, 124], ["MethodsFrozen PBMCs", "CELL", 161, 180], ["serum", "ORGANISM_SUBSTANCE", 255, 260], ["cells", "CELL", 355, 360], ["human PBMCs", "CELL_TYPE", 95, 106], ["cytokine", "PROTEIN", 125, 133], ["MethodsFrozen PBMCs", "CELL_LINE", 161, 180], ["human", "SPECIES", 95, 100], ["human", "SPECIES", 95, 100], ["Correlation coefficients", "TEST", 0, 24], ["intracellular cytokine staining", "TEST", 111, 142], ["MethodsFrozen PBMCs", "TREATMENT", 161, 180], ["warm PBS", "TREATMENT", 209, 217]]], ["HCV pooled synthetic peptides (core peptides # 5, 14, 16, 17 & 27; NS3 peptides # 2, 5, 6, 8 &10; NS4 peptides # 4, 8, 9, 13, 16 or NS5 peptides # NS5a: 6, 24 + NS5b: 5, 19, 27) or individual proteins (core, NS3, NS4 or NS5) were added to the plates at 5 \u03bcg/ml concentration.", [["HCV", "ORGANISM", 0, 3], ["NS3", "ORGANISM", 208, 211], ["NS4", "GENE_OR_GENE_PRODUCT", 213, 216], ["NS5", "ORGANISM", 220, 223], ["NS3", "PROTEIN", 208, 211], ["NS4", "PROTEIN", 213, 216], ["NS5", "PROTEIN", 220, 223], ["HCV", "SPECIES", 0, 3], ["HCV pooled synthetic peptides", "TEST", 0, 29], ["core peptides", "TEST", 31, 44], ["NS3 peptides", "TEST", 67, 79], ["NS4 peptides", "TEST", 98, 110], ["NS5 peptides", "TEST", 132, 144], ["NS5a", "TEST", 147, 151], ["NS5b", "TEST", 161, 165], ["individual proteins", "TEST", 181, 200], ["core", "TEST", 202, 206], ["NS3", "TEST", 208, 211], ["NS4", "TREATMENT", 213, 216], ["NS5", "TREATMENT", 220, 223], ["the plates", "TREATMENT", 239, 249]]], ["The peptides were selected on the basis of their high sequence homologies with Ad proteins, and detection of cross-reactive responses in mouse experiments.", [["mouse", "ORGANISM", 137, 142], ["Ad proteins", "PROTEIN", 79, 90], ["mouse", "SPECIES", 137, 142], ["mouse", "SPECIES", 137, 142], ["Ad proteins", "TEST", 79, 90], ["cross-reactive responses in mouse experiments", "PROBLEM", 109, 154], ["cross-reactive responses", "OBSERVATION", 109, 133], ["mouse experiments", "OBSERVATION", 137, 154]]], ["Phyto-hemagglutinin (PHA, 1 \u03bcg/ml) and media-treated cells were considered as positive and negative controls, respectively.", [["cells", "ANATOMY", 53, 58], ["Phyto-hemagglutinin", "CHEMICAL", 0, 19], ["PHA", "CHEMICAL", 21, 24], ["Phyto-hemagglutinin", "CHEMICAL", 0, 19], ["PHA", "CHEMICAL", 21, 24], ["Phyto-hemagglutinin", "SIMPLE_CHEMICAL", 0, 19], ["PHA", "SIMPLE_CHEMICAL", 21, 24], ["cells", "CELL", 53, 58], ["Phyto-hemagglutinin", "PROTEIN", 0, 19], ["PHA", "PROTEIN", 21, 24], ["media-treated cells", "CELL_LINE", 39, 58], ["Phyto-hemagglutinin (PHA", "TREATMENT", 0, 24], ["media-treated cells", "TREATMENT", 39, 58]]], ["After three days of incubation, cells were treated with 1.5 \u03bcg/ml brefeldin A (Cat.# 00\u20134506, eBiosciences Inc., San Diego, CA, USA) for 5 hours, and stained for extracellular lineage markers using fluorochrome-labeled antibodies (purchased from eBiosciences Inc. San Diego, USA): CD3 (eFluor 450, Cat.# 48\u20130036), CD4 (FITC, Cat.# 11\u20130049) and CD8a (PE, Cat.# 12\u20130089); and for intracellular cytokines: IFN-\u03b3 (APC, Cat.# 17\u20137319) and IL-10 (PE-Cyanine 7, Cat.# 25\u20137108).", [["cells", "ANATOMY", 32, 37], ["extracellular lineage", "ANATOMY", 162, 183], ["intracellular", "ANATOMY", 378, 391], ["brefeldin A", "CHEMICAL", 66, 77], ["brefeldin A", "CHEMICAL", 66, 77], ["FITC", "CHEMICAL", 319, 323], ["cells", "CELL", 32, 37], ["brefeldin A", "SIMPLE_CHEMICAL", 66, 77], ["fluorochrome", "SIMPLE_CHEMICAL", 198, 210], ["CD3", "GENE_OR_GENE_PRODUCT", 281, 284], ["CD4", "GENE_OR_GENE_PRODUCT", 314, 317], ["CD8a", "SIMPLE_CHEMICAL", 344, 348], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 378, 391], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 403, 408], ["APC", "GENE_OR_GENE_PRODUCT", 410, 413], ["Cat.# 17\u20137319", "SIMPLE_CHEMICAL", 415, 428], ["IL-10", "SIMPLE_CHEMICAL", 434, 439], ["PE-Cyanine 7", "SIMPLE_CHEMICAL", 441, 453], ["extracellular lineage markers", "PROTEIN", 162, 191], ["fluorochrome-labeled antibodies", "PROTEIN", 198, 229], ["CD3", "PROTEIN", 281, 284], ["CD4", "PROTEIN", 314, 317], ["intracellular cytokines", "PROTEIN", 378, 401], ["IFN", "PROTEIN", 403, 406], ["\u03b3", "PROTEIN", 407, 408], ["APC", "PROTEIN", 410, 413], ["IL", "PROTEIN", 434, 436], ["extracellular lineage markers", "TEST", 162, 191], ["fluorochrome", "TEST", 198, 210], ["eFluor", "TEST", 286, 292], ["Cat.", "TEST", 298, 302], ["CD4", "TEST", 314, 317], ["FITC", "TEST", 319, 323], ["Cat.", "TEST", 325, 329], ["CD8a", "TEST", 344, 348], ["PE", "TEST", 350, 352], ["Cat.", "TEST", 354, 358], ["intracellular cytokines", "TEST", 378, 401], ["IFN", "TEST", 403, 406], ["APC", "TEST", 410, 413], ["Cat.", "TEST", 415, 419], ["IL", "TEST", 434, 436], ["PE", "TEST", 441, 443], ["Cyanine", "TEST", 444, 451], ["Cat.", "TEST", 455, 459], ["PE", "OBSERVATION", 350, 352], ["PE", "OBSERVATION", 441, 443]]], ["Stained cells were measured in a BD FACS Canto, and data were analyzed using FACS Diva software.", [["cells", "ANATOMY", 8, 13], ["cells", "CELL", 8, 13], ["BD FACS Canto", "CELL_LINE", 33, 46], ["Stained cells", "PROBLEM", 0, 13], ["a BD FACS Canto", "TEST", 31, 46]]], ["The CD3+ T cell population was gated for CD4+ and CD8+ subsets and evaluated separately for IFN-\u03b3 and IL-10 expression.", [["CD3+ T cell", "ANATOMY", 4, 15], ["CD4+", "ANATOMY", 41, 45], ["CD8+ subsets", "ANATOMY", 50, 62], ["CD3", "GENE_OR_GENE_PRODUCT", 4, 7], ["CD4", "GENE_OR_GENE_PRODUCT", 41, 44], ["CD8", "GENE_OR_GENE_PRODUCT", 50, 53], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 92, 97], ["IL-10", "GENE_OR_GENE_PRODUCT", 102, 107], ["CD3", "PROTEIN", 4, 7], ["CD4", "PROTEIN", 41, 44], ["CD8", "PROTEIN", 50, 53], ["IFN", "PROTEIN", 92, 95], ["The CD3", "TEST", 0, 7], ["T cell population", "PROBLEM", 9, 26], ["CD4", "TEST", 41, 44], ["CD8", "TEST", 50, 53], ["IFN", "TEST", 92, 95], ["IL", "TEST", 102, 104]]], ["PBMCs stained with isotype antibodies with corresponding fluorochromes (Cat.# 48\u20134714, 11\u20134714, 12\u20134714, 17\u20134714 and 25\u20134301; purchased from eBiosciences, Inc. San Diego, USA) were used to exclude non-specific binding.", [["PBMCs", "ANATOMY", 0, 5], ["11\u20134714, 12\u20134714, 17\u20134714 and 25\u20134301", "CHEMICAL", 87, 124], ["PBMCs", "CELL", 0, 5], ["PBMCs", "CELL_TYPE", 0, 5], ["isotype antibodies", "PROTEIN", 19, 37], ["PBMCs", "TEST", 0, 5], ["isotype antibodies", "TEST", 19, 37], ["Cat.", "TEST", 72, 76], ["non-specific binding", "PROBLEM", 197, 217], ["isotype antibodies", "OBSERVATION", 19, 37]]], ["Percent increase in cytokine expression was calculated by the formula: [(Antigen treated cells- media control)/ media control] x 100.", [["cells", "ANATOMY", 89, 94], ["cells", "CELL", 89, 94], ["cytokine", "PROTEIN", 20, 28], ["Percent increase in cytokine expression", "PROBLEM", 0, 39], ["(Antigen treated cells", "TREATMENT", 72, 94], ["media control", "TREATMENT", 96, 109], ["media control", "TREATMENT", 112, 125], ["increase", "OBSERVATION_MODIFIER", 8, 16], ["cytokine expression", "OBSERVATION", 20, 39]]], ["The percentage of cells positive for IFN-\u03b3, IL-10 and IFN-\u03b3/IL-10 in the media groups ranged from 0.2\u201310% in different donors.Statistical Analysis ::: Materials and MethodsData were analyzed by Graph-pad Prism software (Graph-pad Software Inc., CA, USA).", [["cells", "ANATOMY", 18, 23], ["cells", "CELL", 18, 23], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 37, 42], ["IL-10", "GENE_OR_GENE_PRODUCT", 44, 49], ["IFN-\u03b3", "GENE_OR_GENE_PRODUCT", 54, 59], ["IL-10", "GENE_OR_GENE_PRODUCT", 60, 65], ["donors", "ORGANISM", 119, 125], ["IFN", "PROTEIN", 37, 40], ["IL-10", "PROTEIN", 44, 49], ["IFN", "PROTEIN", 54, 57], ["IL", "PROTEIN", 60, 62], ["The percentage of cells", "TEST", 0, 23], ["IFN", "TEST", 37, 40], ["\u03b3", "TEST", 41, 42], ["IL", "TEST", 44, 46], ["IFN", "TEST", 54, 57], ["IL", "TEST", 60, 62], ["MethodsData", "TEST", 165, 176], ["Graph", "TEST", 194, 199], ["Prism software", "TEST", 204, 218], ["Graph", "TEST", 220, 225]]], ["Two tailed student t-test was used to determine the significant difference between two groups, and P-values less than 0.05 (<0.05) were considered to be statistically significant.Ethics Statement ::: Materials and MethodsAll animal experiments were approved by University of Alberta Animal Care and Use Committee (protocol number AUP 212 till June 30, 2016) in accordance with the Canadian Council of Animal Care guidelines.", [["Two tailed student t-test", "TEST", 0, 25], ["P-values", "TEST", 99, 107], ["significant", "OBSERVATION_MODIFIER", 52, 63]]], ["The written informed consent was obtained from all adult blood donors.", [["blood", "ANATOMY", 57, 62], ["blood", "ORGANISM_SUBSTANCE", 57, 62], ["donors", "ORGANISM", 63, 69]]], ["All procedures related to human tissue were approved (number 3983 till Nov 9, 2016) and were in accordance with the University of Alberta Human Research Ethics Board (HREB).", [["tissue", "ANATOMY", 32, 38], ["human", "ORGANISM", 26, 31], ["tissue", "TISSUE", 32, 38], ["Human", "ORGANISM", 138, 143], ["human", "SPECIES", 26, 31], ["Human", "SPECIES", 138, 143], ["human", "SPECIES", 26, 31], ["All procedures", "TREATMENT", 0, 14]]]], "PMC7121196": [["IntroductionIn targeted DNA or RNA sequencing, a panel of oligonucleotide probes are used to capture nucleotide contents containing interested sequences, the enriched targets are sequenced using next-generation sequencing (NGS) to achieve sensitive detection and sequence-based analysis [1].", [["nucleotide", "CHEMICAL", 101, 111], ["nucleotide", "CHEMICAL", 101, 111], ["DNA", "CELLULAR_COMPONENT", 24, 27], ["oligonucleotide probes", "DNA", 58, 80], ["IntroductionIn targeted DNA", "TREATMENT", 0, 27], ["RNA sequencing", "TEST", 31, 45], ["a panel", "TEST", 47, 54], ["oligonucleotide probes", "TREATMENT", 58, 80], ["sequence-based analysis", "TEST", 263, 286]]], ["Several methods with comparable performance had been developed and successfully applied to sequencing of exomes, transcriptomes, cancer genes, significant pathogens, etc. [2\u20138].", [["cancer", "ANATOMY", 129, 135], ["cancer", "DISEASE", 129, 135], ["cancer", "CANCER", 129, 135], ["exomes", "DNA", 105, 111], ["cancer genes", "DNA", 129, 141], ["exomes", "PROBLEM", 105, 111], ["cancer genes", "PROBLEM", 129, 141], ["significant pathogens", "PROBLEM", 143, 164], ["significant", "OBSERVATION_MODIFIER", 143, 154], ["pathogens", "OBSERVATION", 155, 164]]], ["Utilizing TruSeq RNA Access protocol and a large panel of oligos for whole-genome capture of 34 human respiratory viral pathogens (TruSeq RVP) enables enriching sequences of respiratory DNA and RNA viruses out of complex clinical specimens and production of genome sequences for genotyping and genetic variant analysis.", [["specimens", "ANATOMY", 230, 239], ["human", "ORGANISM", 96, 101], ["DNA", "CELLULAR_COMPONENT", 186, 189], ["respiratory DNA", "DNA", 174, 189], ["genome sequences", "DNA", 258, 274], ["human", "SPECIES", 96, 101], ["human", "SPECIES", 96, 101], ["TruSeq RNA Access protocol", "TREATMENT", 10, 36], ["a large panel of oligos", "TREATMENT", 41, 64], ["whole-genome capture", "TREATMENT", 69, 89], ["34 human respiratory viral pathogens", "PROBLEM", 93, 129], ["TruSeq RVP", "TREATMENT", 131, 141], ["respiratory DNA", "PROBLEM", 174, 189], ["RNA viruses", "PROBLEM", 194, 205], ["complex clinical specimens", "TEST", 213, 239], ["genome sequences", "TEST", 258, 274], ["genotyping", "TEST", 279, 289], ["genetic variant analysis", "TEST", 294, 318], ["respiratory", "ANATOMY", 102, 113], ["viral pathogens", "OBSERVATION", 114, 129], ["respiratory DNA", "ANATOMY", 174, 189]]], ["The process includes collection, transportation, and storage of respiratory specimens, extraction of DNA and RNA, preparation of TruSeq fragment library, RVP enrichment, NGS and sequence data analysis (Fig. 1).", [["respiratory specimens", "ANATOMY", 64, 85], ["DNA", "CELLULAR_COMPONENT", 101, 104], ["TruSeq fragment library", "DNA", 129, 152], ["collection", "PROBLEM", 21, 31], ["respiratory specimens", "TEST", 64, 85], ["extraction", "TREATMENT", 87, 97], ["DNA and RNA", "PROBLEM", 101, 112], ["preparation of TruSeq fragment library", "TREATMENT", 114, 152], ["RVP enrichment", "TEST", 154, 168], ["NGS and sequence data analysis", "TEST", 170, 200], ["collection", "OBSERVATION", 21, 31], ["respiratory specimens", "OBSERVATION", 64, 85]]], ["The laboratory procedures require approximately 5 days from specimens to NGS run excluding specimen acquisition, NGS instrument run time and post-run data processing and analyses.", [["specimens", "ANATOMY", 60, 69], ["specimen", "ANATOMY", 91, 99], ["NGS run", "TEST", 73, 80], ["specimen acquisition", "TEST", 91, 111], ["NGS instrument", "TEST", 113, 127], ["post-run data processing", "TEST", 141, 165], ["analyses", "TEST", 170, 178]]]], "8de48dc894c401e678b75e135386d9397578c2d8": [["Not only in-house PCRs need to be thoroughly validated in every laboratory, but also 122 commercial kits (Rahman et al., 2020) , as they may contain similar primer/probe mixes and 123 produce incorrectly positive results, which will also result in a low positive predictive value.124As an additional component of quality assurance, the preparation of small sample pools 125 might be considered in areas or scenarios with low prevalences (e.g. among asymptomatic To ensure a high level of diagnostic accuracy, it is highly recommended to pre-test each 153 batch of PCR reagents thoroughly before applying it in routine diagnosis using more than 50 154 negative samples for specificity testing.", [["samples", "ANATOMY", 660, 667], ["a low positive predictive value", "PROBLEM", 248, 279], ["small sample pools", "PROBLEM", 351, 369], ["diagnostic accuracy", "TEST", 488, 507], ["PCR reagents", "TREATMENT", 564, 576], ["specificity testing", "TEST", 672, 691], ["small", "OBSERVATION_MODIFIER", 351, 356], ["low prevalences", "OBSERVATION_MODIFIER", 421, 436]]], ["Furthermore, it is of utmost importance to include also a 155 reasonable number of appropriate controls such as NTCs, negative extraction controls and", [["NTCs", "CANCER", 112, 116], ["NTCs", "CELL_TYPE", 112, 116], ["NTCs", "TREATMENT", 112, 116]]]], "c220a821a1b6b627ec8b7625a3b23314075b1cf3": [["IntroductionOverweight and obesity are the fifth highest risk factors for global death, which corresponds to about 3.4 million deaths yearly, making them a global public health priority and a health challenge [1] .", [["Overweight", "DISEASE", 12, 22], ["obesity", "DISEASE", 27, 34], ["death", "DISEASE", 81, 86], ["deaths", "DISEASE", 127, 133], ["obesity", "PROBLEM", 27, 34], ["global death", "PROBLEM", 74, 86]]], ["According to the World Health Organization (WHO), the obesity rate has tripled since the 1980s.", [["obesity", "DISEASE", 54, 61], ["the obesity rate", "PROBLEM", 50, 66], ["obesity", "OBSERVATION", 54, 61]]], ["In 2014, 39% of the adult population was classified as overweight and 13% as obese [2, 3] , with an 2.1.", [["overweight", "DISEASE", 55, 65]]], ["Search Strategy MEDLINE (via PubMed), EMBASE, the Cochrane Central Register of Controlled Trials and the Web of Science databases were systematically searched, from their inception until March 2020.", [["Controlled Trials", "TREATMENT", 79, 96]]], ["We searched for experimental studies comparing the effects of behavioral weight management interventions using lifestyle (diet and physical activity) mHealth self-monitoring on weight loss.", [["weight loss", "DISEASE", 177, 188], ["experimental studies", "TEST", 16, 36], ["behavioral weight management interventions", "TREATMENT", 62, 104], ["lifestyle (diet and physical activity)", "TREATMENT", 111, 149], ["weight loss", "PROBLEM", 177, 188]]], ["The search strategy for the MEDLINE database is displayed in Appendix A Table A1 .", [["the MEDLINE database", "TEST", 24, 44], ["Appendix", "ANATOMY", 61, 69]]], ["To complete the systematic literature search, we examined the references of the eligible articles.Study SelectionThe included studies had to meet the following inclusion criteria: (i) participants-general population; (ii) design-randomized controlled trials (RCTs), non-randomized controlled trials (non-RCTs) and pilot studies; (iii) type of interventions-studies comparing the effect of lifestyle (diet and physical activity) mHealth self-monitoring (i.e., personal digital assistants (PDAs), smartphones or web-based); and (iv) outcomes-weight change and adherence to behavioral weight management interventions using lifestyle mHealth self-monitoring.", [["participants", "SPECIES", 184, 196], ["Study Selection", "TEST", 98, 113], ["The included studies", "TEST", 113, 133], ["randomized controlled trials (RCTs)", "TREATMENT", 229, 264], ["non-randomized controlled trials (non-RCTs", "TREATMENT", 266, 308], ["pilot studies", "TEST", 314, 327], ["interventions", "TREATMENT", 343, 356], ["lifestyle (diet and physical activity", "TREATMENT", 389, 426], ["weight change", "PROBLEM", 540, 553], ["behavioral weight management interventions", "TREATMENT", 571, 613], ["lifestyle mHealth", "TREATMENT", 620, 637]]], ["The criteria for the exclusion of studies were as follows: (i) non-eligible publication types, such as review articles, editorials, comments, guidelines or case-reports; and (ii) duplicate reports-when this was the case, we extracted the data from the different reports and included in this systematic review the one providing the most detailed data.Data Extraction and Risk of Bias AssessmentAn ad-hoc table summarized the following information from the original reports: (1) year of publication; (2) country; (3) study design; (4) sample characteristics (sample size, age distribution and type of population); (5) baseline means of adiposity parameters (weight, body mass index (BMI) and waist circumference (WC)); (6) type of intervention (PDA, smartphone or web-based); (7) comparison groups; (8) length of intervention; and (9) percentage of dropouts.Data Extraction and Risk of Bias AssessmentThe Cochrane Collaboration's tool for assessing the risk of bias (RoB2) [15] was used to assess the risk of bias of the included RCTs.", [["body", "ANATOMY", 664, 668], ["body", "ORGANISM_SUBDIVISION", 664, 668], ["waist", "ORGANISM_SUBDIVISION", 690, 695], ["the exclusion of studies", "TEST", 17, 41], ["Data Extraction", "TEST", 350, 365], ["sample characteristics", "TEST", 533, 555], ["adiposity parameters", "TEST", 634, 654], ["weight", "TEST", 656, 662], ["body mass index", "TEST", 664, 679], ["BMI", "TEST", 681, 684], ["waist circumference", "TEST", 690, 709], ["intervention (PDA", "TREATMENT", 729, 746], ["intervention", "TREATMENT", 811, 823], ["dropouts", "PROBLEM", 847, 855], ["Data Extraction", "TEST", 856, 871], ["Bias Assessment", "TEST", 884, 899]]], ["The evaluation of six domains is included in this tool: randomization process, deviations from intended interventions, missing outcome data, measurement of the outcome and selection of the reported result.", [["The evaluation of six domains", "TEST", 0, 29], ["randomization process", "PROBLEM", 56, 77], ["intended interventions", "TREATMENT", 95, 117], ["missing outcome data", "TEST", 119, 139]]], ["Each domain could be assessed as having a low risk of bias, some concerns or a high risk of bias.Data Extraction and Risk of Bias AssessmentFor non-RCTs, the ROBINS-I tool was used [16] .", [["Data Extraction", "TEST", 97, 112], ["Bias Assessment", "TEST", 125, 140], ["non-RCTs", "TEST", 144, 152]]], ["This tool evaluates the risk of bias according to seven domains: bias due to confounding, bias in the selection of participants for the study, bias in the measurement of interventions, bias due to deviations from intended interventions, bias due to missing data, bias in the measurement of outcomes and bias in the selection of the reported result.", [["participants", "SPECIES", 115, 127], ["the study", "TEST", 132, 141], ["interventions", "TREATMENT", 170, 183], ["deviations", "PROBLEM", 197, 207], ["intended interventions", "TREATMENT", 213, 235], ["missing data", "PROBLEM", 249, 261]]], ["Overall bias could be considered as \"low risk of bias\" if all domains were classified as \"low risk\", \"moderate risk of bias\" if all domains were classified as \"low risk\" or \"moderate risk\", \"serious risk of bias\" if there was at least one domain rated as \"serious risk\", \"critical risk of bias\" if there was at least one domain rated as \"critical risk\" and \"no information\" if there was no clear indication that the study had a serious or critical risk of bias and there was a lack of information in one or more domains.Data Extraction and Risk of Bias AssessmentThe literature search, data extraction and quality assessment were conducted by two independent reviewers (IC-R and RF-R), and a third reviewer (CA-B) was included when inconsistencies remained after discussion.", [["the study", "TEST", 412, 421], ["Data Extraction", "TEST", 520, 535], ["Bias Assessment", "TEST", 548, 563], ["data extraction", "TEST", 586, 601], ["quality assessment", "TEST", 606, 624]]], ["Kappa statistics was calculated to assess the agreement rate between reviewers.Statistical Analysis and Data SynthesisTo compute the pooled estimate of the ES and its 95% confidence intervals (CIs) for weight change, we used the DerSimonian and Laird method [17] .", [["Kappa statistics", "TEST", 0, 16], ["Statistical Analysis", "TEST", 79, 99], ["Data SynthesisTo", "TEST", 104, 120], ["weight change", "PROBLEM", 202, 215]]], ["A standardized mean difference score was calculated, using Cohen's d index as the ES statistic, in which negative ES values indicate a weight loss in favor of behavioral weight management interventions using lifestyle mHealth self-monitoring.", [["weight loss", "DISEASE", 135, 146], ["A standardized mean difference score", "TEST", 0, 36], ["Cohen's d index", "TEST", 59, 74], ["a weight loss", "PROBLEM", 133, 146], ["behavioral weight management interventions", "TREATMENT", 159, 201], ["lifestyle mHealth", "TREATMENT", 208, 225]]], ["Cohen's d values represented the following: (i) weak effects when values were around 0.2, (ii) moderate effects when values were around 0.5, (iii) strong effects when values were around 0.8 and (iv) very strong effects when values were greater than 1.0 [18] .", [["Cohen's d values", "TEST", 0, 16], ["values", "TEST", 117, 123], ["values", "TEST", 167, 173]]], ["Additionally, a pooled estimate of the mean weight change difference in kg was calculated.Statistical Analysis and Data SynthesisAdherence to behavioral weight management interventions using lifestyle mHealth self-monitoring was calculated as the risk of dropping out of the lifestyle mHealth self-monitoring group versus other interventions or the control group.", [["the mean weight change difference", "PROBLEM", 35, 68], ["Statistical Analysis", "TEST", 90, 110], ["Data SynthesisAdherence", "TREATMENT", 115, 138], ["behavioral weight management interventions", "TREATMENT", 142, 184], ["lifestyle mHealth", "TREATMENT", 191, 208], ["other interventions", "TREATMENT", 322, 341], ["the control group", "TREATMENT", 345, 362]]], ["Relative risk (RR) was used as the risk estimate.Statistical Analysis and Data SynthesisThe heterogeneity of the results across studies was assessed using the I 2 statistic.", [["Relative risk (RR)", "PROBLEM", 0, 18], ["Statistical Analysis", "TEST", 49, 69], ["Data Synthesis", "TEST", 74, 88], ["heterogeneity", "OBSERVATION_MODIFIER", 92, 105]]], ["I 2 values were interpreted as: might not be important (0-40%); may represent moderate heterogeneity (30-60%); Nutrients 2020, 12, 1977 4 of 19 substantial heterogeneity (50-90%); or considerable heterogeneity (75-100%).", [["moderate heterogeneity", "PROBLEM", 78, 100], ["considerable heterogeneity", "PROBLEM", 183, 209], ["moderate", "OBSERVATION_MODIFIER", 78, 86], ["heterogeneity", "OBSERVATION", 87, 100], ["substantial", "OBSERVATION_MODIFIER", 144, 155], ["heterogeneity", "OBSERVATION_MODIFIER", 156, 169], ["considerable", "OBSERVATION_MODIFIER", 183, 195], ["heterogeneity", "OBSERVATION_MODIFIER", 196, 209]]], ["The corresponding p-values were also considered.Statistical Analysis and Data SynthesisSubgroup analyses were performed based on the type of mHealth intervention (PDA, smartphone or web-based), the type of comparison group (usual care, paper record or wait-list) and the length of the intervention (\u22643 months, six months and \u226512 months).", [["The corresponding p-values", "TEST", 0, 26], ["Statistical Analysis", "TEST", 48, 68], ["Data SynthesisSubgroup analyses", "TEST", 73, 104], ["mHealth intervention", "TREATMENT", 141, 161], ["the intervention", "TREATMENT", 281, 297]]], ["Sensitivity analyses were conducted to assess the robustness of the summary estimates and to detect whether any particular study accounted for a large proportion of heterogeneity.", [["Sensitivity analyses", "TEST", 0, 20], ["any particular study", "TEST", 108, 128], ["large", "OBSERVATION_MODIFIER", 145, 150], ["heterogeneity", "OBSERVATION", 165, 178]]], ["Random-effects meta-regressions were used to investigate whether the results were associated with the age of participants and the baseline means of weight, BMI or WC, since these variables may explain the observed heterogeneity.Statistical Analysis and Data SynthesisFinally, the Egger test [19] (p < 0.10 considered as statistically significant [20] ) and a visual inspection of the funnel plots were used to assess publication bias.", [["participants", "SPECIES", 109, 121], ["Random-effects meta-regressions", "TREATMENT", 0, 31], ["BMI", "TEST", 156, 159], ["WC", "TEST", 163, 165], ["the observed heterogeneity", "PROBLEM", 201, 227], ["Statistical Analysis", "TEST", 228, 248], ["Data SynthesisFinally", "TEST", 253, 274], ["the Egger test", "TEST", 276, 290], ["a visual inspection", "TEST", 357, 376], ["the funnel plots", "PROBLEM", 380, 396], ["heterogeneity", "OBSERVATION", 214, 227]]], ["STATA SE software, version 15 (StataCorp, College Station, TX, USA), was used for the statistical analyses.Systematic ReviewTwenty studies [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40] (Figure 1 ) addressing the effect of behavioral weight management interventions using lifestyle mHealth self-monitoring on weight loss were identified, which were conducted in six countries: 12 in the United States [21, 23, 25, 28, 31, [33] [34] [35] [37] [38] [39] [40] , two in the United Kingdom [24, 32] , three in Australia [22, 26, 29] , one in New Zealand [27] , one in South Korea [30] and one in Finland [36] .", [["weight loss", "DISEASE", 362, 373], ["[21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] [35] [36] [37] [38] [39] [40", "SIMPLE_CHEMICAL", 139, 237], ["version", "TEST", 19, 26], ["the statistical analyses", "TEST", 82, 106], ["Systematic ReviewTwenty studies", "TEST", 107, 138], ["behavioral weight management interventions", "TREATMENT", 276, 318], ["weight loss", "PROBLEM", 362, 373]]], ["Reports were published between 2007 and 2019, and they included studies using the following experimental designs: 17 RCTs [21] [22] [23] [24] [25] [26] [27] [28] [29] [31] [32] [33] [34] [35] [36] [37] [38] and three non-RCTs [30, 39, 40] .", [["[21] [22] [23] [24] [25] [26] [27] [28] [29] [31] [32] [33] [34] [35] [36] [37] [38]", "SIMPLE_CHEMICAL", 122, 206], ["studies", "TEST", 64, 71], ["non-RCTs", "TEST", 217, 225]]], ["Regarding the characteristics of the included populations, participants were aged between 20.5 and 59.8 years, with sample sizes ranging from 11 to 131 participants in the lifestyle mHealth self-monitoring intervention groups and from six to 133 participants in the control groups.", [["participants", "ORGANISM", 59, 71], ["participants", "SPECIES", 59, 71], ["participants", "SPECIES", 152, 164], ["participants", "SPECIES", 246, 258], ["sample sizes", "TEST", 116, 128], ["intervention groups", "TREATMENT", 206, 225], ["sizes", "OBSERVATION_MODIFIER", 123, 128]]], ["The baseline weight, BMI and WC of the studies ranged from 62.1 kg to 116.9 kg, from 27.0 kg/m 2 to 40.1 kg/m 2 and from 88.2 cm to 120.4 cm, respectively (Table 1) .", [["The baseline weight", "TEST", 0, 19], ["BMI", "TEST", 21, 24], ["WC", "TEST", 29, 31], ["the studies", "TEST", 35, 46]]], ["The mHealth interventions were delivered through PDAs, smartphones and web-based approaches, while comparator groups included usual care, paper records and wait-lists.", [["The mHealth interventions", "TREATMENT", 0, 25]]], ["The length of the interventions ranged from one to 24 months.", [["the interventions", "TREATMENT", 14, 31], ["length", "OBSERVATION_MODIFIER", 4, 10]]], ["Eight studies performed analyses for more than one time point [24, 27, 28, 33, [35] [36] [37] [38] .", [["[35] [36] [37] [38]", "SIMPLE_CHEMICAL", 79, 98], ["Eight studies", "TEST", 0, 13]]], ["Three studies included two intervention arms [24, 31, 39] .", [["Three studies", "TEST", 0, 13]]], ["Additionally, 16 studies specified the application used for lifestyle mHealth self-monitoring: Lose It! [21, 34, 38, 39] , TXT2BFiT [22] , Dietmate Pro [23] , My Meal Mate [24] , MyFitnessPal [25, 27, 37] , Be Positive Be Healthy [26] , SmartLoss [27] , CalorieKing [28, 34, 39] and Fitbit [30] .", [["CalorieKing [28, 34, 39]", "SIMPLE_CHEMICAL", 254, 278], ["16 studies", "TEST", 14, 24], ["TXT2BFiT", "TEST", 123, 131], ["MyFitnessPal", "TEST", 179, 191], ["SmartLoss", "TEST", 237, 246], ["CalorieKing", "TEST", 254, 265], ["Fitbit", "TEST", 283, 289]]], ["The percentage of dropouts from the lifestyle mHealth self-monitoring intervention group ranged from 5.0% to 54.8% (Table 2 ).Risk of BiasFor RCTs, as evaluated by the RoB2 tool, 47.4% of studies showed some concerns regarding the risk of bias and 52.6% showed a high risk for overall bias (mainly as a consequence of a high risk of bias in the measurement of the outcome domain) (see Appendix A Figure A1 ).", [["the RoB2 tool", "TEST", 164, 177], ["studies", "TEST", 188, 195], ["bias", "TEST", 239, 243], ["overall bias", "PROBLEM", 277, 289], ["percentage", "OBSERVATION_MODIFIER", 4, 14], ["Appendix", "ANATOMY", 385, 393]]], ["Among non-RCTs, as evaluated by the ROBINS-I tool, the risk of bias was scored as moderate in 33.3% of studies and serious in 66.7% (mainly as a consequence of a serious risk of bias in the missing data domain) (see Appendix A Figure A2 ).Meta-AnalysisThe pooled ES of behavioral weight management interventions using lifestyle mHealth self-monitoring on weight loss was \u22120.37 (95%CI: \u22120.54, \u22120.19).", [["weight loss", "DISEASE", 355, 366], ["A2", "PROTEIN", 234, 236], ["studies", "TEST", 103, 110], ["behavioral weight management interventions", "TREATMENT", 269, 311], ["weight loss", "TEST", 355, 366], ["CI", "TEST", 381, 383], ["moderate", "OBSERVATION_MODIFIER", 82, 90], ["Appendix", "ANATOMY", 216, 224]]], ["Additionally, the pooled mean difference in weight was \u22121.78 kg (95%CI: \u22122.70, \u22120.85).", [["weight", "TEST", 44, 50], ["CI", "TEST", 68, 70], ["mean", "OBSERVATION_MODIFIER", 25, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["The heterogeneity between studies was substantial (I2 = 84.6%; p < 0.001) (Figure 2 ).", [["studies", "TEST", 26, 33], ["I2", "TEST", 51, 53], ["heterogeneity", "OBSERVATION", 4, 17], ["substantial", "OBSERVATION_MODIFIER", 38, 49]]], ["The pooled RR for dropping out of the lifestyle mHealth self-monitoring group was 0.78 (95%CI: 0.63, 0.96).", [["The pooled RR", "TEST", 0, 13], ["CI", "TEST", 91, 93]]], ["The heterogeneity between studies was moderate (I2 = 37.8%; p = 0.049) (Figure 3 ).Meta-AnalysisNutrients 2020, 12, x FOR PEER REVIEW 5 of 21Risk of BiasFor RCTs, as evaluated by the RoB2 tool, 47.4% of studies showed some concerns regarding the risk of bias and 52.6% showed a high risk for overall bias (mainly as a consequence of a high risk of bias in the measurement of the outcome domain) (see Appendix Figure A1 ).", [["studies", "TEST", 26, 33], ["I2", "TEST", 48, 50], ["p", "TEST", 60, 61], ["BiasFor RCTs", "TREATMENT", 149, 161], ["the RoB2 tool", "TEST", 179, 192], ["studies", "TEST", 203, 210], ["bias", "TEST", 254, 258], ["overall bias", "PROBLEM", 292, 304], ["moderate", "OBSERVATION_MODIFIER", 38, 46]]], ["Among non-RCTs, as evaluated by the ROBINS-I tool, the risk of bias was scored as moderate in 33.3% of studies and serious in 66.7% (mainly as a consequence of a serious risk of bias in the missing data domain) (see Appendix Figure A2 ).Meta-AnalysisThe pooled ES of behavioral weight management interventions using lifestyle mHealth selfmonitoring on weight loss was \u22120.37 (95%CI: \u22120.54, \u22120.19).", [["weight loss", "DISEASE", 352, 363], ["A2", "PROTEIN", 232, 234], ["studies", "TEST", 103, 110], ["behavioral weight management interventions", "TREATMENT", 267, 309], ["lifestyle mHealth", "TREATMENT", 316, 333], ["weight loss", "PROBLEM", 352, 363], ["CI", "TEST", 378, 380], ["moderate", "OBSERVATION_MODIFIER", 82, 90]]], ["Additionally, the pooled mean difference in weight was \u22121.78 kg (95%CI: \u22122.70, \u22120.85).", [["weight", "TEST", 44, 50], ["CI", "TEST", 68, 70], ["mean", "OBSERVATION_MODIFIER", 25, 29], ["difference", "OBSERVATION_MODIFIER", 30, 40]]], ["The heterogeneity between studies was substantial (I2 = 84.6%; p < 0.001) (Figure 2 ).", [["studies", "TEST", 26, 33], ["I2", "TEST", 51, 53], ["heterogeneity", "OBSERVATION", 4, 17], ["substantial", "OBSERVATION_MODIFIER", 38, 49]]], ["The pooled RR for dropping out of the lifestyle mHealth self-monitoring group was 0.78 (95%CI: 0.63, 0.96).", [["The pooled RR", "TEST", 0, 13], ["CI", "TEST", 91, 93]]], ["The heterogeneity between studies was moderate (I2 = 37.8%; p = 0.049) (Figure 3 ).Subgroup AnalysesSubgroup analyses considering the type of mHealth intervention and the type of comparison group showed that a greater effect was observed when the mHealth intervention used a smartphone Table 3) .Subgroup AnalysesSubgroup analyses considering the type of mHealth intervention and the type of comparison group showed that a greater effect was observed when the mHealth intervention used a smartphone Table 3) .Sensitivity AnalysesThe pooled ES estimate was not significantly different when data from each individual study were removed from the analyses one at a time.Meta-RegressionsThe random-effects meta-regression models for the effects on weight loss and adherence showed that age (p = 0.365 and 0.462) and baseline means of weight (p = 0.724 and 0.593), BMI (p = 0.440 and 0.979) and WC (p = 0.677 and 0.428) were not related to heterogeneity across studies (see Appendix A Table A2 ).Publication BiasEvidence of publication bias was found in both the funnel plot asymmetry and Egger's test (p = 0.016 for effect on weight loss and p = 0.008 for adherence).DiscussionThis systematic review and meta-analysis provides an overview of the evidence supporting lifestyle (diet and physical activity) mHealth self-monitoring, as part of a behavioral weight management approach, as a suitable intervention for weight management in adults with overweight or obesity, resulting in a moderate decrease in weight and higher adherence to intervention, greater than with other interventions.", [["weight loss", "DISEASE", 743, 754], ["weight loss", "DISEASE", 1121, 1132], ["overweight", "DISEASE", 1441, 1451], ["obesity", "DISEASE", 1455, 1462], ["studies", "TEST", 26, 33], ["I2", "TEST", 48, 50], ["p", "TEST", 60, 61], ["Subgroup AnalysesSubgroup analyses", "TEST", 83, 117], ["mHealth intervention", "TREATMENT", 142, 162], ["Subgroup AnalysesSubgroup analyses", "TEST", 296, 330], ["mHealth intervention", "TREATMENT", 355, 375], ["Sensitivity Analyses", "TEST", 509, 529], ["The pooled ES estimate", "TEST", 529, 551], ["each individual study", "TEST", 599, 620], ["The random-effects meta-regression models", "PROBLEM", 682, 723], ["weight loss", "PROBLEM", 743, 754], ["p", "TEST", 786, 787], ["weight", "TEST", 829, 835], ["p", "TEST", 837, 838], ["BMI", "TEST", 859, 862], ["p", "TEST", 864, 865], ["WC", "TEST", 889, 891], ["p", "TEST", 893, 894], ["heterogeneity across studies", "TEST", 934, 962], ["publication bias", "PROBLEM", 1018, 1034], ["the funnel plot asymmetry", "TEST", 1053, 1078], ["Egger's test", "TEST", 1083, 1095], ["weight loss", "PROBLEM", 1121, 1132], ["p", "TEST", 1137, 1138], ["a behavioral weight management approach", "TREATMENT", 1336, 1375], ["a suitable intervention", "TREATMENT", 1380, 1403], ["weight management", "TREATMENT", 1408, 1425], ["obesity", "PROBLEM", 1455, 1462], ["a moderate decrease in weight", "PROBLEM", 1477, 1506], ["intervention", "TREATMENT", 1531, 1543], ["other interventions", "TREATMENT", 1563, 1582], ["moderate", "OBSERVATION_MODIFIER", 38, 46], ["publication bias", "OBSERVATION", 1018, 1034], ["funnel plot", "OBSERVATION", 1057, 1068], ["obesity", "OBSERVATION", 1455, 1462], ["moderate", "OBSERVATION_MODIFIER", 1479, 1487], ["decrease", "OBSERVATION", 1488, 1496]]], ["Additionally, this meta-analysis shows that interventions delivered through smartphones are the most effective mHealth approach to achieve weight management in adult populations with overweight or obesity.", [["overweight", "DISEASE", 183, 193], ["obesity", "DISEASE", 197, 204], ["this meta-analysis", "TEST", 14, 32], ["interventions", "TREATMENT", 44, 57], ["smartphones", "TREATMENT", 76, 87], ["weight management", "TREATMENT", 139, 156], ["obesity", "PROBLEM", 197, 204], ["obesity", "OBSERVATION", 197, 204]]], ["The effect of behavioral weight management interventions using lifestyle mHealth self-monitoring interventions was more pronounced when they were compared to usual care and in the short-term (less than six months).", [["behavioral weight management interventions", "TREATMENT", 14, 56], ["lifestyle mHealth", "TREATMENT", 63, 80], ["monitoring interventions", "TREATMENT", 86, 110]]], ["Furthermore, behavioral weight management interventions using lifestyle mHealth self-monitoring interventions showed a higher adherence than: (i) paper records at any time and (ii) any other intervention at six months and twelve months.DiscussionA previous systematic review on the effect of mHealth applications on weight loss highlighted that the use of these interventions is widely accepted, easy to use and helpful in achieving weight loss goals [12] .", [["weight loss", "DISEASE", 316, 327], ["weight loss", "DISEASE", 433, 444], ["behavioral weight management interventions", "TREATMENT", 13, 55], ["mHealth applications", "TREATMENT", 292, 312], ["weight loss", "PROBLEM", 316, 327], ["these interventions", "TREATMENT", 356, 375]]], ["Additionally, there is evidence for the consistent and significant positive relationship between lifestyle (diet and physical activity) and behavior (self-monitoring) strategies and successful weight management [5] .", [["successful weight management", "TREATMENT", 182, 210], ["significant", "OBSERVATION_MODIFIER", 55, 66], ["positive", "OBSERVATION", 67, 75]]], ["Likewise, our systematic review and meta-analysis supports the notion that mHealth self-monitoring interventions have a moderate effect on reducing weight, which may represent a mean weight loss of 1.78 kg greater than with other intervention types.DiscussionOur results not only show a positive effect on weight loss but also fewer dropouts of subjects included in mHealth interventions in the short and long-term.", [["weight loss", "DISEASE", 183, 194], ["weight loss", "DISEASE", 306, 317], ["a mean weight loss", "PROBLEM", 176, 194], ["weight loss", "PROBLEM", 306, 317], ["mHealth interventions", "TREATMENT", 366, 387], ["moderate", "OBSERVATION_MODIFIER", 120, 128], ["may represent", "UNCERTAINTY", 162, 175], ["positive", "OBSERVATION", 287, 295]]], ["The mechanisms through which behavioral weight management interventions using lifestyle mHealth self-monitoring are effective may be explained from two perspectives: the user and the clinical setting [41] .", [["behavioral weight management interventions", "TREATMENT", 29, 71]]], ["For users, mHealth interventions enhance patients' self-efficacy and empowerment and improve daily life autonomy and adherence to treatment [42] .", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["mHealth interventions", "TREATMENT", 11, 32], ["treatment", "TREATMENT", 130, 139]]], ["Moreover, the mHealth approach reduces contact with the clinical setting and, as a consequence, decreases the workload for health care workers (physicians, nurses and nutritionists, especially in primary care) [43, 44] .DiscussionThere is a variety of devices that could be used for mHealth.", [["a variety of devices", "TREATMENT", 239, 259]]], ["Our subgroup analyses support the notion that smartphones, a technology available to a high proportion of the population worldwide [45] , are the most effective mHealth devices for weight management.", [["weight management", "TREATMENT", 181, 198]]], ["This, along with the high prevalence rates of both physical inactivity and obesity, has triggered a growing interest in the development of smartphone applications for health, fitness and diet, which have increased exponentially in the last few years [46] .", [["physical inactivity", "DISEASE", 51, 70], ["obesity", "DISEASE", 75, 82], ["obesity", "PROBLEM", 75, 82], ["smartphone applications", "TREATMENT", 139, 162], ["physical inactivity", "OBSERVATION", 51, 70], ["obesity", "OBSERVATION", 75, 82], ["increased", "OBSERVATION_MODIFIER", 204, 213], ["exponentially", "OBSERVATION_MODIFIER", 214, 227]]], ["More than half of smartphone users may have downloaded a health application [47] ; however, the use of these applications for clinical outcomes is still very limited and even non-existent in most contexts [48] .DiscussionThe limitations of this study are as follows: (1) the risk of bias assessment showed that a few studies presented some concerns or moderate risk of bias, while most showed a high or serious risk of bias.", [["these applications", "TREATMENT", 103, 121], ["this study", "TEST", 240, 250], ["bias assessment", "TEST", 283, 298], ["a few studies", "TEST", 311, 324], ["moderate risk of bias", "PROBLEM", 352, 373], ["moderate", "OBSERVATION_MODIFIER", 352, 360]]], ["It should be noted that the main reason behind the high risk of bias in the included studies was the impracticality of blinding interventions, but this limitation is difficult to overcome in this type of intervention.", [["blinding interventions", "TREATMENT", 119, 141], ["intervention", "TREATMENT", 204, 216], ["bias", "OBSERVATION", 64, 68]]], ["(2) The lack of studies using devices that did not allow for comparison between them, with reliable results only being obtained for smartphones.", [["devices", "TREATMENT", 30, 37], ["smartphones", "TEST", 132, 143]]], ["(3) The intervention groups could be very different considering that they used different types of applications; however, they have the common characteristic that they were carried out through an mHealth device.", [["The intervention groups", "TREATMENT", 4, 27], ["an mHealth device", "TREATMENT", 192, 209]]], ["(4) Many of the studies did not control for the effect of other covariates which could affect the results, such as educational or socioeconomic level.", [["the studies", "TEST", 12, 23]]], ["(5) Regarding the analysis of adherence, it cannot be assumed that lifestyle mHealth self-monitoring is the only reason for participants to dropout, since these interventions are usually part of a broader behavioral weight management approach.", [["participants", "SPECIES", 124, 136], ["these interventions", "TREATMENT", 155, 174], ["a broader behavioral weight management approach", "TREATMENT", 195, 242]]], ["(6) Finally, this meta-analysis showed publication bias, mainly due to the lack of studies with small sample sizes.DiscussionEven with the risk of being branded as opportunists, we are not reluctant to emphasize the importance of mHealth interventions in times when face-to-face contact must be limited, such as those we are living in currently, particularly in clinical settings, in which the transmission of infectious diseases, namely Influenza or Sars-CoV-2, may be greater.", [["infectious diseases", "DISEASE", 410, 429], ["Influenza", "DISEASE", 438, 447], ["Sars-CoV-2", "ORGANISM", 451, 461], ["this meta-analysis", "TEST", 13, 31], ["publication bias", "PROBLEM", 39, 55], ["studies", "TEST", 83, 90], ["small sample sizes", "PROBLEM", 96, 114], ["mHealth interventions", "TREATMENT", 230, 251], ["infectious diseases", "PROBLEM", 410, 429], ["Influenza", "PROBLEM", 438, 447], ["publication bias", "OBSERVATION", 39, 55], ["small", "OBSERVATION_MODIFIER", 96, 101], ["sample", "OBSERVATION_MODIFIER", 102, 108], ["sizes", "OBSERVATION_MODIFIER", 109, 114], ["infectious", "OBSERVATION", 410, 420], ["greater", "OBSERVATION_MODIFIER", 470, 477]]], ["Additionally, everything appears to indicate that the current concept of treatment will lead to an increase in the use of mHealth in daily clinical practice [49] .ConclusionsIn summary, our study demonstrates that lifestyle mHealth self-monitoring interventions, as part of a behavioral weight management approach, are suitable interventions for short-term weight management in adults with overweight/obesity.", [["overweight/obesity", "DISEASE", 390, 408], ["treatment", "TREATMENT", 73, 82], ["our study", "TEST", 186, 195], ["interventions", "TREATMENT", 248, 261], ["a behavioral weight management approach", "TREATMENT", 274, 313], ["suitable interventions", "TREATMENT", 319, 341], ["short-term weight management", "TREATMENT", 346, 374], ["obesity", "PROBLEM", 401, 408], ["increase", "OBSERVATION_MODIFIER", 99, 107], ["obesity", "OBSERVATION", 401, 408]]], ["Considering our results and the population's accessibility to smartphones, this type of device could be a useful and largely scalable tool for weight management.", [["this type of device", "TREATMENT", 75, 94], ["weight management", "TREATMENT", 143, 160]]], ["Thus, future well designed RCTs and controlled clinical trials with higher statistical power are essential in order to reinforce the evidence, which is still weak, to demonstrate that effective mHealth interventions could eventually change the current paradigm of lifestyle prescription, increasing patients' self-management of disease, developing new clinical practice guidelines and facilitating workflow in everyday clinical consultations.", [["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 299, 307], ["effective mHealth interventions", "TREATMENT", 184, 215], ["lifestyle prescription", "TREATMENT", 264, 286], ["disease", "PROBLEM", 328, 335]]], ["Funding: This study was funded by FEDER funds.Conflicts of Interest:The authors declare no conflict of interest.", [["This study", "TEST", 9, 19]]], ["Risk of bias for randomized controlled trials (RCTs) using the Cochrane Collaboration's tool for assessing the risk of bias (RoB2).", [["randomized controlled trials (RCTs", "TREATMENT", 17, 51]]]], "PMC7233401": [["IntroductionThe recent COVID-19 radiological literature is primarily focused on CT findings5\u201310, which is more sensitive than chest x-ray (CXR).", [["The recent COVID", "TEST", 12, 28], ["CT findings", "TEST", 80, 91], ["chest x-ray", "TEST", 126, 137], ["CXR", "TEST", 139, 142]]], ["In mainland China, CT was often a first-line investigation for COVID-1911,12.", [["COVID-1911,12", "CHEMICAL", 63, 76], ["CT", "TEST", 19, 21], ["COVID", "TEST", 63, 68]]], ["However, this practice placed a huge burden on radiology departments and posed an immense challenge for infection control in the CT suite.", [["infection", "DISEASE", 104, 113], ["an immense challenge", "TREATMENT", 79, 99], ["infection control", "TREATMENT", 104, 121], ["huge", "OBSERVATION_MODIFIER", 32, 36], ["infection", "OBSERVATION", 104, 113]]], ["Some hospitals in China dedicated specific CT scanners for examining suspected COVID-19 patients only13, a practice that is being instituted with difficulty in the United Kingdom14.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96], ["CT scanners", "TEST", 43, 54]]], ["The American College of Radiology notes that CT decontamination required after scanning COVID-19 patients may disrupt radiological service availability, and suggests that portable chest x-ray (CXR) may be considered to minimize the risk of cross-infection15.", [["patients", "ORGANISM", 97, 105], ["patients", "SPECIES", 97, 105], ["CT decontamination", "TREATMENT", 45, 63], ["scanning COVID", "TEST", 79, 93], ["portable chest x-ray", "TEST", 171, 191], ["CXR", "TEST", 193, 196], ["cross-infection15", "PROBLEM", 240, 257]]], ["Italian and British hospitals are beginning to employ CXR as a first-line triage tool due to long reverse transcription polymerase chain reaction (RT-PCR) turnaround times14,16.", [["CXR", "DNA", 54, 57], ["CXR", "TEST", 54, 57], ["long reverse transcription polymerase chain reaction", "PROBLEM", 93, 145], ["RT-PCR", "TEST", 147, 153]]], ["Therefore, in some countries, CXR cannot be superseded by CT in the current pandemic.", [["CXR", "PROTEIN", 30, 33], ["CXR", "TEST", 30, 33], ["CT", "TEST", 58, 60]]], ["As the prevalence of COVID-19 increases, it is also imperative for clinicians of all specialties to recognize COVID-19 features on CXR that may be performed for other purposes.IntroductionTo further our understanding of the radiographic features of COVID-19, our study aims to: (i) describe the chest x-ray appearances of COVID-19, (ii) correlate the chest x-ray appearances with reverse transcription polymerase chain reaction (RT-PCR), (iii) compare chest x-ray findings with CT findings, and (iv) describe the time course of chest x-ray appearances relative to symptom onset.Patients ::: Materials & MethodsA total of 64 patients from four tertiary and regional hospitals in Hong Kong (Queen Mary Hospital, Pamela Youde Nethersole Eastern Hospital, Queen Elizabeth Hospital, and Ruttonjee Hospital) were included from 1st January 2020 to 5th March 2020 (see figure 1).", [["chest", "ANATOMY", 295, 300], ["Patients", "ORGANISM", 578, 586], ["patients", "ORGANISM", 624, 632], ["Patients", "SPECIES", 578, 586], ["patients", "SPECIES", 624, 632], ["COVID", "TEST", 21, 26], ["COVID", "TEST", 110, 115], ["CXR", "TEST", 131, 134], ["COVID", "TEST", 249, 254], ["the chest x-ray", "TEST", 291, 306], ["COVID", "TEST", 322, 327], ["the chest x-ray", "TEST", 347, 362], ["reverse transcription polymerase chain reaction", "PROBLEM", 380, 427], ["RT-PCR", "TEST", 429, 435], ["chest x-ray", "TEST", 452, 463], ["CT findings", "TEST", 478, 489], ["chest x-ray", "TEST", 528, 539], ["symptom onset", "PROBLEM", 564, 577], ["chest", "ANATOMY", 295, 300], ["chest", "ANATOMY", 351, 356], ["chest", "ANATOMY", 452, 457], ["chest", "ANATOMY", 528, 533]]], ["COVID-19 infection was confirmed by RT-PCR on nasopharyngeal swabs and throat swabs.", [["nasopharyngeal swabs", "ANATOMY", 46, 66], ["throat swabs", "ANATOMY", 71, 83], ["infection", "DISEASE", 9, 18], ["nasopharyngeal swabs", "ORGANISM_SUBSTANCE", 46, 66], ["COVID", "TEST", 0, 5], ["infection", "PROBLEM", 9, 18], ["RT", "TEST", 36, 38], ["PCR", "TEST", 39, 42], ["nasopharyngeal swabs", "TEST", 46, 66], ["throat swabs", "TEST", 71, 83], ["infection", "OBSERVATION", 9, 18], ["nasopharyngeal", "ANATOMY", 46, 60], ["throat", "ANATOMY", 71, 77]]], ["Thirty-nine patients had serial RT-PCR results available at the time of writing.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["serial RT-PCR", "TEST", 25, 38]]], ["All patients had CXR upon admission, with follow-up CXRs available for all but one patient.", [["patients", "ORGANISM", 4, 12], ["patient", "ORGANISM", 83, 90], ["patients", "SPECIES", 4, 12], ["patient", "SPECIES", 83, 90], ["CXR", "TEST", 17, 20], ["follow-up CXRs", "TEST", 42, 56]]], ["Timing of symptom onset was obtained from public epidemiological data provided by the Hong Kong Center for Health Protection17.", [["symptom onset", "PROBLEM", 10, 23]]], ["In the case of asymptomatic patients (9/64, 14%), date of first positive RT-PCR was substituted for symptom onset.Image Acquisition & Analysis ::: Materials & MethodsAll CXRs were acquired as computed or digital radiographs following usual local protocols.", [["patients", "ORGANISM", 28, 36], ["CXRs", "CANCER", 170, 174], ["CXRs", "DNA", 170, 174], ["patients", "SPECIES", 28, 36], ["PCR", "TEST", 76, 79], ["symptom onset", "PROBLEM", 100, 113], ["All CXRs", "TEST", 166, 174], ["computed or digital radiographs", "TEST", 192, 223], ["usual local protocols", "TREATMENT", 234, 255]]], ["CXRs were acquired in the posteroanterior (PA) or anteroposterior (AP) projection.", [["CXRs", "GENE_OR_GENE_PRODUCT", 0, 4], ["CXRs", "PROTEIN", 0, 4], ["CXRs", "TEST", 0, 4], ["anteroposterior (AP) projection", "TEST", 50, 81]]], ["Follow-up CXRs were acquired in the AP projection using portable X-ray units.", [["portable X-ray units", "DNA", 56, 76], ["Follow-up CXRs", "TEST", 0, 14], ["portable X-ray units", "TREATMENT", 56, 76]]], ["Over half of the CXRs at presentation were performed in the AP projection (36/64, 56%), with the rest in the PA projection.", [["CXRs", "CANCER", 17, 21], ["PA", "GENE_OR_GENE_PRODUCT", 109, 111], ["CXRs", "DNA", 17, 21], ["the CXRs", "TEST", 13, 21], ["the AP projection", "TEST", 56, 73]]], ["All follow-up CXRs were performed in the AP projection using portable X-ray units in the isolation wards.Image Acquisition & Analysis ::: Materials & MethodsTwo radiologists (HYSL, thoracic radiologist with 15 years of experience; HYFW, general radiologist with 5 years of experience) reviewed all CXRs by consensus.", [["portable X-ray units", "DNA", 61, 81], ["All follow-up CXRs", "TEST", 0, 18], ["the AP projection", "TEST", 37, 54], ["all CXRs", "TEST", 294, 302], ["thoracic", "ANATOMY", 181, 189]]], ["Further review was undertaken by a third radiologist (MYN, thoracic radiologist with 8 years of experience) if there was disagreement.", [["thoracic", "ANATOMY", 59, 67]]], ["Radiographic features including consolidation, ground glass opacities (GGO), and pulmonary nodules were diagnosed according to the Fleischner Society glossary of terms18.", [["pulmonary nodules", "ANATOMY", 81, 98], ["GGO", "DISEASE", 71, 74], ["pulmonary nodules", "CANCER", 81, 98], ["Radiographic features", "TEST", 0, 21], ["consolidation", "PROBLEM", 32, 45], ["ground glass opacities", "PROBLEM", 47, 69], ["GGO", "PROBLEM", 71, 74], ["pulmonary nodules", "PROBLEM", 81, 98], ["consolidation", "OBSERVATION", 32, 45], ["ground glass opacities", "OBSERVATION", 47, 69], ["GGO", "OBSERVATION_MODIFIER", 71, 74], ["pulmonary", "ANATOMY", 81, 90], ["nodules", "OBSERVATION", 91, 98]]], ["Distribution of the lung changes was categorized into (i) peripheral predominance, perihilar predominance (peripheral and perihilar demarcation was defined as halfway between lateral edge of the lung and hilum), or neither; (ii) right, left, or bilateral lung involvement; and (iii) upper zone, lower zone (defined as upper/ lower halves) or no zonal predominance.", [["lung", "ANATOMY", 20, 24], ["perihilar", "ANATOMY", 83, 92], ["perihilar", "ANATOMY", 122, 131], ["lateral edge", "ANATOMY", 175, 187], ["lung", "ANATOMY", 195, 199], ["hilum", "ANATOMY", 204, 209], ["right", "ANATOMY", 229, 234], ["left", "ANATOMY", 236, 240], ["lung", "ANATOMY", 255, 259], ["upper zone", "ANATOMY", 283, 293], ["lower zone", "ANATOMY", 295, 305], ["lung", "ORGAN", 20, 24], ["peripheral", "TISSUE", 107, 117], ["lung", "ORGAN", 195, 199], ["hilum", "MULTI-TISSUE_STRUCTURE", 204, 209], ["lung", "ORGAN", 255, 259], ["upper", "ORGANISM_SUBDIVISION", 318, 323], ["the lung changes", "PROBLEM", 16, 32], ["perihilar predominance (peripheral and perihilar demarcation", "PROBLEM", 83, 143], ["ii) right, left, or bilateral lung involvement", "PROBLEM", 225, 271], ["zonal predominance", "PROBLEM", 345, 363], ["lung", "ANATOMY", 20, 24], ["peripheral", "ANATOMY_MODIFIER", 58, 68], ["predominance", "OBSERVATION_MODIFIER", 69, 81], ["perihilar", "ANATOMY_MODIFIER", 83, 92], ["peripheral", "ANATOMY_MODIFIER", 107, 117], ["perihilar", "ANATOMY_MODIFIER", 122, 131], ["lateral", "ANATOMY_MODIFIER", 175, 182], ["edge", "ANATOMY_MODIFIER", 183, 187], ["lung", "ANATOMY", 195, 199], ["hilum", "ANATOMY", 204, 209], ["right", "ANATOMY_MODIFIER", 229, 234], ["left", "ANATOMY_MODIFIER", 236, 240], ["bilateral", "ANATOMY_MODIFIER", 245, 254], ["lung", "ANATOMY", 255, 259], ["involvement", "OBSERVATION", 260, 271], ["upper", "ANATOMY_MODIFIER", 283, 288], ["zone", "ANATOMY_MODIFIER", 289, 293], ["lower", "ANATOMY_MODIFIER", 295, 300], ["zone", "ANATOMY_MODIFIER", 301, 305], ["upper", "ANATOMY_MODIFIER", 318, 323], ["lower halves", "ANATOMY", 325, 337], ["no", "UNCERTAINTY", 342, 344], ["zonal", "OBSERVATION_MODIFIER", 345, 350], ["predominance", "OBSERVATION", 351, 363]]], ["Presence of pleural effusion was also recorded.Image Acquisition & Analysis ::: Materials & MethodsAll CTs were acquired as non-contrast enhanced volumetric scans of the thorax at 1 to 1.25mm slice thickness following usual local protocols.", [["pleural effusion", "ANATOMY", 12, 28], ["thorax", "ANATOMY", 170, 176], ["slice", "ANATOMY", 192, 197], ["pleural effusion", "DISEASE", 12, 28], ["pleural", "ORGAN", 12, 19], ["thorax", "ORGAN", 170, 176], ["pleural effusion", "PROBLEM", 12, 28], ["All CTs", "TEST", 99, 106], ["non-contrast enhanced volumetric scans of the thorax", "TEST", 124, 176], ["usual local protocols", "TEST", 218, 239], ["pleural", "ANATOMY", 12, 19], ["effusion", "OBSERVATION", 20, 28], ["thorax", "ANATOMY", 170, 176]]], ["HYSL and HYFW reviewed the CTs for presence or absence of consolidation and ground glass opacities.Radiograph Scoring ::: Materials & MethodsTo quantify the extent of infection, a severity score was calculated by adapting and simplifying the Radiographic Assessment of Lung Edema (RALE) score proposed by Warren et al.19 A score of 0-4 was assigned to each lung depending on the extent of involvement by consolidation or GGO (0 = no involvement; 1 = <25%; 2 = 25-50%; 3 = 50-75%; 4 = >75% involvement).", [["Lung", "ANATOMY", 269, 273], ["lung", "ANATOMY", 357, 361], ["infection", "DISEASE", 167, 176], ["Lung Edema", "DISEASE", 269, 279], ["GGO", "DISEASE", 421, 424], ["Lung", "ORGAN", 269, 273], ["lung", "ORGAN", 357, 361], ["HYFW", "DNA", 9, 13], ["the CTs", "TEST", 23, 30], ["consolidation", "PROBLEM", 58, 71], ["ground glass opacities", "PROBLEM", 76, 98], ["infection", "PROBLEM", 167, 176], ["a severity score", "PROBLEM", 178, 194], ["the Radiographic Assessment", "TEST", 238, 265], ["Lung Edema", "PROBLEM", 269, 279], ["A score", "TEST", 321, 328], ["consolidation", "PROBLEM", 404, 417], ["GGO", "PROBLEM", 421, 424], ["involvement", "TEST", 433, 444], ["consolidation", "OBSERVATION", 58, 71], ["ground glass opacities", "OBSERVATION", 76, 98], ["extent", "OBSERVATION_MODIFIER", 157, 163], ["infection", "OBSERVATION", 167, 176], ["Lung", "ANATOMY", 269, 273], ["Edema", "OBSERVATION", 274, 279], ["lung", "ANATOMY", 357, 361], ["consolidation", "OBSERVATION", 404, 417], ["GGO", "OBSERVATION", 421, 424]]], ["The scores for each lung were summed to produce the final severity score.", [["lung", "ANATOMY", 20, 24], ["lung", "ORGAN", 20, 24], ["lung", "ANATOMY", 20, 24]]], ["Examples are given in Figure 2.Real-time Reverse Transcription-Polymerase Chain Reaction (RT-PCR) ::: Materials & MethodsApart from 10 patients who were tested and confirmed using standard Hong Kong Hospital Authority and Department of Health RT-PCR protocol for diagnosis, virologic monitoring was performed using using QuantiNova Probe RT-PCR Kit (QIAGEN, Hilden, Germany) targeting the RNA-dependent RNA polymerase (RdRp)/helicase (Hel) gene of SARS-CoV-2 until patient discharge.", [["patients", "ORGANISM", 135, 143], ["RNA-dependent RNA polymerase", "GENE_OR_GENE_PRODUCT", 389, 417], ["Hel", "GENE_OR_GENE_PRODUCT", 435, 438], ["SARS-CoV-2", "ORGANISM", 448, 458], ["patient", "ORGANISM", 465, 472], ["RNA-dependent RNA polymerase (RdRp)/helicase (Hel) gene", "DNA", 389, 444], ["patients", "SPECIES", 135, 143], ["patient", "SPECIES", 465, 472], ["SARS-CoV", "SPECIES", 448, 456], ["virologic monitoring", "TEST", 274, 294], ["QuantiNova Probe RT-PCR Kit (QIAGEN, Hilden", "TREATMENT", 321, 364], ["the RNA-dependent RNA polymerase (RdRp", "TREATMENT", 385, 423], ["helicase (Hel)", "TREATMENT", 425, 439], ["SARS", "PROBLEM", 448, 452]]], ["The technical methodology of the nucleic acid testing has been previously described 20.Statistical Analysis ::: Materials & MethodsStatistical analysis was performed with IBM SPSS Statistics Subscription software (Build 1.0.0.1347; IBM, New York, USA).", [["nucleic acid", "CHEMICAL", 33, 45], ["the nucleic acid testing", "TEST", 29, 53], ["MethodsStatistical analysis", "TEST", 124, 151]]], ["The difference between CXR severity scores at various time points during the disease course was analyzed by Kruskal-Wallis test.", [["CXR", "PROTEIN", 23, 26], ["CXR severity scores", "TEST", 23, 42], ["Kruskal-Wallis test", "TEST", 108, 127]]], ["To evaluate the sensitivity of CXR, baseline CXR severity scores of >0 were interpreted as positive, which were then compared to initial RT-PCR results by McNemar Chi-squared test.", [["CXR", "PROTEIN", 31, 34], ["CXR", "PROTEIN", 45, 48], ["CXR", "TEST", 31, 34], ["baseline CXR severity scores", "TEST", 36, 64], ["initial RT-PCR", "TEST", 129, 143], ["McNemar Chi-squared test", "TEST", 155, 179]]], ["Comparison of the baseline CXR severity score between initial positive and negative RT-PCR results was assessed by Mann-Whitney U test.", [["the baseline CXR severity score", "TEST", 14, 45], ["PCR", "TEST", 87, 90]]], ["Radiographic and virologic recovery (defined as reaching a CXR severity score of 0 and RT-PCR negative respectively) were compared using paired-sample ttest.", [["Radiographic", "TEST", 0, 12], ["virologic recovery", "TEST", 17, 35], ["a CXR severity score", "TEST", 57, 77], ["RT-PCR", "TEST", 87, 93]]], ["Statistical significance was defined as p <0.05.Patient Characteristics ::: ResultsThe clinical characteristics of the 64 patients on presentation are summarized in Table 1.", [["patients", "ORGANISM", 122, 130], ["Patient", "SPECIES", 48, 55], ["patients", "SPECIES", 122, 130]]], ["There were 26 males (41%) and 38 females (59%), with a mean age of 56 years (range 16 to 96 years).", [["26 males", "OBSERVATION_MODIFIER", 11, 19]]], ["Fever (59%) and cough (41%) were the most frequent symptoms.", [["Fever", "DISEASE", 0, 5], ["cough", "DISEASE", 16, 21], ["Fever", "PROBLEM", 0, 5], ["cough", "PROBLEM", 16, 21], ["the most frequent symptoms", "PROBLEM", 33, 59]]], ["Nine patients (14%) were asymptomatic.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["asymptomatic", "PROBLEM", 25, 37]]], ["The most common co-morbidities were hypertension (20%) and diabetes (13%).Chest x-ray Features ::: ResultsFifty-one of 64 patients demonstrated abnormalities on CXRs at some point during their illness (Table 2, Figure 3).", [["hypertension", "DISEASE", 36, 48], ["diabetes", "DISEASE", 59, 67], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["hypertension", "PROBLEM", 36, 48], ["diabetes", "PROBLEM", 59, 67], ["Chest x-ray", "TEST", 74, 85], ["abnormalities", "PROBLEM", 144, 157], ["CXRs", "TEST", 161, 165], ["hypertension", "OBSERVATION", 36, 48], ["abnormalities", "OBSERVATION", 144, 157]]], ["On baseline CXR, consolidation was the most common finding (30/64, 47%), followed by GGO (21/64, 33%).", [["GGO", "DISEASE", 85, 88], ["baseline CXR", "TEST", 3, 15], ["consolidation", "PROBLEM", 17, 30], ["GGO", "TEST", 85, 88], ["consolidation", "OBSERVATION", 17, 30]]], ["Peripheral (26/64, 41%) and lower zone distribution (32/64, 50%) were the more common locations, and most had bilateral involvement (32/64, 50%).", [["Peripheral", "ANATOMY", 0, 10], ["lower zone", "ANATOMY", 28, 38], ["Peripheral", "TEST", 0, 10], ["lower zone distribution", "TEST", 28, 51], ["bilateral involvement", "PROBLEM", 110, 131], ["lower", "ANATOMY_MODIFIER", 28, 33], ["zone", "ANATOMY_MODIFIER", 34, 38], ["bilateral", "ANATOMY_MODIFIER", 110, 119], ["involvement", "OBSERVATION", 120, 131]]], ["Pleural effusion was found in 2 cases (3%).Chest x-ray Features ::: ResultsBaseline CXR fFindings.\u2014All patients had baseline CXRs upon presentation.", [["Pleural effusion", "ANATOMY", 0, 16], ["Pleural effusion", "DISEASE", 0, 16], ["Pleural", "PATHOLOGICAL_FORMATION", 0, 7], ["patients", "ORGANISM", 103, 111], ["patients", "SPECIES", 103, 111], ["Pleural effusion", "PROBLEM", 0, 16], ["Chest x-ray", "TEST", 43, 54], ["ResultsBaseline CXR fFindings", "TEST", 68, 97], ["baseline CXRs", "TEST", 116, 129], ["effusion", "OBSERVATION", 8, 16]]], ["Twenty patients (31%) had normal baseline CXRs.", [["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["Twenty-six patients (41%) had mild findings with total severity score of 1-2.", [["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["mild findings", "PROBLEM", 30, 43], ["total severity score", "TEST", 49, 69], ["mild", "OBSERVATION_MODIFIER", 30, 34]]], ["More extensive involvement was seen in 13 (20%) and 5 (8%) patients, who had severity scores of 3-4 and 5-6 respectively.", [["patients", "ORGANISM", 59, 67], ["patients", "SPECIES", 59, 67], ["severity scores", "TEST", 77, 92], ["extensive", "OBSERVATION_MODIFIER", 5, 14], ["involvement", "OBSERVATION", 15, 26]]], ["No patient had a severity score of >6 on their baseline CXR.Chest x-ray Features ::: ResultsTime Course of Radiographic Changes on CXR.\u2014The CXR severity scores from symptom onset are illustrated in Figure 4.", [["patient", "ORGANISM", 3, 10], ["CXR", "PROTEIN", 56, 59], ["CXR", "PROTEIN", 131, 134], ["CXR", "PROTEIN", 140, 143], ["patient", "SPECIES", 3, 10], ["a severity score", "TEST", 15, 31], ["their baseline CXR", "TEST", 41, 59], ["Chest x-ray", "TEST", 60, 71], ["Radiographic Changes", "PROBLEM", 107, 127], ["CXR", "TEST", 131, 134], ["The CXR severity scores", "TEST", 136, 159], ["symptom onset", "PROBLEM", 165, 178]]], ["The highest CXR severity score recorded was 8 (of maximum possible score of 8).", [["CXR", "PROTEIN", 12, 15], ["The highest CXR severity score", "TEST", 0, 30]]], ["CXR severity scores changed over time (Figure 4, p=0.01).", [["CXR", "PROTEIN", 0, 3], ["CXR severity scores", "TEST", 0, 19], ["Figure", "TEST", 39, 45]]], ["Peak severity was reached at 10-12 days, at which the median CXR severity score was 3.", [["CXR", "PROTEIN", 61, 64], ["Peak severity", "TEST", 0, 13], ["the median CXR severity score", "TEST", 50, 79]]], ["Of the 20 patients who had normal baseline CXRs, 7 developed abnormalities on follow-up radiographs.CXR Correlation with RT-PCR ::: ResultsEach patient underwent a median of 3 (IQR: 1-4, range 1-15) RT-PCR tests.", [["patients", "ORGANISM", 10, 18], ["patient", "ORGANISM", 144, 151], ["CXR", "DNA", 100, 103], ["patients", "SPECIES", 10, 18], ["patient", "SPECIES", 144, 151], ["7 developed abnormalities", "PROBLEM", 49, 74], ["follow-up radiographs", "TEST", 78, 99], ["CXR", "TEST", 100, 103], ["RT-PCR", "TEST", 121, 127], ["RT-PCR tests", "TEST", 199, 211]]], ["On presentation, 60 out of 64 patients (94%) had both baseline CXRs and initial RT-PCR testing performed within the first 24 hours, while 4 out of 64 patients (6%) had CXR and RT-PCR performed within 48 hours.", [["patients", "ORGANISM", 30, 38], ["patients", "ORGANISM", 150, 158], ["patients", "SPECIES", 30, 38], ["patients", "SPECIES", 150, 158], ["baseline CXRs", "TEST", 54, 67], ["initial RT-PCR testing", "TEST", 72, 94], ["CXR", "TEST", 168, 171], ["RT-PCR", "TEST", 176, 182]]], ["The CXR severity scores at baseline showed no significant difference between patients with positive or negative PCR at initial testing (p=0.62) (Figure 5).", [["patients", "ORGANISM", 77, 85], ["CXR", "PROTEIN", 4, 7], ["patients", "SPECIES", 77, 85], ["The CXR severity scores", "TEST", 0, 23], ["positive or negative PCR", "PROBLEM", 91, 115], ["initial testing", "TEST", 119, 134], ["no", "UNCERTAINTY", 43, 45], ["significant", "OBSERVATION_MODIFIER", 46, 57]]], ["Of the 58 (91%) patients who tested positive on initial RT-PCR, 38 (59%) had abnormalities on baseline CXR.", [["patients", "ORGANISM", 16, 24], ["CXR", "PROTEIN", 103, 106], ["patients", "SPECIES", 16, 24], ["initial RT-PCR", "TEST", 48, 62], ["abnormalities", "PROBLEM", 77, 90], ["baseline CXR", "TEST", 94, 106]]], ["Six patients (9%) were negative on initial RT-PCR, but demonstrated abnormalities on baseline CXR, two of which are shown in Figures 2a & 2b.", [["patients", "ORGANISM", 4, 12], ["CXR", "PROTEIN", 94, 97], ["patients", "SPECIES", 4, 12], ["initial RT-PCR", "TEST", 35, 49], ["abnormalities", "PROBLEM", 68, 81], ["baseline CXR", "TEST", 85, 97], ["abnormalities", "OBSERVATION", 68, 81]]], ["Of these six patients, 5 subsequently tested positive after 24 hours, and 1 tested positive after 48 hours.CXR Correlation with RT-PCR ::: ResultsUsing RT-PCR results as gold standard, the observed detection rate of baseline RT-PCR was 58/64, 91% sensitivity [95% CI: 83-97%]), which was higher than baseline CXR (44/64, 69% sensitivity [95% CI: 56-80%]) (p=0.009).CXR Correlation with RT-PCR ::: ResultsTwenty-three patients had follow-up virologic recovery; 18 patients had follow up to chest xray recovery.", [["chest", "ANATOMY", 489, 494], ["patients", "ORGANISM", 13, 21], ["patients", "ORGANISM", 417, 425], ["patients", "ORGANISM", 463, 471], ["CXR", "DNA", 107, 110], ["CXR", "DNA", 365, 368], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 417, 425], ["patients", "SPECIES", 463, 471], ["CXR", "TEST", 107, 110], ["RT-PCR", "TEST", 128, 134], ["PCR", "TEST", 155, 158], ["PCR", "TEST", 228, 231], ["sensitivity", "TEST", 247, 258], ["CI", "TEST", 264, 266], ["CXR", "TEST", 309, 312], ["sensitivity", "TEST", 325, 336], ["CI", "TEST", 342, 344], ["CXR", "TEST", 365, 368], ["RT-PCR", "TEST", 386, 392], ["chest xray", "TEST", 489, 499], ["chest", "ANATOMY", 489, 494]]], ["The mean time from initial positive RT-PCR to negative RT-PCR was 8\u00b17 days (n=23, range 1-24 days).", [["PCR", "TEST", 39, 42], ["RT-PCR", "TEST", 55, 61]]], ["The mean time from initial positive CXR to negative CXR was 6\u00b15 days (n=18, range 1-18 days).", [["initial positive CXR", "TEST", 19, 39], ["CXR", "TEST", 52, 55]]], ["Five patients never exhibited radiographic abnormalities and were not included in the radiographic recovery group.", [["patients", "ORGANISM", 5, 13], ["patients", "SPECIES", 5, 13], ["radiographic abnormalities", "PROBLEM", 30, 56]]], ["There was no statistically significant difference in the recovery time for RT-PCR and CXR recovery groups (p=0.33).Chest x-ray correlation with CT ::: ResultsTwenty-eight of 64 patients (44%) in our cohort had CT performed within 48 hours of a CXR at a mean of 11\u00b17 days (range 0-26 days) after symptom onset.", [["patients", "ORGANISM", 177, 185], ["patients", "SPECIES", 177, 185], ["RT-PCR", "TEST", 75, 81], ["CXR recovery groups", "TEST", 86, 105], ["Chest x-ray", "TEST", 115, 126], ["CT", "TEST", 144, 146], ["ResultsTwenty", "TEST", 151, 164], ["CT", "TEST", 210, 212], ["a CXR", "TEST", 242, 247], ["symptom onset", "PROBLEM", 295, 308], ["no", "UNCERTAINTY", 10, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49]]], ["Twenty-four of 28 patients had CXR severity scores >0, all of whom had positive findings on CT.", [["patients", "ORGANISM", 18, 26], ["patients", "SPECIES", 18, 26], ["CXR severity scores", "TEST", 31, 50], ["CT", "TEST", 92, 94]]], ["Four patients had negative CXRs, of whom 3 had negative CTs as well, while 1 demonstrated ground glass opacities on CT (Figure 6).DiscussionThe main feature of consolidation on chest x-ray in COVID-19 pneumonia is consistent with previously published case series9,21.", [["chest", "ANATOMY", 177, 182], ["pneumonia", "DISEASE", 201, 210], ["patients", "ORGANISM", 5, 13], ["chest", "ORGAN", 177, 182], ["patients", "SPECIES", 5, 13], ["CXRs", "TEST", 27, 31], ["ground glass opacities", "PROBLEM", 90, 112], ["CT", "TEST", 116, 118], ["consolidation", "PROBLEM", 160, 173], ["chest x-ray", "TEST", 177, 188], ["COVID", "TEST", 192, 197], ["pneumonia", "PROBLEM", 201, 210], ["ground glass opacities", "OBSERVATION", 90, 112], ["consolidation", "OBSERVATION", 160, 173], ["chest", "ANATOMY", 177, 182], ["pneumonia", "OBSERVATION", 201, 210], ["consistent with", "UNCERTAINTY", 214, 229]]], ["Of the 58 (58/64, 91%) patients who tested positive on initial RT-PCR, 38 (38/64, 59%) had abnormalities on baseline chest x-ray (CXR).", [["patients", "ORGANISM", 23, 31], ["patients", "SPECIES", 23, 31], ["initial RT", "TEST", 55, 65], ["PCR", "TEST", 66, 69], ["abnormalities", "PROBLEM", 91, 104], ["baseline chest x-ray", "TEST", 108, 128], ["CXR", "TEST", 130, 133], ["chest", "ANATOMY", 117, 122]]], ["Forty patients had abnormal baseline CXR.", [["patients", "ORGANISM", 6, 14], ["CXR", "PROTEIN", 37, 40], ["patients", "SPECIES", 6, 14], ["abnormal baseline CXR", "PROBLEM", 19, 40]]], ["Six patients showed CXR abnormalities before eventually testing positive on RT-PCR.", [["patients", "ORGANISM", 4, 12], ["CXR", "PROTEIN", 20, 23], ["patients", "SPECIES", 4, 12], ["CXR abnormalities", "TEST", 20, 37], ["testing", "TEST", 56, 63], ["RT", "TEST", 76, 78], ["PCR", "TEST", 79, 82]]], ["Sensitivity of initial RT-PCR (91% [95% CI: 83-97%]) was higher than that of baseline CXR (69% [95% CI: 56-80%]) (p = 0.009).", [["CXR", "PROTEIN", 86, 89], ["initial RT", "TEST", 15, 25], ["PCR", "TEST", 26, 29], ["CI", "TEST", 40, 42], ["CXR", "TEST", 86, 89], ["CI", "TEST", 100, 102]]], ["Radiographic (mean 6 \u00b1 5 days) and virologic recovery (mean 8 \u00b1 7 days) were not significantly different (p= 0.33).", [["Radiographic", "TEST", 0, 12], ["virologic recovery", "TEST", 35, 53], ["mean", "TEST", 55, 59]]], ["Consolidation was the most common finding (30/64, 47%), followed by GGO (21/64, 33%).", [["GGO", "DISEASE", 68, 71], ["Consolidation", "PROBLEM", 0, 13], ["GGO", "TEST", 68, 71], ["most common", "OBSERVATION_MODIFIER", 22, 33]]], ["These had a peripheral (26/64, 41%) and lower zone distribution (32/64, 50%) with bilateral involvement (32/64, 50%).", [["lower zone", "ANATOMY", 40, 50], ["bilateral involvement", "PROBLEM", 82, 103], ["peripheral", "ANATOMY_MODIFIER", 12, 22], ["lower", "ANATOMY_MODIFIER", 40, 45], ["zone", "ANATOMY_MODIFIER", 46, 50], ["bilateral", "ANATOMY_MODIFIER", 82, 91]]], ["Pleural effusion was not common (2/64, 3%).", [["Pleural", "ANATOMY", 0, 7], ["Pleural effusion", "DISEASE", 0, 16], ["Pleural", "ORGAN", 0, 7], ["Pleural effusion", "PROBLEM", 0, 16], ["effusion", "OBSERVATION", 8, 16]]], ["The severity of CXR findings peaked at 10-12 days from the date of symptom onset.DiscussionWe demonstrated that the common CT findings of bilateral involvement, peripheral distribution, and lower zone dominance5,9,10,22 can also be appreciated on CXR.", [["lower zone", "ANATOMY", 190, 200], ["CXR", "PROTEIN", 16, 19], ["CXR", "PROTEIN", 247, 250], ["CXR findings", "TEST", 16, 28], ["symptom onset", "PROBLEM", 67, 80], ["the common CT", "TEST", 112, 125], ["bilateral involvement, peripheral distribution, and lower zone dominance5", "PROBLEM", 138, 211], ["CXR", "TEST", 247, 250], ["severity", "OBSERVATION_MODIFIER", 4, 12], ["bilateral", "ANATOMY_MODIFIER", 138, 147], ["involvement", "OBSERVATION", 148, 159], ["peripheral", "ANATOMY_MODIFIER", 161, 171], ["distribution", "OBSERVATION_MODIFIER", 172, 184], ["lower", "ANATOMY_MODIFIER", 190, 195], ["zone dominance5", "OBSERVATION", 196, 211]]], ["Peak CXR severity score at 10-12 days after symptom onset is commensurate with previous findings on CT, where peak severity was reported at 6-11 days8,23.", [["CXR", "PROTEIN", 5, 8], ["Peak CXR severity score", "TEST", 0, 23], ["symptom onset", "PROBLEM", 44, 57], ["CT", "TEST", 100, 102], ["peak severity", "TEST", 110, 123]]], ["The proportion of patients in our study exhibiting abnormal radiographic findings (51/64, 80%) is higher than that in the case series of 9 patients published by Yoon et al.21 (5/9, 56%).", [["patients", "ORGANISM", 18, 26], ["patients", "ORGANISM", 139, 147], ["patients", "SPECIES", 18, 26], ["patients", "SPECIES", 139, 147], ["our study", "TEST", 30, 39], ["abnormal radiographic findings", "PROBLEM", 51, 81], ["higher", "OBSERVATION_MODIFIER", 98, 104]]], ["Furthermore, CXR abnormalities were detectable in 6 patients whose initial RT-PCR was negative (6/64, 9%).", [["patients", "ORGANISM", 52, 60], ["CXR", "PROTEIN", 13, 16], ["patients", "SPECIES", 52, 60], ["CXR abnormalities", "TEST", 13, 30], ["initial RT-PCR", "TEST", 67, 81]]], ["Baseline CXR sensitivity was 69% [95% CI: 56-80%].", [["CXR", "PROTEIN", 9, 12], ["Baseline CXR sensitivity", "TEST", 0, 24], ["CI", "TEST", 38, 40]]], ["Albeit lower than the reported 97-98% sensitivity of CT6,24, our results suggest that CXR can play a role in the initial screening of COVID-19.", [["COVID-19", "CELL", 134, 142], ["CXR", "PROTEIN", 86, 89], ["CT6", "TEST", 53, 56], ["CXR", "TEST", 86, 89], ["COVID", "TEST", 134, 139]]], ["Although further studies are needed, in the scenario where there is high clinical suspicion of COVID-19 it is conceivable that a positive CXR may obviate the need for a CT, thus reducing burden on CT units in this pandemic.DiscussionIn our patient subgroup with both CXR and CT available (n=28), all positive CXRs were also positive on CT, and only 1 patient (1/4, 25%) had a falsely negative CXR when compared to CT.", [["patient", "ORGANISM", 240, 247], ["CXRs", "CANCER", 309, 313], ["patient", "ORGANISM", 351, 358], ["patient", "SPECIES", 240, 247], ["patient", "SPECIES", 351, 358], ["further studies", "TEST", 9, 24], ["COVID", "TEST", 95, 100], ["a positive CXR", "TEST", 127, 141], ["a CT", "TEST", 167, 171], ["CT units", "TEST", 197, 205], ["this pandemic", "PROBLEM", 209, 222], ["both CXR", "TEST", 262, 270], ["CT", "TEST", 275, 277], ["all positive CXRs", "TEST", 296, 313], ["CT", "TEST", 336, 338], ["CT", "TEST", 414, 416]]], ["A major caveat is that during the study period, our institutions did not routinely perform CT for all COVID-19 patients.", [["patients", "ORGANISM", 111, 119], ["patients", "SPECIES", 111, 119], ["the study", "TEST", 30, 39], ["CT", "TEST", 91, 93], ["all COVID", "TEST", 98, 107], ["major", "OBSERVATION_MODIFIER", 2, 7], ["caveat", "OBSERVATION", 8, 14]]], ["CT was performed later in the disease course (11 days on average) than CXR.", [["CXR", "PROTEIN", 71, 74], ["CT", "TEST", 0, 2], ["CXR", "TEST", 71, 74]]], ["CT was reserved for patients with clinical deterioration or poor response to treatment.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["CT", "TEST", 0, 2], ["clinical deterioration", "PROBLEM", 34, 56], ["treatment", "TREATMENT", 77, 86]]], ["Thus, the CT group in our study was likely skewed towards patients with more severe radiological manifestations.DiscussionThe role of CXR in clinical monitoring is less clear.", [["patients", "ORGANISM", 58, 66], ["CXR", "PROTEIN", 134, 137], ["patients", "SPECIES", 58, 66], ["the CT group", "TEST", 6, 18], ["our study", "TEST", 22, 31], ["more severe radiological manifestations", "PROBLEM", 72, 111], ["CXR", "TEST", 134, 137], ["clinical monitoring", "TEST", 141, 160], ["severe", "OBSERVATION_MODIFIER", 77, 83]]], ["In our subgroups that were followed to both virologic (n=23) and radiographic (n=18) recovery, there was no statistically significant difference in their mean durations to recovery.", [["radiographic", "TEST", 65, 77], ["no", "UNCERTAINTY", 105, 107], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["difference", "OBSERVATION_MODIFIER", 134, 144]]], ["For comparison, in a subgroup analysis of 57 cases by Ai et al., 42% of patients showed improvement on CT prior to RT-PCR becoming negative, with the rest either showing progression on CT, or only showing improvement after RT-PCR normalization6.", [["patients", "ORGANISM", 72, 80], ["patients", "SPECIES", 72, 80], ["a subgroup analysis", "TEST", 19, 38], ["CT", "TEST", 103, 105], ["RT-PCR", "TEST", 115, 121], ["CT", "TEST", 185, 187], ["RT-PCR normalization6", "TEST", 223, 244], ["negative", "OBSERVATION", 131, 139]]], ["With the situation further confounded by reports of COVID-19 patients testing positive on RT-PCR again after discharge25,26, our opinion is that imaging should be used as an adjunct to clinical parameters in monitoring of disease course, until further evidence is available.DiscussionOur study has several limitations.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["COVID", "TEST", 52, 57], ["patients testing", "TEST", 61, 77], ["RT-PCR", "TEST", 90, 96], ["imaging", "TEST", 145, 152], ["clinical parameters", "TEST", 185, 204], ["disease course", "TREATMENT", 222, 236], ["DiscussionOur study", "TEST", 274, 293]]], ["First, not all patients were followed to their final outcome, thus correlation with disease course is truncated for some patients.", [["patients", "ORGANISM", 15, 23], ["patients", "ORGANISM", 121, 129], ["patients", "SPECIES", 15, 23], ["patients", "SPECIES", 121, 129]]], ["The intervals between serial CXRs and RT-PCR testing were dictated by clinical need and not uniform, thus potentially affecting the precision of our analysis.", [["serial CXRs", "TEST", 22, 33], ["RT-PCR testing", "TEST", 38, 52], ["our analysis", "TEST", 145, 157]]], ["Fourth, there is a lack of a non-COVID-19 control group and CT was only available for a subgroup, thus limiting evaluation of the sensitivity and specificity of CXR.", [["CXR", "PROTEIN", 161, 164], ["a non-COVID", "TEST", 27, 38], ["CT", "TEST", 60, 62], ["the sensitivity", "TEST", 126, 141], ["CXR", "TEST", 161, 164]]], ["In summary, we describe the features of COVID-19 on CXR, to complement the publications on CT.", [["COVID-19", "DNA", 40, 48], ["CXR", "PROTEIN", 52, 55], ["COVID", "TEST", 40, 45], ["CXR", "TEST", 52, 55], ["CT", "TEST", 91, 93]]], ["Baseline CXR had a sensitivity of 69% in our cohort.", [["CXR", "PROTEIN", 9, 12], ["Baseline CXR", "TEST", 0, 12], ["a sensitivity", "TEST", 17, 30]]], ["As the COVID-19 pandemic threatens to overwhelm healthcare systems worldwide, CXR may be considered as a tool for identifying COVID-19, but is less sensitive than CT.", [["CXR", "PROTEIN", 78, 81], ["the COVID", "TEST", 3, 12], ["CXR", "TEST", 78, 81], ["COVID", "TEST", 126, 131], ["CT", "TEST", 163, 165]]]]}